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Abstract
This thesis covers work investigating the effects of fluorine incorporation on the structure, 
biological activity, and NMR properties of anticancer chalcones as well as novel methods for 
the inclusion of fluorinated moieties into organic compounds.
The first chapter looks at the use o f silanes as carriers of small fluorinated nucleophiles which 
can be activated by fluoride anion catalysis to deliver such nucleophiles to organic 
electrophiles such as aldehydes. The synthesis of a group of such silanes and an assessment of 
their reactivity towards aromatic aldehydes is described.
The second and third chapters describe the synthesis and compare the structures and biological 
activities o f four series of chalcones; chapter two looks at chalcones which have non 
fluorinated groups (a nitrile group and an ethyl ester group) on the a  position and chapter three 
looks at chalcones which have F and CF3 groups on that position. A comparison of the effects 
of substitution, at both the a  position and on the B ring, on structure and cytotoxicity of these 
compounds is given. Several o f the fluorinated chalcones were found to be highly cytotoxic 
and further assessment o f their tubulin-binding properties was carried out.
Chapter four looks at some unusual, long range fluorine-hydrogen coupling interactions which 
have been observed in the NMR spectra o f certain types o f chalcones. The effects of various 
substitutions and structural changes on these coupling patterns are examined.
In addition a brief study into the dimerisation of chalcones is described.
The final chapter looks at the use o f FAR type reagents to generate asymmetric fluorinated 
amides using secondary chiral amines. Synthesis o f a number of chiral amines from proline and 
their addition, with limited success, to trifluorovinyl styrenes is discussed.
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BBN 9-Borabicyclo[3.3.1 ]nonane
Bu Butyl
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HOBT 1 -Hydroxybenzotriazole
LDA Lithium diiospropylamide
LiHMDS Lithium hexamethyldisilazane
Me Methyl
NBS A-bromosuccinimide
NIS TV-iodosuccinimide
NMR Nuclear Magnetic Resonance
PCC Pyridinium chlorochromate
PDC Pyridinium dichromate
Ph Phenyl
Pr Propyl
'Pr wo-Propyl
R Any alkyl or aryl group
SAR Structure Activity Relationship
TBAF Tetrabutylammonium fluoride
TBDMS rerr-Butyldimethylsilyl
TBDPS rerr-Butyldiphenylsilyl
TFA Trifluoroacetic acid
TFAA Trifluoroacetic anhydride
THF Tetrahydrofuran
TIPS Triisopropylsilyl
TMS Trimethylsilyl
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Chapter 1 Silane Chemistry
Chapter One
1.1 Introduction
Despite the highly beneficial effects that fluorine is being found to have on biologically active
fluorinated groups to organic compounds.
The trifluoromethyl group in particular is a very useful target for many potential drug 
candidates, although the existing methods of delivering this group are exceedingly limited. In 
theory the CF3 group could come in the form of one of three synthons -  [CF3- ] [CF3+], or the 
[CF3 ] radical.
Sources o f [CF3+] include compounds like trifluoromethyl-/>chlorophenyl(2,4-dimethyl) 
phenylsulfonium hexafluoroantimonate (1) and trifluoromethyl-/?-chlorophenyl-p- 
anisylsulfonium hexafluoroantimonate (2), which have been shown by Yagupol’skii to deliver 
the [CF3*] synthon to sodium /?-nitrothiophenolate {Scheme 1.1), generating />nitrophenyl 
trifluoromethyl sulphide.2 However, both reagents 1 and 2 are hygroscopic and difficult to
Scheme 1.1 -  Electrophilic trifluoromethylation.
Umemoto et al. developed a series o f reagents o f the type 3, which trifluoromethylate a range
compounds, 1 there are relatively few reagents currently available that can selectively deliver
synthesise.
0 2N Na+ 1 or 2 0 2N
S S
CF3
of organic nucleophiles.3 The reactivity o f these compounds can be tuned by varying X (which 
can be S, Se or Te) and the electronic properties o f the aryl substituents R 1 and R2.
3
Figure 1.1 Umemoto reagents.
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In 1998 Shreeve4 expanded on this and published work on a very similar group of electrophilic 
trifluoromethylating agents of the type Ar2S+CF3 (TfO~) which were used to deliver the 
trifluoromethyl group to aromatic rings, again these could be tuned by altering the nature of the 
aryl groups. In particular, it was found that having electron withdrawing groups such as NO2 
and F on the rings increased the reactivity, whilst electron donating groups reduced it.
All of these reagents, however, are expensive and difficult to prepare, requiring several steps to 
synthesise and are all hygroscopic and therefore difficult to store for long periods.
The [CFf] radical can be generated photochemically by irradiation of such molecules as 
CF3COSR and CF3SO2SR, and then used to trifluoromethylate disulfides and alkenes {Scheme
1. 2 ).5
CO
CF3COSEt » ’CF3
hv ’ SEt
R1
r2 = ^r3 F3Q R\ / R1 F3C\ R3\ /R1
+
R2 SR R2 H
+ CF3SR
Scheme 1 .2 -  Free radical trifluoromethylation.
While this reaction does show some regioselectivity, in that the radical prefers to add to the 
less hindered end of the C=C double bond, it is low yielding, unpredictable and therefore not 
very suitable for use in the synthesis o f large, complicated drug candidates.
This leaves [CF3_] as the most convenient synthon,6 although the trifluoromethyl anion itself is 
unstable; it rapidly decomposes into fluoride and difluorocarbene7 and must therefore be 
stabilised by conversion into a more convenient form.
The reagent currently used for this purpose is trifluoromethyltrimethylsilane (Ruppert’s 
reagent,8 4), which is used as a [CYf] synthetic equivalent and when activated by fluoride, can 
deliver the trifluoromethyl nucleophile to a range o f organic electrophiles. The most well 
documented use of trifluoromethyltrimethylsilane is in the addition of CF3 to aldehydes and 
ketones to generate secondary and tertiary trifluoromethyl alcohols {Scheme 1.3).
8
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O
y
R1 R2
4
M03SiCF3
Me3SiF
+
R1
OH
cfT
I+
Scheme 1.3 Nucleophilic trifluoromethylation using Ruppert’s reagent.
The chemistry o f Ruppert’s reagent has been extensively reviewed.9,10 It has been used to 
deliver [CF3~] to a range o f other carbonyl compounds (including enones,11 porphyrins,12
esters, 13 aminoesters,lzt amides, 10 imines, 10 thiocyanates and selenocyanates1'), as well as 
aromatic rings (via ipso attack18 and F" substitution19) and has even been shown to be able to 
introduce fluorocarbon ligands into metal complexes.
Ruppert’s reagent was first made in 1984 by condensation of CF3Br and Me3SiCl with 
(Et2N)3P {Scheme 1.4) 21 However, use of CF3Br is now restricted due to its long survival in 
the atmosphere. Although a number o f alternative methods of making the reagent have been
99developed, including the replacement of CF3Br with CF3I and use of aluminium based 
reductants,23 none o f these are as effective and there is now call for the development of more 
reagents that can act as a source o f [CF3“].
Et2N NEt2
X~CF3 
Et2N
14 15 16 17>
NEt,
Et2N -P x
NEt2
+
Br—CF3
Br Me3Si—Cl
Me3Si CF3 
4
Et2N NEt2
X ~ C F 3 
Et2N Br
Scheme 1.4 Synthesis o f  trifluoromethyltrimethylsilane.
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As a result, a number o f recent publications have sought to provide more useful, cheaper and 
greener alternatives to trifluoromethyltrimethylsilane.
Shono et al. have found that fluoroform can be deprotonated by a range of bases in the 
presence of DMF and used to add the trifluoromethyl nucleophile to benzaldehyde to create the 
alcohol 5 .24 Normant and co-workers expanded on this and showed that the trifluoromethyl 
anion was in fact captured by the DMF, since the same reaction failed when THF was used.25
They suggested that in place of the trifluoromethyl anion, the intermediate 6 was formed. It is 
this species that then delivers the trifluoromethyl group when the aldehyde is added {Scheme 
1.5).
O ♦ K+K
DMF C? H 9  K+
rF3C I NMe2 ^  _ Ph CF3 + DMF5fs^ - h
Scheme 1.5 Nucleophilic trifluoromethylation using 6.
This hypothesis was backed up when they hydrolysed the reaction mixture before addition of 
any electrophiles and 19F NMR revealed the presence of CF3CHO.
Roques26 sought to synthesise similar reagents such as 7 from fluoral hydrate without the 
presence of metal counterions {Scheme 1.6).
OH OH
f 3c ^ o h  _______  f 3c T Nr 2 7
+ +
r 2n h  h2o
Scheme 1.6 -  Aminat ion offluoral hydrate.
Although this was shown to be successful by 19F NMR, isolation of the hemiaminal 7 from the 
equilibrium proved difficult when the hydrate was used because of the presence o f water. So 
they generated the aldehyde itself by dehydration o f the hydrate (P2O5/H3PO4) and reacted this 
with the amines {Scheme 1.7). This enabled the products to be isolated in THF solution, which 
were then shown to react as expected with benzaldehyde in the presence of base, although the 
yields were lower than had been achieved previously.
10
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OH P2O5 O
f 3c t  'h o h  H3PO4 f 3c ^ h
r 2n h
OH
f 3c t  v j n r 2
1) PhCHO
2) AcOH
NaOtBu
O Na
F3C ' 'h n r 2
Scheme 1.7 Nucleophilic trifluoromethylation using 7.
Use of N(TMS)3 / F" as base in this reaction resulted in formation of the silylether 8 (Figure
1.2) rather than the above intermediate 7. 27
Me3Si
F*C
O
H
8
Me3Si
FoC'
NMe, H
N
O
Me3Si
F3C
0
Ph
10
N
Figure 1.2 -  Reagents fo r  nucleophilic trifluoromethylation.
Although 8 could not be isolated, replacement of the DMF with A-formylmorpholine resulted 
in a relatively stable reagent 9. Interestingly, of a range o f A-formylamines used, N- 
formylmorpholine was the only one that gave satisfactory results. Reagent 9 was shown to
behave in much the same way as Ruppert’s reagent, although two equivalents of the reagent
28and higher temperatures were required to give good yields.
A similar piece of work by Motherwell et al. looked at the reaction of 
trifluoromethylacetophenone with A,A-dimethyltrimethylsilylamine, which resulted in 
formation of the reasonably stable reagent 10. This, too, was shown to react well with a range 
of aromatic aldehydes and ketones in the presence of catalytic CsF, delivering the 
trifluoromethyl nucleophile.29 They proposed a catalytic reaction mechanism (Scheme 1.8), 
similar to that o f Ruppert’s reagent.
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CsF
Ph
Ph
OH
NMe-
C s1
O
f 3c
Ph I
10
Scheme 1 .8 -  Nucleophilic trifluoromethylation using 10.
Work within our own group has found that siloxanes can be very useful in the delivery of 
hydride nucleophiles. PMHS (polymethylhydrosiloxane) and 1,1,3,3-tetramethyldisiloxane jn 
the presence of fluoride catalyst such as TBAF can reduce aldehydes and ketones to their 
corresponding alcohols, and if  quinidine chiral ammonium fluorides are used, the reaction 
becomes asymmetric31 with e.e.’s o f up to 71% (Scheme 1.9).
1) (MeO)3SiH, 
Cat. (10 mol%)
2) NaOH
OH
Cat. = Ph
'OH
Scheme 1.9 — Asymmetric reduction o f  acetophenone using siloxane.
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The above reduction using siloxanes is also much faster than reduction using equivalent silanes 
-  PMHS reduces acetophenone in high yields in under a minute whereas it takes hours for the 
same reaction to occur using an equivalent silane. It is believed that this is due to the formation 
of a silonate intermediate (11) which would be extremely reactive.
O
n  n  ^  ^  ^  A  H0  Nu0 N A  ... Qn . F T 'H \ /Me3Si Si, SiMe3 _____ ^ sSi sSiMe3 - — -  NSi, SiMe3 ,  ^
Me Nu Me7 Nu Me Nu R H
11
Scheme I .10 Formation o f  silonate intermediate.
If this is the case then siloxanes should also be useful reagents in the delivery of other 
nucleophiles. This has already been seen with allyl groups and it is expected to work with 
fluorinated groups too.
1.2.1 Trifluorovinyl Nucleophile
A range o f silanes o f the type Nu-SiMe2Ph (12) were made where ‘Nu’ represents a fluorinated 
nucleophile. In some cases (those of the nucleophiles C2F3 and C6F5) similar silanes have been 
used previously to deliver the same fluorinated nucleophiles to organic electrophiles, with 
varying degrees of success.33 Although the use of more reactive silanes with the difluorophenyl 
group, C6H3F2, as described here, is novel. These were made in order to assess their reactivity 
towards organic electrophiles with the intention of then forming the basis for a comparison 
with the equivalent siloxane reagents.
The alcohols 13a to 13f were made by reaction of silanes with various aldehydes (Scheme 
1.11) and, with the exceptions o f 13e and 13f,34 are all novel and full characterisation data is 
given in chapter 6 ; all were shown to contain the correct fluorinated group by and 19F NMR 
and high resolution mass spec confirmed they had the correct molecular ion.
13
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F
12a-c
Ar
[H
Nu
A r^"O H
13a-f
OH F
13a
OH F OH F
O 13c
,0 13d
OH F OH F
13e
FqC
13f
Scheme 1.11 -  Addition o f  fluorinated nucleophiles to aryl aldehydes using silanes.
Firstly dimethyl(trifluorovinyl)phenylsilane (12a) was made in high yield (81%) by double 
deprotonation o f 1,1,1,2-tetrafluoroethane, using two equivalents of BuLi in THF, according to 
a method developed by Burdon et al,35 This generated the trifluorovinyl anion which was then 
substituted for the chlorine in chlorodimethylphenylsilane (.Scheme 1.12). The structure of 12a 
was confirmed by ]H and 19F NMR and mass spectrometry, as shown in chapter 6 ; the three 
double doublet peaks at -85.7  (Tff = 23.5, 47 Hz), -114.2 (Jff = 47, 160 Hz) and -197.0 (Jff = 
23.5, 160 Hz) in the 19F NMR corresponded to the three fluorine atoms, each one coupled to 
each o f the others. Likewise the *H NMR showed the phenyl protons as a pair of complex 
multiplets at around 7.3 and 7.5 ppm, and the methyl protons as one singlet at 0.41 ppm.
Bu
r V F
Bu H< V F F \ -  PhMe2SiCI F Y S iP h M e 2
F ^ F  F ^ F
12a
Scheme 1.12 Synthesis o f  12a.
The vinylsilane 12a was then used to add the trifluorovinyl nucleophile to 3,5- 
dimethoxybenxaldehyde to generate 13a in the same way as Ruppert’s reagent.
14
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The *H NMR spectrum of 13a showed a singlet at 3.73 ppm corresponding to the two 
equivalent methoxy groups, a doublet at 6.20 ppm with a Jhf value of 36 Hz, corresponding to 
the a  proton coupled to the fluorine atom at the p position, and two doublets at 6.41 {para) and 
6.63 {ortho) with Jhh values of 2.4 Hz for the aromatic protons. The 19F NMR had the same 
pattern as was seen in 12a - i.e. three double doublets at -66.5, -72.0 and -131.1 with Jff 
values of 23.5, 52 and 155 Hz (the p fluorine was also coupled to the a  proton) - but shifted up 
field as a result of the electron withdrawing properties of the aryl group.
A range o f tests were carried out, looking at different catalysts and reaction conditions for this 
reaction. While the trifluorovinyl nucleophile was found to react under certain conditions, the 
yields were disappointing. Results are summarised in Table 1.1 (where the yield is shown as 
0% the aldehyde was recovered unreacted with the exception of the 4-nitro-benzaldehyde in 
which case the reaction turned deep indigo and no product or starting material could be 
isolated).
Aldehyde Catalyst (mol%) Time, Temperature Yield and Product
3,5-dimethoxy­
benzaldehyde
TBAF (1M in 
THF), 100 mol%
48 hrs, 80 °C no 
solvent
9%, 13a
3,5-dimethoxy­
benzaldehyde
TBAF (1M in 
THF), 10 mol%
48 hrs, 80 °C in THF 0%
3,5-dimethoxy-
benzaldehyde
TBAF (1M in 
THF), 10 mol%
48 hrs, room temp in 
THF
0%
3,5-dimethoxy­
benzaldehyde
NBu4SiPh3F2, 100 
mol%
3 days, 80 °C in THF 0%
3,5-dimethoxy­
benzaldehyde
CsF, 100 mol% 3 days, 80 °C 0%
3,5-dimethoxy­
benzaldehyde
CuF2/dppb, 
10 mol%
24 hrs, room temp, 
(under air) in THF
0%
4-nitro-
benzaldehyde
TBAF (1M in 
THF), 100 mol%
48 hrs, 80 °C in THF 0%
4-chloro-
benzaldehyde
TBAF (1M in 
THF), 100 mol%
48 hrs, 80 °C in THF 0%
Table 1.1 -  Reaction conditions and yields fo r  reactions o f  12a with aryl aldehydes.
Initially 3,5-dimethoxybenzaldehyde was used as the electrophile and TBAF as fluoride 
source, since TBAF is the catalyst of choice for reactions with Rupperf s reagent. The reaction 
conditions were varied from stirring at room temperature with 10 mol% of catalyst to heating 
at 80 °C with no solvent and stoichiometric quantities of catalyst. This was done to see how 
harsh the reaction conditions needed to be in order for reaction to take place. In the case of the
15
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trifluorovinyl nucleophile the reaction only worked under the most extreme conditions, and 
even then the yields were very low. Since most of the aldehyde in this case was recovered 
unreacted, it would suggest that the trifluorovinyl nucleophile was reacting in some other way 
in the reaction mixture faster than it was reacting with the aldehyde. The most obvious 
explanation for this was that water had contaminated the hygroscopic TBAF. In order to test 
this tetrabutylammonium difluorophenylsilicate was used as a non-hygroscopic fluoride 
source.36 This, however, was found to work no better than TBAF.
Ruppert’s reagent was then used on the same aldehyde under reflux at 80 °C with one 
equivalent of TBAF in THF as catalyst, as a test of the TBAF. After only 24 hrs the reaction 
had gone to completion and the product 13d was extracted in quantitative yield without the 
need for column purification. This would suggest that water was not responsible for the 
disappointing yields in this reaction.
Scheme 1.13 -  Test reaction using Ruppert's reagent.
As mentioned previously, Hiyama et al. have used Et3SiCF=CF2 to deliver the trifluorovinyl 
nucleophile to alkyl and aryl aldehydes under catalysis by tris(diethylamino)sulfonium 
difluorotrimethylsilicate (TASF).37 They also reported low yields, despite using the silane in 
excess. The only explanation given in their publication was the a  or p-elimination of a 
fluoride anion from the vinyl nucleophile (which they believed to be present as a naked anion 
rather than a pentavalent silicon species) forming the fluoride salt of TAS+ and an alkyne
Two more catalysts were then tried. Cesium fluoride was flame-dried under vacuum to ensure 
it was anhydrous. This did not lead to any improvement. Copper(II) fluoride/dppb (dppb = 
PPh2-(CH2)4-PPh2) has recently been found to catalyse hydrosilylation of ketones, under an 
atmosphere of air.38 Use of this catalyst again did not work on our system.
Two other, more electrophilic aldehydes (4-chlorobenzaldehyde and 4-nitrobenzaldehyde) 
were also used but again no improvement was seen.
13d
species.
16
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1.2.2 Pentafluorophenyl Nucleophile
After limited success with the trifluorovinyl nucleophile, dimethyl(pentafluoro- 
phenyl)phenylsilane (12b) was synthesised and used in a similar range of tests to see if the 
pentafluorophenyl nucleophile could be delivered with any improvement in yield. Again the 
synthesis o f this reagent was straightforward. Pentafluorophenyl lithium was made by addition 
of BuLi to bromopentafluorobenzene in THF (according to the method developed by Frohn39 
and co-workers) and then added to chlorodimethylphenylsilane to generate silane 12b in 83% 
yield {Scheme 1.14). 19F NMR analysis showed three multiplet peaks corresponding to the 
ortho (-128 ppm), meta (-164 ppm) and para  (-154 ppm) fluorine atoms and the ]H NMR 
showed the phenyl protons as two complex multiplets at around 7.3 and 7.4 ppm, and the 
methyl protons as a singlet at 0.6 ppm. Mass spec data showed the [M+H]+ molecular ion at 
303.0623.
BuLi PhMe?SiCI
SiMe^Ph
Scheme 1.14 -  Synthesis o f  12b.
A similar range o f tests was carried out to determine how well this acted as a source of 
pentafluorophenyl nucleophile. (Once again, where the yield is shown as 0% the aldehyde was 
recovered unreacted, except for 4-nitro-benzaldehyde).
Aldehyde C atalyst (moI%) Time, Temperature Yield and Product
3,5-dimethoxy­
benzaldehyde
TBAF (1M in 
THF), 100 mol%
48 hrs, 80 °C no 
solvent
20%, 13b
3,5-dimethoxy-
benzaldehyde
TBAF (1M in 
THF), 10 mol%
48 hrs, 80 °C in THF 11%, 13b
3,5-dimethoxy­
benzaldehyde
TBAF (1M in 
THF), 10 mol%
48 hrs, room temp in 
THF
0%
3,5-dimethoxy-
benzaldehyde
NBu4SiPh3F2, 100 
mol%
48 hrs, 80 °C in THF 0%
3,5-dimethoxy-
benzaldehyde
CsF, 100 mol% 5 days, 80 °C in THF 0%
3,5-dimethoxy-
benzaldehyde
CuF2/dppb, 
10 mol%
24 hrs, room temp, 
(under air) in THF
0%
17
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4-nitro-
benzaldehyde
TBAF (1M in 
THF), 100 mol%
48 hrs, 80 °C in THF 0%
4-chloro-
benzaldehyde
TBAF (1M in 
THF), 100 mol%
48 hrs, 80 °C in THF 0%
Table 1.2 -  Reaction conditions and yields fo r  reactions o f 12b with aryl aldehydes.
Again the reaction was carried out initially on 3,5-dimethoxybenzaldehyde using TBAF as 
catalyst and varying the extremity of conditions.
The structure of 13b was confirmed by proton NMR -  singlet at 3.72 ppm corresponding to the 
6 methoxy protons, singlet at 6.06 ppm corresponding to the a  proton and doublets at 6.33 and 
6.47 (Jhh = 2.1 Hz) corresponding to the para  and ortho protons respectively. The mass spec, 
also showed a large peak at 315.0641, corresponding to (M-F)+.
This time a significant improvement, a two-fold increase, was seen in the yields of 13b over 
13a for reaction under the same conditions. The silane 12b was also found to react when 
TBAF was used in catalytic amounts, unlike 12a. Clearly the pentafluorophenylsilane is better 
able to deliver its nucleophile to the aldehyde than the trifluorovinyl analogue, but still the 
reaction did not go to completion.
Again this silane was then used with the same alternative fluoride sources and aldehydes that 
had been used with the previous reagent, and no improvement was seen. Since the use of non- 
hygroscopic fluoride sources, as well as comparisons with Ruppert’s reagent, have eliminated 
the possibility of damp or contaminated TBAF being responsible for the low yields, it is likely 
that the fluoride nucleophiles are decomposing in some way before reaction with the aldehyde 
can take place, presumably by elimination of a fluoride anion which in this case would result in 
a benzyne species.
Hiyama et al. also looked at the use of aromatic nucleophiles such as C6F5, C6CI5 and 3 ,5-0 2 - 
C6F3 in their paper and also saw improved yields, concluding that the fluoride elimination and 
subsequent decomposition is much less favourable in the case of aromatic nucleophiles than in 
vinyl nucleophiles.
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1.2.3 2,4-Difluorophenyl Nucleophile
Br
BuLi PhMe?SiCI
SiMe2Ph
Scheme 1.15 -  Synthesis o f  12c.
The silane 12c was made in the same way as the pentafluoro-analogue and reacted with 3,5- 
dimethoxybenzaldehyde to generate 13c. Structure o f 12c was, again confirmed by 19F and *H 
NMR analysis -  19F NMR showing two multiplets and *H NMR showing the same singlet 
methyl and multiplet phenyl peaks as were seen in 12a and 12b but also three separate 
multiplets for the three aromatic protons on the 2,4-difluorophenyl ring. Since 12c was novel, 
13C NMR, IR and mass spec data were also recorded. This time not only was there a significant 
improvement in the yields o f 13c but also the conditions needed for the reaction to occur were 
shown to be much less harsh. ]H NMR of 13c contained a singlet at 3.70 ppm corresponding 
to the 6 methoxy protons, a singlet at 5.96 ppm corresponding to the a  proton, two doublets at 
6.30 and 6.47 (Jhh = 2.1 Hz) corresponding to the para and ortho protons respectively and 
three multiplets corresponding to the 3’, 5’ and 6 ’ protons on the 2,4-difluorophenyl group. The 
two reagents 12a and 12b had only been able to react when TBAF was used as fluoride source, 
and the reaction was heated under reflux. The 2,4-difluorophenyl nucleophile, however, was 
found to add to the aldehyde when TBAF was used in catalytic quantities at room temperature. 
The reaction was also seen to work with NBu4SiPh3F2 as fluoride source and with 
benzaldehyde and 4-trifluoromethylbenzaldehyde, though once again no reaction took place 
with 4-chlorobenzaldehyde and reaction with 4-nitro-benzaldehyde resulted in an inseparable 
mixture:
Aldehyde Catalyst (mol%) Time,
Temperature
Yield and Product
3,5 dimethoxy 
benzaldehyde
TBAF (1M in 
THF), 100 mol%
48 hrs, 80 °C no 
solvent
39%, 13c
3,5 dimethoxy 
benzaldehyde
TBAF (1 M in  
THF), 10 mol%
48 hrs, 80 °C in 
THF
31%, 13c
3,5 dimethoxy 
benzaldehyde
TBAF (1M in 
THF), 10 mol%
48 hrs, room temp 
in THF
19%, 13c
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3,5 dimethoxy 
benzaldehyde
CuF2/dppb, 
10 mol%
48 hrs, room temp, 
(under air) in THF
0%
3,5 dimethoxy 
benzaldehyde
NBu4SiPh3F2, 100 
mol%
48 hrs, 80 °C in 
THF
23%, 13c
benzaldehyde TBAF (1 M in  
THF), 10 mol%
48 hrs, 80 °C in 
THF
17%, 13e
4-trifluoromethyl-
benzaldehyde
TBAF (1 M in  
THF), 10 mol%
48 hrs, 80 °C in 
THF
29%, 13f
4-nitro-
benzaldehyde
TBAF (1 M in  
THF), 10 mol%
48 hrs, 80 °C in 
THF
0%
4-chloro-
benzaldehyde
TBAF (1 M in  
THF), 10 mol%
48 hrs, 80 °C in 
THF
0%
Table 1.3 -  Reaction conditions and yields fo r  reactions o f  12c with aryl aldehydes.
Clearly the aromatic nucleophiles are much more stable to fluoride elimination than the 
trifluorovinyl nucleophile and thus able to react with the electrophiles in much better yields. In 
the case of the difluorophenyl group this is much more the case than with a pentafluorophenyl 
species. This is consistent with the electronic properties of the benzyne species which would 
form from fluoride elimination of these nucleophiles. Tetrafluorobenzyne would be more 
stable than a monofluoro equivalent because the four electron-withdrawing fluorine atoms 
would be better able to stabilise the electron rich benzyne ring, thus fluoride elimination from a 
pentafluorophenyl nucleophile would be more favourable than from a difluorophenyl 
nucleophile.
1.3 Application to Potential Anticancer Agents
These silane reagents were also used in an attempt to deliver fluorinated nucleophiles to the 
alkyl bromine electrophile (14).
BP;
CH-jCOOH o
87, 43%
O OH OH
Br
TsOH
Br
14, 74%
Scheme 1 .1 6 - Synthesis and protection o f  87.
This was made by addition of Br2 to 3,4,5-trimethoxyacetophenone, followed by protection of 
the carbonyl group with 2,3-butandiol.
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It was then reacted with each o f the silanes under those conditions which gave the best yields 
with the aldehydes (,Scheme 1.17). The expected products 15a-c could then have been 
deprotected and used in the chalcone synthesis discussed in later chapters.
F
12a-c 14
Nu
15a-c
LL t)
F F
F
a b
Nu =
Scheme 1.17 -  Reaction o f  14 with silanes 12a-c.
No reaction took place, however, with any o f the three silanes. This could be because this 
particular alkyl bromide is too sterically hindered. However, it is more likely that the silanes 
cannot be used as a source of CF3' for subsequent Sn2 reactions because this would require 
CF3‘ to be present as the naked anion. Examples o f Sn2 reactions using Ruppert’s reagent as a 
source o f CF3' are absent from the literature.
1.4 Summary and Conclusions
In summary it has been shown that silanes o f the type Me2PhSiNu, where Nu represents a 
small fluorinated nucleophile, can be used to deliver such nucleophiles to electrophilic 
carbonyl compounds. This reaction seems to give the highest yields when the nucleophile used 
is aromatic, in particular the nucleophile [C6H3F2 ] works well.
This area of research, despite some interesting results, could not be continued due to lack of 
industrial support.
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Chapter Two
2.1 Introduction
Chalcones, 1,3-diarylprop-l-enones, are a class of organic compounds consisting of two aryl 
rings linked by an a,P~unsaturated ketone moiety {Figure 2.1). Some chalcones are natural 
products found in various plant species around the world and in the last decade or so they have 
been shown to display a wide range o f medicinal properties. This, combined with the ease with 
which chalcones can be synthesised in large numbers, makes them a very useful target for 
pharmaceutical study.
O R’
Norathyriol
OH 0
A r  ^  ''ArJ ^
R
Chalcone
Figure 2.1 -  Norathyriol and chalcone structures.
Drugs such as norathyriol {Figure 2.1) which can block the release of hormones from mast 
cells are effective against various inflammatory diseases including asthma, rhinoconjunctivitis 
and urticaria.40 Hsieh et al. published work on the anti inflammatory effects of chalcones in 
1998.41 A series of chalcones were synthesised by Claisen-Schmidt condensation of 
appropriate acetophenones with aryl aldehydes {Scheme 2.1) and their anti inflammatory 
activity was tested in vitro and in vivo. Many were found to be active and evidence was given 
suggesting that the activity o f these chalcones, like that of norathyriol, was due to suppression 
o f the release of chemical mediators from mast cells.
R
Barium Hydroxide 
Octahydrate
Scheme 2.1 -  Chalcone synthesis.
The use of chalcones as anti-malarials to target malarial cysteine protease was investigated by 
Li and co-workers in 1995.42 The enzyme is believed to be crucial in the degradation of 
haemoglobin43 and compounds which block it have proven effective against Chloroquine- 
resistant strains of malaria.44 Modifications to a lead, which was designed computationally to 
block malarial cysteine protease and not mammalian cysteine protease, led the authors to 
investigate the use o f chalcones for this purpose. SAR studies on a series o f chalcones led to a 
few active compounds, the most potent of which was 16 {Scheme 2.2). In this report there was
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strong evidence that they were effective against Chloroquine-resistant strains, suggesting that 
they act through malarial cysteine protease inhibition.
O
Ar’^ ^ A r 2
Lead designed by DOCK
16 =
Cl
Scheme 2.2 -  Anti-malarial chalcones.
Kromann and co-workers recently published a study on the synthesis o f a series of anti­
bacterial chalcones and compared their activity with that of 17, which was derived from the 
known anti-bacterial chalcone Licochalcone A {Figure 2 .2 )45
OHHO HO
17
Licochalcone A
Figure 2.2 -  Anti-bacterial chalcones.
They synthesised the chalcones in the usual manner -  condensation of the appropriate aryl 
aldehyde and acetophenone in the presence of NaOH in ethanol.
The aim o f the study was to increase the acidity o f the hydroxyl group on the A ring, making 
the molecule more hydrophilic and improving bioavailability. Their first approach was to 
substitute electron-withdrawing fluorine groups on the A ring to make the phenol more acidic. 
In compounds 18 and 19 this was done {Figure 2.3) and, while it was found that it did increase 
acidity, at the same time it was also found to reduce biological activity.
Their second approach, which was much more successful, was to replace the hydroxyl group 
with a carboxylic acid. This resulted in compounds such as 20 and 21 which were almost as 
potent as Licochalcone A and 17, and at the same time had much improved hydrophilicity.
23
Chapter 2 Non Fluorinated Chalcones
19
HOOC HOOC
20
Figure 2.3 Anti-bacterial chalcones.
Investigation into the substitutions on the B ring led to the most active compound 21.
This was then tested further to assess the kinetics o f bacterial killing. Surprisingly, it was found 
to have a different mode o f action to Licochalcone A; this compound was bacteriostatic and 
while it inhibited bacterial growth, it did not actually kill the bacteria in the same way that 
Licochalcone A and 17 did. This can be an advantage in anti-bacterial drugs, as bacteriostatic 
compounds are usually less toxic to humans than bactereocidal drugs.
The use of chalcones as anticancer agents is another relatively new field, in the late 1980’s and 
early 1990’s a number o f publications brought to light the antimitotic properties of chalcones 
and similar compounds. Sukumaran et al. isolated dihydrochalcone in 1991 from a fern called 
Pityrogramma calomelanos and found that it showed some cytotoxicity.46
O 0 0
CurcuminDihydrochalcone
Figure 2.4 -  Dihydrochalcone and related structure curcumin.
This was expanded upon in 1995 when they made a range of synthetic chalcones and 
structurally related compounds47 and carried out a simple SAR study on the effects of having 
Cl, OMe, NO2, OH and CH3 substituents in different positions on the rings. A comparison of 
the cytotoxicities of around 34 compounds led to the general conclusion that the addition of Cl, 
OMe and NO2 to the aryl rings reduced activity, whereas the presence of OH and CH3 
improved in vitro activity. However in the case o f the methyl substituted chalcones, activity in 
vivo was reduced. The only explanation given in the paper for the actual mechanism of the 
chalcones’ cytotoxicity was an observation that they are structurally similar to curcumin,48 a
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known antioxidant and chemopreventative compound found in tumeric which acts by 
scavenging superoxide radicals.
Other papers at around the same time, however, described studies of synthetic chalcones which 
resemble such known tubulin inhibitors as combretastatin A-4, colchicine and 
podophyllotoxin, with the intention of designing molecules specifically to block the colchicine- 
binding site of tubulin.
number o f a-methyl and a-hydrogen chalcones, they discovered the drug MDL 27048. This 
was shown in a number o f follow-up publications to bind to tubulin, with strong evidence that
any of these papers, however, for the fact that both the cytotoxicities and tubulin bindings were 
much greater with a methyl group in place o f a proton on the a-carbon.
The discovery was made within our own group that the a,p~unsaturated ketone (E)-1-(4’- 
hydroxyphenyl)but-l-en-3-one (22), which was isolated from the plant Scutellaria barbata, 
had some antimitotic activity against human leukaemia cells. The IC50 value, which gives the 
concentration o f a compound needed to reduce cell growth by 50% in a certain cell line (in this 
case human leukaemia cell K562), was 60 pM 53 and this led to an investigation into chalcones.
0
Combretastatin A-4 Colchicine P Podophyllotoxin
MDL-27048
Figure 2.5 Known tubulin inhibitors.
In 1987 Edwards et al. made the first mention of this.49 After looking at the cytotoxicities of a
the methoxy-substituted A ring fits into the colchicine-binding site,50,51 it was also speculated 
that the B ring amine group interacted with a sulfhydryl residue. No explanation was given in
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Of numerous simple chalcones screened, the most active was found to be 23 {Figure 2.6). It 
was also found that the activity o f pure {E)-\somer was a great deal higher than a mixture of 
(E)- and (Z)-isomers.54
Further investigation into these chalcones revealed that activity was much improved by 
inclusion of a methyl group at the a-position, which is consistent with the potency o f MDL 
27048 above, this discovery lead to the synthesis o f 24 with an IC50 of 0.21 nM.
Figure 2.6 -  Chalcones designed to bind to tubulin.
X-ray crystallography studies of chalcones with the C-2 methyl group showed that they adopt 
an s-trans conformation, i.e. the C=C and C =0 double bonds are arranged trans across the C-C 
single bond, which due to the conjugated nature o f the chalcone molecule has some double 
bond character {Figure 2 .7), whereas less active derivatives with only a proton at that position 
are shown to be in an s-cis form. This can be explained by steric factors; chalcones are usually 
more stable in the s-c/s form but in the case of alpha methyl chalcones such as 24 are forced 
into the s-trans conformation by the relatively bulky methyl group. It would appear that the 
antimitotic properties o f these compounds are improved by this structural change and would be 
reasonable to conclude that s-trans chalcones are better able to fit into the colchicine binding 
site of tubulin.
Figure 2.7 -  s-cis/s-trans isomerism.
While there is a great deal of evidence for some chalcones binding to tubulin and inhibiting its 
polymerisation, not all anticancer chalcones share this mode of action. There are many papers 
which describe cytotoxic chalcones that show no evidence of tubulin binding.
O
O O
s -c is .
s -tra n s
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Chalcones such as 25 and 26 have been found to have IC50 values in the sub micromolar range 
(figure 2 .8 )55 In the case o f 25, tests into the source of this cytotoxicity revealed that it blocks
its polymerisation and preventing the formation o f microtubules, which play a vital role in the 
formation of the mitotic spindle. At the same time, however, other chalcones with very similar 
structures such as 26, which is similarly cytotoxic, do not show the same evidence of tubulin 
binding. Their activity was accredited to the alkylation of the compounds via a biological 
Michael addition, which has already been seen to infer anticancer properties on (£)-l-arylbut- 
l-en-3-ones o f the type 27.56
Figure 2 .8 -  Anticancer chalcones.
Aryl quinolones, of the type 28 and 29 (Figure 2.9), which share many structural features with
Figure 2.9 -  Anticancer quinolones and chalcones.
Comparisons with the other members o f the same series led the authors to conclude that the 
presence o f both the methylenedioxy group at the 4 ’, 5’ position and the methoxy at the 3- 
position were needed for high cytotoxicity.
In an effort to understand the mode of action o f these chalcones they converted 30 into the 
corresponding epoxide 31, destroying the double bond character of the a ,p  unsaturated ketone 
moiety (Scheme 2.3). They also did this with some o f the other T  -amino chalcones and in all
cells in the G2/M phase of mitosis,55 consistent with the molecule binding to tubulin, blocking
O O
27
O
chalcones, show some cytotoxicity.57 Lee et al. have also made a series of 2’-aminochalcones 
and analysed their anticancer properties,58 since the 2’-aminochalcones are similar to aryl 
quinolones but with the B ring uncyclised.
It was found that they, too, showed some activity, the most potent of them being 30.
28 29 30
27
Chapter 2 Non Fluorinated Chalcones
cases found that doing so rendered the compounds inactive (cytotoxicities in most cases were 
roughly 10 fold less for the chalcones than epoxides). They concluded from this that the double 
bond is an essential feature responsible for anticancer activity in chalcones and as a result 
postulated that their mode of action was an alkylation process involving cellular thiols such as 
glutathione.
0
H20 2 / NaOH
NH
31
Scheme 2.3 Chalcone epoxidation.
This is not conclusive, however, as the epoxides would also be electrophilic and may also be 
able to undergo the same alkylation process. None of these chalcones were tested for tubulin 
binding and therefore tubulin inhibition cannot be ruled out as a mode of action, it may be that 
conversion to epoxides reduces activity by altering the structure of the chalcones and hindering 
tubulin binding.
Another biological target for some chalcones is the enzyme 5-lipoxygenase (5-LO), which 
mediates the biosynthesis of leukotrienes. Inhibitors of 5-LO have antiinflammatory properties 
and have been shown to have potential as treatments for asthma, psoriasis, and dermatitis59 as 
well as being able to kill human prostate cancer cells.60 Chalcones have previously exhibited 5- 
LO inhibition61 and a more recent publication by Miyataka and co-workers looked at the 
biological effects o f a series o f fluorinated chalcones.62 They found that almost all of the 
chalcones they made had potent 5-LO inhibitory properties, although the inclusion of fluorine 
in the compounds was not seen to have any great effect on their biological activity when 
compared to the non fluorinated compounds. The same chalcones were then tested for 
cytotoxicity against a range o f cells and some were found to be active.
In particular compound 32, the most active, was screened against a HCC panel of 39 cell lines. 
The results showed that 32 had a similar overall effect on the cells to the vinca alkaloid 
vincristine, a known chemotherapy drug whose mode of action is tubulin inhibition (although 
the vinca alkaloids are active at a different tubulin binding site to that of colchicine and the 
chalcones described previously). Chalcone 32, however, was not shown to exhibit any tubulin- 
binding effects when tested.
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Vincristine
MeO
33
O COOH O COOH
Figure 2.10 -  Anticancer chalcones.
Yet another reported target for anticancer chalcones is the p53 gene. This is inactivated by 
binding to the MDM2 protein, which is over expressed in cancer cells, preventing apoptosis
ft'Xand allowing cells to divide uncontrollably. Some chalcones, such as 33 and 34, have been 
shown to bind to the MDM2/p53 complex,64 releasing p53 and allowing the cell to continue its 
normal cycle.
The chalcones 33 and 34 are not very selective, however, and kill both cancerous and normal 
cells. Kahn et al. have synthesised and tested a range of chalcones in which the carboxylic acid 
of the above chalcones was replaced by a boronic acid in the hope that they would prove more 
selective.65 They found that many o f these, 35 in particular, were up to ten times more toxic 
towards malignant cells than healthy cells.
Despite the above anomalies, it does appear from the literature that most cytotoxic chalcones 
act through tubulin binding. Tubulin itself is a heterodimer, consisting of two subunits called 
a-, and p- tubulin which link together to form the heterodimer. This dimer can couple together
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to make profilaments consisting o f alternating a  and (3 units, 12 or more profilaments can then 
further link together to make pipe-like structures called microtubules.
These structures have a + and a -  end, with tubulin dimers constantly adding to the + end and
being removed from the -  end. Microtubules play an important role in a number of
biochemical processes vital to cell life, one of these is the formation of the mitotic spindle,
without which mitosis would not be able to take place.66
The tubulin molecule has three known binding sites, which are identified by the natural 
products which are known to bind to them: Taxol® and its derivatives bind to one site and 
prevent the depolymerisation o f microtubules,67 vinca alkaloids such as vincristine bind to 
another site, and colchicine binds to the third.68
Colchicine is an alkaloid extracted from the seeds of Colchicum autumnale, the autumn crocus 
or meadow saffron. It is known to bind very strongly to the tubulin dimer, resulting in 
distortion of the secondary structure and inhibiting microtubule formation. Colchicine has been 
used as a treatment for gout for centuries, Colchicum autumnale is described in the De Materia 
Medica, a pharmacopoeia used by the Romans it the first century AD.69 It is believed that 
inhibition of microtubule formation prevents a cellular process called amoeboid motility and 
this in turn prevents leukocyte migration, which is a response to crystallisation of excess uric 
acid in the blood, believed to be the cause of gout.70 It has also been considered as a 
chemotherapy drug but has proved too toxic for clinical use. SAR studies on the molecule in 
the hope that will lead to the design of less toxic tubulin inhibitors have been abundant.71
Andreu and co-workers carried out two detailed studies on the binding of colchicine to 
tubulin.72,73 In the first they found that the B ring is not necessary for inhibition of tubulin 
polymerisation and synthesised a range of biphenyls in an effort to understand the role of the A 
and C rings. They found that those best able to bind to tubulin were compounds with a -COM e 
group in the 4’ position o f the C ring,72 such as 36.
O
Colchicine P
36
higure 2.11 Colchicine and related biphenyl 36.
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They expanded on this two years later with a similar study on the role of the A ring.73 From
this study they concluded that, while the presence of the three methoxy groups of the A ring 
improves the strength o f the drug-tubulin binding, this was not in fact because they bind to 
tubulin. They concluded instead that the role of these methoxy groups must be in maintaining 
the correct configuration o f the biaryl system by preventing movement of the molecule within 
the binding site.
Other natural products which bind to the colchicine site o f tubulin include Podophyllotoxin, 
Steganacin and Combretastatin.
Figure 2.12 -  Naturally occurring tubulin inhibitors.
Podophyllotoxin has been known as a pure compound for around 120 years, although it has 
been used in an impure form for much longer (the first recorded mention of it is in an English 
book called Leech Book o f  Bald  dating from 900-950 AD in which roots o f wild chervil and 
juniper needles, both o f which contain podophyllotoxin derivatives, are used in salves for
Podophyllotoxin is found in a number o f plant species but it is most commonly extracted from 
a resin called podophyllin which comes from the roots of American mandrake (Podophyllum
numerous studies into microtubule inhibition. It has been found to have similar tubulin
O
Colchicine P  Podophyllotoxin
Combretastatin
Tropolone methyl 
etherCombretastatin A-4 Steganacin
74xcancer ).
peltatum).75 The pure compound was first isolated in 188076 and has since been the subject of
inhibitory properties to colchicine77 and studies with radiolabeled colchicine showed that
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colchicine and podophyllotoxin compete for tubulin binding, which would suggest that they
78share the same binding site. However, it has also been shown that other molecules, such as 
tropolone methyl ether, compete with colchicine for tubilin binding but not podophyllotoxin.79 
It is believed, therefore, that the binding sites of podophyllotoxin and colchicine in fact overlap 
and that this area o f overlap is on the (3 part on the tubulin heterodimer (the colchicine binding 
site is known to be close to the a  tubulin-p tubulin link80).81
Steganacin and Combretastatin are much more recent discoveries. Steganacin and its 
derivatives are extracted from the east African tree Stegantaenia araliacea and, as with 
podophyllotoxin, it has been used in an impure form in the native medicines o f the area for a 
long time82 but was isolated as a pure compound in 197383 and was shown to display some 
antimitotic activity.
Structurally Steganacin is similar to Podophyllotoxin as well as colchicine with a three ring 
system containing one trimethoxybenzene ring and another with similar oxygenated 
substituents. It also has four chiral centres, as does podophyllotoxin.
Steganacin has been shown to be a competitive inhibitor of colchicine binding to tubulin, 
which suggests that like podophyllotoxin it shares the same binding site (or at least overlaps it), 
and is a slightly more potent inhibitor o f microtubule formation than colchicine.84 As well as 
inhibiting polymerisation, it also induces slow depolymerisation when added to microtubules 
that have formed.85
Combretastatin and its derivatives are found primarily in the bark of Combretum ca ff rum, a 
tree from south Africa and like podophyllotoxin, steganacin and colchicine have been used in 
traditional medicines before they were isolated as pure compounds.86
Again combretastatin shares structural features with colchicine (Figure 2.12) -  the 
trimethoxybenzene ring is present in both and the B ring of combretastatin resembles the C 
ring o f colchicine -  but overall it is a much simpler compound.
Combretastatin itself is an effective inhibitor o f tubulin, again binding to the colchicine binding 
site87 but some of its derivatives, in particular combretastatin A4, are even more potent; 
combretastatin A4 is one of the most powerful tubulin inhibitors known.88
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2.2.1 a-Nitrile Chalcones
Initially a series of chalcones o f the type 39 with a nitrile group at the a  position were 
synthesised and their cytotoxicities examined, these were made to probe the effects of s-cis/s- 
trans isomerism on cytotoxicity. They were made by Knoevenagel addition of a range of 
benzaldehydes to the keto nitrile 38. This nitrile 38 was made by addition of the X H 2CN 
nucleophile to ester 37, which was made by standard esterification of 3,4,5-trimethoxybenzoic 
acid.
EtOH
Cat. H2S 0 4
ArCHO
Cat.
N
H
37, 81%
NaH,
MeCN
38, 83%
39
Scheme 2.4 -  Synthesis o f  a-nitrile chalcones.
Their cytotoxicities are listed in Table 2.1. (Cytotoxicities are expressed as IC50 values, this 
gives the concentration of the compound needed to reduce cell growth by 50% in a particular 
cell culture. In the case o f all cytotoxicities measured in this project, the cell line used was
89K562, human chronic myelogenous leukemia cell line. )
Ar group substitution Compound number % Yield IC50 value (compound 
with IC50 greater than 
10 pM are considered 
inactive)
3,4-Methylenedioxy 39a 35 >10 pM
4-Methoxy 39b 76 >10 pM
3-OTBDMS-4-
methoxy
39c 40 >10 pM
3-Hydroxy-4-
methoxy
39d 60 4.2 pM
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3,4-Dimethoxy 39e 79 >10 pM
2,3,4-Trimethoxy 39f 76 >10 pM
4-T rifluoromethyl 39g 51 >10 pM
2-Fluoro-4-methoxy 39h 41 >10 pM
3-Fluoro-4-methoxy 39i 25 >10 pM
3-Bromo-4-m ethoxy 39j 52 >10 pM
Table 2.1 -  Yields and cytotoxicities o f  a-nitrile chalcones.
In the case of 39d the acidic hydroxy group was protected by conversion to the TBDMS ether 
prior to the Knoevenagel condensation (Scheme 2.5). This was done to prevent direct reaction 
between the phenol and the basic piperidine catalyst in the Knoevenagel reaction. The 
protecting group was removed afterwards using TBAF.
OH
° " O C
TBDMSCI OTBDMS
NH O
40, 69%
38
Piperidine
O
CN
OH
39d, 60%
O
TBAF
CN
OTBDMS
39c, 40%
Scheme 2.5 -  Phenol protection and deprotection.
1 ITStructures of all these chalcones were confirmed by H and C NMR and, since they are all 
novel, full characterisation is given in chapter 7. For example the NMR of 39a showed 2 
singlet methoxy peaks at 3.74 and 3.76 ppm, a singlet at 5.93 ppm corresponding to the two 
methylenedioxy protons, the protons on the B ring appeared as two doublets at 6.74 ppm (Jhh 
= 8.1 Hz) and 7.61 ppm ( J h h  = 1.5  Hz) corresponding to protons 5”  and 2”  respectively, each 
of which is coupled to proton 6”  (a double doublet at 7.27 ppm), the 2’ and 6’ A ring protons 
were a singlet at 6.99 ppm and the p proton was a singlet at 7.84.
Most of the chalcones were inactive, although the 3-hydroxy-4-methoxy analogue 39d was 
significantly more cytotoxic than the others. This is consistent with previous findings within
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the group but 39d is still roughly 104 times less active than a-methyl 24 above (IC50 = 0.21 
nM)90 which is surprising given the similarities in the structures.
Although unfortunately none of the nitrile chalcones formed suitable crystals for their structure 
to be resolved, nOe experiments on chalcone 39b revealed a 29% enhancement at proton H(3 
when irradiated at proton H2/H6 (Figure 2.13). This suggests that, like chalcone 24 this 
compound adopts the s-trans conformation. Alpha nitrile chalcones are well known in the 
literature and most are assumed to adopt this structure, although, with the exception of some 
work by Currie et al on the UV/Vis spectra of a-nitrile chalcones91 and similar compounds,92 
there is little evidence to support this.
It seems most likely, then, that the nitrile chalcones adopt the structure shown, although it 
remains unclear why they are so much less active than their methyl analogues.
O
CN
H2HP
O
s -tra n s  39b
CN
H2
s - c is  39b
Figure 2.13 -  s-cis/s-trans structures.
The nitrile group, while similar in size to the methyl group, does have very different electronic 
properties. The methyl group is weakly electron donating, whereas the nitrile is electron 
withdrawing. This may be the reason for the inactivity of the a-nitrile chalcones.
The CN group is also more polar, less hydrophobic than a methyl group and capable of acting 
as an H-bonding acceptor. It is possible, since a number of studies have shown that the 3- 
hydroxy-4-methoxy substitution pattern on the B ring seems to provide the maximum 
cytotoxicity and it is believed that this is a result of hydrogen bonding action of the phenolic 
OH group, that the nitrogen atom of the nitrile group, in this case, interferes with that process - 
either by binding intramolecularly to the OH group or intermolecularly to the biological target.
2.2.2 a-E ster Chalcones
The second series of chalcones synthesised were a-ethyl esters of the type 42. Again these 
chalcones were made by Knoevenagel condensation of aryl aldehydes with the p-keto ester 41,
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which itself was made by addition o f sodium 3,4,5-trimethoxyacetophenone enolate to diethyl 
carbonate {Scheme 2.6).
O Ar
A r ^ OOEtEtO OEt
Na
41,67%
OEt
Scheme 2.6 Synthesis o f  a-ester chalcones.
Once again these compounds were all novel and full characterisation is given in the 
experimental section. The ]H NMR of 42a showed the ethyl group as a triplet (1.24 ppm) and 
quartet (4.27 ppm) with a coupling constant of 7.1 Hz, three methoxy peaks as singlets at 3.80, 
3.86 and 3.96 ppm, the B ring protons were two doublets (Jhh = 8.9 Hz) at 6.80 {meta 
positions) and 7.34 ppm {ortho positions), the ortho protons on A ring were a singlet at 7.25 
ppm and the (3 proton a singlet at 7.94 ppm.
In this case, however, o f the 10 aldehydes used, only 5 resulted in a chalcone product. The 
chalcones which were formed were tested for biological activity, the results shown in Table 
2 . 2 .
Ar group substitution Compound number % Yield IC50 value (compound 
with IC50 greater than 
10 jliM are considered 
inactive)
4-Methoxy 42a 11 >10 pM
3-OTBDMS-4-
methoxy
42b 57 4.29 pM
3-Hydroxy-4-
methoxy
42ca 70 0.87 pM
3,4-Dimethoxy 42d 35 >10 pM
2,3,4-Trimethoxy 42e 48 >10 pM
a) As for the nitrile chalcones 42c was made by deprotection of 42b.
Table 2.2 -  Yields and cytotoxicities o f  a-ester chalcones.
The most active is, again, the 3-hydroxy-4-methoxy compound, 42c, as one would expect. 
What is unusual this time is that the second most active chalcone is 42b, the protected version
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of 42c. The unexpectedly high activity of this may be due to loss of the protecting group from 
the sample before or during the bioassay so that in fact the activity seen is that of 42c.
42c is 10 fold more active than its nitrile analogue, 39d, but still much less active that the a- 
methyl chalcone 24. In the case of 42c, crystals were grown of suitable quality for X-ray 
analysis and showed that, while the molecule does adopt the s-trans conformation, it has an E 
configured double bond. This is surprising given that the steric strain involved in this structure 
means that the molecule is twisted out of the flat geometry which normally makes chalcones so 
stable and allows them to resonate. However it is not unknown for a-ester chalcones to adopt 
this sterically hindered conformation91 and it does explain the biological inactivity which is 
observed.
C(210)
C(222)
C(213)
>C(217) C(214)C(218) C(110)
C(120J C(112)C(122)
C(118) C(117)
Figure 2.14 -  X-ray crystal structure o f 42c.
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2.3 Summary and Conclusions
The synthesis of two series of chalcones and assessment of their biological properties has been 
described. Neither a-nitrile nor a-ethyl ester chalcones have shown very promising anticancer 
activity, even when substituted with the 3-hydroxy-4-methoxy B-ring, which usually renders 
chalcones most cytotoxic.
In the case of a-ethyl ester chalcones this inactivity is easily explained as a result of their 
unusual structure. In the case of a-nitrile chalcones, it is believed to be a result of the 
electronic properties o f the nitrile group, although in the absence of X-ray data, structural 
effects cannot be ruled out.
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Chapter Three
3.1 Introduction
Despite being the most abundant halogen in the earth’s crust, fluorine is exceedingly rare in the 
field of biochemistry, only 6 unique categories of fluorinated natural products have ever been 
isolated and almost nothing is known about the biochemistry of fluorination.
The most common naturally occurring fluorinated compound is fluoroacetate (43). This is 
found in a number of plant species in small concentrations, although some have been found to 
accumulate it in sufficient quantities to make them toxic. For example, the highest known 
concentration of fluoroacetate in a plant is in Dichapetalum braunii - a shrub found in 
Tanzania whose seeds contain up to 8000 ppm fluoroacetate93 and many other toxic 
fluoroacetate accumulators have been found in Australia.94
O’Hagan et al. have recently isolated an enzyme from Streptomyces cattleya called 5’-fluoro- 
5’-deoxyadenosine synthase which was shown by crystallographic analysis to synthesise 
fluoroacetate. The reaction seems to involve attack by a fluoride anion at the 5’ position of S- 
adenosyl-L-methionine (SAM), releasing L-methionine and forming 5’-fluoro-5’- 
deoxyfluoroadenosine, which is then converted to fluoroacetate by an as yet unknown 
mechanism {Scheme 3.1 )95
Scheme 3.1 - Biosynthesis o f  fluoroacetate.
Animal species in areas where such plants are common tend to show unusually high tolerance 
for fluoroacetate, particularly herbivores; in fact the caterpillar Sindrus albimaculatus, which 
feeds on a fluoroacetate-containing plant called Dichapetalum cymosum, stores up the
OH OH 43
O
OH OH
SAM + Methionine
fluoroacetate and uses it as a defence mechanism.96 Enzymes involved in the metabolism of
97fluoroacetate have been isolated from bacteria such as Moraxella sp and are believed to act as 
shown in Scheme 3.2.
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105
105 A s p  ^
O
+
o
43
O
Scheme 3.2 Metabolism o f  fluoroacetate.
Aspartate-105 acts as nucleophile, displacing fluoride in a Sn2 process to leave an ester, then 
histidine-272 deprotonates a water molecule and the resulting hydroxide anion hydrolyses the 
ester releasing glycolate.
The reason fluoroacetate is normally toxic is that it is converted in vivo to (2/?,3/?)-fluorocitrate 
(44) by substituting for acetate in the Krebs cycle. Unfortunately, of the four isomers of 
fluorocitrate, the only one produced in this process is (2/^,3/^)-fluorocitrate which is also the
98only one which is toxic (Figure 3.1). Its toxicity is believed to be due to its inhibition of 
aconitase and other enzymes involved in the transport and metabolism of citrate."
In fluoroacetate-accumulating plants, however, fluoroacetate is metabolised differently, it is 
either anabolised into long chain co-fluoro fatty acids100 such as co-fluorooleic acid, 45 or 
catabolised into volatile organics. Although little is known about the latter process, 
fluoroacetate in this case is believed to leave the plant as either fluoroacetone or 
fluoroacetaldehyde.101
HO, .COOH 
HOOC^X^COOH F COOH
F
44
45
NH2
46
Figure 3.1 Fluorinated natural products.
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Possibly the most interesting biological organofluorine compound is nucleocidin 46, a natural 
product isolated from Streptomyces calvus, which was found in an Indian soil sample. This has 
some antibiotic activity but has proven too toxic for clinical use. Surprisingly, it contains a 
fluorine atom on the ribose ring in a position which suggests that it did not come from 
fluoroacetate. Unfortunately, however, recent attempts to isolate more of the compound from 
freeze-dried samples of the bacteria have failed and so further investigation into the
103biosynthesis of this compound has been delayed until more of the bacteria can be collected.
Despite being so rare in nature, fluorinated molecules often have very useful biological 
properties and have recently received a great deal of attention as drug candidates. The fluorine 
atom has a Van der Waals radius of 1.47 A, which is in between that of hydrogen ( 1.20 A) and 
oxygen (1.52 A ).104 This, along with it’s high eletronegativity (4.0) makes fluorine a useful 
mimic for a number o f organic functional groups such as = 0 , -H and -OH.
Element (X) Van der Waals 
radius (A)
CH2-X Bond 
length (A)
CH2-X Bond
energy
(kcal/mol)
Electro­
negativity
H 1.20 1.09 99 2.1
0 1.52 1.43 85 3.5
F 1.47 1.39 116 4.0
Table 3.1 Relative properties o f  fluorine, hydrogen and oxygen.
Replacement of hydrogen with fluorine results in only minor steric changes105 but does have a 
significant effect on the electronic properties of the molecule, changing pA^ a, dipole moments 
and stability of neighbouring groups. Since the C-F bond is so much stronger that the C-H 
bond, it is much more resistant to attack by cytochrome P450 and hence this substitution is 
often used to improve the biological half-life of drug candidates.106
Fluorine is also often used to replace the hydroxyl group, as it is believed to be able to act as a
107hydrogen bond acceptor. Although this has been disputed; the F...H  bond is significantly 
weaker than the O ...H  (2.38 kcal/mol and 5 kcal/mol respectively).
In addition to a single fluorine atom being used in drug candidates, small fluorinated groups 
can also act as isosteres for existing groups; 2 ,6-difluorophenol group has been used to replace 
carboxylic acid groups,108 CF2 has been used to replace CH2105 as well as O in phosphate 
esters109 and the CF2H group has replaced OH as a H-bond donor.110 The highly lipophilic CF3 
group is also frequently used in drug candidates as a mimic for isopropyl groups,111 as well as 
*butyl and phenyl groups.112
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When fluorine is introduced into drug candidates it alters the steric, electronic and lipophilic 
properties of the molecule and in many cases has been shown to improve biological activity as 
well as metabolic properties.113 There are numerous fluorinated drugs currently on the market 
or in development for treatment of a wide range of conditions.114
Roflumilast (47) is a fluorinated derivative of Piclamilast which inhibits phosphodiesterase 
enzyme 4 (PDE4) and is currently in clinical trials as a treatment for asthma (Figure 3.2).115 
The related amide 48 has similar anti-inflammatory properties and in particular shows 
selectivity towards certain subtypes of PDE4.
47 48
Figure 3.2 Fluorinated anti-inflammatory drugs.
Fluorinated drugs have found use in treatment of heart disease, with Cerivastatin (49) and 
Rosuvastatin (50) being found to reduce low-density lipoprotein cholesterol (LDL-C) levels in 
hypercholesterolaemic patients’ blood (Figure 3.3). Although 49 has been withdrawn as a drug 
due to adverse side effects on muscle.116
Ezetimibe (51) works by inhibiting cholesterol excretion from the gall bladder117 and BMS 
201038 (52) inhibits Microsomal triglyceride transfer protein (MTP), which is used in the 
transport of cholesterol.118
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OH OH O
49
OH OH O
N N
0 = S = 0
HN
52
53
Figure 3.3 -  Fluorinated drugs.
Prozac (Fluoxetine, 53) is a selective serotonin reuptake inhibitor which lowers the level of the 
neurotransmitter serotonin in the brain, improving mood and is a popular treatment for 
depression, obsessive-compulsive disorder and severe shyness.119
A few efforts have been made to design fluorinated anti-malarials to replace drugs such as 
Primaquine (54) and Pyronaridine (55) which are encountering increasing resistance. 
Compound 56 is a fluorinated derivative of Primaquine, in which a fluorine atom was 
incorporated in an attempt to hinder in vivo conversion into more toxic metabolites.120 
Pyronaridine analogues 57 and 58 have both shown promising antimalarial activity, in fact 57 
is more active than 55 but also more toxic, whereas 58 has more tolerable toxicity but reduced
activity {Figure 3.4). 121
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Other examples of fluorinated anti malarials include 59 which is novel and unrelated to any 
existing drugs and should prove very useful in combating drug-resistant malaria strains.122
OH
54
55
OH
N
NH
58
N
59
Figure 3.4 Fluorinated drugs.
Fluorine has also found much use in anticancer drugs. Iressa (60) is a tyrosine kinase inhibitor 
which blocks signal pathways key to the mitosis of cancer cells.123 Derivatives of this such as 
61 and, in particular 62, have been rationally designed to improve physical properties.124 In all 
these cases the biological half-life of the drug is improved by the presence of the fluorine
hindering metabolism. 125
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Cl Cl
O v  N
CN
rr'-c ..J
62
Figure 3.5 Fluorinated anticancer drugs.
Benzothiazoles such as 63 (Figure 3.6) are another class of anticancer agents designed to 
inhibit tyrosine kinases. These display an unusual dose-response relationship in certain cell 
lines; at low (nanomolar) concentrations they are cytotoxic but at micromolar concentrations
metabolism of the drugs by sensitive cells resulting in a 6-hydroxylated metabolite 64 which 
encourages cell growth.
In an attempt to block this metabolism, Hutchinson et al. synthesised a series of fluorinated 
analogues and their activities and metabolic profiles were analysed. They found that 
compounds with a fluorine at the 5 position and a halogen or methyl group at the 3’ position 
were the most cytotoxic of the fluorinated benzothiazoles and also that the presence of a 5- 
fluoro group blocked the oxidative metabolism at the 6 position,127 this enabled them to 
confirm earlier suspicions that this metabolism was responsible for the deactivation of the non- 
fluorinated compounds. The most active and metabolically stable candidate was found to be
they cause what is called a second growth phase (SGP).126 This has been attributed to the
65
63 64, 6-hydroxy metabolite of 63.
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66
Figure 3.6 Anticancer benzothiazoles.
Another target for anticancer study is the enzyme Topoisomerase I, against which fluorinated 
Camptothesin analogue 66 has been shown to display high activity. 128
A less conventional treatment o f cancer, called photodynamic therapy (PDT), involves the use 
of a mixture o f porphyrins known as hematoporphyrin derivatives (HpD). This mixture, 
consisting of protoporphyrin (67), Hematoporphyrin (68) and 3-vinyl-8-(l-hydroxyethyl)- 
deuteroporphyrin (69) as well as a number of other minor components (Figure 3 .7), can bind in 
vivo to tumour cells and, when irradiated, fluoresces red enabling detection of cancer at an 
early stage.129 HpD also contains some porphyrins which generate active oxygen species such 
as peroxide, superoxide and hydroxyl radical when photosensitised.130 These highly reactive 
species can oxidise and kill cancerous cells and thus be used in treatment as well as detection
c  131of cancer.
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NH
HOOC COOH HOOC
HO
NH N OH NH N ^ OH
COOH HOOC COOH
67 68 69
NaOOC COONa
CF
NH N ^ CF
NaOOC COONa
70 71
OH
OH
NH N ^ CF
NaOOC COONa
72
Figure 3.7 -  HpD andfluor inated porphyrins.
The problem with HpD itself is that it is a mixture and is light-sensitive. The search for 
alternative PDT drugs has led to the investigation o f fluorinated porphyrins.
Replacement of the vinyl groups o f 67 with difluorovinyl groups led to synthesis of 70 and 71 
which were shown to selectively bind to specific types of cancer cells -  70 was localised to 
gastric cancer cells, whereas 71 to rat ascite hepatoma cells. Derivatives of 68 such as 72 were
132found to be taken up effectively by human liver cancer cells.
The discovery was made by Yamazaki and co-workers that the asymmetric hydrolysis of 
certain esters by cancer cells resulted in a slightly different enantiomeric ratio in the products
133compared to the same esters hydrolysed by normal cells. This was attributed to different 
combinations of esterases in cancer/normal cells, some of which are selective towards S  
enantiomers and others towards R  enantiomers so that a racemic mixture of a chiral ester may 
be hydrolysed to give a different enantiomeric excess by one cell compared to another. In 
theory there could even be a reversal o f chirality between cancer cells and healthy cells. They
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found that with the fluorinated ester 73 there was a particularly large change in e.e. of acid 
product (% e.e. differing by 6.8) in different types of healthy brain/brain tumor cells.134
COOEt
0
73
Figure 3.8 Fluorinated ester.
This led them to further investigate the effect with the intention of designing a fluorinated ester 
prodrug which would be hydrolysed in cancer cells to give the active enantiomer of a 
chemotherapy drug but at the same time hydrolysed in normal cells to give an inactive
enantiomer. They found that in the case o f 74 not only did the e.e. vary depending on the
11 <
particular cell used to hydrolyse the ester, but in some cases it was reversed (Scheme 3.3).
COOH
S-75
COOH+
R-75
COOEt
74
Cell type Configuration of 
75, (% yield)
Enantiomeric 
excess (%)
Anr4 (cancer) 5,(18) 69.3
Anri 3-1 (cancer) 5 ,(9 ) 64.8
H4-II-E (cancer) 5 ,(9 ) 33.1
McA-RH7777
(cancer)
R, (40) 54.8
Liver (healthy) R, (26) 34.3
Scheme 3.3 Stereospecific enzymatic hydrolysis o f  esters in different cells.
As mentioned in chapter two , 2-phenyl-4-quinolones show reasonable cytotoxicity and tubulin
inhibition. SAR studies by Lee and co workers led to the discovery o f the fluorinated
1 ^ 6compound 76, which demonstrated good in vivo as well as in vitro activity. Further studies 
into the effects of the ketone and amine groups in the molecule on its activity showed that
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conversion of the ketone into an enol ether (as in 77) destroyed the cytotoxicity of the molecule 
as well as its ability to inhibit tubulin, as did replacement of the ketone with a thioketone (as in 
78).137 Replacement of the amino hydrogen with a BOC group (79) overall reduced the tubulin 
inhibition, although 79 was more potent than 76 against some sensitive cancer cells, possibly 
due to conversion into a more cytotoxic metabolite. They found the most potent of the 2- 
phenyl-4-quinolones to be fluorinated 80.
COOEt
76 77
80
78 79
Figure 3.9 -  Fluorinated anticancer quinolones.
In addition to the beneficial medicinal properties incorporation o f 19F can impart, the isotope 
18F can be used in positron emission tomography (PET). This enables the drug to be followed 
through absorption, metabolism and excretion within the body and can offer a wealth of real 
time data on the in vivo life of the drug.138 Although this tool is limited by the short half-life 
(/1/2 = 109.6 mins) o f lgF which makes synthesis of drugs containing 18F very difficult,139 
nevertheless there are some reagents available that can deliver both nucleophilic 18F synthons 
(such as Bu4N 18F, K 18F, Cs18F, Br18F and I18F) and electrophilic synthons (such as 18F2 and 
CH 3C0018F).140 These enable 18F to be incorporated into some drug molecules, in particular
18F substitution in steroids such as estradiol leads to 81 {Figure 3.10), which is a very useful
tool in imaging o f breast cancers. 141
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OH OH
HO HO
81a 81b
Figure 3.10 Fluorinated estradiol.
3.2.1 a-Fluoro Chalcones
Following the investigation into a-nitrile and a-ester chalcones, including some with 2-fluoro- 
4-methoxy, 3-fluoro-4-methoxy and 4-trifluoromethyl B rings, a series of chalcones with a 
fluorine atom in the alpha position were made with the intention of investigating the effects of 
this substitution on both the biological activity and the structure of the chalcones. In particular 
the effect of the alpha fluorine atom on the s-cis / s-trans conformation was of interest.
Synthesis of these chalcones (83) proved to be more problematic than was first expected. The 
intention was, again, to synthesise the ketone (82) and add the aryl aldehydes via the same 
Knoevenagel reaction as had been used in chapter two {Scheme 3.4).
H
8382 H
Scheme 3.4 -  Knoevenagel synthesis o f  a-fluoro chalcones.
Initially the synthesis of 82 from (3-ketoester 41 (which was used in chapter 2.2.2 to make the 
ester chalcones) was attempted using the Selectfluor™ reagent 84142, as shown in Scheme 3.5.
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COOEtCOOEt
NaOH
COOH
Scheme 3.5 -  Synthesis o f  82 via electrophilic fluorination o f  41.
In this attempt, however, the fluorination step proved inefficient and resulted in a mixture of 
mono and di-fluorinated products as well as unreacted starting material. This has been seen 
before when fluorinating this type of compound using Selectfluor™ 143
So the silyl enol ether 86 was made by generation o f the enolate of ketone 85 and protection 
with TMS chloride (38%), this is a much more nucleophilic species than the ester 41 and, 
under mild conditions, is only able to react with one equivalent of F+. Reaction with 
Selectfluor was carried out according to Scheme 3.6.
2 BR
84, 60%1) LDA
2) TMSCI
85 86, 38% 82
Scheme 3.6 -  Synthesis o f  82 via electrophilic fluorination o f  silyl enol ether 86.
This time the fluorination step was successful, although the yield of 82 was moderate (60%). 
However, the product had a very similar retention time on a column to the ketone 85, which 
was formed in the work up by hydrolysis of 86 so that less than 10% yield of the product 
overall was isolated as pure material.
51
Chapter 3 Fluorinated Chalcones
So a third method was employed involving the oxidative bromination of ketone 85 using 
bromine in acetic acid, followed by fluorination of the resulting bromoketone 87 with 
potassium fluoride in the presence of 18-crown-6 catalyst (Scheme 3.7):
spectrum showed that the molecule contained two methoxy peaks at 3.84 and 3.85 ppm, the 
two a  protons were a doublet ( J h f  = 47 Hz) at 5.49 ppm and the aryl protons, a singlet at 7.07 
ppm. High resolution mass spectrometry showed a [M+H]+ molecular ion at 229.0874, within 
acceptable limits of the structure shown.
The a-fluorochalcones 83 were then made via Knoevenagel condensation with the 
benzaldehydes (Scheme 3.4). The yields, cytotoxicities and, for the most cytotoxic chalcones, 
tubulin inhibition assays are shown in Table 3.2. Cytotoxicities are expressed as IC50 values, as 
described in chapter two, as are tubulin inhibition values.
The tubulin inhibition assay is the easiest way to see the effects of a compound on the 
polymerisation of tubulin in vitro. Tubulin, if  it is over a critical concentration and the 
temperature is >30 °C, polymerises in the presence o f GTP and Mg2+. The tubulin assay used 
here involves warming a mixture of tubulin, GTP and the test compound from 0 °C to 37 °C. 
Formation o f the microtubules, which result from tubulin polymerisation, causes the solution to 
become turbid and increases the optical density, which is proportional to the concentration of 
microtubules present in the solution and can be measured. By plotting the concentration of the 
test compound against the degree of inhibition o f tubulin assembly, therefore, a value for the 
concentration needed to inhibit polymerisation by 50% (i.e. a value of IC50) can be 
calculated.144
Where IC50 > 1 0  j liM , the compound is considered inactive.
O O O
Br2 + AcOH
+ 18-crown-6
85 87, 43% 82, 94%
Scheme 3.7 -  Synthesis o f  82 via bromination o f  85.
This time the fluoroketone 82 was made in good yield (41% overall). Analysis of the *H NMR
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Ar group 
substitution
Compound
number
Yield (%) Cytotoxicity
IC50
Tubulin
inhibition
ICso
3,4-Methylenedioxy 83a 84 0.8 pM N/A
4-Methoxy 83b 68 0.39 pM 4.6 pM
3-Hydroxy-4-
methoxy
83c 75 13.7 nM 0.6 pM
3,4-Dimethoxy 83d 23 1.21 pM N/A
2,3,4-Trimethoxy 83e 86 >10 pM N/A
2-Fluoro-4-methoxy 83f 74 1.19 pM N/A
3-Fluoro-4-methoxy 83g 28 0.77 pM N/A
3-Bromo-4-methoxy 83 h 18 6.0 pM N/A
Table 3.2 Yields, cytotoxicities and tubulin inhibition assays for a-fluoro chalcones.
Proton NMR analysis of all these chalcones showed a coupling constant Jh-f of between 36 and 
43 Hz for the vinyl proton H(3, corresponding to the trans configuration shown (cis F-H 
coupling constants are <20 Hz).145 Full structural confirmation is given in the case of the a- 
fluorochalcone 83c, for which X-ray crystal analysis showed the molecule adopting the s-trans 
conformation (Figure 3.11). This is surprising because the s-trans conformation in a chalcone 
is believed to be a result of steric strain between the alpha group and the A ring and therefore 
indicative of a bulky alpha group. It would seem that much less steric strain is needed for the 
molecule to adopt the s-trans conformation than one might expect.
0 (4 )
F(1)
C(10)
C(3)
C(8) C<11)
kO(5)0(3] C(9) C(18)
C(17)C(4)
C(6)
C(16)C(5)
0 (6)C(14)
C(15)0 (2)
C(19)C(D
Figure 3.11 -  X-ray crystal structure of 83c
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It has been shown previously within our own group that the potency of chalcones is improved 
when they are forced to adopt the s-trans conformation, as this structure more closely 
resembles that of combretastatin A4 and is better able to fit the colchicine-binding site of the 
tubulin dim er.54 This can be seen in the crystal structures shown in Figure 3.12, in which the 
steric bulk of the a-methyl group forces the molecule into the s-trans conformation whereas 
with only a proton in that position the molecule is more stable in the much less active s-cis 
conformation.
/ O
s -cis, IC50 = 4.3 nM s -trans, IC50 = 0.21 nM
Figure 3.12 -  s-cis/s-trans isomerism.
This time a dramatic improvement in the biological activities of the chalcones was seen over 
the a-nitrile and a-ester analogues, most of these a-fluoro chalcones had sub-micromolar 
cytotoxicities and in particular the 3-hydroxy-4-methoxy compound 83c was extremely active 
with an IC50 of 13 nM. Further tests on this compound revealed that it was a potent inhibitor of 
tubulin polymerisation (tululin inhibition IC50 = 0.6 pM), which suggests, as expected, that its 
mode of action is blocking of the colchicine binding site on tubulin.
The next most active chalcone was the 4-methoxy compound, 83b, which lacks the hydroxy 
group in the 3 position. This is in the region of 100 fold less cytotoxic and 10 fold less potent 
an inhibitor of tubulin polymerisation than 83c, which suggests that the 3-hydroxy group plays 
a vital role in binding to the tubulin molecule. This is consistent with what is already known 
about chalcones.54
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The 3-fluoro-4-methoxy derivative, 83g, had roughly the same cytotoxicity as 83b, despite the 
presence of the fluorine in the same position as the hydroxy group of 83c. Clearly the fluorine 
in this case does not substitute for the OH group and if indeed the unusually high activity of 
83c is due to hydrogen bonding interactions within the colchicine binding site o f tubulin, then 
the fluorine atom of 83g is unable to undergo the same interactions.
In the same way the 3-bromo-4-methoxy chalcone, 83h, was much less cytotoxic - 10 times 
less active than 83g - as would be expected.
The 3,4-dimethoxy compound 83d had around the same cytotoxicity as 83b and 83g which 
suggests that the methoxy group on the 3 position was also unable to interact in the same way 
as the hydroxy group in that position but at the same time it was not enough of a steric 
hindrance to reduce the activity. The same can be said for the 2-fluoro-4-methoxy and 3,4- 
methylenedioxy B rings, 83f and 83a. In the case of the 2,3,4-trimethoxy chalcone 83e, 
however, there must be a steric hindrance to tubulin binding because this was the only 
compound in this series to have a cytotoxicity greater than 10 pM. Likewise the inactivity of 
83h is probably due to steric factors.
3.2.2 a-Trifluoromethyl Chalcones
The next series of chalcones to be examined were those with a CF3 group in the alpha position 
88. Synthesis of this series proved less straightforward than that of previous chalcones. In order 
to make them by the Knoevenagel reaction that had been used before, the following ketone 89 
would have to be made {Scheme 3.8).
[CF3] A r ^ O
89 88
Scheme 3.8 -  Knoevenagel synthesis o f  a-trifluoromethyl chalcones.
This would require a CF3+ synthon, all sources of which are unstable and expensive (as 
discussed in chapter one).
Another option was to add the trifluoromethyl group to the a-bromochalcones 90 via a Pd 
catalysed coupling reaction {Scheme 3.9). There is some precedent in the literature for this146
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but the reagent used (methyl difluorofluorosulfonylacetate acid) is very expensive and has to 
be used in excess.
O c 0
F .s
0
Pd(pph3)4
90 88
Scheme 3.9 Synthesis o f  a-trifluoromethyl chalcones via Pd cross-coupling.
This highlights the problems associated with incorporation of a trifluoromethyl group into an 
organic molecule, as seen in chapter one.
The method eventually employed in the synthesis of 88 was via the diketone 94. This was 
made from the dimethylhydrazone 92 of 3,4,5-trimethoxybenzaldehyde, by reaction with 
trifluoroacetic anhydride followed by hydrolysis, according to the method developed by 
Kamitori et al. {Scheme 3.10).U1
/
h 2n - n
\
92, 98%
N.
TFAA
93, 80%
H2S 0 4
OK
CF
OMe
94a
MeOH
94, 77%
Scheme 3.10 - Synthesis o f  diketone 94.
Recrystalisation of 94 from MeOH resulted in the hemiacetal 94a. However when left in an 
open container for 2-3 days at room temperature the compound turned back into pure keto-
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form of 94. The *H NMR spectrum of 94 showed two methoxy peaks at 3.84 and 3.92 ppm 
and the 2 and 6 aromatic protons as a singlet at 7.57 ppm. The 19F NMR spectrum showed the 
CF3 group as a singlet at -81.0 ppm.
Aldehydes were converted to phosphonium salts 97a-h via alcohols 95a-h and chlorides 96a-h 
(with the exceptions of the 4-methoxy and 4-trifluoromethyl compounds where the chlorides 
were purchased directly) according to Scheme 3.11. All these reactions gave quantitative yields 
and the known alcohols and chlorides were identified by NMR spectroscopy and used in 
subsequent reactions without further purification.
Ketone 94 was used in Wittig reactions with the appropriate phosphonium salt 97 to make the 
chalcones 88. It was found that the conventional Wittig reaction using NaOMe as base in 
MeOH gave very low yields (5%-10 %) in this case so the reaction was carried out in THF 
using lithium hexamethyldisilazane base according to the method developed by 
Katzenellenbogen et a /,148 this resulted in much more satisfactory yields (Table 3.3).
p p h 3 + Cl
A T X I  ------------ ► A r " " p p h3
96 97, quantitative
yield.
LiHMDS
CF
CF:
88
Scheme 3.11 -  Wittig reaction between 94 and phosphonium salts 97.
Because there were two carbonyl groups in the diketone 94 it was possible that the Wittig 
reaction had taken place on the other carbonyl group to that which was intended and formed 
compound 98 (Scheme 3.12), although this was thought to be unlikely because of the 
activating, electron-withdrawing effects that the trifluoromethyl group would have on the alpha 
carbonyl.
Ar/ ^ 0  NaBH< -  A r ^ O H  —
95
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H[k . Ar
LHMDS
Ar PPh3
94
A r\^ P P h 3 
LHMDS
O Hp
88
Scheme 3.12 Alternative Wittig products.
The Wittig reactions all resulted in pure compounds, as seen in the ]H and 13C NMR spectra so 
there is no doubt that only one of these isomers was made in the reactions. The proton NMR 
data of the chalcones 88 were compared with that o f known compound 99.149
CL
H2'
OMe
H6'
,0
99
Figure 3.13 -  Known unsaturated ester.
In the 'h  NMR spectrum of 99 protons H2’ and H6’ are reported to form a singlet peak at 6.44 
ppm, whereas in the chalcones described here the ortho proton peak comes at roughly 7.0-7.2 
ppm (see chapter 8). This is consistent with these protons being in conjugation with the 
electron withdrawing carbonyl group in the chalcones 88 and hence shifted downfield. In 
addition, the nOe data discussed below revealed no enhancement at HP when irradiated at 
H2’/H6’, suggesting that these protons were not spatially close as they would be in Z-98. Since 
if 98 were formed it is unlikely, from both a steric and electronic point of view, that it would 
form E  isomer, this is further evidence that the structure 88 is correct.
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The Wittig reaction was successful with all the aryl groups with the exception of the 3-fluoro- 
4-methoxy and 3-bromo-4-methoxy ylids. Those chalcones which were isolated were tested for 
cytotoxicity and tubulin binding and the results summerised in Table 3.3, once again 
cytotoxicity and tubulin inhibition are expressed as I C 5 0  values.
Ar group substitution Compound
number
Yield
(%)
Cytotoxicity IC50 Tubulin 
inhibition IC50
3,4-Methylenedioxy 88a 58 0.44 pM 3.2 pM
4-Methoxy 88b 64 84.6 nM 3.7 pM
3-OTBDMS-4-
methoxy
88c 49 >10 pM N/A
3-Hydroxy-4-methoxy 88d 86 79.4 nM 3.9 pM
3,4-Dimethoxy 88e 71 0.61 pM >10 pM
2,3,4-Trimethoxy 88f 36 1.99 pM N/A
4-T rifluoromethyl 88g 83 0.21 pM N/A
2-Fluoro-4-methoxy 88h 22 0.18 pM 0.7 pM
Table 3.3 -  Yields, cytotoxicities and tubulin inhibition assays for a-trifluoromethyl chalcones.
As before, in the case of 88d the chalcone was initially made with a TBDMS protecting group 
on the hydroxy substituent which was later removed with TBAF {Scheme 3.13).
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OTBDMSTBDMSCI
OTBDMS
94
LiHMDS
Cl
Ph3P
OTBDMS
o '
97c
TBAF
OH
CF;
88d
Scheme 3.13 -  Phenol protection and deprotection.
Unfortunately none of these chalcones gave suitable crystals for X-ray analysis and so we are 
not absolutely certain that the structural assignment is correct. In order to understand whether 
the molecules adopted the s-cis or s-trans conformation, however, !H nOe experiments were 
carried out with 88d and 88g. Protons 2’ and 6’ were irriadiated with the intention of seeing 
what enhancement that had on proton p, and surprisingly no effect was seen at all, which 
means that these chalcones may well be adopting the s-cis conformation. One might expect, 
given the fact that alpha methyl chalcones are known the be s-trans and given the similar size 
of methyl and trifluoromethyl groups, that steric factors would force these molecules into the s- 
trans conformation. It could be, however, that the electrostatic repulsion between the carbonyl 
oxygen and the fluorine atoms o f the trifluoromethyl group overrides this steric effect so that 
the molecules are in fact s-cis.
This, along with the results discussed in section 3.2, reveals a very interesting reversal between 
the effects of fluorine and hydrogen on s-trans / s-cis isomerism of chalcones as illustrated in 
Figure 3.14.
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O
a-CH3, s -trans a-H, s -cis
O 0
a-C F3, s -cis
a-F, s -trans
Figure 3.14 -  Effects o f  fluorine on s-cis/s-trans isomerism.
Again, as with all previous chalcones the most cytotoxic of this series was 88d with the 3- 
hydroxy-4-methoxy B ring, but in the case of these s-cis compounds there were also some 
significant differences.
Firstly the IC50 values o f these compounds range from 80 nM to 2 pM - a much smaller range 
than with the alpha fluoro chalcones (13 nM to 10 pM). The 4-methoxy chalcone 88b is once 
again the second most cytotoxic, this time having more or less the same activity as 88d. It 
would seem therefore that the hydroxy group in these chalcones is less crucial to the 
cytotoxicity than in previous cases. It could be that one of the fluorine atoms in the 
trifluoromethyl group forms a H bond with the hydroxy group and this prevents it from 
hydrogen bonding within the binding site of the enzyme thus the activity is basically the same 
as 88b which has no hydroxy group. Or it could be that because these chalcones are s-czs the 
structural change is such that they fit into the tubulin-binding site in a way that does not allow 
the OH group to undergo the same hydrogen bonding that is seen in s-trans chalcones.
In addition when these two chalcones were tested for tubulin polymerisation inhibition, it was 
found that while they had similar values, they were not the most potent.
Most of the other chalcones in this set fall within roughly the same range; 88a, 88e, 88g and 
88h all have cytotoxicities in the 0.1 pM range and so are around ten fold less cytotoxic than 
88b and 88d. When 88a, 88e, and 88h were tested for tubulin inhibition, however, they were 
found to differ significantly. 88a showed roughly the same tubulin inhibition as 88b and 88d,
61
Chapter 3 Fluorinated Chalcones
despite being less cytotoxic, 88e was effectively inactive with regard to tubulin inhibition and 
88h was the most potent tubulin inhibitor of the set. While it is clear that these chalcones are 
both very cytotoxic and, in most cases, potent inhibitors of tubulin polymerisation, it would 
seem that these two properties do not display a simple linear relationship. It may be that in 
addition to tubulin binding, these molecules have a second mode of action which contributes to 
their cytotoxicity.
The least active compound is 88f with a 2,3,4-trimethoxy B ring with an IC50 of 2 pM -  100 
fold less active than 88b and 88d. It would seem that the loss of activity in this case is due 
again to steric bulk, i.e. the bulkier the B ring, the more hindrance there is to binding in the 
active site of tubulin and hence the less cytotoxic the chalcone.
3.3 Summary and Conclusions
Chalcones with a-fluoro and a-trifluoromethyl substitutions, especially 83c and 88d, have 
shown very high cytotoxicity against the human chronic myelogenous leukemia cell, K562. 
Further investigation into the biological properties of these fluorinated chalcones revealed 
potent tubulin polymerisation inhibition, which accounts, at least in part, for their powerful 
cytotoxicities.
Chalcones which have fluoro and trifluoromethyl groups in the a-position also display some 
unusual structural features, especially in relation to their s-cis / s-trans conformations. 
Normally chalcones will adopt the s-cis conformation unless forced into the s-trans 
conformation by steric repulsion between a relatively bulky a-group, such as a methyl group, 
and the A-ring. Both a-fluoro and a-trifluoromethyl chalcones, however, seem to be 
exceptions to this rule; a-fluoro chalcones, which one would expect to be s-cis due to the small 
size of the fluorine atom, are in fact s-trans and a-trifluoromethyl chalcones, which one would 
expect to be s-trans, are s-cis (although in the latter case the structural assignment is based only 
on NMR data since no crystals suitable for X-ray analysis could be grown). The conformation 
of the a-trifluoromethyl chalcones, at least, can be explained in terms of the electrostatic 
repulsion which would exist between the carbonyl oxygen and the fluorine atoms in the s-trans 
conformation.
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Chapter Four
4.1.1 Introduction (Long Range Fluorine Couplings)
It is well known that fluorine is able to cause unusual, long-range, NMR coupling patterns with 
other atoms, there are numerous examples in the literature and a few of these are described 
below.
Charushin and co-workers150 have observed what is commonly known as ‘through-space’ 
coupling effects in fused fluoroquinolones of the type 100 and 101 (Figure 4.1):
Y O Y O
COOZCOOZ
101100
Figure 4.1 -  Through-space NMR coupling in fluoroquinolones.
Several examples of these compounds were made as antibacterial targets and the 19F spectra of 
all o f them showed that FI was coupled not only to F2 and F3 or H3 (where Y=F or H) but 
also to H I2 ( J f h  = 2.0-3.8 Hz). In the case of 100, coupling is also seen between FI and FI 1 
( J f f  = 3.5-4.0 Hz). In the *H spectra H9 is coupled to F10 (J f if  = 10.3-10.5 Hz) and F ll  (J h f  =  
7.3-7.5 Hz) but H12 is coupled to F10 ( J h f  = 7.1-7.5 Hz), F l l  ( J h f  = 10.5-11.6 Hz) and FI (J h f  
= 2.0-3.8 Hz). It is believed that these unusual interactions between FI, H12 and F l l  are a 
result o f through space effects.
In the same publication the authors converted 100a into 102 by refluxing with pyridine and 
pyrrolidine (Scheme 4.1).
COOEtCOOEt
NH +
100a 102
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Scheme 4.1 -  Pyrrolidine substitution.
The NMR data of 102 showed more interesting couplings; F2 is seen as a double triplet due to 
coupling with both F3 (J Ff  = 19.6 Hz) and H5’ ( J f h  = 3.4 Hz) and FI 1 demonstrates coupling 
to F10 ( J f f  = 21.5 Hz), H12 (J FH = 11.1 Hz) and H2’ (J FH = 3.5 Hz).
It is believed that the magnitude of these through space coupling effects is related to the spatial 
separation between the two atoms involved. This was demonstrated in a paper by Jaime- 
Figueroa et al.151 They looked at 4-substituted-l-acetyl-8-fluoronaphthalenes 103.
103
Figure 4.2 -  4-substituted-l-acetyl-8-fluoronaphthalene.
In these compounds there is coupling between the fluorine atom at the 8 position and both the 
carbon and protons of the acetyl methyl group which is believed to be due to through-space 
interactions.
It was found that by altering the nature of the X group on the 4 position, the value of the F-H 
coupling constant, J f h ,  could be changed; when X is electron-donating the coupling constant 
increases (X = OMe, J f h  = 4.15 Hz) and when X is electron-withdrawing the coupling constant 
is reduced (X = SOMe, J f h  = 3.15 Hz). In addition it was shown that the nature of the NMR 
solvent similarly altered the value of coupling constant. When the NMR spectrum of 103a (X = 
F) was run in polar solvents such as DMSO-ck the JFh  coupling constant was significantly 
lower (2.51 Hz) than when it was run in non-polar solvents such as CDCI3 (3.64 Hz).
Exactly the same effects were seen on the J f c  coupling constant between F8 and the methyl 
carbon.
These observations were explained as a result o f the dihedral angle between the plane of the 
acetyl group and the naphthyl ring system. In the case of 103a (X = F) X-ray crystal analysis 
showed this angle to be 65° with the oxygen o f the acetyl group and the F4 fluorine in an anti 
orientation due to electrostatic repulsion. When X is more electron-donating (103b, X = OMe), 
the potential charge of the acetyl oxygen would be increased, the repulsion would increase and 
the methyl group would be pushed closer to the fluorine, increasing the coupling constant.
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Similarly when polar solvents are used, the partial negative charge of the oxygen would be 
better stablised, the electrostatic repulsion would be reduced and steric factors would pull the 
fluorine and the methyl group apart, reducing the coupling constant.
l-ter/-butyl-8-fluoronaphthalene (104) also shows some unusual NMR properties and further 
demonstrates the dependence on distance of the through-space coupling effect.
F *Bu
104
Figure 4.3 -  7-tert- butyl-8-fluoronaphthcilene.
In 1993, Gribble and co-workers examined the carbon and proton NMR of 104 at different 
temperatures.152 They found that at 230K the 13C NMR showed the methyl carbons of the t- 
butyl group as a doublet at 8 32.9 ppm ( J c f  = 12 Hz) but as the temperature was lowered, this 
decoalesced and at 110K formed two distinct peaks; a broad singlet at 8b 35.9 and a doublet at 
8a 30.8 ( J c f  = 19 Hz). This is consistent with a slowing down of rotation about the C-C bond 
between the ring and the t-butyl group. At 230K rotation is too fast to be seen on the NMR 
timescale and all three methyl groups are seen as equivalent but at 110K the NMR detects two 
different types of methyl group. The doublet is due to two methyl groups lying on either side of 
the ring and the singlet represents a unique carbon atom lying parallel to the plane of the ring. 
This means that at 11 OK the molecule exists as one of the two conformations {Figure 4.4).
104a 104b
Figure 4.4 -  Alternative comformations o f  104.
As one would expect, molecular modelling calculations imply a strong repulsive force between 
the methyl group B and the fluorine atom in 104a and so it is believed that the most stable 
conformation of BFN is 104b. The fact that through-space coupling is observed between 
fluorine and the A carbons but not the B carbon demonstrates the distance dependence of this 
effect.
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There have been a number of studies into the mechanism of through-space coupling effects of 
fluorine and it is generally believed that the effect is caused by overlap between lone pair 
orbitals in the two crowded atoms.153 In particular, the case of fluorine-fluorine through-space 
coupling has been studied in detail and it is thought that interaction between the two 2p lone- 
pair orbitals on the fluorine atoms enables the transmission of nuclear spin information.154
Mallory et al. in particular have published a number of studies in this area, many of which 
relate to 1,8-difluoronaphthalenes. They theorised that since the F-F spatial separation, c /f f ,  in 
1,8-difluoronaphthalene was around 2.58A there should be a small degree of a  overlap 
between the lone pair orbitals on the fluorine atoms. This would result in a weakly bonding and 
a weakly antibonding orbital and, while no net chemical bonding would result from this, it 
should explain the so called through-space NMR coupling seen in the NMR data.
If this is the case, then the magnitude of the coupling constant, J f f ,  should show an exponential 
dependence on dFF, such that J f f  should approach 0 as dFF approaches infinity. Some distance 
dependence o f the F-F coupling effect can easily be seen in the case of 1,8- 
difluoronaphthalenes 105 compared to 4,5-difluorophenanthrenes 106 and bridged 1,8- 
difluoronaphthalenes 107 (Figure 4.5), the J f f  values o f 105 range from around 60-85 Hz, the 
J f f  values of 106 are in the range of 165-175 Hz and those of 107 are between 30-35 Hz.
F F F F
X Y
105
JFF = 60-85 Hz
106
JFF = 165-175 Hz
X -Y
107
JFF = 30-35 Hz
Figure 4.5 -  Through-space coupling in fluorinatedpolyaromatics.
In the case of 106, however, there may be some contribution to the difference in Jff from the 
angle of the overlapping lone pairs as well as the F-F separation. So these compounds were not 
included in the following investigation.
A range of compounds of the type 105 and 107 were made in which subtle variations in X and 
Y were used to change the F-F separation. In the case of 105 increasing the steric bulk of X 
and Y distorted the molecule and pushed the fluorine atoms closer together. In the case of 107 
variation in the X-Y bond length imposed angular strain on the system and pulled the fluorine 
atoms apart. In all these cases the J f f  values of the molecules were measured and values of dFF 
were calculated computationally. The value of J f f  was then plotted against dpF and they were
66
Chapter 4 Long Range NMR Couplings and Dimerisation
found to display an exponential relationship. This would suggest, assuming the through bond 
F-F coupling in these molecules is negligible, that the through-space coupling is, as expected, a 
result of lone pair overlap.
This effect has not only been observed directly, as in the cases described above where two 
fluorine atoms are spatially close together, bizarrely it can also take place when the fluorine 
atoms are separated by another group, as long as the group contains a lone pair and is 
positioned so that that orbital can interact with each o f the fluorine atoms.
One example of this is when two fluorine atoms are separated by a phenyl ring, such as in the 
case of l,5,8-trifluoro-9,10-diphenyl-anthracene (108).155 FI in this molecule is reported to 
couple to F8 with a coupling constant of 6.4 Hz, a significantly stronger coupling than is seen 
in compound 109 ( J f i , f 8  =  1 1  Hz) which lacks the intervening phenyl group (.Figure 4.6).
The crystal structure of 108 shows the C9 phenyl group to be perpendicular to the plane of the 
anthracene ring system and the FI and F8 atoms are each 2.6 A from the C l ’ atom of the 
phenyl ring, so it is believed that the increased F-F coupling in this case is caused by 
transmission of nuclear spin information from fluorine atom to fluorine atom via the n orbitals 
of the phenyl ring.
108 109
Figure 4 .6 -  Through-space coupling via an intervening group.
Fluorine-nitrogen156 and fluorine-carbon157 through-space coupling patterns have also been 
studied in some detail and the same correlation between coupling constant and spatial 
separation as has been described for fluorine-fluorine couplings appears to relate to these cases 
as well. It is believed that similar lone pair overlap interactions are responsible for the observed 
effects.
The case of through-space coupling between fluorine and hydrogen, however, is much less 
well understood, despite numerous publications in which the effect has been reported. It is 
known that, like F-F couplings, they are independent of the chemical shifts of the atoms 
involved.158 But apart from this there are few papers which look in detail at the actual 
mechanism of through space F-H coupling.
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Mallory and co-workers looked at this effect in 1975 by comparing the coupling constants 
between two fluorine atoms with those between fluorine and hydrogen atoms in a series of
was not seen in the F-H couplings.159 This is illustrated by the fact that the values of J fh  in 110, 
111 and 112 were not parallel to the values of J f f  in 113, 114 and 115 {Figure 4.7). Since 
fluorine and hydrogen are similar in atomic radii, one would expect that the spatial distances 
between F and H in 110, 111 and 112 to be representative of those between F and F in 113, 
114, and 115. The coupling constants, however, do not follow this pattern.
Figure 4.7 -  Through-space coupling between two fluorine atoms or a fluorine atom and a 
hydrogen atom.
Mallory hypothesised, therefore, that in the case of through-space F-H coupling it is the 
distance between the fluorine atom and the carbon to which the proton is attached, rather than 
the proton itself, which determines the value of the coupling constant.
A computational study by Wasylishen et al. at around the same time looked at the effect of 
orientation as well as proximity of the H and F nuclei on the coupling effects but was unable to 
reach any significant conclusions.160 They followed up more recently with a paper which 
concluded that fluorine-proton coupling showed the same dependence on dF-c that F-F 
coupling shows on dF-F- They also showed that angular effects play a significant role such that 
the F-H coupling was much greater when the atoms are aligned (i.e. coupling between F and 
HI was greater than between F and H2/H3/H4 in Figure 4.8) This was attributed to 
interactions between molecular orbitals on fluorine and carbon, although no explanation seems 
to be given for why the fluorine cannot interact directly with the proton.
polyaromatics. They found that while the F-F couplings seemed to depend on F-F distance, this
110 JHF = 2.6 Hz 111 Jhf = 14.5 Hz 112 JHF = 1-7 Hz
113 JFF = 174 Hz 114 JFF = 43.2 Hz 115 JFF = 5.3 Hz
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H -F
H2 H4 
H1
H3
Figure 4.8 Spatial orientation neededfor 19F -H  through-space coupling.
Not all long range coupling effects of fluorine can be explained by these ‘through-space’ 
orbital overlaps, however. In 1981 England et al. studied the synthesis of the following bicyclic 
compounds via a Diels Alder reaction between an aryl alkyne and perfluoroacryloyl fluoride 
(Scheme 4.2).
\  / / F
F2
F3
O
NaHCO
F1
116
Scheme 4.2 -  Synthesis o f  116 via Diels Alder coupling.
They observed some unusual coupling in the proton and fluorine NMR spectra of the product 
116. The proton NMR showed that the vinyl proton HI was coupled to all three fluorine atoms 
and the proton decoupled 19F NMR showed that each fluorine atom is coupled to each of the 
others. Coupling between fluorines FI and F3 cannot be a ‘through-space’ interaction because 
of the distance and the number of bonds separating them, it is thought to be a special type of 
through-bond coupling due to the planar property of the molecule and the resulting 
conjugation. Similar coupling patterns are not seen in 4,4’-difluorobiphenyl 117 because the 
two rings are forced into perpendicular planes by steric hindrances.161 But in similar 
compounds which contain two /rara-fluorobenzene rings linked by groups such as -N=N- and - 
CH=CH- (118 and 119) which allow them to adopt a planar conformation, coupling is seen
between the two fluorine atoms 162
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N.
N
118 119
Figure 4.9 -  Planar and non-planar biphenyls.
In the case of 116 the oxygen in the ortho position of the A-ring reduces the steric interaction 
enough to enable the molecule to resonate and adopt the planar conformation.163
4.1.2 Introduction (Single-Crystal to Single-Crystal Reactions)
There have been a few observed cases of organic crystals growing in such a way that, upon 
irradiation, they are able to undergo dimerisations and polymerisations within the crystal 
phase. These ‘single-crystal to single-crystal’ transformations are of great interest in fields such 
as polymer science because the stereochemistry of the products is determined by the nature of 
the monomer lattice. This derives from the topochemical postulate which states that ‘reactions 
in the solid state proceed with minimal atomic and molecular movement’164 and implies that a 
conformationally sensitive reaction will only take place if the orientation of monomers within 
the lattice allows it. It should be possible, therefore, to design crystals which, upon irradiation, 
react to give polymeric products with specific symmetries.165 There is some debate, however, 
as to whether such reactions are truly homogeneous166 or whether they take place at crystal 
defects.167
There are several known types of single-crystal to single-crystal transformation; 
polymerisation of diacetylenes,168 [4+4] dimerisation of anthracenes169 and [2+2] 
cyclodimerisations o f cinnamic acids and their derivatives. The latter have been o f particular 
interest in studying the single-crystal to single-crystal effect. Jones et al. published a few 
studies on the photodimerisation o f 120 and 121.
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Br
OO
120 121
Br
Br
Scheme 4.3 -  Solid state dimerisations.
They found that the dimerisation reactions of these molecules were indeed single-crystal to 
single-crystal transformations,170 although in the case of 121 the monomer crystal must be 
irradiated slowly to prevent cracking due to the larger changes in crystal parameters between 
monomer and dimer.
Then, in a later study, they looked at X-ray data on some intermediate, partially reacted 
crystals consisting of both monomer and dimer in an attempt to understand the mechanism in 
more detail. In particular they wanted to know whether the reaction took place at defects within 
the crystal or whether it genuinely took place within the lattice. Their conclusion was that, at 
least in these two cases, while the dimerisation is homogeneous and does occur within the 
lattice, it nevertheless takes place at different rates in different parts of the crystal depending on 
the amount of radiation received.171
In order to be able to predict whether or not a given monomer crystal would be able to undergo 
[2+2] cyclodimerisations, a few attempts have been made to define necessary parameters 
which would allow reaction to take place.172
Turowska-Tyrk and co-workers used the following set of parameters to predict whether or not 
a [2+2] cyclodimerisation reaction could take place in a series of chalcones. (Single-crystal to 
single-crystal dimerisations had already been observed in crystals of chalcones.173)
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• Distance between C=C double bonds, d, should be < 4.2 A.
• Angle between the line of one carbon double bond and a carbon atom of the 
neighbouring molecule C=C... C, a , should be as close to 90° as possible.
• Angle formed between the two C=C double bonds of adjacent molecules,x, should be as 
close to 0° as possible.
• Angle between the two planes formed by the two >C=C< units, <(>, should be as close to 
0° as possible.
• Angle between the plane of one >C=C< unit and the plane of the two C=C bonds from 
that and an adjacent molecule, k, should be as close to 90° as possible.
The ideal system is described in Figure 4.10.
< 4 .2  A
Figure 4.10 -  Parameters necessary fo r  single-crystal to single-crystal dimer isations.
They were then able to successfully predict which of the following five chalcones {Figure 
4.11) would undergo [2+2] cyclodimerisation in the crystal phase based on the above
parameters. 174
0
122
OH
124
123
OH
126OH
125
Figure 4.11 -  Chalcones which may undergo single-crystal to single-crystal dimer isations.
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Chalcone d (A) a  (deg) x (deg) 4> (deg) K (deg) Able to 
react in 
crystal 
form
(Y/N)
122 3.890 94.86 0 0 67.67 Y
123 4.197 104.90 180 0 64.30 N
124 3.895 99.94 0 0 58.77 N
125 >4.5 N
126 >4.4 N
Table 4.1 -  Key parameters for single-crystal to single-crystal dimerisations o f  chalcones.
Chalcones 123, 125 and 126 did not react because of unacceptable values of x, d and d 
respectively and 122 did under go a single-crystal to single-crystal dimerisation, as the 
dimensions would suggest. The only anomaly was 124 in which the values in the table would 
suggest that it should be able to react when in fact it did not. This has been attributed to 
hydrogen bonding within the crystal structure, which restricts the movement of monomer 
molecules to such an extent that they are unable to get close enough to react.
4.2.1 Long range NMR Coupling in Chalcones
It has been observed within our group that certain fluorinated chalcones display unusual, long 
range, fluorine-proton coupling in the proton NMRs. In particular, in chalcones which have a 
fluorine atom in the ortho position on the A ring and a hydrogen on the alpha position {Figure 
4.12), there seems to be a coupling interaction between the fluorine atom and the protons in the 
alpha and beta positions, which both appear as double doublets in the proton NMR. (It is worth 
noting that where similar chalcones are reported in the literature the alpha and beta protons are 
usually recorded as simple doublets with no Jh f contribution).175
R
Figure 4.12 -  2-Fluoro-a-hydrogen chalcones.
This was investigated in further detail by synthesising more chalcones of this type and studying 
the NMR and X-ray data. This would enable us to see what effects the fluorine atom has on
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conformation and whether this coupling effect can be used as a tool to probe conformational 
effects.
Synthesis of alpha hydrogen chalcones is very straightforward and the following were made by 
Claisen-Schmidt condensation of the appropriate acetophenone and benzaldehyde with
176 177methanolic sodium hydroxide {Scheme 4.4). All are novel with the exceptions of 129, 131,
135 + 142178 and 138 + 141179 although where these are reported in the literature the J h f  
coupling is ignored. The proton NMR data is summarised in Table 4.2.
O
+
Scheme 4.4 - Claisen-Schmidt synthesis o f  chalcones.
Yield
(%)
A-Ring B-Ring a-H P-H
5 1 6 J\w
127 57 3,4,5-trimethoxy 2-fluoro-4-methoxy 7.51 0 15.9 7.79 0
128 73 2-fluoro 4-methyl 7.37 2.7 15.7 7.75 1.4
129 71 2-fluoro 3,5-dimethoxy 7.36 2.7 15.7 7.67 1.7
130 62 3-fluoro-4-methoxy 4-methyl 7.48 0 15.6 7.82 0
131 56 2,4-dimethoxy 3,4-difluoro 7.47 0 15.7 7.59 0
132 34 2-fluoro-4-methoxy 2-fluoro-5-bromo 7.45 2.9 15.8 7.73 1.9
133 52 2-fluoro-4-methoxy 2,4,5-trimethoxy 7.40 2.9 15.7 8.09 2.1
134 80 2-fluoro-4-methoxy 3,4,5-trimethoxy 7.36 2.9 15.6 7.71 2.0
135 44 2-fluoro-4-methoxy 4-methyl 7.44 2.9 15.6 7.79 2.0
136 79 2-fluoro-4-methoxy 2-fluoro-4-bromo 7.56 2.8 15.7 7.83 1.2
137 77 2-fluoro-4-methoxy 3,5-dimethoxy 7.43 2.8 15.6 7.71 2.0
NaOH
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138 57 2-fluoro-4-methoxy 4-methoxy 7.37 3.0 15.5 7.78 2.0
139 87 2-fluoro-4-methoxy 2,4-dimethoxy 7.39 3.0 15.7 7.97 2.2
140 34 2-fluoro-4-methoxy 2,3,4-trimethoxy 7.49 3.0 15.8 7.98 2.2
141 49 2-fluoro-4-methoxy 2-fluoro-4-methoxy 7.46 2.9 16.0 7.88 2.0
142 26 2-fluoro-4-methoxy 3-fluoro-4-methoxy 7.32 2.7 15.5 7.69 0
143 30 2-fluoro-4-methoxy 3-hydroxy-4-methoxy 7.35 2.8 15.5 7.73 2.1
144 64 2-fluoro-4-methoxy 3,4-methylenedioxy 7.31 2.9 15.5 7.72 2.1
145 70 2-fluoro-4-methoxy 3-bromo-4-methoxy 7.34 2.7 15.6 7.68 2.0
146 12 2-fluoro-4-methoxy 4-trifluoromethyl 7.46 3.0 15.6 7.71 2.0
Table 4.2 -  Yeitds and NMR properties o f  a-hydrogen chalcones.
It is clear from this data that coupling occurs between the fluorine atom on the 2’ position of 
the A-ring and both the a  and p protons of the double bond (the exception to this is in the case 
of 142 where, for some reason, coupling is only seen to the a  proton). No coupling occurs 
when the fluorine atom is on the 3’ position on the A-ring, as can be seen in example 130 and 
no effect is seen when a fluorine atom is on the B-ring regardless of it’s position, as shown by 
chalcones 127, 131, 132, 136, 141 and 142. In the cases of 132, 136, 141 and 142 there is a 
fluorine atom on both rings but the coupling effect is the same as when there is only the 
fluorine on the 2’ position of the A-ring.
The coupling constants to the alpha proton range from 2.7 to 3.0 Hz and for the beta proton,
1.2 to 2.2 Hz. In the case of the alpha proton, this is a small variation is probably not the result 
o f any difference in the electronic properties of the two rings; this is illustrated by chalcones 
138 and 146 both of which have a coupling constant o f 3.0 Hz between the fluorine and the 
alpha proton despite the fact that 138 has an electron donating /?ara-methoxy group on the B- 
ring and 146 has an electron-withdrawing trifluoromethyl group in the same position. In the 
case of the beta proton there is a much more significant variation although again there is no 
obvious correlation between the value of the coupling constant and the electronic nature of the 
substituents on the rings.
Since the fluorine atom in these compounds is separated from the alpha and beta protons by 
four and five carbon atoms respectively it is unlikely that this is a normal through-bond
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coupling interaction, this is supported by the fact that no other positions on either the A or B 
ring seem to facilitate this interaction when substituted with fluorine.
It was possible to grow suitable crystals of three of these chalcones for X-ray analysis and their 
structures, along with some data derived from them, are shown below.
Figure 4.13 -  X-ray crystal structure o f 139.
Figure 4.14 -  X-ray crystal structure o f 140.
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F(3) F(2)
.F(1)
C(4)
)C(3)
C(2)C(6)
C<1)
C(7)F(4)
C(12)
C(1
0(2)
C(16)C(14)C(17)
C(15)
Figure 4.15 -X -ra y  crystal structure o f 146.
R'
RR
<!>1 (°) (1>2 (°) F-Ca
interspatial 
distance (A)
F-Cp
interspatial 
distance (A)
139 160 168 2.82 4.00
140 149 173 2.86 4.03
146 168 170 2.80 4.01
Table 4.3 -  Structural data fo r  crystaline 2-fluoro- a-hy drogen chalcones.
As would be expected for alpha hydrogen chalcones, the X-ray data shows the molecules to be 
orientated in the s-cis conformation. And in all three cases the fluorine atom is shown to be 
positioned anti to the carbonyl oxygen due, presumably, to electrostatic repulsions between 
these two highly electronegative atoms. Dihedral angles (|)1 and <J>2 all approach 180°, showing 
the molecules to be relatively flat, which indicates good 7i-overlap. (The X-ray data shows the 
configuration only in the crystalline state, of course, and it is likely that in solution there is 
some rotation about the single bonds, although it is reasonable to assume that the molecule 
would spend most of the time in the orientation shown.)
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This means that the fluorine atom is positioned relatively close to the a  carbon in space (2.82, 
2.86 and 2.80 A for 139, 140 and 146 respectively) and, since it is believed that in the case of 
fluorine-hydrogen through-space coupling, the interaction is due to overlap between the lone 
pairs on the F atom and on the C atom to which the H is attached, this supports the idea that 
this coupling, at least, is due to a through-space interaction.
The X-ray data also shows, however, that the beta proton (and the beta carbon) is not only 
much too far from the fluorine to interact through space, it is also separated from it by the C=C 
double bond, this makes it very unlikely that a through-space interaction would take place 
between these two atoms. Since, due to the number of atoms separating them, this coupling 
effect is equally unlikely to be the result o f a conventional through-bond interaction, it would 
seem that this is a very unusual type of coupling interaction.
There are limited explanations for this unusual effect. One is that in solution, unlike the 
crystalline state, the molecule has sufficient rotational freedom about the CO-C=C single bond 
to allow it to adopt the s-trans conformation for some of the time, and that in this conformation 
a through-space interaction is able to take place between the fluorine atom and Cp.
Figure 4.16-  Interconversion o f  s-cis and s-trans isomers in solution.
Another explanation is that some sort of through-bond coupling is responsible; it could be that 
since the crystal structures seem to show the C-F bond roughly perpendicular to the C=C 
double bond, the through-space interaction between F and C a is transmitted through the vinyl 
bond to Hp. (Something similar to this is discussed above, in which a fluorine-fluorine 
through-space coupling is transmitted through a phenyl group.155)
Or the coupling could simply be a very long range through-bond effect, resulting from the high 
degree of resonance within the chalcone molecule. Again an example of this is discussed in the
163introduction although the effect is not very well understood and it offers no explanation for 
the fact that this coupling is only possible when the fluorine is in the 2 ’ position.
In order to test the first of these hypotheses a range of alpha methyl chalcones were made. It is 
well known that alpha methyl chalcones are predominantly s-trans so if the F-Hp coupling 
constant in the alpha methyl compounds is the same as has been observed in alpha hydrogen
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chalcones, that would suggest that the latter is a result of the molecule adopting the s-trans 
conformation in solution.
Initially ketone 148 was made by ethyl Grignard addition to 2-fluoro-4-methoxybenzaldehyde 
followed by oxidation with KMnC>4 (Scheme 4.5). Condensation of chalcones from 148 was 
more difficult than in the case of the alpha hydrogen chalcones and reaction was carried out by 
refluxing the ketone and aldehyde mixture with piperidine and acetic acid in ethanol.
F OH
1) EtMgBr
2) H+
147, 88%
KMnO
H
AC T 'A r' 148, 97%
Scheme 4.5 -  Synthesis o f  a-methyl chalcones.
Yield
(%)
A-Ring B-Ring P-H
5 <7hf
149 23 2-fluoro-4-methoxy 2,4-dimethoxy 7.16 0
150 20 2-fluoro-4-methoxy 2,3,4-trimethoxy 7.30 0
151 53 2-fluoro-4-methoxy 3-fluoro-4-methoxy 7.00 0
152 18 2-fluoro-4-methoxy 3,4-methylenedioxy 7.03 0
153 61 2-fluoro-4-methoxy 3-bromo-4-methoxy 7.09 0
154 40 2-fluoro-4-methoxy 4-trifluoromethyl 7.09 0
Table 4.4 -  Yeilds and NMR properties o f  a-methyl chalcones.
None of these chalcones display any coupling interaction between the fluorine atom and the 
beta hydrogen and in all cases Hp appears as a singlet in the proton NMR. This is surprising 
since there is a through-space interaction between F2’ and H a in the alpha hydrogen chalcones 
and one would expect F2’ and CP to be significantly closer in this case.
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Unfortunately no X ray data could be obtained for any of these compounds, although the 
results of nOe experiments on 151 and 153 show a 1.96 and 1.92% enhancement at H6’ 
respectively when irradiated at Hp. That there is such an nOe effect is consistent with the 
compounds adopting the s-trans conformation rather than s-cis, and the fact that the 
enhancement in both cases is so small is probably due to restricted rotation about the Ar-CO 
bond with the F and O positioned anti most of the time.
It may be that in this conformation the F2’ and Cp atoms are so close together that steric 
hindrance between them forces the molecule to twist in such a way that the atoms are out of 
plane and therefore cannot undergo through-space coupling. This effect is seen in compound 
112 above, although in that example the through-space coupling is not eliminated, merely 
reduced.
It is clear, though, from these results that the coupling observed in the alpha hydrogen 
chalcones between the fluorine atom on the T  position and the proton on the P position is not 
due to any direct through-space coupling. This must mean that through-bond interactions play 
at least some role in the observed NMR coupling. If the coupling is transmitted entirely 
through bonds and is a result o f the highly conjugated nature of the chalcone molecule, similar 
to the effect described by England et al.,m  then it remains to be seen why a similar effect is 
not observed between alpha and beta protons and fluorine atoms in different positions within 
the molecule, and also why no such coupling occurs in the equally conjugated alpha methyl 
chalcones. It seems more likely, at this point, that the observed effects are a combination of 
through-space and through-bond interactions and the F2’ atom is coupled through space to the 
C=C double bond and that this effect is then transferred through bonds to the alpha and beta 
protons.
4.2.2 Cytotoxicities
The cytotoxicities of these compounds were also tested and are shown below in Table 4.5.
A Ring B ring a  Position Cytotoxicity
(pM)
127 3,4,5-trimethoxy 2-fluoro-4-methoxy H 1.8
128 2-fluoro 4-methyl H 9.5
129 2-fluoro 3,5-dimethoxy H 3.6
130 3-fluoro-4-methoxy 4-methyl H >10
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131 2,4-dimethoxy 3,4-difluoro H >10
132 2-fluoro-4-methoxy 2-fluoro-5-bromo H 8.5
133 2-fluoro-4-methoxy 2,4,5-trimethoxy H >10
134 2-fluoro-4-methoxy 3,4,5-trimethoxy H 6.0
135 2-fluoro-4-methoxy 4-methyl H >10
136 2-fluoro-4-methoxy 2-fluoro-4-bromo H >10
137 2-fluoro-4-methoxy 3,5-dimethoxy H >10
138 2-fluoro-4-methoxy 4-methoxy H >10
139 2-fluoro-4-methoxy 2,4-dimethoxy H >10
140 2-fluoro-4-methoxy 2,3,4-trimethoxy H 9.8
141 2-fluoro-4-methoxy 2-fluoro-4-methoxy H >10
142 2-fluoro-4-methoxy 3-fluoro-4-methoxy H >10
143 2-fluoro-4-methoxy 3-hydroxy-4-methoxy H 4.5
144 2-fluoro-4-methoxy 3,4-methy lenedioxy H >10
145 2-fluoro-4-methoxy 3 -bromo-4-methoxy H >10
146 2-fluoro-4-methoxy 4-trifluoromethyl H >10
149 2-fluoro-4-methoxy 2,4-dimethoxy Me 9.7
150 2-fluoro-4-methoxy 2,3,4-trimethoxy Me 1.9
151 2-fluoro-4-methoxy 3-fluoro-4-methoxy Me 2.1
152 2-fluoro-4-methoxy 3,4-methylenedioxy Me >10
153 2-fluoro-4-methoxy 3-bromo-4-methoxy Me 1.9
154 2-fluoro-4-methoxy 4-trifluoromethyl Me >10
Table 4.5 -  Cytotoxicities o f  a-hydrogen and a-methyl chalcones.
Of those chalcones with a 2-fluoro-4-methoxy A-ring, most are inactive (cytotoxicity >10 pM) 
when there is only a proton in the alpha position. As expected, the most active is 143 with a 3- 
hydroxy-4-methoxy B-ring, but 134 with a 3,4,5-trimethoxy B-ring is almost as active, which 
suggests that the 3-hydroxy group on the B-ring is much less important in this case than it has 
been in previous chalcones. This could be because they are s-cis.
The a-methyl compounds are s-trans and therefore generally more active, 151 is particularly 
active, as one would expect since the 3-fluoro-4-methoxy B-ring most closely resembles the 3- 
hydroxy-4-methoxy ring. More surprising is the activity of 150 and 153, both of which are 
much more active than one would expect given the bulky nature of the 2,3,4-trimethoxy and 3- 
bromo-4-methoxy B-rings. In previous chalcone series these B-rings have been shown to 
reduce activity. It could be that since the A-ring in these particular chalcones is smaller than
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usual, the compound is able to fit into the tubulin binding site the opposite way round. Bulky 
B-rings also seem to increase the activity in the a-hydrogen chalcones, as seen in 134 and 140. 
The most active of all these chalcones is 127 with the 3,4,5-trimethoxy A-ring.
4.3 Dimerisation of Chalcones
During the course of the X-ray analysis of compound 139, it was found that in addition to 
the yellow crystals of the chalcone monomer described above, there was also a very small 
percentage of another white crystal present. This was found to be the head-tail cyclobutyl 
dimer, 155, as shown below. The mechanism by which this had formed was of interest, in 
particular whether it was the result of a single-crystal to single-crystal transformation of the 
monomer crystal or whether it had formed from solution as a separate polymorph (either of 
dimer or of a monomer which had dimerised upon exposure to light).
Figure 4.17 -X -ray crystal structure o f 155.
Studies of the initial sample suggested that the monomer crystal which made up the bulk of the 
sample had not formed the dimer; the distance between the C=C double bonds was > 5 A (for 
single-crystal to single-crystal dimerisations this needs to be <4.2 A .174), there was no 
intermediate crystal present i.e. the sample only contained purely monomer and purely dimer 
crystals, and further irradiation of the sample by high energy UV failed to induce any more 
dimerisation.
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This means that either the dimer formed from solution and crystallised out as a separate 
compound or that a different polymorph of the monomer was formed which was able to 
undergo single-crystal to single-crystal dimerisation and did so before the X ray analysis took 
place.
In order to distinguish between these two possibilities, a new batch of compound 139 was 
synthesised, this time in darkness, to be analysed by X-ray powder diffraction and solid state 
NMR.181
4.4 Summary and Conclusions
Certain chalcones have been shown to display some unusual, long range NMR coupling 
interactions. In particular a-hydrogen chalcones with a fluorine atom on the ortho position of 
the A-ring show coupling between this fluorine atom and the a- and p-hydrogen atoms. Since 
this effect is not observed in chalcones with fluorine atoms on other positions, or in a-methyl 
chalcones, it is believed that this interaction is caused by a ‘through-space’ orbital interaction 
between the fluorine atom and the a-carbon, which is then passed ‘through-bonds’ to the 
hydrogen atoms. Further study is needed, however, before the effect can be fully understood.
Dimerisation of one of these chalcones has also been observed, although there is no evidence 
that the dimerisation process is a single-crystal to single-crystal reaction.
83
Chapter 5 FAR Chemistry
Chapter Five
5.1 Introduction
It has already been shown that incorporation of certain fluorinated synthons into organic 
molecules is often problematic. Inclusion of fluorine atoms themselves is less so; [F+] is 
available in the form of electrophilic N-F based reagents such as Selectfluor™ 182 and \F~] is 
available simply as salts such as KF, CsF and tetrabutylammonium fluoride (TBAF), which is 
particularly useful for its solubility in organic solvents.
Another convenient source of [F~] are the fluoroalkylamine reagents (FARs) such as the 
Yarovenko reagent, 2-chloro-l,l,2-trifluorotriethylamine (156). These are able to react 
specifically with alcohols, substituting fluorine for OH- . A few such compounds have been 
studied but compound 156 has been found to be the most effective and convenient one-step 
method of converting OH to F.183
The addition of diethylamine to chlorotrifluoroethylene to generate 2-chloro-1,1,2- 
trifluorotriethylamine was first carried out by Pruett et al. 184 but its utility as a fluorination
1R5agent was first realised by Yarovenko. The only real disadvantage of this reagent is that it is 
unstable and so cannot be stored for more than a few days. It has to be made freshly by 
addition of diethylamine to chlorotrifluoroethene and used almost immediately. The reaction 
with alcohols is believed to proceed as shown in Scheme 5.1 m
R F 
Cl
H F FX F
+    X ^ NEt2
Cl H
156
Cl H
HO-R
F- ^ N E t 2--------------   r C C - ^ 2  '  ;.X .C N E t2
FJ 0
+ HF
Cl H
RF + ^ X ^ N E ts  F '
Cl H Cl
hCn b 2
157
Scheme 5.1 -  Fluorination o f  alcohols using the Yarovenko reagent (Sm2 mechanism).
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This Sn2 mechanism accounts for most of the examples in the literature but not all; there are 
some cases where the stereochemistry of the products indicates that an SnI reaction involving 
a carbonium ion intermediate must be taking place (Scheme 5.2).187
157
Scheme 5.2 -  Alternative SnI mechanism.
Primary alcohols nearly always react cleanly with 156 to give high yields of fluorides, 
secondary alcohols usually react as well, although yields are reduced because of side reactions 
which can also take place. Tertiary alcohols (with the exception of bicyclooctanols188) do not 
usually react at all with 156 and when they do it is usually the products of side reactions which 
are recovered. Common side reactions which can take place include esterification, elimination 
of water or, in cases where a carbonium ion is formed, rearrangement. These are believed to 
stem from the intermediate 157.
157 +
F
157
Scheme 5.3 -  Side reactions possible during fluorination o f  alcohols.
Other side reactions can sometimes occur involving the attack of 157 by alternative 
nucleophiles in place of F", usually from the solvent.
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As mentioned previously, a major advantage of this type of reagent is that they are selective to 
alcohols and are usually inert to other functional groups. An exception to this rule is in the case 
of amines; there have been some attempts to selectively fluorinate alcohols in the presence of 
primary and secondary amines but all have failed, unless the amine is protected.189
As a result of this selectivity the Yarovenko reagent is able to convert hydroxy groups into 
fluorides in many large, complicated drug molecules and analysis of these has lead to a great 
deal of understanding of the biological properties of fluorine.
Alkaloids such Morphine, Codeine and other related structures have been successfully 
fluorinated using the Yarovenko reagent (Scheme 5.4) 190 Efforts have also been made to 
fluorinate carbohydrates using 156, although with much less success.191
HO.HO.
156
1
N— N—
Morphine
Scheme 5.4 -  Fluorination o f  morphine.
The reagent has been used most extensively, however, in the fluorination of hydroxysteroids 
and it is this area which makes up most of the existing literature regarding the Yarovenko 
reagent. Reaction of hydroxysteroids with 156 depends on numerous factors. Generally when 
the hydroxy group is a primary alcohol situated on a side chain of the steroid skeleton 
fluorination works very well with minimal side reactions.192 When the hydroxy group is a 
secondary or tertiary alcohol attached directly to the ring system, however, the results are much 
more variable. In some cases the reaction can proceed cleanly to give high yields of the 
fluorinated product; 16-hydroxysteroids in particular usually react veiy well.193
OMe OMe
156
OH
Scheme 5.5 -  Fluorination o f  16-hydroxysteroids.
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In other cases the reaction predominantly gives by-products and sometimes reaction does not
occur at all. An interesting example of this is in the case of the tetrahydroxy steroid 158
(,Scheme 5.6) which selectively undergoes fluorination by 156 at the 6-position without
1affecting any of the other three hydroxy groups.
156 HO OHHO OH
OHOK
OH
158
Scheme 5.6 -  Selective fluorination o f  tetrahydroxy steroid 158.
Few publications on the Yarovenko reagent have been released in recent years, most of the 
work on fluorination of steroids and other biological compounds was carried out in the 60s and 
early 70s. The few papers to be published since then deal mainly with the problem of the 
Yarovenko reagent’s short shelf-life.
As mentioned above, synthesis of the Yarovenko reagent involves addition of diethylamine to 
the highly volatile chlorotrifluoroethylene, this can be achieved via a few different procedures 
but all o f these involve high pressure and require rigorously anhydrous conditions.194 Thus a 
similar reagent with comparable fluorinating power but which could be stored for longer 
periods would be extremely useful.
Ishikawa and co-workers developed a shelf-stable reagent 159, very similar to 156 which 
demonstrated similar reactivity towards alcohols (Figure 5.1).195 Although this can be stored 
for much longer periods than 156, it is still not sufficiently stable to be available commercially.
NEt
159
Figure 5.1 More stable alternative to Yarovenko reagent.
Banks et al. focussed their attention on development of a polymer-bound version of the 
Yarovenko reagent and were able to synthesise polymer 160.196 This was not only an effective
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fluorinating agent, it was stable enough to be stored for several months under N2 without loss 
of reactivity and had the advantages associated with polymer bound reagents in terms of 
product isolation.
EtNH2
CH2CI
c f 2=c fc i
CH2NHEt CH2NEtCF2CHCI CH2NEtCF2CHCI
160
c h 2ci
2 : 3
Scheme 5.7 -  Polymer boundfluorinating agent.
Another paper by Dmowski and co-workers looked at a,a-difluorobenzyldimethylamine (161) 
and diethyltrifluoromethylamine (162) as alternatives to the Yarovenko reagent (,Scheme 5.8). 
These were synthesised by reaction of the amides with SF4 and KF.197
A - /  8F«*KF-  <QY
/ N
161
SF4 + KF
\= = /  N— 
/
N
O
F\  F
N^X
F
162
Scheme 5.8 -  More stable alternatives to Yarovenko reagent.
Both of these were found to react with alcohols in a similar way to the Yarovenko reagent and 
to display the same inertness towards other functional groups. What was of particular interest, 
however, was that reagent 162 in contrast to the Yarovenko reagent was found to be more 
reactive towards secondary and tertiary alcohols than it was towards primary alcohols, this 
makes it a useful alternative.
All of the research on fluoroalkylamine reagents carried out to date concentrates on the 
fluorination of alcohols but there is also some potentially interesting chemistry regarding the 
reagent itself.
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w
X F
R
H-N
R
163
x ' £ v '
H R 
164
R’OH
H R 
165
H20 0
OH
H
166
Scheme 5.9 ~ Asymmetric synthesis o f  a-fluorocarboxylic acid.
In the general case shown in Scheme 5.9 the FAR reagent 164 contains a chiral centre. If the 
configuration at this centre could be controlled by chiral R groups on the amine 163, then it 
could react with an alcohol (or water) to give a chiral amide 165, hydrolysis o f which could 
provide a convenient, asymmetric route to a-fluorocarboxylic acid 166 and allow recovery of 
the amine. Some preliminary studies into achieving this objective are outlined below.
5.2.1 Synthesis of Trifluorostyrenes
Synthesis of a number of trifluorostyrenes was carried out according to the method developed 
by Burton et al.]9S involving palladium-catalysed cross-coupling of a trifluorovinylzinc 
chloride with the appropriate aryl iodide.
v
F
2 LDA ZnCI:
Li +
- fh fClZn F
Pd(PPh3)4 A  /
Arl Ar F
167-171
Scheme 5.10 -  Synthesis o f  trifluorostyrenes.
A number of trifluorostyrenes were made by this method as outlined in Table 5.1.
Compound Number Ar group Yield3
167 Phenyl 0%
168 4-Methoxyphenyl 82%
169 3-Methylphenyl 58%
170 3,4-Dimethoxyphenyl 63%
171 4-Nitrophenyl 0%
a) Yields calculated from NMR data 
Table 5.1 -  Yeilds o f  trifluorostyrenes.
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In the case of 170, the 3,4-dimethoxyphenyliodide (172) was made first by NIS iodination of
3,4-dimethoxybenzene199 as shown in Scheme 5.11.
8.5 Hz) at 6.79 ppm corresponding to H6, and another at 6.84 (Jhh = 1.9 Hz) corresponding to 
H3, both of which were coupled to a double doublet, H5, at 6.92 ppm. Both the methoxy peaks 
and the aromatic peaks showed a significant shift from the starting material 172, which had a 
similar pattern of peaks at 3.88 and 3.89 ppm (methoxy protons), and 6.65, 7.14 and 7.25 ppm
(Jff = 25, 44 Hz), 117.0 (Jff = 44, 170 Hz) and 175.0 (JFf = 25, 170 Hz). Mass spectrometry 
also showed a molecular ion at m/e = 219.0630, corresponding to [M+H]+.
Although this compound is novel, full characterisation could not be obtained due to the impure 
nature of the sample.
Scheme 5.11 -  Synthesis o f  170.
Unfortunately of those trifluorostyrenes which were isolated, all were impure and contained 
unreacted starting material and, in some cases, w-butyl aromatics formed from excess BuLi in
Scheme 5.12 -  Side reaction in synthesis o f  trifluorostyrenes.
Neither of these impurities could be removed from the desired product by chromatography and 
attempts to purify the styrenes by distillation resulted only in quantitative dimerisation of the 
styrene {Scheme 5.13) 200 In the case of 185, the dimer of 168, the NMR data showed a roughly 
1:1 mixture of the trans and cis isomers; the ]H NMR had methoxy peaks at 3.71 and 3.78 ppm 
(cis and trans respectively) and two pairs of doublets (Jhh = 8.8 Hz) at 6.74, 6.91 (for the 3’ 
and 5’ protons) and 7.09 and 7.93 ppm (for the 2 ’ and 6’ protons), with the cis isomer 
appearing upfield of the trans. Similarly the 19F NMR shows the trans isomer appears as two 
singlets at -124.6 and -156.7 ppm, and the cis isomer is a pair of doublets (Jff = 255 Hz) at -
H NMR data from 170 showed two methoxy peaks at 3.79 and 3.80 ppm, one doublet (Jhh =
(aromatic protons). In addition the 19F NMR of 170 showed 3 double doublet peaks at 101.5
F
NIS I CIZnCoF
Pd(PPh3)4
172, 97% 170, 63%
the LDA.
BuLi
BuZnCI P d (P P h 3)4 » A r - B u+
ZnCI2
Arl
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121.5 and -128.4 and a singlet at -162.8 ppm. This distinctive 19F NMR pattern is characteristic 
of dimers of this type, and is clearly seen in the paper by Sauvetre et a l 200
J v  -F A  .FF\ F 
2 H
Ar F F 7
"Ar +
F -7
F Ar F
Scheme 5.13 -  Dimerisation o f  trifluorostyrenes.
So the following reactions had to be carried out using impure styrene.
"Ar 
F F 'Ar
5.2.2 Addition of Non Chiral Amines to Trifluorostyrenes.
Reaction of styrenes 168 -  170 with three commercially available amines (diethylamine, 
piperidine and pyrrolidine) was attempted in order to generate FAR-type compounds, which 
would hydrolyse on aqueous work up to give amides {Scheme 5.14). The results are 
summarised in Table 5.2. Initially these reactions were carried out at room temperature and 
under basic conditions.
R
h _ K f  n
F F R F\ /  D H20  °
ArK    *scr -----   'yVF H R  h F R
168-170 173 Ar = OMe, R = Et 
174 Ar = OMe, NR2 = N
175 Ar = OMe, NR2 = r /  ^
Scheme 5.14 -  Addition o f  non-chiral amines to trifluorostyrenes.
Diethylamine Pyrrolidine Piperidine
168 173, 11% 174, 19% 175, 13%
169 0% 0% 0%
170 0% 0% 0%
Table 5.2 Yields o f  a-fluoro amides.
19F NMR analysis of crude reaction mixtures in all cases showed, by loss of the three 
distinctive double doublets, that the styrene had reacted. However, presumably because of the
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impure nature of the starting material, aqueous work up and extraction yielded a mixture of 
products which proved very difficult to separate. Although in the case of 168 the amides were 
isolated, yields were low and isolation was problematic.
Structures of 173,174 and 175 were confirmed by *H and 19F NMR. For example in the case of 
174 the proton NMR showed one large multiplet between 1.69 and 1.82 ppm corresponding to 
protons 3’ and 4’ on the pyrrolidine ring and a group of multiplets between 3.09 and 3.53 ppm 
caused by the four magnetically inequivalent 2’ and 5’ protons; the methoxy group appeared as 
a singlet at 3.75 ppm and the a  proton as a doublet at 5.78 ppm (Jhf = 49.2 Hz), the aryl 
protons were a doublet (Jhh = 8.5 Hz) at 6.85 ppm and a double doublet (Jhh = 8.5, Jh f = 1.7  
Hz) at 7.35 ppm.
In an attempt to get the addition to work with 169 and 170, the reaction was repeated at higher 
temperatures (80-90 °C). This resulted in an equally inseparable mixture, analysis of which by 
,9F NMR and mass spectrometry showed that most of the styrene had dimerised.
5.2.3 Addition of Chiral Amines to Trifluorostyrenes.
The following chiral amines were synthesised from L-proline as shown in Scheme 5.15.
The esters were made by reaction with the appropriate alcohols in the presence of thionyl 
chloride.201 L-prolinol was made by reduction of the amino acid with U A IH 4,202 and the 
alcohol was then protected with trityl chloride. And 184 was made by BOC protection of L- 
proline, followed by esterification, Grignard addition and deprotection with TFA.203
All these chiral amines are known compounds with the exception of trityl protected (S)- 
prolinol, 180. !H NMR of 180 showed multiplet peaks at 1.68 -  1.73, 1.80 -  1.84, 2.84 -  2.94, 
and 3.30 -  3.33 ppm corresponding to the protons on the pyrrolidine ring at positions 3, 4, 5 
and 2 respectively. The coupling between these magnetically inequivalent protons could not be 
fully analysed. The two protons on the side chain and the aromatic protons also appeared as 
multiplets at 3.05 -3 .1 1  and 7.21 -  7.45 ppm. More clear is the 13C NMR which shows the C2, 
C3, C4 and C5 carbons at 58.4, 28.1, 25.1 and 46.3 ppm respectively and the side chain carbon 
at 66.5 ppm. The trityl group appears as a tertiary carbon at 86.3 and the aromatic carbons at 
126.9, 127.8, 127.9 (para, ortho and meta positions) and 144.2 (C l’ position). High resolution 
mass spectrometry showed the molecular ion ([M+H]+) at 344.2017.
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OH
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ROH
SOCIs
LiAH
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R = Et, 176, 94% 
iPr, 177, 85% 
nBu, 178, 88%
CPh3CI
N
H OH 
179, 88%
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MeOH
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O
N
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Ph
Ph 
OH
TFA
N
' OMe Boc
182, 74% 
PhMgBr
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Ph 
OH
184, 38%
Ni
Boc
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Scheme 5.15 -  Synthesis o f  proline based chiral amines.
Initially esters 176, 177 and 178 were made and reaction of these with styrene 168 was carried 
out under neutral conditions, no reaction occurred and only unreacted starting materials were 
recovered. The reaction was then repeated at 80 °C but, again heating only resulted in 
dimerisation of the styrene.
168 185
Scheme 5.16 -  Dimerisation o f  168.
Compounds 180 and 184 were then made (Scheme 5.15) and addition of these to 168 was 
carried out under basic conditions at room temperature. Again, in both cases, this resulted in 
crude mixtures of products and, although 19F NMR showed, as before, that no styrene remained 
in either reaction, the amide products could not be isolated as pure compounds, despite 
repeated chromatography columns. Careful analysis of the crude lH NMR did show, in both 
cases, that the alpha proton was present as a pair of doublets (Jhf ~ 50 Hz) at around 6  ppm, 
this would correspond to a pair of diastereoisomers and enabled the ratio of the
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diastereoisomers in the amide products to be determined, although at this stage the 
configuration of the newly created chiral centre of the major diastereoisomer could not be 
determined.
Amine R Ratio of 
a  protons
Diastereoisomeric
excess
180 CH2OCPh3 2:5 43%
184 C(Ph2)OH 2:3 20%
Figure 5.2 -  Diastereoisomeric excess in addition o f  chiral amines to trifluorine 161.
5.3 Summary and Conclusions
While it has been shown that addition of amines to trifluorostyrenes is successful and, in the 
case of chiral amines, does result in asymmetry at the a  position, the impure nature of the 
styrenes used has meant that yields are low and isolation of the products is very difficult. 
Unfortunately this has meant that the amide diastereoisomers cannot yet be separated and their 
absolute configurations cannot yet be assigned. Nevertheless this provides at least proof-of- 
principle that the reaction can be used to provide stereochemically enriched a-fluoroamides. 
Further study of this process is clearly required.
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Chapter Six
6.1 Silane Synthesis
General Considerations: All reagents were purchased from commercial suppliers except 
those described below and used without further purification.
Thin layer chromatography was performed using Merck silica gel 60 F254 plates. Column 
chromatography was performed using silica gel 60 (220-440 mesh). Melting points were 
obtained using an uncalibrated Electrothermal digital melting point apparatus model 9100. IR 
spectra was obtained for all previously unreported compounds using a Perkin Elmer 1600 
series FTIR instrument. Elemental analyses were performed by Warwick Analytical Services 
Ltd. NMR and 13C NMR were carried out on a Bruker 400 MHz spectrometer and 19F 
NMR on a Bruker 300 MHz spectrometer; chemical shifts for *H NMR are referenced to 
tetramethylsilane (TMS) as an internal standard, chemical shifts for 19F to CFCI3 and chemical 
shifts for 13C NMR are referenced to the solvent used. Low resolution mass spectra were 
determined using a Fisons VG Platform II Quadrupole instrument. High resolution mass 
spectroscopy was carried out by the EPSRC national mass spectrometry service centre at 
Swansea University.
Dimethyl(trifluorovinyl)phenylsilane (12a)204
1,1,1,2-Tetrafluoroethane (3.5 g, 34.3 mmol) was condensed into a round-bottomed flask at -78 
°C, dry ether (20 ml) was added and the mixture was stirred for 30 mins. «-Butyllithium (15 ml 
of a 1.6 M solution in hexanes) was added drop-wise with stirring and the solution was kept at 
-78 °C for a further 2.5 hrs. Chlorodimethylphenylsilane (2 g, 12.0 mmol) was then added and 
the mixture was allowed to warm up to room temperature and was stirred overnight. Aqueous 
work up followed by extraction into ether, drying over MgSCU and evaporation yielded 12a 
(2.05 g, 81%) as a pale yellow oil, after purification by column chromatography (9:1 
hexane:ethyl acetate, v/v). 'H  NMR 8 (400 MHz; CDCI3), 0.41 (6H, s, SiMe2), 7.24-7.33 (3H, 
m, H3, H4 and H5), 7.45-7.52 (2H, m, H2 and H6 ); 19F NMR 8 (283 MHz; CDCI3), -85.7 (IF, 
dd, J  23.5, 47 Hz), -114.2 (IF, dd, J  47, 160 Hz), -197.0 (IF, dd, J  23.5, 160 Hz). (Found 
[M+H]+, 217.0659, C,0H12SiF3 requires [M+H]+, 217.0660).
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DimethyI(pentafluorophenyl)phenylsilane (12b)205
F
Bromopentafluorobenzene (2.8 g, 11.3 mmol) was dissolved in dry ether (20 ml) at -78  °C. n- 
Butyllithium (4.5 ml of a 2.5 M solution in hexanes) was added drop-wise with stirring and the 
solution was kept at -78 °C for a further 2.5 hrs. Chlorodimethylphenylsilane (1.9 g, 11.1 
mmol) was then added and the mixture was allowed to warm up to room temperature and 
stirred overnight. Aqueous work up followed by extraction into ether, drying over M gS04 and 
evaporation yielded 12b (2.99 g, 83%) as a pale yellow oil, after purification by column 
chromatography (9:1 hexane ethyl acetate, v/v). *H NMR 8 (400 MHz; CDCI3), 0.61 (6H, s, 
SiMe2), 7.26-7.34 (3H, m, H3, H4 and H5), 7.43-7.46 (2H, m, H2 and H6 ); 19F NMR 6 (283 
MHz; CDCI3), -128.4 (2F, m), -153.7 (IF, m), -163.6 (2F, m). (Found [M+H]+, 303.0623, 
C,4Hi2SiF5 requires [M+H]+, 303.0628).
Dimethyl(2,4-difluorophenyl)phenylsilane (12c)
2,4-Difluorobromobenzene (3 g, 15.5 mmol) was dissolved in dry ether (20 ml) at -78 °C. n- 
Butyllithium (7 ml of a 2.5 M solution in hexanes) was added drop-wise with stirring and the 
solution was kept at -78 °C for a further 3 hrs. Chlorodimethylphenylsilane (2.6 g, 15.2 mmol) 
was then added and the mixture was allowed to warm up to room temperature and stirred 
overnight. Aqueous work up followed by extraction into ether, drying over M gS04 and 
evaporation yielded 12c (2.21 g, 67%) as a pale yellow oil, after purification by column 
chromatography (9:1 hexane ethyl acetate, v/v). VmaX (CHCI3) 3070 w, 2959w, 1599s, 1487m, 
1400s, 1252m, 1133m, 1071m, 966m, 837s cm '1; 'H NMR S (400 MHz; CDC13), 0.50 (6H, s, 
SiMe2), 6.52-6.65 (1H, m, H3’), 6.70 -  6.79 (1H, m, H5’), 7.15 (1H, q, J  8.8 Hz H6 ’), 7.26 -
7.30 (3H, m, H3, H4 and H5), 7.44 -  7.64 (2H, m, H2 and H6 ); 19F NMR 8 (283 MHz; CDC13), 
-98.0 (IF, m), -110.6 (IF, m); 13C NMR 8 (100 MHz; CDC13), 2.3 (s, SiMe2), 103.5 (dd, J  38, 
47 Hz, C3’), 111.3 (dd, J  6 , 32 Hz, C5’), 120.1 (dd, J  7 .5, 45 Hz, C l ’), 128.0 (s, C3 and C5),
129.5 (s, C4), 133.1 (s, C l), 133.8 (s, C2 and C6 ), 137.1 (dd, J  15, 22 Hz, C6 ’), 164.2 (dd, J
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18, 249 Hz, C4’), 168.0 (dd, J  17, 251 Hz, C2’); (Found [M-F]+, 229.0845, C ,4H 14FSi requires 
[M-F]+, 354). (229.0849)
6.2 Reaction with Aldehydes
General procedure for the addition of nucleophiles to aldehydes—Aldehyde (0.15 mmol) 
and silane (0.15 mmol) were added to a round-bottomed flask and dissolved in dry THF (15 
ml). Fluoride catalyst was then added and the mixture was stirred at the listed temperature. 
After a given time, the reaction mixture was quenched with 1M HC1 (10 ml), extracted into 
ethyl acetate, dried and evaporated. Where necessary, products were purified by 
chromatography (hexane:ethyl acetate 3:7 v/v).
Reaction conditions as detailed in Table 6.1:
Silane Aldehyde Catalyst (mol%) Time,
Temperature
Yield 
of 13
Dimethyl(trifluorovinyl)
phenylsilane
3,5-dimethoxy-
benzaldehyde
TBAF (1M in THF), 
100 mol%
48 hrs, 80 
°C no 
solvent
9%
Dimethyl(trifluorovinyl)
phenylsilane
3,5-dimethoxy-
benzaldehyde
TBAF (1M in THF), 
10 mol%
48 hrs, 80 
°C in THF
0%
Dimethyl(trifluorovinyl)
phenylsilane
3,5-dimethoxy-
benzaldehyde
TBAF (1M in THF), 
10 mol%
48 hrs, room 
temp in 
THF
0%
Dimethyl(trifluorovinyl)
phenylsilane
3,5-dimethoxy-
benzaldehyde
NBu4SiPh3F2, 100 
mol%
3 days, 80 
°C in THF
0%
Dimethyl(trifluorovinyl)
phenylsilane
3,5-dimethoxy-
benzaldehyde
CsF, 100 mol% 3 days, 80 
°C
0%
Dimethyl(trifluorovinyl)
phenylsilane
3,5-dimethoxy-
benzaldehyde
CuF2/dppb, 
10 mol%
24 hrs, room 
temp, 
(under air) 
in THF
0%
Dimethyl(trifluorovinyl)
phenylsilane
p-nitro-
benzaldehyde
TBAF (1M in THF), 
100 mol%
48 hrs, 80 
°C in THF
0%
Dimethyl(trifluorovinyl)
phenylsilane
/>-chloro-
benzaldehyde
TBAF (1M in THF), 
100 mol%
48 hrs, 80 
°C in THF
0%
Dimethyl(pentafluoroph
enyl)phenylsilane
3,5-dimethoxy-
benzaldehyde
TBAF (1M in THF), 
100 mol%
48 hrs, 80 
°C no 
solvent
20%
Dimethyl(pentafluoroph
enyl)phenylsilane
3,5-dimethoxy-
benzaldehyde
TBAF (1M in THF), 
10 mol%
48 hrs, 80 
°C in THF
11%
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Dimethyl(pentafluoroph
enyl)phenylsilane
3,5-dimethoxy-
benzaldehyde
TBAF (1M in THF), 
10 mol%
48 hrs, room 
temp in 
THF
0%
Dimethyl(pentafluoroph
enyl)phenylsilane
3,5-dimethoxy-
benzaldehyde
NBu4SiPh3F2, 100 
mol%
48 hrs, 80 
°C in THF
0%
Dimethyl(pentafluoroph
enyl)phenylsilane
3,5-dimethoxy-
benzaldehyde
CsF, 100 mol% 5 days, 80 
°C in THF
0%
Dimethyl(pentafluoroph
enyl)phenylsilane
3,5-dimethoxy-
benzaldehyde
CuF2/dppb, 
10 mol%
24 hrs, room 
temp, 
(under air) 
in THF
0%
Dimethyl(pentafluoroph
enyl)phenylsilane
p-nitro-
benzaldehyde
TBAF (1M in THF), 
100 mol%
48 hrs, 80 
°C in THF
0%
Dimethyl(pentafluoroph
enyl)phenylsilane
p-chloro-
benzaldehyde
TBAF (1M in THF), 
100 mol%
48 hrs, 80 
°C in THF
0%
Dimethyl(2,4-
difluorophenyl)phenylsil
ane
3,5 dimethoxy 
benzaldehyde
TBAF (1M in THF), 
100 mol%
48 hrs, 80 
°C on 
solvent
39%
Dimethyl(2,4-
difluorophenyl)phenylsil
ane
3,5 dimethoxy 
benzaldehyde
TBAF (1M in THF), 
10 mol%
48 hrs, 80 
°C in THF
31%
Dimethyl(2,4-
difluorophenyl)phenylsil
ane
3,5 dimethoxy 
benzaldehyde
TBAF (1M in THF), 
10 mol%
48 hrs, room 
temp in 
THF
19%
Dimethyl(2,4-
difluorophenyl)phenylsil
ane
3,5 dimethoxy 
benzaldehyde
CuF2/dppb, 
10 mol%
48 hrs, room 
temp.
(under air) 
in THF
0%
Dimethyl(2,4-
difluorophenyl)phenylsil
ane
3,5 dimethoxy 
benzaldehyde
NBu4SiPh3F2, 100 
mol%
48 hrs, 80 
°C in THF
23%
Dimethyl(2,4-
difluorophenyl)phenylsil
ane
benzaldehyde TBAF (1M in THF), 
10 mol%
48 hrs, 80 
°C in THF
17%
Dimethyl(2,4-
difluorophenyl)phenylsil
ane
P-
trifluoromethyl-
benzaldehyde
TBAF (1M in THF), 
10 mol%
48 hrs, 80 
°C in THF
29%
Dimethyl(2,4-
difluorophenyl)phenylsil
ane
p-nitro-
benzaldehyde
TBAF (1M in THF), 
10 mol%
48 hrs, 80 
°C in THF
0%
Dimethyl(2,4-
difluorophenyl)phenylsil
ane
p-chloro-
benzaldehyde
TBAF (1M in THF), 
10 mol%
48 hrs, 80 
°C in THF
0%
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Table 6.1
l-(3,5-Dimethoxy-phenyl)-2,3,3-trifluoro-prop-2-en-l-ol (13a)
/O
Yellow oil. v„!ax (CHCI3) 3247w,br, 1607m, 1520w, 1486s, 1286w, 1132m, 936w cm '1; 
‘H NMR 5 (400 MHz; CDC13), 3.73 (6H, s, OMe), 6.20 (1H, d, J 3 6  Hz, Ar2CHOH), 6.41 (1H, 
d, J  2.4 Hz, H4), 6.63 (2H, d , ./ 2.4 Hz, H2 and H6 ); l9F NMR 8 (283 MHz; CDCI3), -66.5 (IF, 
ddd, J  23.5, 36, 52 Hz) -72.0 (IF, dd, J  52, 155 Hz), -131.1 (IF, dd, J  23.5, 155 Hz); 13C NMR 
8 (100 MHz; CDCI3), (Insufficient sample for clear I3C NMR); (Found [M+H]+, 249.0730, 
CnHnOsF, requires [M+H]+, 249.0739).
Pentafluorophenyl 3,5-dimethoxybenzylalcohol (13b)
OH F
/ O  F
Cubic, colourless crystals, m.p. 132-133 °C; (Found: C, 54.33; H, 3.32. C 15H 11O3F5 requires C, 
53.90; H, 3.32%); v ^ C H C fe )  3376m,br, 1599s, 1500s, 1298w, 1205m, 1156s, 1060m, 
987m, 908m c m 1; ‘H NMR 8 (400 MHz; CDC13), 3.72 (6H, s, OMe), 6.06 (1H, s, Ar2CHOH), 
6.33 (1H, d, J  2.1 Hz, H4), 6.47 (2H, d, J  2.1 Hz, H2 and H6); 19F NMR 8 (283 MHz; CDCI3), 
-144.8 (3F, m), -162.8 (2F, m); 13C NMR 8 (100 MHz; CDCI3), (Insufficient sample for clear 
13C NMR); (Found [M-F]+, 315.0641, C.sHnOsF! requires [M-F]+, 315.0644).
2’,4’-difluorophenyl 3,5-dimethoxybenzylalcohol (13c)
OH
/ O
Colourless oil. Vm^CHCb) 3422s,br, 2940m, 1598s, 1460m, 1289m, 1205s, 1157s, 1061m, 
966m, 850 c m 1; NMR 6 (400 MFlz; CDC13), 3.70 (6H, s, OMe), 5.96 (1H, s, Ar2CHOH),
6.30 (1H, d, J  2.1 Hz, H4), 6.47 (2H, d, /2 .1  Hz, H2 and H6), 6.61-6.73 (1H, m, H3’), 6.78-
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6.89 (1H, m, H5’), 7.30 (1H, q, J  7.9 Hz, H6 ’); 19F NMR 5 (283 MHz; CDClj), -1U .0 (IF, m), 
-114.2 (IF, m); n C NMR 8 (100 MHz; CDC13), 55.4 (s, OMe), 69.4 (s, CHOH), 99.5 (s, C4),
103.8 (d d ,J  25, 51 Hz, C3’), 104.2 (s, C2 and C6 ), 111.4 (dd, J 4 ,  21 Hz, C5’), 126.8 (dd, J 4 ,  
14 Hz, C l ’), 128.7 (dd, J 6, 10H z,C 6’), 145.1 (s ,C l), 159.7 (dd, J  12, 247H z,C 4’), 160.9 (s, 
C3 and C5), 162.3 (dd, J  12, 247 Hz, C2’); (Found [M+H]+, 281.0985, Ci5H 150 3F2 requires 
(M+H]+, 281.0989).
Trifluoromethyl 3,5-dimethoxybenzylalcohol (13d)
OH
CF3
Colourless oil. vmax (CHCI3) 3453s,br, 2943m, 1601s, 1464s, 1265s, 1157s, 1065s, 836m c m 1; 
'H NMR 8 (400 MHz; CDC13), 3.81 (6H, s, OCH3), 4.93 (1H, q, J  6.7 Hz, ArCHOH), 6.50 
(1H, d, J 2 .2  Hz, H4), 6.64 (2H, d, J  2.2 Hz, H2 and H6 ); l9F NMR 8 (283 MHz; CDC13), -77.9 
(3F, d, J  6.7 Hz); 13C NMR 8 (100 MHz; CDCI3), 55.4 (s, OMe), 72.6 (q, J  51 Hz, CHOH),
101.3 (s, C4), 105.6 (s, C2 and C6), 124.1 (q, J2 5 2  Hz, CF3), 136.4 (s, C l), 160.8 (s, C3 and 
C5); (Found [M+H]+, 237.0738, CioH120 3F3 requires [M+H]+, 237.0739).
(2,4-Difluoro-phenyI)-phenyl-methanol (13e)206
OH F
Colourless oil; 'H NMR 8 (400 MHz; CDCI3), 5.98 (1H, s, CHOH), 6.51-6.64 (1H, m, H3’), 
6.75-6.86 (1H, m, H5’), 7.23-7.34 (5H, m, H2, H3, H4, H5 and H6), 7.41 (1H, q, J  8.0 Hz,
H6 ’).
(2,4-Difluoro-phenyl)-(4-trifluoromethyl-phenyl)-methanol (13f)206
OH F
F3C'
Colourless oil; ‘H NMR 8 (400 MHz; CDCI3), 6.11 (1H, s, CHOH), 6.74-6.96 (2H, m, H3’ and 
H5’), 7.39 (1H, q, J  7.9 Hz, H6 ’), 7.50 (2H, d, J  8.3 Hz, H2 and H6), 7.60 (2H, d, J  8.3 Hz, H3 
and H5).
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6.3 Anti-cancer Chemistry
2-Ethyl-4,5-dimethyl-2-(3,4,5-trimethoxy-phenyl)-[l,3]dioxolane (14)
/O
2-Bromo-l-(3’,4,,5’-trimethoxy-phenyl)-ethanone (1 g, 3.6 mmol), 2,3-butanediol (0.35 g, 3.9 
mmol) and p-toluene-sulfonic acid (0.1 g, 0.5 mmol) were dissolved in toluene (50 ml) and 
refluxed at 110 °C overnight. The mixture was diluted with ether (100 ml), washed with water, 
dried over MgSC>4 and evaporated under vacuum to give 14 as a colourless oil (1.14 g, 88%); 
Vmax (CHCI3) 2936m, 1683w, 1591s, 1503s, 1456s, 1413s, 1331s, 1232m, 1127s, 1006m, 926w 
cm '1; ‘H NMR 8 (400 MHz; CDCI3), 1.19 (6H, d, J  5.5 Hz, Me), 3.54 (2H, s, CH2Br), 3.80 
(6H, s, OMe), 3.83 (3H, s, OMe), 4.10-4.14 (2H, m, OCHMe), 6.68  (2H, s, ArH); 
l3C NMR 5 (100 MHz; CDCI3), 14.2 (s, Me), 36.8 (s, CH2Br), 55.1 (s, OMe), 55.4 (s, OMe),
73.5 (s, OCHMe), 101.9 (s, C2 and C6 ), 104.5 (s, CAr), 135.2 (s, C l), 136.8 (s, C4), 152.0 (s, 
C3 and C5); (Found [M+H]+, 361.0652, Ci5H210 579Br requires [M+H]+, 361.0651).
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Chapter Seven
7.1 CN Chalcones
Ethyl 3,4,5-trimethoxybenzoate (3 7 ) 2 0 7
O
3,4,5-Trimethoxybenzoic acid (9 g, 42 mmol) was dissolved in ethanol (50 ml). Cone, sulfuric 
acid (2 ml) was added and the solution was refluxed at 85 °C with stirring. After 3 hours the 
reaction mixture was cooled to room temperature, the solvent evaporated under vacuum and 
the residue taken up in ether (20 ml). This was washed with water and sat. NaHC03, dried over 
MgSCU and evaporated to yield white crystals (8.3 g, 81%). m.p. 53-55 °C (lit.m.p. 2 0 7 60 °C); 
]H NMR 6  (400 MHz; CDC13), 1.41 (3H, t, J 7.0 Hz, CH2 CH3), 3.91 (3H, s, OMe), 3.92 (6 H, s, 
OMe), 4.39 (2H, q, J 7.0 Hz, CI^CTTs), 7.32 (2H, s, H2 and H6 ).
3-Oxo-3-(3’,4’,5Mrimethoxyphenyl)propionitriIe (38)208
O
CN
Ethyl 3,4,5-trimethoxybenzoate (37, 3.45 g, 14.4 mmol) and 60% dispersion sodium hydride in 
mineral oil (1.25 g, 31 mmol) were added to dry toluene (50 ml) under nitrogen and the 
suspension heated to 90 °C. Acetonitrile (1.5 ml, 29.3 mmol) was added drop wise with stirring 
and the mixture was stirred at 90 °C for a further 24 hrs. It was then cooled to room 
temperature and filtered. The filtrate was dissolved in water and the pH adjusted to 4 with 1M 
HC1. This was then extracted with DCM, dried over MgSC>4 and evaporated under vacuum to 
leave a crude solid, recrystallisation from 50/50 EtOH/water yielded yellow crystals (2.8 g, 
83%). m.p. 138-140 °C (lit. m.p. 2 0 9  139-140 °C); (Found: C, 60.82; H, 5.60; N, 5.88. 
C 12H13O4N requires C, 61.27; H, 5.53; N, 5.96%); vnMX(CHCl3) 2941s, 2267m, 1679s, 1582s, 
1502s, 1459s, 1338m, 1117m, 989m, 757s cm'1; 'H NMR 5 (400 MHz; CDC13), 3.87 (6 H, s, 
OMe), 3.88 (3H, s, OMe), 4.00 (2H, s, CH2 CN), 7.08 (2H, s, H2’ and H6 ’); 13C NMR 5 (100 
MHz; CDCI3 ), 29.3 (s, C2), 56.4 (s, OMe), 61.1 (s, OMe), 106.0 (s, C2’ and C6 ’), 114.0 (s,
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C3), 129.3 (s, C l ’), 143.9 (s, C4’), 153.3 (s, C3’ andC5’), 186.0 (s, C l); (Found [M+H]+, 236, 
C 12H 14O4N requires [M+H]+, 236).
General procedure for the synthesis of chalcones—3-Oxo-3-(3,4,5-
trimethoxyphenyl)propionitrile (38, 0.1 g, 0.43 mmol) and the appropriate aryl aldehyde (0.45 
mmol) were warmed in ethanol (50 ml) until they dissolved. The solution was then cooled to 
room temperature and piperidine (3-5 drops) was added. If after 48 hours the chalcone product 
had not precipitated out, the ethanol was removed under vacuum and the residue partitioned 
between DCM and water. The DCM fraction was evaporated and the chalcone isolated by 
column chromatography (7:3 hexane:ethyl acetate, v/v).
3-Benzo[l,3]dioxol-5-yl-2-(3\4’,5’-trimethoxybenzoyI)acryIonitrile (39a)
O
CN
Yellow crystals (35%); m.p. 180-182 °C; (Found: C, 65.83; H, 4.85; N, 3.95. C2oHi7N06 
requires C, 65.40; H, 4.63; N 3.81%); VmaxfCHCb) 2940w, 2248w, 1660m, 1609w, 1581m, 
1504m, 1454m, 1416m, 1332s, 1276m, 1216m, 1129s, 1034w, 999w, 924w, 854w, 754m cm'1; 
]H NMR 6 (400 MHz; CDC13), 3.74 (6H, s, OMe), 3.76 (3H, s, OMe), 5.93 (2H, s, OCH20), 
6.74 (1H, d ,J  8.1 Hz, H5” ), 6.99 (2H, s, H2’ andH 6 ’), 7.27 (1H, dd, J  1.5, 8.1 Hz, H6 ” ), 7.61 
(1H, d, J  1.5 Hz, H2” ), 7.84 (1H, s, H3); 13C NMR 6 (100 MHz; CDC13), 56.4 (s, OMe), 61.4 
(s, OMe), 102.8 (s, OCH20), 107.0 (s, C2), 107.3 (s, C2’ and C6 ’), 109.4 (s, C2” ) overlapping
109.4 (s, C6” ), 118.3 (s, CN), 126.8 (s, C5” ), 130.5 (s, C l” ), 131.3 (s, C l’), 143.0 (s, C4’),
149.1 (s, C4” ), 152.9 (s, C3” ), 153.4 (s, C3’ and C5’), 155.7 (s, C3), 188.0 (s, Cl); (Found 
[M+H]+, 368.1134, C20Hi8NO6 requires [M+H]+, 368.1134).
3-(4” -Methoxyphenyl)-2-(3’,4’,5’-trimethoxybenzoyl)acrylonitrile (39b)
O
CN
Yellow powder (76%); m.p. 132-133 °C; (Found: C, 67.77; H, 5.55; N, 3.88. C2oHi90 5N 
requires C, 67.99; H, 5.38; N, 3.97%); vmax(CHCl3) 2940w, 2250m, 1660m, 1583s, 1510s, 
1455m, 1414m, 1333s, 1268s, 1172s, 1127s, 1027m, 999m, 829m, 754s c m 1; 1H NMR 5 (400
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MHz; CDCI3), 3.74 (3H, s, OMe), 3.76 (6H, s, OMe), 3.78 (3H, s, OMe), 6.85 (2H, d, J  8.9 Hz, 
H3”  and H5” ), 7.01 (2H, s, H2’ and H6 ’), 7.91 (2H, d, J  8.9 Hz, H2” and H6 ” ) overlapping, 
7.94 (1H, s, H3); l3C NMR 8 (100 MHz; CDCI3), 55.7 (s, OMe), 56.4 (s, OMe), 61.1 (s, OMe),
106.2 (s, C2), 106.9 (2C, s, C2” and C6 ” ), 114.9 (s, C3’ and C5’), 118.1 (s, CN), 124.8 (s, 
C l ’), 131.1 (s, C l” ), 133.9 (s, C2’ and C6 ’), 142.5 (s, C4” ), 153.0 (s, C3”  andC5” ), 155.4 (s, 
C3), 164.0 (s, C4’), 187.8 (s, C l); (Found [M+H]+, 354.1343, C2 0 H2 0 O5N requires [M+H]+, 
354.1341).
(O)-TBDMS-isovanilin (40)210
Isovanillin (1.56 g, 10.3 mmol) was dissolved in DMF (15 ml). TBDMS-C1 (1.76 g, 11.7 
mmol) and imidazole (0.82 g) were added and the mixture was stirred overnight at room 
temperature. Water (100 ml) was then added and the product was extracted into chloroform, 
dried over MgSC>4 and evaporated under vacuum. Column chromatography (8:2 hexane:ethyl 
acetate, v/v) yielded a brown oil (1.875 g, 69%). JH NMR 6 (400 MHz; CDCI3), 0.01 (6H, s, 
SiMe2), 0.83 (9H, s, 'Bu), 3.72 (3H, s, OMe), 6.78 (1H, d, J  8.3 Hz, H5), 7.20 (1H, d, J  1.9 Hz, 
H2), 7.31 (1H, dd, J  1.9, 8.3 Hz, H6), 9.64 (1H, s, CHO).
3-[3” -(te/*-ButyldimethylsiIyloxy)-4” -methoxyphenyl]-2-(3%4’,5,-trimethoxybenzoyI)- 
acrylonitrile (39c)
CN
A brown viscous oil (40%); Vm^CHCb) 3015m, 2937m, 2859m, 2210w, 1659m, 1584s, 
1504s, 1464s, 1442s, 1415s, 1333s, 1276s, 1242s, 1169s, 1129s, 789w, 753m, 730m, 665m cm' 
*; *H NMR 5 (400 MHz; CDC13), 0.01 (6H, s, SiMe2), 0.80 (9H, s, lBu), 3.70 (3H, s, OMe), 
3.71 (6H, s, OMe), 3.72 (3H, s, OMe), 6.74 (1H, d, J  8.5 Hz, H5” ), 6.97 (2H, s, H2’ and H6 ’), 
7.46 (1H, dd, J  2.0, 8.5 Hz, H6 ” ), 7.49 (1H, d, J  2.0 Hz, H2” ), 7.81 (1H, s, H3); 
13C NMR 8 (100 MHz; CDC13), -4.2 (s, SiC(CH3)3), -3.2 (s, SiMe2), 26.0 (s, C(CH3)3), 53.9 (s, 
OMe), 56.1 (s, OMe), 61.4 (s, OMe), 102.3 (s, C2), 107.2 (s, C2’ and C6 ’), 112.9 (s, C2” ),
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117.0 (s, CN), 117.4 (s, C5” ), 126.7 (s, C6 ” ), 126.1 (C l” ), 131.4 (s, C l’), 142.2 (s, C3” ),
146.6 (s, C4’), 151.9 (s, C4” ), 153.4 (s, C3’ and C5’), 155.5 (s, C3), 188.5 (s, C l); (Found M*, 
483.2079, C26H33N0 6Si requires M+, 483.2072).
3-(3” -Hydroxy-4” -methoxyphenyl)-2-(3’,4’,5,-trimethoxybenzoyl)acrylonitrile (39d)
O
CN
OH
3-[3” -(ter/-Butyldimethylsilyloxy)-4” -methoxyphenyl]-2-(3,,4,,5’-trimethoxybenzoyl)- 
acrylonitrile (39c, 0.254 g, 0.5 mmol) was dissolved in dry THF (20 ml) and TBAF (1 ml of a 
1 M solution in THF) was added. This was stirred for 30 mins after which time water (50 ml) 
was added. The mixture was extracted with ethyl acetate, dried over MgSC>4 and evaporated 
under vacuum. The residue was purified by column chromatography (7:3 hexane.ethyl acetate, 
v/v) to give yellow crystals (0.117 g, 60%); m.p. 145-147 °C; (Found: C, 65.36; H, 5.57; N, 
3.59. C20H 19NO6 requires C, 65.04; H, 5.15; N 3.79%); v ^  (CHC13) 2938s, 2255m, 1583m, 
1506m, 1415m, 1331m, 1282m, 1127s, 754w cm '1; *H NMR 5 (400 MHz; CDC13), 3.86 (6H, s, 
OMe), 3.88 (3H, s, OMe), 3.94 (3H, s, OMe), 5.65 (1H, s, ArOH), 6.91 (1H, d, J  8.5 Hz, H5” ), 
7.12 (2H, s, H2’ and H6 ’), 7.58 (1H, dd, 72.2, 8.5 Hz, H6 ” ), 7.65 (1H, d , /2 .2  Hz, H2” ), 7.96 
(1H, s, H3); l3C NMR 8 (100 MHz; CDCI3), 56.6 (s, OMe), 56.7 (s, OMe), 61.4 (s, OMe),
106.7 (s, C2), 107.3 (s, C2’ and C6 ’), 111.2 (s, C2” ), 116.8 (s, CN), 118.2 (s, C5” ), 125.8 (s, 
C6” ), 126.6 (C l” ), 131.4 (s, C l ’), 142.9 (s, C3” ), 146.4 (s, C4’), 151.7 (s, C4” ), 153.4 (s, 
C3’ and C5’), 155.9 (s, C3), 188.3 (s, C l); (Found [M+H]+, 370.1281, C2oH20N 0 6 requires 
[M+H]+, 370.1285).
3-(3,%4” -DimethoxyphenyI)-2-(3%4’,5’-trimethoxybenzoyl)-acrylonitrile (39e)
O
CN
Yellow powder (79%); m.p. 172-173 °C; (Found: C, 66.13; H, 5.66; N, 3.67. C21H21NO6 
requires C, 65.80; H, 5.48; N 3.66%); vmax(CHCl3) 2942w, 2205w, 1657m, 1583m, 1505s, 
1466m, 1415m, 1333s, 1280s, 1216m, 1165m, 1127s, 1018m, 850w, 756m cm'1; 
*H NMR 6 (400 MHz; CDC13), 3.87 (6H, s, OMe), 3.89 (3H, s, OMe), 3.92 (3H, s, OMe), 3.93
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(3H, s, OMe), 6.89 (1H, d, J  8.5 Hz, H5” ), 7 08 (2H, s, H2’ and H6’), 7.46 (1H, dd, J2 .1 , 8.5 
Hz, H6” ), 7.84 (1H, d, J  2.1 Hz, H2” ), 8.02 (1H, s, H3); 13C NMR 8 (100 MHz; CDC13), 56.5 
(s, OMe), 56.6 (s, OMe), 56.8 (s, OMe), 61.4 (s, OMe), 106.5 (s, C2), 107.3 (s, C2’ and C6’),
111.4 (s, C2” ), 112.0 (s, C5” ), 118.7 (s, CN), 125.4 (s, C6” ), 128.8 (s, C l” ), 131.5 (s, C l’),
142.9 (s, C4’), 149.7 (s, C4” ), 153.4 (s, C3’ and C5’), 154.3 (s, C3” ), 156.1 (C3), 188.1 (s, 
C l); (Found [M+HJ+, 384.1441, C21H22NO6 requires [M +H f, 384.1447).
2-(3%4\5’-Trimethoxybenzoyl)-3-(2” ,3” ,4” -trimethoxyphenyI)-acrylonitrile (39f)
O
CN
/ O
Yellow powder (76%); m.p. 144-145 °C; (Found: C, 63.82; H, 5.68; N, 3.32. C22H23NO7 
requires C, 63.92; H, 5.57; N 3.39%); vims(CHC13) 2943w, 2237w, 1656m, 1581s, 1497s, 
1462m, 1414s, 1330m, 1292s, 1214m, 1171w, 1127s, 1097s, 1004m, 754w cm'1; 
'H  NMR 5 (400 MHz; CDC13), 3.80 (3H, s, OMe), 3.86 (6H, s, OMe), 3.88 (3H, s, OMe), 3.89 
(3H, s, OMe), 3.90 (3H, s, OMe), 6.75 (1H, d, J9 .0  Hz, H3” ), 7.10 (2H, s, H2’ andH 6’), 8.22 
(1H, d, J 9.0 Hz, H2” ), 8.40 (1H, s, H3); l3C N M R8 (100 MHz; CDC13), 56.3 (s, OMe), 56.4 
(s, OMe), 61.0 (s, OMe), 61.1 (s, OMe), 62.1 (s, OMe), 107.0 (s, C2), 107.4 (s, C5” ), 107.6 (s, 
C2’ and C6’), 118.0 (s, CN), 119.0 (s, C l” ), 125.0 (s, C6” ), 131.1 (s, C l ’), 141.8 (s, C3” ),
142.5 (s, C4’), 149.9 (s, C2” ), 153.0 (s, C4” ), 155.0 (s, C3’ and C5’), 158.6 (s, C3), 188.2 (s, 
Cl); (Found [M+H]+, 414.1554, C22H24NO7 requires [M+H]+, 414.1553).
3-(4’ ’-T rifluoromethyIphenyl)-2-(3’,4%5’-trimethoxybenzoyI)-acrylonitrile (39g)
O
CN
CF
White powder (51%); m.p. >230 °C; (Found: C, 61.78; H, 4.14; N, 3.21. C2oH16N 0 4F3 requires 
C, 61.38; H, 4.09; N 3.58%); vmax(CHCl3) 2950w, 2362w, 1716w, 1512w, 1463s, 1377s, 
1331m, 1168w, 1129m, 1069w, 721m c m 1; ‘H NMR, 5(400 MHz; d6-DMSO), 3.67 (3H, s, 
OMe), 3.75 (6H, s, OMe), 6.55 (1H, s, H3), 6.97 (2H, s, H2’ and H6’), 7.78 (2H, d, J  8.8 Hz, 
H3” and H5” ), 7.80 (2H, d, J  8.8 Hz, H2”  and H6” ); 19F NMR 8 (283 MHz; CDC13), -60.7
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(IF, s); 13C NMR 8 (100 MHz; d6-DMSO), 56.3 (s, OMe), 60.3 (s, OMe), 103.0 (s, C2), 107.6 
(s, C2’ and C6’), 117.4 (s, CN), 123.3 (q, J  249 Hz, CF3), 124.1 (s, C3”  and C5” ), 126.9 (s, 
C2” and C6” ), 131.0 (q ,J 5 0  Hz, C4” ) 131.1 ( s ,C l’), 136.6 (s,C3), 139.0 (s, C l” ), 142.5 (s, 
C4’), 155.0 (s, C3’ and C5’), 188.3 (s, C l); (Found [M+H]+, 392.1107, C2oH|7N0 4F3 requires 
[M +Hf, 392.1109).
3-(2” -Fluoro-4’ ’-methoxyphenyl)-2-(3’,4’,5’-trimethoxy benzoy l)acry lonitrile (39h)
O
CN
Yellow needles (41%); m.p. 168-170 °C; (Found: C, 64.58; H, 5.02; N, 3.83. C2oH18N 0 5F 
requires C, 64.69; H, 4.85; N 3.77%); (CHC13) 3452s,br, 2208w, 1660m, 1617m, 1581m,
1503w, 1336w, 1300w, 1282w, 1219m, 1130m, 1097w, 1024w, 853w, 756w cm '1; NMR 
. 6 (400 MHz; CDC13), 3.86 (3H, s, OMe), 3.89 (6H, s, OMe), 3.91 (3H, s, OMe), 6.65 (1H, dd, 
72.5, 12.2 Hz, H3” ), 6.79 (1H, dd, 72.5, 9.0 Hz, H5” ), 7.10 (2H, s, H2’ and H6’), 8.28 (1H, s, 
H3), 8.46 (1H, dd, J  8.8, 8.8 Hz, H6” ); 19F NMR 8(283 MHz; CDCU), -108.6 (IF, m); 
13C NMR 8 (100 MHz; CDCU), 58.9 (s, OMe), 59.2 (s, OMe), 63.9 (s, OMe), 104.6 (d, J  25 
Hz, C3” ), 109.8 (s, C2’ and C6’), 110.7 (s, C2), 114.3 (d, J  17 Hz, C l” ), 115.9 (d, J  11 Hz, 
C5” ), 120.4 (s, CN), 133.3 (d, J  56 Hz, C6” ), 145.5 (s, C l ’), 149.1 (d, J  8 Hz, C4” ), 155.9 (s, 
C3’ and C5’), 166.5 (d, J  256 Hz, C2” ), 168.3 (s, C4’), 168.4 (s, C3), 190.4 (s, C l); (Found 
[M+H]+, 372.1241, C2oH]9N05F requires [M+H]+, 372.1247).
3-(3” -Fluoro-4” -methoxy-phenyl)-2-(3,,4%5,-trimethoxy-benzoyl)-acrylonitriIe (39i)
O
CN
Yellow crystals (25%); m.p. 163-164 °C; (Found: C, 64.41; H, 4.83; N, 3.74. C2oHi805NF 
requires C, 64.70; H, 4.85; N, 3.77%); vmax(CHCl3) 3438s,br, 2280w, 1655m, 1582m, 1506s, 
1415m, 1332s, 1287s, 1210m, 1127s, 1019w, 754m cm '1; 'H NMR 8 (400 MHz; CDCU), 3.87 
(6H, s, OMe), 3.89 (3H, s, OMe), 3.93 (3H, s, OMe), 7.01 (1H, dd, J  8.5, 8.5 Hz, H5” ), 7.13 
(2H, s, H2’ and H6’), 7.75 (1H, d, J  8.5 Hz, H6” ), 7.88 (1H, dd, J  2.2, 12.0 Hz, H2” ), 7.97 
(1H, s, H3); 19F NMR 8 (283 MHz; CDCU), -132.2 (IF, m); 13C N M R 8(100  MHz; CDCU),
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56.4 (s, OMe), 56.5 (s, OMe), 61.1 (s, OMe), 107.0 (s, C2’ andC 6 ’), 108.7 (s, C2), 109.8 (d, J  
256 Hz, C3” ), 114.3 (d, J  1 Hz, C l” ), 114.7 (d, J  8  Hz, C5” ), 117.4 (s, CN), 128.3 ( d , J \ 7  
Hz, C6 ” ), 130.7 (s, C l ’), 142.8 (d, J  51 Hz, C4” ), 153.0 (s, C3’ and C5’), 160.1 (d ,J 2 5  Hz, 
C2” ), 161.0 (s, C4’), 163.0 (s, C3), 187.2 (s, Cl); (Found [M+H]+, 372.1244, C2 0 H 1 9NO5F 
requires [M+H]+, 372.1247).
3-(3” -Bromo-4” -methoxyphenyl)-2-(3’,4’,5’-trimethoxybenzoyl)acrylonitrile (39j)
O
CN
Yellow crystals (52%); m.p. 168-169 °C; (Found: C, 55.41; H, 4.21; N, 3.10. CzoHigNOsBr 
requires C, 55.56; H, 4.17; N 3.24%); Vmax (CHC13) 3428s,br, 2242w, 1658m, 1583s, 1497s, 
1414m, 1332m, 1275m, 1127s, 1012w, 754m cm'1; NMR 6  (400 MHz; CDCI3), 3.87 (6 H, s, 
OMe), 3.89 (3H, s, OMe), 3.92 (3H, s, OMe), 6.96 (1H, d, J  8 . 8  Hz, H5” ), 7.12 (2H, s, H2’ 
and H6 ’), 7.94 (1H, s, H3) 8.07 (1H, dd, J  2.3, 8 . 8  Hz, H6 ” ), 8.16 (1H, d, J  2.3 Hz, H2” ); 
13C NMR 6  (100 MHz; CDCI3), 56.8 (s, OMe), 57.1 (s, OMe), 61.5 (s, OMe), 107.3 (s, C2’ 
and C6 ’), 108.1 (s, C2), 112.4 (s, C3” ), 113.0 (s, C5” ), 118.0 (s, CN), 126.3 (s, C6 ” ), 131.1 
(s, C l” ), 132.7 (s, C l ’), 137.2 (s, C2 ” ), 143.1 (s, C4’), 153.4 (s, C3), 154.0 (s, C3’ and C5’),
160.2 (s, C4” ), 187.6 (s, C l); (Found [M+H]+, 432.0442, C2oH19N0579Br requires [M+H]+, 
432.0441).
7.2 Ester Chalcones
Ethyl 3-oxo-3-(3\4%5’-trimethoxyphenyl)propionate (41)211
O O
/ O
Diethyl carbonate (50 ml) and dibutyl ether (50 ml) were heated to reflux and sodium (2 g, 87 
mmol) was added cautiously with stirring over 30 mins. The resulting purple solution was 
stirred for 30 mins and then 3,4,5-trimethoxyacetophenone (4 g, 19 mmol) was added over 30 
mins more. The reaction mixture was refluxed for a further 4 hours, cooled to room 
temperature and poured over crushed ice and acetic acid (200 ml). This was extracted into 
ether, evaporated and recrystallisation from methanol yielded 41 as white needles (3.5 g, 67%).
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m.p. 90-91 °C (lit. m.p.212 93-94 °C); lH NMR 5(400 MHz; CDC13), 1.28 (3H, t, J  7.1 Hz, 
CH3), 3.93 (6H, s, OMe), 3.94 (3H, s, OMe), 3.98 (2H, s, COCH2CO) 4.23 (2H, q, J  7.1 Hz, 
CH2), 7.27 (2H, s, H2’ and H6 ’).
(The following chalcones were prepared by reaction of 41 with aldehydes according to the 
procedure described above)
(Z)-2-Ethoxycarbonyl-3-(4” -Methoxyphenyl)-l-(3’,4’,5’-trimethoxypheiiyl)propen-l-one
(42a)
OEt
Pale oil ( 11%); vmax(CHCl3) 2937w, 1714s, 1602s, 1513m, 1414m, 1328s, 1254s, 1175s, 
1126s, 1024w cm '1; *H NMR 5 (400 MHz; CDC13), 1.24 (3H, t, J  7.1 Hz, CH3), 3.80 (3H, s, 
OMe), 3.86 (6H, s, OMe), 3.96 (3H, s, OMe), 4.27 (2H, q, J  7.1 Hz, CH2), 6.80 (2H, d, J  8.9 
Hz, H3” and H5” ), 7.25 (2H, s, H2’ and H6 ’), 7.34 (2H, d, J  8.9 Hz, H2”  and H6 ” ), 7.94 
(1H, s, H3). 13C NMR 5 (100 MHz; CDC13), 14.2 (s, CH3), 55.3 (s, OMe), 56.2 (s, OMe), 61.0 
(s, OMe), 61.4 (s, CH2), 106.4 (s, C2’ and C6 ’)> 114.3 (s, C3”  and C5” ), 125.4 (s, C2), 128.3 
(s, C l” ), 131.3 (s, C l ’), 132.3 (s, C2”  and C6 ” ), 142.4 (s, C3), 143.2 (s, C4’), 153.2 (s, C3’ 
and C5’), 161.4 (s, C4” ), 165.4 (s, COOEt), 195.0 (s, C l); (Found [M+H]+, 401.1602, 
C22H2507 requires [M+H]+, 401.1600).
(Z)-2-Ethoxycarbonyl-3-[3” -(^/t-Butyl-dimethyl-silanyloxy)-4” -methoxy-phenyl]-l- 
(3 ’ ,4’,5’-trimethoxyphenyl)propen-l -one(42b)
OEt
/ O
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Dark brown oil (57%); vmax (CHCI3) 2937s, 2857m, 1733s, 1713s, 1665s, 1616m, 1510s, 
1443s, 1373s, 1267s, 1247s, 1188s, 1162s, 1130s, 1094m, 1000s, 910m, 844s, 810m, 785m, 
738s, 704s cm '1; NMR 5 (400 MHz; CDC13), 0.00 (6H, s, Si(CH3)2), 0.91 (9H, s, C(CH3)3),
1.28 (3H, t, J  7.0 Hz, OCH2CH3), 3.80 (3H, s, OMe), 3.85 (6H, s, OMe), 3.92 (3H, s, OMe), 
4.25 (2H, q, J  7.0 Hz, OCH2CH3), 6.76 (1H, d, J  8.5 Hz, H5” ), 6.83 (1H, d, J  2.2 Hz, H2” ),
7.02 (1H, dd, J  2.2, 8.5 Hz, H6 ” ), 7.26 (2H, s, H2’ and H6 ’), 7.86 (1H, s, H3); 
13C NMR 5 (100 MHz; CDC13), -4.9 (s, SiMe2), 14.2 (s, CH2CH3), 18.3 (s, CMe3), 25.6 (s, 
C(CH3)3), 55.4 (s, OMe), 56.2 (s, OMe), 60.9 (s, OMe), 61.4 (s, CH2CH3), 106.4 (s, C2’ and 
C6 ’), 111.6 (s, C5” ), 121.9 (s, C2” ), 125.6 (s, C2), 126.1 (s, C6 ” ), 128.1 (s, C l” ), 131.3 (s, 
C l ’), 142.4 (s, C3), 143.2 (s, C3” ), 144.9 (s, C4’), 153.3 (s, C3’ and C5’), 153.3 (s, C4” ),
165.4 (s, COOEt), 194.7 (s, C l); (Found [M+H]+, 531.2410, C28H390 8Si requires [M+H]+, 
531.2414).
(Z)-2-Ethoxycarbonyl-3-(3” -Hydroxy-4” -methoxy-phenyl)-l-(3\4%5’- 
trimethoxyphenyI)propen-l-one (42c)
OH
OEt
Pale yellow, cubic crystals (70%); m.p. 123-125 °C; (Found: C, 63.46; H, 5.84. C22H2408 
requires C, 63.46; H, 5.77%); vmax(CHCl3) 3412s,br, 2938s, 1664s, 1581s, 1510s, 1459m, 
1324m, 1251s, 1128s, 754s cm '1; JH NMR 6 (400 MHz; CDC13), 1.14 (3H, t ,J 7 .1  Hz, CH3), 
3.76 (6H, s, OMe), 3.77 (3H, s, OMe), 3.84 (3H, s, OMe), 4.16 (2H, q, J  7.1 Hz, CH2), 5.67 
(1H, s, OH), 6.65 (1H, d, J  8.1 Hz, H5” ), 6.84 (1H, dd, J  2.2, 8.1 Hz, H6 ” ), overlapping 6.85 
(1H, d, J  2.2 Hz, H2” ), 7.14 (2H, s, H2’ and H6 ’), 7.78 (1H, s, H3). 13C NMR 5 (100 MHz; 
CDC13), 14.2 (s, CH3), 55.9 (s, OMe), 56.2 (s, OMe), 60.9 (s, OMe), 61.5 (s, CH2), 106.4 (s, 
C2’ and C6 ’), 110.5 (s, C2” ), 116.0 (s, C5” ), 123.7 (s, C6 ” ), 126.3 (s, C2), 128.9 (s, C l” ),
131.4 (s, C l ’), 142.5 (s, C3), 143.1 (s, C3” ), 145.5 (s, C4’), 148.5 (s, C4” ), 153.2 (s, C3’ and 
C5’), 165.3 (s, COOEt), 194.7 (s, C l); (Found [M+H]+, 417.1547, C22H250 8 requires [M+H]+, 
417.1544).
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(Z)-2-Ethoxycarbonyl-3-(3’\ 4 ” -dimethoxy-phenyl)-l-(3’,4%5’-trimethoxyphenyl)propen- 
1-one(42d)
OEt
Colourless oil (35%); v ^ C H C fe )  2938s, 1713s, 1582s, 1414m, 1325m, 1228s, 1127s, 1023m 
cm '1; *H NMR 5 (400 MHz; CDC13), 1.16 (3H, t, J  7.1 Hz, CH2CH3), 3.57 (3H, s, OMe), 3.76 
(6H, s, OMe), 3.78 (3H, s, OMe), 3.84 (3H, s, OMe) 4.18 (2H, q, J  7.1 Hz, CH2CH3), 6.69 
(1H, d, J  8.4 Hz, H5” ), 6.77 (1H, d, J  1.8 Hz, H2” ), 6.94 (1H, dd, J  1.8, 8.4 Hz H6 ” ), 7.17 
(2H, s, H2’ and H6 ’) 7.82 (1H, s, H3). 13C NMR 5 (100 MHz; CDC13), 14.2 (s, CH3), 55.6 (s, 
OMe), 55.9 (s, OMe), 56.3 (s, OMe), 61.0 (s, OMe), 61.5 (s, CH2), 106.3 (s, C2’ and C6 ’),
110.9 (s, C2” ), 112.3 (s, C5” ), 125.0 (s, C6 ” ), 125.6 (s, C2), 128.5 (s, C l” ), 131.4 (s, C l’),
142.5 (s, C3), 143.3 (s, C4’), 148.7 (s, C4” ), 151.0 (s, C3” ), 153.3 (s, C3’ and C5’), 165.3 (s, 
COOEt), 194.9 (s, C l); (Found [M+H]+, 431.1701, C23H270 8 requires [M+H]+, 431.1706).
(Z)-2-Ethoxycarbonyl-3-(2” ,3” ,4”-trimethoxy-phenyl)-l-(3,,4%5,- 
trimethoxyphenyI)propen-l-one (42e)
OEt
Yellow oil (48%); (C H C l,) 2940s, 2363w, 1714s, 1585s, 1462s, 1326s, 1229s, 1100s, 
1006s, 704m cm'1; ]H NMR 5 (400 MHz; CDC13), 1.13 (3H, t, J  7.1 Hz, CH2CH3), 3.73 (6H, 
s, OMe), 3.77 (6H, s, OMe), 3.83 (3H, s, OMe), 3.86 (3H, s, OMe), 4.18 (2H, q, J  7.1 Hz, 
CH2CH3), 6.39 (1H, d, J  8.8 Hz, H5” ), 6.87 (1H, d, 7 8 .8  Hz, H6 ” ), 7.12 (2H, s, H2’ and H6 ’), 
8.14 (1H, s, H3); 13C NMR 5 (100 MHz; CDC13), 14.2 (s, CH3), 55.9 (s, OMe), 56.2 (s, OMe),
60.8 (s, OMe), 60.9 (s, OMe), 61.3 (s, OMe), 61.5 (s, CH 2), 106.3 (s, C2’ and C6 ’), 107.3 (s, 
C5” ), 120.0 (s, C l” ), 125.1 (s, C6 ” ), 129.3 (s, C2 ), 131.4 (s, C l ’), 137.7 (s, C3), 141.8 (s,
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C4’), 142.9 (s, C3” ), 153.1 (s, C3’ and C5’), 155.8 (s, C2” ), 156.0 (s, C4” ), 165.3 (s, 
COOEt), 194.6 (s, C l); (Found [M+H]+, 461.1806, C24H29O9 requires [M+H]+, 461.1812).
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Chapter Eight
8.1 a-Fluorochalcones
3,4,5-Trimethoxyacetophenone trimethylsilyl enol ether (86)213
O
Diisopropylamine (5.5 g, 54.5 mmol) was dissolved in dry THF (100 ml) at 0 °C and BuLi (20 
ml of a 2.5 M solution in hexanes) was added drop-wise with stirring. This was then cooled to 
-78 °C and 3,4,5-trimethoxyacetophenone (10 g, 47.6 mmol) was added, followed by HMPA 
(8.5 ml). After a further 10 mins, trimethylsilylchloride (6.0 g, 55.0 mmol) in THF (20 ml) 
was added and the mixture was left to warm slowly to room temperature. It was then diluted 
with hexane (100 ml), washed with water and sat. NaCl solution, dried over MgSC>4 and 
evaporated under vacuum to leave a colourless oil (5.1 g, 38%). *H NMR 6 (400 MHz; CDCI3) 
0.05 (9H, s, Si(CH3)3), 3.64 (6H, s, OMe), 3.67 (3H, s, OMe), 4.21 (1H, s, (Z)=CH), 4.63 (1H, 
s, (£)=CH), 6.66 (2H, s, ArH).
Fluorination of 3,4,5-trimethoxyacetophenone ‘buty Idimethylsily 1 enol ether
3.4.5-Trimethoxyacetophenone ^utyldimethylsilyl enol ether (0.1 g, 0.31 mmol) and 
Selectfluor™ (0.11 g, 0.31 mmol) were dissolved in acetonitrile (10 ml) and stirred at room 
temperature for 2 hrs. The acetonitrile was then evaporated and the residue was partitioned 
between water and dichloromethane. Evaporation of the DCM yielded 0.083 g of oil, *H NMR 
analysis of which showed it to be a 3:2 mixture of 3,4,5-trimethoxyacetophenone : 2’-fluoro-
3.4.5-trimethoxyacetophenone.
2’-Bromo-3,4,5-trimethoxyacetophenone (87)214
3,4,5-Trimethoxyacetophenone (10 g, 47.6 mmol) was dissolved in acetic acid (50 ml) and 
stirred at room temperature. Bromine (2.5 ml, 48.8 mmol) was added drop-wise with stirring
O
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and the mixture was then left for a further 2 hrs. Water (200 ml) was added and the product 
was extracted into DCM, washed with sat. NaCl, dried over MgSC>4 and evaporated to leave a 
black oil. Purification by silica chromatography using a 3:7 mixture of EtOAc : hexane 
(Rf=0.23) yielded 87 as white crystals (5.71 g, 43%). m.p. 67-68 °C (lit.215 m.p. 68-70 °C); 
'H NMR 8 (400 MHz; CDC13), 3.86 (6H, s, OMe), 3.87 (3H, s, OMe), 4.35 (2H, s, H2’), 7.19 
(2H, s, H2 and H6 ); (Found [M+H]+, 289, C ,iH i30 479Br requires [M+H]+, 289).
2’-Fluoro-3,4,5-trimethoxyacetophenone (82)
O
Potassium fluoride (4.0 g, 71 mmol) was dried by heating in a 2 neck, round bottomed flask 
with a Bunsen flame under high vacuum and then cooled to room temperature under N2. 2’- 
Bromo-3,4,5-trimethoxyacetophenone (1.1 g, 4.0 mmol) and 18-crown-6 (0.2 g, 0.76 mmol) in 
dry MeCN (20 ml) were then added and the mixture was refluxed for 24 hrs. The solvent was 
then removed under vacuum and the residue partitioned between DCM and water. The DCM 
fraction was dried and evaporated to leave a brown oil, purification by silica chromatography 
using a 4:6 mixture of EtOAc : hexane (Rf=0.22) yielded 82 as yellow crystals (0.75 g, 94%). 
m.p. 120-122 °C; (Found: C, 58.46; H, 5.83. C nH 130 4F requires C, 57.89; H, 5.74%); 
Vmax (CHCI3) 2944m, 2359m, 1702s, 1587s, 1463s, 1416s, 1326m, 1128s, 990 m, 820w cm '1; 
'H  NMR 8 (400 MHz; CDC13), 3.84 (6H, s, OMe), 3.85 (3H, s, OMe), 5.49 (2H, d, 747.0 Hz, 
H2’), 7.07 (2H, s, H2 and H6 ); l9F NMR 8 (283 MHz; CDCI3), -173.4 (IF, t, J  47 Hz); 
,3C NMR 8 (100 MHz; CDC13), 56.4 (s, OMe), 61.0 (s, OMe), 83.6 (d, J  226 Hz, C2’), 105.3 
(s, C2 and C3), 128.8 (s, C l), 143.4 (s, C4), 153.3 (s, C3 and C5), 192.3 (d, J  15 Hz, C l’); 
(Found [M+H]+, 229.0874, C n H l40 4F requires [M+H]+, 229.0876).
General procedure for the synthesis of a-fluorochalcones—2’-Fluoro-3,4,5- 
trimethoxyacetophenone (82, 0.1 g, 0.44 mmol) and the appropriate aryl aldehyde (0.45 mmol) 
were warmed in ethanol (50 ml) until they dissolved. The solution was then cooled to room 
temperature and piperidine (3-5 drops) was added. If after 48 hours the chalcone product had 
not precipitated out, the ethanol was removed under vacuum and the residue partitioned 
between DCM and water. The DCM fraction was evaporated and the chalcone isolated by 
column chromatography (7:3 hexane:ethyl acetate, v/v).
114
Chapter 8 Experimental Section C3
(Z)- 3-Benzo [ 1 ,3] dioxol-5-y 1-2-fluoro-l -(3%4’ ,5’-tr  imethoxy pheny l)prop-2-en-1 -one (83a)
O
Yellow crystals (84%); m.p. 127-129 °C; (Found: C, 62.71; H, 4.76. C19H 17O6F requires C, 
63.33; H, 4.72%); (CHC13) 3009m, 1667w, 1581s, 1502m, 1450s, 1416m, 1337s, 1228w,
1135s, 1037w, lOOOw, 930w, 888w, 799w, 751s cm '1; ]H NMR 6 (400 MHz; CDCI3), 3.86 
(6H, s, OMe), 3.88 (3H, s, OMe), 5.96 (2H, s, 0C H 20 ), 6.78 (1H, d, J  36 Hz, H3), 6.80 (1H, d, 
J  8.1 Hz, H5” ) 7.08 (1H, d, J  8.1 Hz, H6 ” ), 7.10 (2H, s, H2’ and H6 ’), 7.28 (1H, s, H2” ); 
19F NMR 8 (283 MHz; CDC13), -122.0 (IF, d, J  36 Hz); 13C NMR 8 (100 MHz; CDC13), 56.3 
(s, OMe), 61.0 (s, OMe), 101.7 (s, 0CH 20 ), 106.9 (d, J  5 Hz, C3), 108.7 (s, C2’ and C6 ’),
109.9 (d, J  11 Hz, C2” ), 120.1 (d, J  6 Hz, C5” ), 125.5 (d, J  4 Hz, C6 ” ), 126.4 (d, J  7 Hz, 
C l” ), 131.3 (s, C l ’), 142.4 (s, C4’), 148.2 (s, C4” ), 149.3 (s, C3” ), 152.9 (s, C3’ and C5’),
153.7 (d, J  269 Hz, C2), 186.4 (d, J  28 Hz, C l); (Found [M+H]+, 361.1081, 
requires [M+H]+, 361.1082).
(Z)-2-Fluoro-3-(4” -methoxyphenyl)-l-(3’,4,,5’-triniethoxyphenyl)prop-2-en-l-one (83b)
O
Yellow crystals (68%); m.p. 75-76 °C; (Found: C, 65.21; H, 5.46. C 19H 19O5F requires C, 65.90; 
H, 5.49%); Vmax (CHCI3) 3430s, 2938m, 1658m, 1602s, 1512s, 1462m, 1332s, 1257s, 1173s, 
1127s, 1029m, 756m cm '1; ‘H NMR 5 (400 MHz; CDCI3), 3.80 (3H, s, OMe), 3.86 (6H, s, 
OMe), 3.88 (3H, s, OMe), 6.81 (1H, d, J  37 Hz, H3), 6.89 (2H, d, J  8.8 Hz, H3”  and H5” ), 
7.10 (2H, s, H2’ and H6 ’), 7.62 (2H, d, J  8.8 Hz, H2” and H6 ” ); l9FN M R 5(283 MHz; 
CDCI3), -121.8 (IF, d, J  37 Hz); 13C NMR § (100 MHz; CDCI3), 55.4 (s, OMe), 56.3 (s, OMe),
61.0 (s, OMe), 106.9 (d, J  5 Hz, C2’ and C6 ’), 114.4 (s, C3” andC 5” ), 120.2 (d, J 6 Hz, C3),
124.1 (d, J 4  Hz, C l” ), 131.4 (s, C l ’), 132.5 (d, / 8  Hz, C2” and C6 ” ), 142.3 (s, C4’), 152.9 
(s, C3’ and C5’), 153.6 (d, J  268 Hz, C2), 161.0 (d, J  3 Hz, C4” ), 186.6 (d, J  27 Hz, Cl); 
(Found [M +Hf, 347.1285, C 19H20O5F requires [M+H]+, 347.1289).
115
Chapter 8 Experimental Section C3
(Z)-2-Fluoro-3-(3” -hydroxy-4” -methoxyphenyl)-l-(3\4’,5’-trimethoxypheiiyl)prop-2-en- 
1-one(83c)
OH
Yellow crystals (75%); m.p. 132-135 °C; (Found: C, 62.39; H, 5.16. C19H 19O6F requires C, 
62.98; H, 5.25%); v ^ C H C ls )  3423w,br, 2940 M, 1579s, 1506s, 1415m, 1334m, 1253m, 
1127s, lOOlw, 755w cm '1; *H NMR 5 (400 MHz; CDCI3), 3.86 (6H, s, OMe), 3.88 (3H, s, 
OMe), 3.89 (3H, s, OMe), 5.60 (1H, s, ArOH), 6.77 (1H, d, J  37 Hz, H3), 6.83 (1H, d, J  8.4 
Hz, H5” ), 7.11 (2H, s, H2’ and H6 ’), 7.15 (1H, dd, J  2.0, 8.4 Hz, H6 ” ), 7.33 (1H, d, J  2.0 Hz, 
H2” ); 19F NMR 8 (283 MHz; CDCI3), -121.6 (IF, d, J 3 7  Hz); 13C NMR 8 (100 MHz; CDC13),
56.0 (s, OMe), 56.3 (s, OMe), 61.0 (s, OMe), 106.9 (d, J  5 Hz, C3), 110.6 (s, C2’ and C6 ’),
116.3 (d, J  10 Hz, C2” ), 120.1 (d, J  5 Hz, C5” ), 124.1 (d, J  8 Hz, C6 ” ), 124.9 (d, J  4 Hz, 
C l” ), 131.3 ( s ,C l’), 142.3 (s, C4’), 145.7 (s, C3” ), 148.2 ( d , /3 H z ,  C4” ), 152.9 (s, C3’ and 
C5’), 153.8 (d, J  269 Hz, C2), 186.5 (d, J  28 Hz, C l); (Found [M+H]+, 363.1243, Ci9H2o0 6F 
requires [M+H]+, 363.1244).
(Z)-3-(3” ,4” -Dimethoxyphenyl)-2-fluoro-l-(3,,4%5,-trimethoxyphenyl)prop-2-en-l-one
(83d)
O
Yellow crystals (23%); m.p. 98-100 °C; (Found: C, 63.42; H, 5.55. C20H21O6F requires C, 
63.83; H, 5.59%); v ^ C H C ls )  2939s, 1658m, 1580s, 1514s, 1463s, 1416s, 1334s, 1222s, 
1126s, 1024m, 855w, 807w, 755s c m 1; ‘H NMR 5 (400 MHz; CDC13), 3,86 (6H, s, OMe), 
3.87 (3H, s, OMe), 3.88 (3H, s, OMe), 3.88 (3H, s, OMe), 6.80 (1H, d, 7  36 Hz, H3), 
overlapping 6.85 (1H, d, 7  8.2 Hz, H5” ), 7.10 (2H, s, H2’ and H6 ’), 7.21 (1H, dd, J  1.8, 8.2 
Hz, H6 ” ), 7.26 (1H, d, 7  1.8 Hz, H2” ); 19F NMR 8 (283 MHz; CDCU), -121.8 (IF, d, J  36 
Hz); l3C NMR 8 (100 MHz; CDCU), 56.2 (s, OMe), 56.3 (s, OMe), 56.7 (s, OMe), 61.4 (s, 
OMe), 107.3 (d, J 5 Hz, C3), 111.4 (s, C2’ andC 6 ’), 113.1 (d, J  10 Hz, C2” ), 120.8 (d ,7 6  Hz, 
C5” ), 124.6 (d, 7 4  Hz, C6” ), 125.3 (d, 7  8 Hz, C l” ), 131.8 (s, C l ’), 142.6 (s, C4’), 149.3 (s,
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C4” ), 151.1 (d, J  3 Hz, C3” ), 153.3 (s, C3’ andC 5’), 154.0 (d, J  268 Hz, Cl),  186.8 (d, J  21 
Hz, C l); (Found [M+H]+, 377.1399, C20H22O6F requires [M+H]+, 377.1395).
(Z)-2-Fluoro-3-(2” ,3” ,4” -trim ethoxyphenyl)-l-(3’,4 \5 ’-trimethoxypheiiyl)-prop-2-en-l- 
one (83e)
O
Yellow crystals (86%); m.p. 127-129 °C; (Found: C, 61.88; H, 5.64. C21H23O7F requires C, 
62.07; H, 5.67%); vmax(CHCl3) 2942m, 1650w, 1583s, 1496s, 1462s, 1415s, 1327m, 1302s, 
1221m, 1128s, 1097s, 1006m, 800w, 757w cm'1; 'H  NMR 8 (400 MHz; CDC13), 3.90 (3H, s, 
Me), 3.93 (3H, s, OMe), 3.95 (6H, s, OMe), overlapping 3.95 (3H, s, OMe), 3.97 (3H, s, 
OMe), 6.79 (1H, d, J9 .0  Hz, H5” ), 7.19 (2H, s, H2’ and H6 ’), 7.30 (1H, d, J 38 Hz, H3), 7.80 
(1H, d, J  9.0 Hz, H6 ” ); 19FN M R 8(283 MHz; CDC13), -121.5 (IF, d, J  38 Hz); 
13C NMR 8 (100 MHz; CDC13), 56.1 (s, OMe), 56.3 (s, OMe), 60.9 (s, OMe), 61.0 (s, OMe),
61.7 (s, OMe), 106.9 (d, J 4  Hz, C3), 107.7 (s, C2’ and C6 ’), 114.5 (d, J 4  Hz, C5” ), H8.3 (d, 
J 5 Hz, C l” ), 126.2 (d, J 15 Hz, C6 ” ), 131.6 (s, C l ’), 142.1 (d, J  17 Hz, C3” ), 146.9 (s, C2” ), 
152.6 (s, C4’), 152.9 (s, C3’ and C5’), 154.2 (d, J  245 Hz, C2), 155.3 (s, C4” ), 186.7 (d ,./2 7  
Hz, C l); (Found [M+H]+, 407.1504, C21H24O7F requires [M+H]+, 407.1501).
(Z)-2-Fluoro-3-(2” -fluoro-4” -methoxyphenyl)-l-(3,,4,,5,-trimethoxyphenyI)prop-2-en-l- 
one (83f)
O
Yellow crystals (74%); m.p. 143-144 °C; (Found: C, 62.64; H, 4.94. C19H18O5F2 requires C, 
62.64; H, 4.95%); Vmax (CHCI3) 2957m, 1620s, 1583m, 1504m, 1455m, 1414m, 1332s, 1294s, 
1237s, 1131s, 1106m, 1000m, 876m, 844w, 805w, 759m cm '1; 'H NMR 8 (400 MHz; CDC13),
3.79 (3H, s, OCH3), 3.86 (6H, s, OCH3), 3.88 (3H, s, OCH3), 6.61 (1H, dd, J  2.4, 12.2 Hz, 
H3” ), 6.73 (1H, dd, J  2.4, 8.9 Hz, H5” ), 7.08 (1H, d, J  37 Hz, H3), 7.10 (2H, s, H2’ and H6 ’), 
7.92 (1H, dd, J  8.9, 8.9 Hz, H6 ” ); 19F NMR 8 (283 MHz; CDC13), -111.6 (IF, m), -120.4 (IF, 
d, J  37 Hz); l3C NMR 8 (100 MHz; CDCI3), 55.8 (s, OMe), 56.3 (s, OMe), 61.0 (s, OMe),
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101.5 (d, J  25 Hz, C3” ), 107.0 (d ,J 4 H z , C3), 111.0 (d, J 3  Hz, C T  andC 6 ’), 111.9 (m, C5” 
and C l” ), 131.2 (s, C l ’), 131.8 (d d ,J 3 , 15 Hz, C6 ” ), 142.4 (s, C4’), 153.0 (s, C3’ and C5’),
154.1 (d, J  270 Hz, C2), 161.8 (d, J  252 Hz, C2” ), 162.4 (d ,J 9 H z , C4” ),186.4 (d ,J2 7 H z , 
C l); (Found [M+H]+, 365.1200, Ci9H 190 5F2 requires [M+H]+, 365.1195).
(Z)-2“Fluoro-3-(3” -fluoro-4” -methoxyphenyl)-l-(3’,4’,5’-trimethoxyphenyl)prop-2-en-l- 
one (83g)
O
Yellow crystals (28%); m.p. 123-126 °C; (Found: C, 62.49; H, 4.95. Ci9H 180 5F2 requires C, 
62.64; H, 4.95%); VmaX (CHC13) 2940 M, 1660w, 1581s, 1517s, 1463m, 1416m, 1330s, 1278m, 
1235w, 1128s, 1002w, 761w c m 1; lU NMR 6 (400 MHz; CDC13), 3.86 (6H, s, OMe), 3.88 
(3H, s, OMe), overlapping 3.88 (3H, s, OMe), 6.77 (1H, d, J  36 Hz, H3), 6.93 (1H, dd, J  8.5,
8.5 Hz, H5” ), 7.12 (2H, s, H2’ and H6 ’), 7.33 (1H, dd, J  1.6, 8.5 Hz, H6 ” ), 7.50 (1H, dd, J
1.6, 12.5 Hz, H2” ); 19FN M R 5(283 MHz; CDC13), -117.9 (IF, d, J  36 Hz), -134.0 (IF, m); 
13C NMR 8 (100 MHz; CDC13), 56.5 (s, OMe), 56.7 (s, OMe), 61.4 (s, OMe), 107.2 (d, J  5 Hz, 
C3), 107.9 (d, J  8 Hz C2” ), 110.8 (s, C2’ and C6 ’), 114.4 (d, J 4 H z ,  C5” ), 122.1 (s, C6 ” ),
127.9 (d J 5  Hz, C l” ), 131.3 (s, C l’), 142.4 (s, C4’), 150.9 (d, J2 6 3  Hz, C3” ), 153.2 (s, C3’ 
and C5’), 154.2 (d, J  268 Hz, C2), 154.4 (d, J  9 Hz, C4” ), 186.5 (d, J  28 Hz, Cl); (Found 
[M +Hf, 365.1190, Ci9Hi90 5F2 requires [M+H]+, 365.1195).
(Z)-3-(3” -Bromo-4” -methoxyphenyl)-2-fluoro-l-(3%4,,5’-trimethoxyphenyl)prop-2-en-l- 
one(83h)
O
Yellow crystals (18%); m.p. 132-134 °C; (Found: C, 53.75; H, 4.28. CigHisOsFBr requires C, 
53.65; H, 4.24%); vmax(CHCl3) 2941w, 1655w, 1581s, 1498s, 1461 w, 1415m, 1329m, 1173m, 
1127s, 1054m, 1002m c m 1; 'H NMR 5 (400 MHz; CDC13), 3.86 (6H, s, OMe), 3.88 (3H, s, 
OMe), 3.89 (3H, s, OMe), 6.75 (1H, d, J  36.3 Hz, H3), 6.88 (1H, d, J  8.6 Hz, H5” ), 7.12 (2H, 
s, H2’ and H6 ’), 7.58 (1H, d, J  1.9, 8.6 Hz, H6 ” ), 7.89 (1H, d, J  1.9 Hz, H2” );
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19F NMR 8 (283 MHz; CDC13), -119.9 (IF, d, J  36 Hz); l3C NMR 8 (100 MHz; CDC13), 56.3 
(s, OMe), 56.4 (s, OMe), 61.1 (s, OMe), 107.0 (d, J 6 Hz, C3), 111.8 (s, C2’ and C6 ’), 112.2 (s, 
C3” ), 118.2 (d, J  6 Hz, C5” ), 125.4 (d ,J 4 H z , C6 ” ), 131.0 (s, C l’), 131.4 (d, J  8 Hz, C2” ),
135.3 (s, C l” ), 135.4 (s, C4’), 142.5 (s, C4” ), 153.0 (s, C3’ and C5’), 154.1 (d ,J273  Hz, C2),
186.1 (d, J 2 8  Hz, C l); (Found [M+], 424.0305, Ci9H 190 5F79Br requires [M+], 424.0316).
8.2 a-Trifluoromethyl chalcones
A^ ,Ar-Dimethyl-A^-(3,4,5-trimethoxybenzylidene)hydrazine (92)216
3,4,5-Trimethoxybenzaldehyde (3.7 g, 18.9 mmol) was stirred in benzene (10 ml) at room 
temperature, A(A/-dimethylhydrazine (1.5 ml, 20 mmol) was added drop-wise and stirred for 4 
hours. After this time the mixture was dried over MgS04  and the solvent removed under 
vacuum. Recrystallisation from MeOH yielded 92 (4.47 g, 99%). m. p. 74-75 °C; 
'H NMR 5 (400 MHz; CDC13), 2.89 (6H, s, NMe2), 3.78 (3H, s, OMe), 3.82 (6H, s, OMe), 
6.75 (2H, s, ArH).
3-(Dimethylhydrazono)-l,l»l“trifluoro-3-(3, ,4’,5,-trimethoxyphenyl)propan-2-one (93)
Ar,A-Dimethyl-A-(3,4,5-trimethoxybenzylidene)hydrazine (92, 4 g, 16.8 mmol) and 2,6- 
lutidine (4.9 ml, 42 mmol) were dissolved in dry chloroform (40 ml) and cooled in crushed ice. 
Trifluoroacetic anhydride (24 ml, 171 mmol) was dissolved in dry chloroform (80 ml) and 
added drop-wise through a pressure equalised dropping funnel. The mixture was then stirred at 
room temperature for 48 hours, washed with 1M HC1 (30 ml), water (30 ml) and sat. Na2C0 3 
(30 ml), the solvent removed under vacuum and the residue purified by silica column 
chromatography (1:1 ethyl acetate:hexane) to yield 93 (4.45 g, 80%) as a brown oil. 
vma, (CHClj) 3436s,br, 2938w, 1685s, 1582m, 1507m, 1127s, 1002w, 849w cm'1;
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‘H NMR 5 (400 MHz; CDC13), 3.04 (6H, s, NMe2), 3.77 (3H, s, OMe), 3.79 (6H, s, OMe),
6.35 (2H, s, H2’ and H6 ’); 19F N M R 5(283 MHz; CDCI3), -68.8 (3F, s); l3C N M R 8(100 
MHz; CDCI3), 47.3 (m, NMe2), 56.6 (s, OMe), 61.3 (s, OMe), 108.2 (s, C2’ and C6 ’), 118.8 (q, 
,7 290 Hz, Cl), 128.6 (s, C l ’), 131.7 (s,C 3) 138.5 (s, C4’), 153.1 (s, C3’ andC 5’), 178.3 (d, J  
28 Hz, C2); (Found [M+H]+, 335.1216, Ci4H 180 4N2F3 requires [M+H]+, 335.1219).
3,3,3-Trifluoro-l-(3\4%5’-trimethoxyphenyl)propane-l,2-dione (94)
O
/ O
3-(Dimethylhydrazono)-1,1,1 -trifluoro-3-(3,4,5-trimethoxyphenyl)propan-2-one (93, 4.4 g,
13.2 mmol) was dissolved in 5 M H2SO4 (50 ml), heated to 60 °C and stirred at this 
temperature for 48 hrs. The mixture was then extracted into ether, dried over MgSC>4 and 
evaporated under vacuum. Recrystallisation from methanol yielded 94a which on standing 
gave 94 as a pale yellow powder (2.96 g, 77%). m. p. 89-91 °C; vmax (CHCI3) 3406s, 2944m, 
1678s, 1582s, 1504s, 1332s, 1128s, br, 998m cm '1; 'H NMR 8 (400 MHz; CDCI3), 3.84 (6H, s, 
OMe), 3.92 (3H, s, OMe), 7.57 (2H, s, H2’ and H6 ’); ,9F N M R 5(283  MHz; CDCI3), -81.0 
(3F, s); ,3C N M R5(100 MHz; CDCI3), 56.3 (s, OMe), 61.1 (s, OMe), 108.9 (s, C2’ andC 6 ’),
121.3 (q, J  285 Hz, C3), 126.3 (s, C l’), 144.9 (s, C4’), 152.8 (s, C3’ and C5’), 191.6 (s, Cl),
196.1 (q, J  33 Hz, C2); (Found [M+NHi]+, 310.0901, Ci2Hi50 5NF3 requires [M+NH,]+, 
310.0897).
General procedure for the synthesis of alcohols 95— The appropriate aldehyde (1.5 mmol) 
was dissolved in ethanol (10 ml) and cooled in ice. NaBRj (2 mmol) was added and the 
reaction stirred at room temperature overnight. The solvent was then removed under vacuum 
and the residue partitioned between DCM and water, the DCM fraction was dried over MgSCU 
and evaporated under vacuum to give 95 in quantitative yield.
Benzo[l,3]dioxol-5-ylmethanol (95a)217
lU NMR 6 (400 MHz; CDC13), 4.46 (2H, s, CH2OH), 5.85 (2H, s, OCH20), 6.67-6.71 (2H, m, 
H5 and H6 ), 6.76 (1H, s, H2).
[3-(te/f-Butyldimethylsilanyloxy)-4-methoxyphenyl]-methanol (95c)218
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*H NMR 8 (400 MHz; CDC13), (0.00 (6H, s, SiMe2), 0.84 (9H, s, CMe3), 3.65 (3H, s, OMe), 
4.41 (2H, s, CH2OH), 6.69 (1H, d, 7  7.6 Hz, H5), 6.73 (1H, dd, 7  1.9, 7.6 Hz, H6), 6.76 (1H, d,
71.9 Hz, H2).
(3,4-Dimethoxy pheny l)methanol (95e)217
]H NMR 8 (400 MHz; CDC13), 3.72 (3H, s, OMe), 3.73 (3H, s, OMe), 4.45 (2H, s, CH2OH), 
6.68 (1H, d, 7  8 .1 Hz, H5), 6.73 (1H, d, 7  8 .1 Hz, H6 ), 6.77 (1H, s, H2).
(2,3,4-TrimethoxyphenyI)methanol (95f)219
'H NMR 8 (400 MHz; CDC13), 3.88 (3H, s, OMe), 3.89 (3H, s, OMe), 3.97 (3H, s, OMe), 4.63 
(2H, s, CH2OH), 6.66 (1H, d, 78 .4  Hz, H5), 6.99 (1H, d, 78 .4  Hz, H6).
(2-Fluoro-4-methoxyphenyl)methanol (95h)220
F
!H NMR 8 (400 MHz; CDC13), 3.82 (3H, s, OMe), 4.50 (2H, s, CH2OH), 6.64 (1H, dd, 7 2.5,
11.9 Hz, H3), 6.71 (1H, dd,72.5, 8.5 Hz, H5), 7.31 (1H, dd ,78 .5 , 8.5 Hz, H6).
(3-Bromo-4-methoxypheny 1 )methanol (95i)221
*H NMR 8 (400 MHz; CDC13), 3.83 (3H, s, OMe), 4.53 (2H, s, CH2OH), 6.81 (1H, d, 7  8.2 Hz, 
H5), 7.20 (1H, d, 78.2 Hz, H6), 7.49 (1H, s, H2).
121
Chapter 8 Experimental Section C3
(3-Fluoro-4-methoxyphenyl)methanol (95j )222
HO
H NMR 5 (400 MHz; CDC13), 3.79 (3H, s, OMe), 4.34 (2H, s, CH2OH), 6.83 (1H, dd, J  8.2,
8.2 Hz, H5), 6.96 (1H, d, J  8.6 Hz, H6 ), 7.01 (1H, d, J  13.7 Hz, H2).
General procedure for the synthesis of chlorides 96— The alcohol 95 (1.5 mmol) was 
dissolved in DCM and stirred at room temperature. SOCl2 (2 mmol) was added and the 
reaction mixture was refluxed at 60 °C overnight. The solvent was then removed under 
vacuum to give 96 in quantitative yield.
5-Chloromethylbenzo[l,3]dioxole (96a)217
‘H NMR 5 (400 MHz; CDCI3), 4.55 (2H, s, CH2C1), 6.00 (2H, s, OCH20 ), 6.80 (1H, d, J  7.9 
Hz, H5), 6.87 (1H, dd, J  1.7, 7.9 Hz, H6), 6.91 (1H, d, J  1.7 Hz, H2).
^/■t-Butyl-(5-chloromethyl-2-methoxyphenoxy)dimethylsilane (96c)223
NMR 6 (400 MHz; CDCI3), (0.00 (6H, s, SiMe2), 0.84 (9H, s, CMe3), 3.65 (3H, s, OMe),
4.36 (2H, s, CH2C1), 6.65 (1H, d, J  8.2 Hz, H5), 6.73 (1H, d, J  2.2 Hz, H2), 6.78 (1H, dd, J 2.2,
8.2 Hz, H6 ).
4-Chloromethy 1-1,2-dimethoxy benzene (96e)217
H NMR 6 (400 MHz; CDC13), 3.90 (3H, s, OMe), 3.92 (3H, s, OMe), 4.59 (2H, s, CH2C1), 
6.84 (1H, d, J  8.0 Hz, H5), 6.93-6.96 (2H, m, H2 and H6 ).
1 -Chloromethyl-2,3,4-triinethoxybenzene (96f)224
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!H NMR 8 (400 MHz; CDC13), 3.80 (3H, s, OMe), 3.81 (3H, s, OMe), 3.92 (3H, s, OMe), 4.54 
(2H, s, CH2C1), 6.59 (1H, d, J  8.5 Hz, H5), 6.98 (1H, d, J  8.5 Hz, H6).
1 -Chloromethy l-2-fluoro-4-methoxy benzene (96h)220
F
*H NMR 5 (400 MHz; CDCI3), 3.83 (3H, s, OMe), 4.63 (2H, s, CH2C1), 6.66 (1H, dd, J  2.5,
11.7 Hz, H3), 6.76 (1H, dd, J 2.5, 8.6 Hz, H5), 7.32 (1H, dd, J  8.6, 8.6 Hz, H6).
2-Bromo-4-chloromethyl-l-methoxybenzene (96i)225
*H NMR 8 (400 MHz; CDC13), 3.84 (3H, s, OMe), 4.46 (2H, s, CH2C1), 6.80 (1H, d, J  8.4 Hz, 
H5), 7.23 (1H, dd, J2.2,  8.4 Hz, H6), 7.52 (1H, d, J 2 .2  Hz, H2).
4-Chloromethyl-2-fluoro-l-methoxybenzene (96j)226
*H NMR 8 (400 MHz; CDC13), 3.80 (3H, s, OMe), 4.44 (2H, s, CH2C1), 6.83 (1H, dd, J  8.4,
8.4 Hz, H5), 7.00 (1H, d d ,/2 .0 , 8.4 Hz, H6), 7.05 (1H, dd ,72 .0 , 11.7 Hz, H2).
General procedure for the synthesis of phosphonium salts 97— The chloride 96 (1.5 mmol) 
and triphenylphosphine (1.5 mmol) were refluxed in dry toluene for 4 hours. The reaction 
mixture was cooled to 0 °C and the phosphonium salt 97 filtered off in quantitative yield.
Benzo[l,3]dioxol>5-ylniethyltripheny]phosphoniuni chloride (97a)227
Chapter 8 Experimental Section C3
]H NMR 8 (400 MHz; CDC13), 5.66 (2H, d, J  14.0 Hz, CH2P), 6.07 (2H, s, 0CH 20), 6.72-6.81 
(3H, m, H2, H5 and H6), 7.82-7.96 (15H, m, PPh3)
(4-Methoxybenzyl)triphenylphosphonium chloride (97b)228
Cl
]H NMR 8 (400 MHz; CDCI3), 3.80 (3H, s, OMe), 5.69 (2H, d, J  13.8 Hz, CH2P), 6.48 (1H, d, 
J  8.7 Hz, H3 and H5), 7.05 (1H, dd, J  1.9, 8.7 Hz, H2 and H6), 7.82-7.96 (15H, m, PPh3)
|3-(terf-ButyldimethylsiIanyloxy)-4-methoxybenzyl]triphenylphosphonium chloride
(97c)229
'H NMR S (400 MHz; CDC13), 0.03 (6H, s, SiMe2), 0.87 (9H, s, CMe3), 3.78 (3H, s, OMe), 
5.33 (2H, d, J  13.7 Hz, CH2P), 6.30 (1H, t, J 2 .0  Hz, H2), 6.66 (1H, d, J  8.3 Hz, H5), 6.91-6.94 
(1H, m, H6), 7.63-7.78 (15H, m, PPh3).
(3,4-Dimethoxybenzyl)triphenylphosphonium chloride (97e)
'H NMR 8 (400 MHz; CDC13), 3.56 (3H, s, OMe), 3.75 (3H, s, OMe), 5.61 (2H, d, J  13.8 Hz, 
CH2P), 6.63 (1H, d, J  8.4 Hz, H5), 6.70 (1H, t, J  2.2 Hz, H2), 7.44 (1H, dt, J  2.2, 8.4 Hz, H6), 
5.55-7.73 (15H, m, PPh3).
• 231Triphenyl(2,3,4-trimethoxybenzyl)phosphonium chloride (97f)
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'H NMR 8 (400 MHz; CDCI3), 3.52 (3H, s, OMe), 3.60 (3H, s, OMe), 3.80 (3H, s, OMe), 5.33 
(2H, d, J  13.4 Hz, CH2P), 6.50 (1H, d, J  8.6 Hz, H5), 7.07 (1H, dd, J  1.9, 8.6 Hz, H6).
TriphenyI(4-trifluoromethy lbenzyI)phosphonium chloride (97g)232
Cl
lH NMR 5 (400 MHz; CDC13), 5.95 (2H, d, J  15.5 Hz, CH2P), 7.32-7.37 (4H, m, H2, H3, H5 
and H6), 7.61-7.86 (15H, m, PPh3)
(2-Fluoro-4-methoxybenzyl)triphenyIphosphonium chloride (97h)233
Cl F
'H NMR 8 (400 MHz; CDC13), 3.74 (3H, s, OMe), 5.53 (2H, d, J  13.7 Hz, CH2P), 6.38 (1H, 
dd, J2 .4 , 11.7 Hz, H3), 6.57 (1H, dd, J 2.4, 8.7 Hz, H5), 7.52 (1H, ddd, J2 .4 , 8.7, 8.7 Hz, H6), 
7.63-7.84 (15H, m, PPh3).
(3-Bromo-4-methoxybenzyl)triphenylphosphonium chloride (97i)234
Cl
]H NMR 8 (400 MHz; CDC13), 3.75 (3H, s, OMe), 5.51 (2H, d, J  14.0 Hz, CH2P), 6.63 (1H, d, 
J  8.5 Hz, H5), 6.73 (1H, t, J  2.3 Hz, H2), 7.43 (1H, dt, J  2.3, 8.5 Hz, H6), 5.57-7.76 (15H, m, 
PPh3).
235(3-Fluoro-4-methoxybenzyI)triphenylphosphoniuni chloride (97j)
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'H NMR 5 (400 MHz; CDCI3 ), 3.83 (3H, s, OMe), 5.60 (2H, d, J  14.1 Hz, CH2P), 6 . 6 6  (1H, d, 
./ 11.8 Hz, H2), 6.76 (1H, dd, 8 .6 , 8 . 6  Hz, H5), 7.14 (1H, d, J  8 . 6  Hz, H6 ), 7.65-7.82 (15H, m, 
PPI1 3).
General procedure for the synthesis of chalcones 8 8 — Phosphonium chloride 97 (1 mmol) 
was dissolved in dry THF (5 ml) and cooled in ice. LiHMDS (1 ml of a 1 M solution in THF) 
was added drop-wise and stirred for 10 mins. Diketone 94 (1.1 mmol) in THF (5 ml) was then 
added to resulting the red solution and the reaction mixture was warmed to room temperature 
and refluxed at 80 °C overnight. The mixture was then quenched with 1 M HC1 (10 ml) and 
extracted with ether, dried over MgSC>4 and evaporated under vacuum.)
(Z)-3-Benzo[l,3]dioxoI-5-yI-2-(Trifluoromethyl) -l-(3 ’,4’,5’-trimethoxyphenyl)prop-2-en- 
1 -one(8 8 a)
O
Pale yellow oil (58%); v^CCHCb) 2941m, 1661m, 1582m, 1504s, 1415m, 1327m, 1250s, 
1127s, 841m cm 1; 'H NMR 8  (400 MHz; CDC13), 3.61 (6 H, s, OMe), 3.70 (3H, s, OMe), 5.73 
(2H, s, CH2), 6.47 (1H, d, J  8.0 Hz, H5” ), overlapping 6.48 (1H, d, J  1.3 Hz, H2” ), 6.61 (1H, 
dd, J  1.3, 8.0 Hz, H6 ” ), 6.97 (2H, s, H2’ and H6 ’), 7.15 (1H, s, H3); 19F NMR 8  (283 MHz; 
CDCI3), -62.0 (3F, s); 13C NMR 8  (100 MHz; CDCI3 ), 56.2 (s, OMe), 61.0 (s, OMe), 101.7 (s, 
CH2), 105.1 (q, J  273 Hz, CF3), 107.0 (s, C2’ and C6 ’), 108.7 (d, J  24 Hz, C2” ), 121.1 (s, 
C6 ” ), 125.5 (s, C5” ), 126.1 (s, C l” ), 126.7 (q, J 2 9  Hz, C2), 130.4 (s, C l’), 136.4 (q, / 6  Hz, 
C3), 143.7 (s, C4’), 148.1 (s, C4” ), 149.4 (s, C3” ), 153.2 (s, C3’ and C5’), 191.5 (s, Cl); 
(Found [M+H]+, 411.1049, QcftgOsFj requires [M+H]+, 411.1050).
(Z)-2-(Trifluoromethyl)-3-(4” -methoxyphenyl)-l-(3’,4’,5,-trimethoxyphenyl)prop-2-en-l- 
one (8 8 b)
O
Pale yellow oil (64%); vmax(CHCl3 ) 2939w, 1661m, 1604m, 1512m, 1330 M, 1126s, 1030w 
c m 1; 'H NMR 8  (400 MHz; CDC13), 3.69 (3H, s, OMe), 3.74 (6 H, s, OMe), 3.83 (3H, s,
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OMe), 6.67 (1H, d, J  8.8 Hz, H3” and H5” ), 7.12 (2H, s, H2’ and H6’), overlapping 7.13 (2H, 
d, J  8.8 Hz, H2” and H6” ), 7.34 (1H, s, H3); 19F NMR 6 (283 MHz; CDC13), -62.0 (3F, s); 13C 
NMR 5(100 MHz; CDC13), 55.3 (s, OMe), 56.2 (s, OMe), 61.0 (s, OMe), 107.0 (s, C2’ and 
C6’), 114.3 (C3”  and C5” ), 124.6 (s, C l ’), 130.4 (s, C l” ), 131.5 (s, C2” and C6” ), 136.7 (s, 
C3), 143.6 (s, C4’), 153.1 (s, C3’ and C5’), 161.1 (s, C4” ), 191.8 (s, C l), (C2 and CF3 signals 
were too weak to detect with any certainty); (Found [M+H]+, 397.1261, C2oH2oOsF3 requires 
[M+H]+, 397.1257).
(Z)-2-(Trifluoromethyl)-3-[3” -(te/t-Butyldimethylsilanyloxy)-4, ’-methoxyphenyl]-l- 
(3 ’ ,4%5’-trimethoxy pheny l)prop-2-en-l -one (88c)
CF
/ O
Pale yellow oil (49%); vmax(CHCl3) 2934m, 1662m, 1581m, 1513s, 1415m, 1328m, 1256s, 
1128s, 840 M cm '1; lU NMR 5 (400 MHz; CDC13), 0.00 (6H, s, SiMe2), 0.92 (9H, s, C(CH3)3),
3.79 (3H, s, OMe), 3.85 (6H, s, OMe), 3.92 (3H, s, OMe), 6.74 (1H, d, J  8.4 Hz, H5” ), 
overlapping 6.75 (1H, d, J  2.1 Hz, H2” ), 6.91 (1H, dd, J  2.1, 8.4 Hz, H6” ), 7.24 (2H, s, H2’ 
and H6’), 7.36 (1H, s, H3); 19F NMR 5 (283 MHz; CDC13), -61.9 (3F, s); 13C NMR 5 (100 
MHz; CDC13), -4.9 (s, SiMe2), 18.3 (s, CMe3), 25.6 (s, C(CH3)3), 55.3 (s, OMe), 56.2 (s, 
OMe), 61.0 (s, OMe), 104.5 (q, /2 7 6  Hz, CF3), 107.6 (s, C2’ and C6’), 111.5 (s, C5” ), 121.5 
(s, C2” ), 124.8 (d, J  14 Hz, C6” ), 125.8 (q, J 3 0  Hz, C2), 128.5 (d, J  12 Hz, C l” ), 130.4 (s, 
C l’), 132.3 (q, J  11 Hz, C3), 143.6 (s, C4’), 145.0 (s, C3” ), 153.0 (s, C4” ), 153.2 (s, C3’ and 
C5’), 191.5 (s, C l); (Found [M+H]+, 527.2068, C26H340 6F3Si requires [M+H]+, 527.2071).
(Z)-2-(Trifluoromethyl)-3-(3,,-hydroxy-4” -methoxyphenyl)-l-(3’,4,,5’- 
t rimethoxy pheny l)prop-2-en-l-one (88d)
O
/ O
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Pale yellow oil (86%); vmax(CHCl3) 3430s,br, 2941m, 1660m, 1583s, 1513m, 1415m, 1327s, 
1262s, 1127s, 913w, 732m cm '1; 'H NMR 5 (400 MHz; CDCI3), 3.72 (6H, s, OMe), 3.74 (3H, 
s, OMe), 3.80 (3H, s, OMe), 5.74 (1H, s, OH), 6.57 (1H, d, J  8.4 Hz, H5” ), 6.68 (1H, dd, J2 .1 ,
8.4 Hz, H6 ” ), 6.76 (1H, d, J  2.1 Hz, H2” ), 7.08 (2H, s, H2’ and H6 ’), 7.27 (1H, s, H3); 19F 
NMR 8 (283 MHz; CDCI3), -62.1 (3F, s); l3C NMR 8 (100  MHz; CDCI3), 56.2 (s, OMe), 61.0 
(s, OMe), 65.9 (s, OMe), 108.8 (q, J  296 Hz, CF3), 107.0 (s, C2’ and C6 ’), 110.5 (s, C2” ),
115.5 (s, C5” ), 122.7 (s, C6 ” ), 125.4 (s, C l” ), 126.5 (q, J 3 0  Hz, C2), 130.5 (s, C l ’), 136.7(d, 
J  6 Hz, C3), 143.5 (s, C4’), 145.6 (s, C3” ), 148.2 (s, C4” ), 153.1 (s, C3’ and C5’), 191.6 (s, 
Cl); (Found [M+H]+, 413.1207, C20H20O6F3 requires [M+F1]+, 413.1206).
(Z)-2-(Trifluoromethyl)-3-(3” ,4” -dimethoxypheiiyI)-l-(3’,4 \5 ’-trimethoxypheiiyl)prop-2- 
en-l-one (88e)
O
/O
Pale yellow oil (71%); vM  (CHCI3) 2940 M, 1661m, 1583m, 1517m, 1464m, 1415w, 1331m, 
1263s, 1127s, 1024m, 732m cm '1; ‘H NMR 8 (400 MHz; CDCI3), 3.56 (3H, s, OMe), 3.73 
(6H, s, OMe), 3.77 (3H, s, OMe), 3.82 (3H, s, OMe), 6.65-6.68 (2H, m, H2”  and H5” ), 6.82 
(1H, dd, J 2 .0 , 8.4 Hz, H6 ” ), 7.14 (2H, s, H2’ and H6 ’), 7.34 (1H, s, H3); l9F NMR 8(283 
MHz; CDCI3), -62.0 (3F, s); 13C NMR 8 (100 MHz; CDC13), 55.9 (s, OMe), 56.2 (s, OMe),
61.0 (s,O M e),65.9 (s,OMe), 106.9(s, C2’ andC 6’), 110.9 (s, C2” ), 111.9(s, C5” ), 123.9(s, 
C l” ), 124.7 (s, C6 ” ), 126.1 (q, J 3 0  Hz, C2), 130.5 (s, C l ’), 136.6 (q, J 6  Hz, C3), 143.8 (s, 
C4” ), 148.7 (s, C3” ), 150.8 (s, C4’), 153.2 (s, C3’ and C5’), 191.8 (s, C l), (CF3 signal was too 
weak to detect with any certainty); (Found [M+H]+, 427.1365, C21H22O6F3 requires [M+H]+, 
427.1363).
(Z)-2-(T^ifIuoromethyl)-3-(2” v3” ,4” -trimethoxyphenyl)-l-(3’,4,,5,- 
trimethoxyphenyl)prop-2-en-l-one (88f)
O O
/ O
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Pale yellow oil (36%); vmax (CHCI3) 2942w, 1662m, 1584m, 1415m, 1126s, 759w cm '1; 
'H NMR 5 (400 MHz; CDClj), 3.65 (3H, s, OMe), 3.68 (3H, s, OMe), 3.72 (6H, s, OMe), 3.77 
(3H, s, OMe), 3.84 (3H, s, OMe), 6.31 (1H, d, J  8.7 Hz, H5” ), 6.71 (1H, d, J  8.7 Hz, H6 ” ),
7.03 (2H, s, H2’ and H6 ’), 7.59 (1H, d, J  1.3 Hz, H3); 19F NMR 5 (283 MHz; CDC13), -62.0 
(3F, s); l3C NMR 8 (100 MHz; CDCI3), (Insufficient sample for clear 13C NMR); (Found 
[M+H]+, 457.1470, C22H24O7F3 requires [M+H]+, 457.1469).
(Z)-2-(Trifluoromethyl)-3-(4” -trifluoromethylphenyl)-l-(3’,4,,5,-trimethoxyphenyl)prop- 
2-en-l-one (88g)
O
O
White powder (83%); m.p. 73-76 °C; (Found: C, 55.37; H, 3.70. C20H 16O4F6 requires C, 55.30; 
H, 3.69%); vraax (CHC13) 2944w, 1661s, 1582s, 1415s, 1323s, 1125s, 1067m, 849m cm’1; 
'H NMR 8 (400 MHz; CDC13), 3.65 (6H, s, OMe), 3.75 (3H, s, OMe), 6.99 (2H, s, H2’ and 
H6 ’), 7.23 (2H, d, J  8.3 Hz, H3”  and H5” ), 7 32 ( 1H, s, H3), overlapping 7.35 (2H, d, J  8.3 
Hz, H2” and H6 ” ); 19F NMR 8(283 MHz; CDC13), -62.6 (3F, s), -62.9 (3F, s); l3C NMR 
8(100 MHz; CDC13), (Insufficient sample for clear 13C NMR); (Found [M+H]+, 435.1022, 
C20H 17O4F6 requires [M+H]+, 435.1026).
(Z)-2-(Trifluoromethyl)-3-(2” -fluoro-4”-methoxyphenyI)-l-(3’,4’,5,- 
trimethoxyphenyl)prop-2-en-l-one (88h)
0  F
Pale yellow oil (22%); v ^ C H C fe )  2942w, 1665m, 1504m, 1464s, 1329s, 1128s, 1002m, 
836m, 758s cm'1; ]H NMR 5 (400 MHz; CDC13), 3.60 (3H, s, OMe), 3.68 (6H, s, OMe), 3.75 
(3H, s, OMe), 6.31 (1H, dd, J  2.4, 8.7 Hz, H5” ), 6.42 (1H, dd, 72.4, 12.3 Hz, H3” ), 6.92 (1H, 
dd, J  8.7, 8.7 Hz, H6 ” ), 7.01 (2H, s, H2’ and H6 ’), 7.37 (1H, s, H3); 19F NMR 8 (283 MHz; 
CDCI3), -62.0 (3F, s), -81.0 (IF, m); 13C NMR 8 (100 MHz; CDC13), 55.7 (s, OMe), 56.1 (s, 
OMe), 61.0 (s, OMe), 101.6 (d, J  25 Hz, C3” ), 106.8 (s, C2’ and C6’), 110.5 (s, C5” ), 113.0 
(d, J  20 Hz, C l” ), 126.1 (q, J  30 Hz, C2), 129.6 (s, C6” ), 130.3 (s, C l ’), 130.9 (s, C3), 143.6
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(s, C4’), 153.1 (s, C3’ and C5’), 160.8 (d, J  251 Hz, C2” ), 162.7 (s, C4” ), 191.2 (s, C l), (CF3 
signal was too weak to detect with any certainty); (Found [M+H]+, 415.1162, C20H19O5F4 
requires [M+H]+, 415.1163).
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Chapter Nine
9.1 a-H 19F Chalcones
General procedure for the synthesis of a-hydrogen chalcones—2-Fluoro-4- 
methoxyacetophenone (0.17 g, 1.0 mmol) and aldehyde (1.1 mmol) were dissolved in 1M 
NaOH in methanol (5 ml, 5 mmol) and left standing until the chalcone precipitated out.
(£)-3-(2” -Fluoro-4” -methoxyphenyI)-l-(3’,4’,5’-triinethoxyphenyl)propen-l-one (127)
Yellow crystals (57%); m.p. 136-138 °C; (Found: C, 65.60; H, 5.50. C 19H 19O5F requires C, 
65.90; H, 5.49%); v ^ C H C h )  2940w, 1660m, 1569s, 1505s, 1414w, 1328m, 1272m, 1158s, 
1128s, 1089w, 1003w, 854w cm '1; !H NMR 8 (400 MHz; CDC13), 3.88 (3H, s, OMe), 3.96 
(3H, s, OMe), 3.97 (6H, s, OMe), 6.69 (1H, dd, J2 .4 , 12.6 Hz, H3” ), 6.78 (1H, dd, J  2.4, 8.7 
Hz, H5” ), 7.29 (2H, s, H2’ and H6 ’), 7.51 (1H, d, J  15.9 Hz, H2), 7.59 (1H, dd, J  8.7, 8.7 Hz, 
H6 ” ), 7.79 (1H, d, J  15.9 Hz, H3); 19F NMR 6 (283 MHz; CDC13), -110.3 (IF, m); 13C NMR 
6 (100 MHz; CDC13), 55.8 (s, OMe), 56.4 (s, OMe), 61.0 (s, OMe), 102.1 (d, J  25 Hz, C3” ),
106.0 (s, C2’ and C6 ’), 110.9 (s, C2), 115.7 (d, J  12 Hz, C l” ), 121.8 (d, J, 7 Hz, C5” ), 130.9 
(d, J 5 Hz, C6 ” ), 133.6 (s, C l ’), 137.7 (s, C3), 142.3 (s, C4’), 153.1 (s, C3’ andC 5’), 162.7 (d, 
J  12 Hz, C4” ), 162.8 (d, J2 5 3  Hz, C2” ), 189.4 (s, C l); (Found [M+H]+, 347.1289, C19H20O5F 
requires [M+H]+, 347.1289).
( E )-1 -(2 ’-Fluoropheny l)-3-/Moly lpropen-1 -one (128)
F O
Yellow crystals (73%); m.p. 69-70 °C; (Found: C, 79.87; H, 5.42. C16H 13OF requires C, 80.00; 
H, 5.42%); V n^C H C h) 2365w, 1661s, 1592s, 1480m, 1453m, 1330w, 1154w, 987m, 814s 
cm '1; ]H NMR 6 (400 MHz; CDC13), 2.41 (3H, s, CH3), 7.16-7.22 (1H, m, H3’) overlapping 
7.24 (2H, d, J  8.0 Hz, H2” and H6 ” ) overlapping 7.26-7.31 (1H, m, H5’)> 7.37 (1H, dd, J2 .7 ,
15.7 Hz, H2), 7.51-7.57 (1H, m, H4’) overlapping 7.55 (2H, d, J  8.0 Hz, H3” and H5” ), 7.75 
(1H, dd, J  1.4, 15.7 Hz, H3), 7.83 (1H, ddd, J  1.9, 7.6, 7.6 Hz, H6 ’); 19F NMR 6 (283 MHz;
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CDCb), - 1 1 0 . 8  (IF, m); ,3C NMR 8  ( 1 0 0  MHz; CDCI3), 21.6 (s, Me), 116.5 (d, J23  Hz, C3’),
124.5 (d, J 4 Hz, C2), 124.7 (d, J 6  Hz, C5’), 127.2 (s, C l’), 128.7 (s, C2” andC6 ” ), 129.7 (s, 
C3” and C5” ), 131.0 (d, J  3 Hz, C6 ’), 132.0 (s, C l” ), 133.8 (d ,J 9 H z , C4’), 141.3 (s, C3),
145.1 (s, C4” ), 161.2 (d, J  251 Hz, C2’), 189.3 (s, Cl); (Found [M+H]+, 241.1025, C16H14OF 
requires [M+H]+, 241.1023).
(£)-3-(3” ,5” -Dimethoxyphenyl)-l-(2’-fluorophenyl)propen-l-one (129)236
Yellow needles (71%); m.p. 70-71 °C; (Found: C, 71.32; H, 5.27. C17H1 5O3F requires C, 71.33; 
H, 5.24%); v „  (CHC13) 2940w, 1665m, 1609s, 1452m, 1288s, 1205s, 1155s, 1060m, 767 cm' 
'; ‘H NMR 6  (400 MHz; CDCI3 ), 3.85 (6 H, s, OMe), 6.54 ( 1H, t, J  2.2 Hz, H4 ” ), 6.78 (2H, d, 
J  2.2 Hz, H2” and H6 ” ), 7.16 - 7.22 ( 1 H, m, H3’), 7.28 (1H, dt, J0 .9 , 7.5 Hz, H5’), 7.36 (1H, 
dd, J  2.7, 15.7 Hz, H2), 7.52-7.58 (1H, m, H4’), 7.67 (1H, dd, J  1.7, 15.7 Hz, H3), 7.83 (1H, 
ddd, J  1.9, 7.5, 7.5 Hz, H6 ’); l9F NMR 5 (283 MHz; CDCI3 ), -110.8 (IF, m); 13C NMR 8  (100 
MHz; CDCI3 ), 55.5 (s, OMe), 103.0 (s, C4” ), 106.4 (s, C2” and C6 ” ), 116.6 (d, J  23 Hz, 
C3’), 124.5 (d, J  3 Hz, C2), 126.1 ( d ,J 6 Hz, C5’), 127.0 (d, J  13 Hz, Cl ’), 131.0 (d, J  3 Hz, 
C6 ’), 134.0 (d ,J9H z, C4’), 136.6 ( s ,C l” ), 144.9 (s,C3), 161.0 (s,C 3” andC5” ), 161.2(d,J 
252 Hz, C2’), 189.1 (d ,./ 2  Hz, Cl)); (Found [M+H]+, 287.1080, CnH 1 60 3F requires [M+H]+, 
287.1078).
(£)-l-(3’-FIuoro-4’-methoxyphenyI)-3-/>-tolylpropeii-l-oiie (130)
O
Yellow crystals (62%); m.p. 141-143 °C; (Found: C, 75.12; H, 5.48. Ci7 H!5 0 2 F requires C, 
75.56; H, 5.56%); vmax (CHCI}) 1661m, 1594s, 1510w, 1435w, 1139s, 983w, 807s cm 1; 
‘H NMR 6  (400 MHz; CDCI3), 2.46 (3H, s, CH3), 4.00 (3H, s, OMe), 7.06 (1H, dd, J  8.4, 8.4 
Hz, H5’), 7.25 (2H, d, J  8.0 Hz, H3” and H5” ), 7.48 (1H, d, J  15.6 Hz,H2), 7.57 (2H, d, J 8.0 
Hz, H2” and H6 ” ), 7.82 (1H, d, J 15.6, H3), 7.83 -  7.89 (2H, m, H2’ and H6 ’); 19F NMR 8  
(283 MHz; CDCls), -134.2 (IF, m); ,3C NMR 8(100 MHz; CDCI3), 21.6 (s, Me), 56.3 (s, 
OMe), 112.3 (d, J  2 Hz, C5’), 116.2 (d, J  19 Hz, C2’), 120.1 (s, C2), 125.7 (d, .7 3 Hz, C6 ’),
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128.5 (s, C2” and C6 ” ), 129.7 (s, C3”  and C5” ), 131.5 (d,Y5 Hz, C l’), 132.1 (s, C l” ), 141.2 
(s, C4” ), 144.8 (s, C3), 151.7 (d, J  11 Hz, C4’), 152.0 (d, J  246 Hz, C3’), 187.9 (s, Cl); 
(Found [M+H]+, 271.1130, C 17H 16O2F requires [M+H]+, 271.1129).
(£)-3-(3” ,4” -Difluorophenyl)-l-(2’,4’-dimethoxyphenyl)propen-l-one (131)237
O
Pale yellow crystals (56%); m.p. 130-131 °C; (Found: C, 65.13; H, 4.44. C 17H 14O3F2 requires 
C, 67.11; H, 4.61%); v ^ C H C ls )  1663w, 1601s, 1514m, 1469w, 1271s, 1131m, 970m, 808m 
c m 1; lH NMR 5 (400 MHz; CDC13), 3.89 (3H, s, OMe), 3.94 (3H, s, OMe), 6.51 (1H, d, J 2.1, 
Hz, H3’), 6.59 (1H, dd, J  2.1, 8.7 Hz, H5’), 7.19 (1H, dd, J  8.4, 18.2 Hz, H5” ), 7.30-7.34 (1H, 
m, H2” ), 7.39-7.44 (1H, m, H6 ” ), 7.47 (1H, d, J 15.7 Hz, H2), 7.59 (1H, d, J  15.7 Hz, H3),
7.80 (1H, d, J  8.7 Hz, H6 ’); 19F NMR 6 (283 MHz; CDC13), -134.8 (IF, m), 136.9 (IF, m); 13C 
NMR 6 (100 MHz; CDC13), 55.6 (s, OMe), 55.8 (s, OMe), 98.6 (s, C3’), 105.3 (s, C5’), 116.2 
(d, J  17 Hz, C2” ), 117.7 (d, J  18 Hz, C5” ), 121.8 (s, C l ’), 125.1 ( q , /3 H z ,  C2), 128.0 (d ,J 2  
Hz, C6 ” ), 132.8 (m, C l” ), 133.1 (s, C6 ’), 139.3 (s, C3), 150.6 (dd, J  13, 237 Hz, C3” ), 151.2 
(dd, J  13, 237 Hz, C4” ), 160.6 (s, C2’), 164.5 (s, C4’), 189.7 (s, C l); (Found [M+H]+, 
305.0991, Ci7H 150 3F2 requires [M+H]+, 305.0989).
(£)-3-(5” -Bromo-2” -fluorophenyl)-l-(2’-fluoro-4’-methoxyphenyl)propen-l-one (132)
F O F
Br
Yellow crystals (34%); m.p. 127-130 °C; (Found: C, 54.45; H, 3.00. Ci6H n02F2Br requires C, 
54.39; H, 3.12%); vmax (CHC13) 2462w, 1614s, 1487m, 1316w, 1230m, 1099, 990m, 830m cm‘ 
'H NMR 8 (400 MHz; CDClj), 3.81 (3H, s, OMe), 6.59 (1H, dd, J  2.4, 13.1 Hz, H3’), 6.73 
(1H, dd, J  2.4, 8.8 Hz, H5’), 6.94 (1H, dd, J  8 .8 , 9.8 Hz, H3” ), 7.36-7.41 (1H, m, H4” ), 7.45 
(1H, dd, .72.9, 15.8 Hz, H2), 7.68 (1H, dd, J  2.4, 6.5 Hz, H6 ” ), 7.73 (1H, dd, J  1.9, 15.8 Hz, 
H3), 7.82 (1H, dd, J  8.8, 8.8 Hz, H6 ’); 19F NMR § (283 MHz; CDC13), -106.2 (IF, m), -116.0 
(IF, m); 13C NMR 8 (100 MHz; CDCI3), 55.9 (s, OMe), 101.8 (d, J  27 Hz, C3’), 111.0 (d, 7  2 
H z,C 5’), 117.3 (d, J 3  Hz, C l’), 118.0 (d ,J 2 4 H z , C3” ), 119.2 (d, J 12 Hz, C5” ), 125.1 (d, /  
13 Hz, C2), 128.8 (d, J 13 Hz, C l” ), 131.6 (d ,J 3  Hz, C6 ” ), 132.8 (d, J 4  Hz, C6 ’), 134.3 (d, J
133
Chapter 9 Experimental Section C4
9 Hz, C4” ), 134.5 (s, C3), 160.6 (d, J  253 Hz, C2” ), 163.3 (d, J  252 Hz, C2’), 164.9 (d, J  12 
Hz, C4’), 186.5 (s, C l); (Found [M+H]+, 352.9983, Ci6H 120 2F279Br requires [M+H]+, 
352.9983).
(£)-l-(2’-Fluoro-4’-methoxyphenyl)-3-(2” ,4” ,5” -trimethoxyphenyl)propen-l-one (133)
/ O
Yellow crystals (52%); m.p. 108-110 °C; (Found: C, 65.18; H, 5.06. C 19H 19O5F requires C, 
65.90; H, 5.49%); vmax(CHCl3) 2937m, 2360m, 1652m, 1613s, 1509m, 1290s, 1020m cm’1; 
]H NMR 6 (400 MHz; CDCI3), 3.89 (3H, s, OMe), 3.91 (6H, s, OMe), 3.96 ( 3H, s, OMe), 
6.52 (1H, s, H3” ), 6.66 (1H, dd, J2 .3 , 12.8 Hz, H3’), 6.80 (1H, dd, J2 .3 , 8.7 Hz, H5’), 7.13 
(1H, s, H6 ” ) 7.40 (1H, dd, J  2.9, 15.7 Hz, H2), 7.88 (1H, dd, J  8.7, 8.7 Hz, H6 ’), 8.09 (1H, dd, 
J  2.1, 15.7 Hz, H3); 19F NMR 8 (283 MHz; CDCI3), -107.0 (IF, m); 13C NMR 5(100 MHz; 
CDCI3), 55.8 (s, OMe), 56.1 (s, OMe), 56.4 (s, OMe), 56.5 (s, OMe), 96.8 (s, C3” ), 101.8 (d, J  
27 Hz, C3’), 110.6 (d, J  3 Hz, C5’), 111.1 (s, C6 ” ), 115.5 (s, C l” ), 120.3 (d, J  13 Hz, C l’),
123.6 (d, J  8 Hz, C2), 132.6 (d, J  5 Hz, C6 ’), 139.3 (s, C3), 143.2 (s, C5” ), 152.4 (s, C4” ),
154.7 (s, C2” ), 162.7 (d ,J2 4 9  Hz, C2’), 164.1 (d ,J 9 H z , C4’), 187.7 (d, J  4 Hz, Cl); (Found 
[M+H]+, 347.1289, C19H20O5F requires [M+H]+, 347.1289).
(£)-l-(2’-Fluoro-4’-methoxyphenyl)-3-(3” ,4,%5” -trimethoxyphenyl)propen-l-one (134)
F O
/ O
Yellow powder (80%); m.p. 101-102 °C; (Found: C, 65.05; H, 5.05. C19H19O5F requires C, 
65.90; H, 5.49%); (CHC13) 2256w, 1591s, 1418m, 1323w, 1256m, 1125s, 999m, 819m
cm '1; 'H NMR 5. (400 MHz; CDC13), 3.90 (3H, s, OMe), 3.92 (3H, s, OMe), 3.94 (6H, s, 
OMe), 6.68 (1H, dd, J  2.4, 13 Hz, H3’), 6.82 (1H, dd, J  2.4, 8.7 Hz, H5’), 6.87 (2H, s, H2”  
and H6 ” ), 7.36 (1H, dd, J  2.9, 15.6 Hz, H2), 7.71 (1H, dd, J  2.0, 15.6 Flz, H3), 7.90 (1H, dd, J
8.7, 8.7 Hz, H6 ’); l9F NMR 8 . (283 MHz; CDCI3), -106.7 (IF, m); 13C NMR 5(100 MHz; 
CDCI3), 55.9 (s, OMe), 56.2 (s, OMe), 61.0 (s, OMe), 101.8 (d, J  27 Hz, C3’), 105.6 (s, C2”  
and C6 ” ), 110.8 (d, J  8 Hz, C5’), 119.6 (d, J  13 Hz, C l ’), 124.9 (d, J  8 Hz, C2), 130.4 (s,
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C l” ), 132.7 (d, J  5 Hz, C6 ’), 140.2 (s, C4” ), 144.1 (s, C3), 153.4 (s, C3” andC 5” ), 163.1 (d, 
J  272 Hz, C2’), 164.5 (d, J  10 Hz, C4’), 187.1 (d, J  4 Hz, C l); (Found [M+H]+, 347.1288, 
C i^o O sF  requires [M+H]+, 347.1289).
(/s)-l-(2’-Fluoro-4’-methoxyphenyl)-3-p-tolylpropen-l-one (135)238
F O
Yellow powder (44%); m.p. 125-128 °C; (Found: C, 74.97; H, 5.59. C 17H 15O2F requires C, 
75.56; H, 5.56%); v,™ (CHCI3) 2266w, 1655m, 1588s, 1443w, 1334m, 1241m, 1104w, 988m, 
813m cm '; 'H NMR 8. (400 MHz; CDCI3), 2.41 (3H, s, CH3), 3.89 (3H, s, OMe), 6.67 (1H, 
dd, 7  2.4, 13 Hz, H3’), 6.81 (1H, dd, J  2.4, 8.7 Hz, H5’), 7.23 (2H, d, 7  8.0 Hz, H3” and H5” ), 
7.44 (1H, dd, 7  2.9, 15.6 Hz, H2), 7.55 (2H, d, 7  8.0 Flz, H2”  and H6 ” ), 7.79 (1H, dd, 7  2.0,
15.6 Hz, H3), 7.90 (1H, dd, 7  8.7, 8.7 Hz, H6 ’); 19F NMR 8  (283 MHz; CDCI3), -106.7 (IF, 
m); 13C NMR 8(100 MHz; CDCI3), 21.6 (s, Me), 55.9 (s, OMe), 101.8 (d ,7 2 7  Hz, C3’), 110.8 
(d ,7 2 H z ,C 5 ’), 119.8 (d, J  13 Hz, C l’), 124.6 (d, 7 9  Hz, C2), 128.6 (s, C2” andC 6 ” ), 129.7 
(s, C3” and C5” ), 132.2 (s, C l” ), 132.7 (d, 7  5 Hz, C6 ’), 141.0 (s, C4” ), 144.1 (s, C3), 163.0 
(d, 7  252 Hz, C2’), 164.5 (d, 7  12 Hz, C4’), 187.3 (d, J  4 Hz, C l); (Found [M+H]+, 288.1395, 
Ci7H,60 2F requires [M+H]+, 288.1394).
(£)-3-(4” -Bromo-2” -fluorophenyl)-l-(2,-fluoro-4,-methoxyphenyl)propen-l-one (136)
F O F
Yellow crystals (79%); m.p. 98-102 °C; (Found: C, 54.15; H, 2.98. C ieH n C ^B r requires C, 
54.39; H, 3.12%); vmax (CHCI3) 1660w, 1615s, 1494m, 1332m, 1240m, llOOw, 805w cm'1; 
'H NMR 8 (400 MHz; CDCI3), 3.90 (3H, s, OMe), 6.67 (1H, dd, 7  2.2, 13.1 Hz, H3’), 6.81 
(1H, dd, 7  2.2, 8.8 Hz, H5’), 7.31 -  7.37 (2H, m, H3”  and H5” ), 7.53 (1H, dd, 7  7.9, 7.9 Hz, 
H6 ” ) overlapping 7.56 (1H, dd, 7  2.8, 15.7 Hz, H2), 7.83 (1H, dd, 7  1.2, 15.7 Hz, H3) 7.91 
( 1H, dd, J  8.8, 8.8 Hz, H6 ’); 19F NMR 8 (283 MHz; CDCU), -106.4 (IF, m), -111.2 (IF, m); 
l3C NMR 8 (100 MHz; CDC13), 55.9 (s, OMe), 101.8 (d, 7 2 7  Hz, C3’), 111.0 (d, 7 8  Hz, C5’),
119.3 (d, 7  12 Hz, C l ’), 119.9 (d, 725  Hz, C3” ), 122.3 (d, 7  11 Hz, C l” ), 124.5 (d ,7  10 Hz, 
C4” ), 127.9 (d, 7 3  Hz, C5” ), 128.2 (d, 7 9  Hz, C2), 130.2 (d ,7  12 Hz, C6 ” ), 132.8 (d,7 4  Hz,
135
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C6 ’), 135.1 (s, C3), 161.2 (d, J  257 Hz, C2” ), 162.3 (d, J  253 Hz, C2’), 164.8 (d, J  12 Hz, 
C4’), 186.7 (s, C l); (Found [M+H]+, 352.9985, Ci6H 120 2F279Br requires [M+H]+, 352.9983).
(£)-3-(3” ,5” -Dimethoxyphenyl)-l-(2’-fluoro-4,-methoxyphenyl)propen-l-one (137)
F O
/ O
Yellow crystals (77%); m.p. 88-89 °C; (Found: C, 68.26; H, 5.31. C 18H 17O4F requires C, 68.35; 
H, 5.38%); Vniax (CHCI3) 2943w, 1614s, 1457, 1284m, 1245m, 1205m, 1156s, 1116w, 836w 
c m 1; *H NMR 6 (400 MHz; CDCI3), 3.86 (6H, s, OMe), 3.90 (3H, s, OMe), 6.54 (1H, t, J2 .2  
Hz, H4” ), 6.68 (1H, dd, J  2.4, 13 Hz, H3’), 6.79 (2H, d, J  2.2 Hz, H2” and H6” ), 6.81 (1H, 
dd, J  2.4, 8.9 Hz, H5’), 7.43 (1H, dd, J  2.8, 15.6 Hz, H2), 7.71 (1H, dd, J  2.0, 15.6 Hz, H3); 
7.90 (1H, dd, J  8.6, 8.6 Hz, H6’); 19F NMR $ (283 MHz; CDCI3), -106.5 (IF, m); 13C NMR 
6 (100 MHz; CD C13), 55.5 (s, OMe), 55.9 (s, OMe), 101.8 (d, J  27 Hz, C3’), 102.7 (s, C4” ),
106.3 (s, C2” and C6” ), 110.8 (s, C5’), 119.7 (d, J  16 Hz, C l ’), 126.1 (d, J  8 Hz, C2), 132.7 
(d, J  4 Hz, C6’), 136.9 (s, C l” ), 143.9 (s, C3), 161.0 (s, C3” and C5” ), 162.1 (d ,J2 5 2  Hz, 
C2’), 164.6 (d, J  12 Hz, C4’), 187.2 (s, C l); (Found [M+H]+, 317.1184, Ci8Hi80 4F requires 
[M+H]+, 317.1184).
(£)-l-(2 ,-Fluoro-4,-methoxyphenyl)-3-(4,,-methoxyphenyl)propen-l-one (138)239
F O
Yellow needles (57%); m.p. >250 °C; (Found: C, 70.36; H, 5.27. Ci?H150 3F requires C, 71.33; 
H, 5.24); VmaxtCHC^) 3407s, 2273w, 1420m, 1282w, 846m c m 1; ]H NMR 8 (400 MHz; 
CDCI3), 3.88 (3H, s, OMe), 3.90 (3H, s, OMe), 6.68 (1H, dd, J2 .4 , 13 H zH 3’), 6.81 (1H, dd, J
2.4, 8.8 Hz, H5’), 6.95 (2H, d, J  8.6 Hz, H3” and H5” ), 7.37 (1H, dd, J  3.0, 15.5 Hz, H2), 7.61 
(2H, d, J  8.6 Hz, H2” and H6 ” ), 7.78 (1H, dd, J  2, 15.5 Hz H3), 7.90 (1H, dd, J  8.7, 8.7 Hz, 
H6 ’); 19F NMR 5 (283 MHz; CDC13), -107.0 (IF, m); 13C NMR 5 (100 MHz; CDC13), 55.4 (s, 
OMe), 55.9 (s, OMe), 101.8 (d, J  27 Hz, C3’), 110.7 (s, C5’), 114.4 (s, C3”  and C5” ), 116.7 
(d,Y14 Hz, C l’), 123.3 ( d , / 8 Hz, C2), 127.7 (s, C l” ), 130.3 (s, C2” and C6 ” ), 132.6 (d ,Y 5 
Hz, C6 ’), 143.9 (s, C3), 161.6 (s, C4” ), 164.5 (d, J  262 Hz, C2’), 164.9 (d, J  11 Hz, C4’),
188.1 (s, C l); (Found [M+H]+, 287.1080, Ci7Hi60 3F requires [M+H]+, 287.1079).
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(£)-3-(2” ,4” -Dimethoxyphenyl)-l-(2’-fluoro-4’-methoxyphenyl)propen-l-one (139)
F O
Yellow cubes (87%); m.p. 100-102 °C; (Found: C, 68.36; H, 5.37. C18H17O4F requires C, 
68.35; H, 5.38%); v„,aX (CHC13) 2973w, 1650w, 1613s, 1501m, 1456m, 1235s, 1114s, 1017m, 
837w cm '1; *H NMR 8 (400 MHz; CDCI3), 3.79 (3H, s, OMe), 3.80 (3H, s, OMe), 3.82 (3H, s, 
OMe), 6.39 (1H, d, J2 .4  Hz, H3” ), 6.46 (1H, dd, J2 .4 , 8.6 Hz, H5” ), 6.58 (1H, dd, J2 .4 , 13.0 
Hz, H3’), 6.71 (1H, dd, J  2.4, 8.7 Hz, H5’), 7.39 (1H, dd, J  3.0, 15.7 Hz, H2), 7.50 (1H, d, J
8.6 Hz, H6 ” ), 7.79 (1H, dd, J  8.6 , 8.6 Hz, H6 ’), 7.97 (1H, dd, J  2.2, 15.7 Hz, H3); 19F NMR 
8 (283 MHz; CDCI3), -106.9 (IF, m); 13C NMR 8 (100 MHz; CDCI3), 50.2 (s, OMe), 55.5 (s, 
OMe), 55.8 (s, OMe), 98.3 (s, C3” ), 101.8 (d ,7 2 7  Hz, C3’), 105.5 (s, C5” ), 110.5 (d ,J 2  Hz, 
C5’), 117.0 (s, C l” ), 120.0 (d ,J 1 3 H z ,C l’), 123.6 (d, 7  8 Hz, C2), 130.8 (s, C6 ” ), 132.5 (d ,J  
5 Hz, C6 ’), 139.9 (s, C3), 161.6 (s, C2” ), 161.8 (d, J2 6 8  Hz, C2’), 164.1 (s, C4” ), 164.2 (d, J  
12 Hz, C4’), 188.2 (d, J  4 Hz, C l); (Found [M+H]+, 317.1181, C jg H ^ F  requires [M+H]+, 
317.1184).
(J£)-l-(2’-Fluoro-4’-methoxyphenyI)-3-(2” ,3” ,4” -trimethoxyphenyl)propeii-l-one (140)
F O
Yellow cubses (34%); m.p. 81-84 °C; (Found: C, 65.65; H, 5.53. C19H 19O5F requires C, 65.90; 
H, 5.49%); Vinax (CFIC13) 2941 w , 1614s, 1495s, 1464s, 1258s, 1097s, 1016m, 799w c m 1; 
'H NMR 5 (400 MHz; CDC13), 3.89 (3H, s, OMe), 3.91 (3H, s, OMe), 3.93 (3H, s, OMe), 3.96 
(3H, s, OMe), 6.68 (1H, dd, J  2.4, 13.0 Hz, H3’), 6.74 (1H, d, J  8.8 Hz, H5” ), 6.81 (1H, dd, J
2.4, 8.8 Hz, H5’), 7.40 (1H, d, J  8.8 Hz, H6 ” ), 7.49 (1H, dd, J  3.0,15.8 Hz, H2), 7.90 (1H, dd, 
J  8.6 , 8.6 Hz, H6 ’), 7.98 (1H, dd, J  2.2, 15.8 Hz, H3); 19F NMR § (283 MHz; CDC13), -106.8 
(IF, m); 13C NMR 8 (100 MHz; CDCI3), 50.3 (s, OMe), 55.9 (s, OMe), 60.9 (s, OMe), 61.4 (s, 
OMe), 101.8 (d ,J 2 7  Hz, C3’), 107.6 (s, C5” ), 110.7 ( d , J 2  Hz, C5’), 119.8 (d ,J  13 Hz, C l’),
121.9 (s, C l” )> 124.0 (s, C6” ), 124.7 (d, /  8 Hz, C2), 132.6 (d, J 4 Hz, C6 ’), 139.4 (s, C3),
142.3 (s, C3” ), 153.8 (s, C2” ), 155.7 (s, C4” ), 163.1 (d, J 2 5 2  Hz, C2’), 164.2 (d, J  12 Hz, 
C4’), 187.9 (s, C l); (Found [M+H]+, 347.1288, C19H20O5F requires [M+H]+, 347.1289).
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(is)-l,3-Bis-(0-fluoro-p-methoxyphenyl)propen-l-one (141)239
F O F
Yellow powder (49%); m.p. 85-87 °C; CHN analysis failed -  sample did not combust 
completely; Vmax^HCfO 3448m, 1612s, 1442m, 1238m, 1116m, 753s cm '1; *H NMR 6 (400 
MHz; CDC13), 3.86 (3H, s, OMe), 3.89 (3H, s, OMe), 6.67 (1H, dd, J  12.8, 2.4 Hz, H3”  or 
H3’), 6.68 (1H, dd, J  12.8, 2.4 Hz, H3”  or H3’) 6.76 (1H, dd, J  2.4, 8.7 Hz, H5”  or H55), 6.81 
(1H, dd, J2 .4 , 8.7 Hz, H5”  or H5’), 7.46 (1H, d d ,J2 .9 , 16.0 Hz, H2), 7.58 (1H, dd, 7  8.7, 8.7 
Hz, H6” ), 7.88 (1H, dd, J  2.0, 16.0 Hz, H3), overlapping 7.90 (1H, dd, J  8.7, 8.7 Hz, H6’); 19F 
NMR 5  (283 MHz; CDC13), -106.6 (IF, m), -110.8 (IF, m); 13C NMR 6(100 MHz; CDC13),
55.8 (s, OMe), 55.9 (s, OMe), 101.7 (d, J 2 5  Hz, C3’ or C3” ), 102.0 (d, J 2 6  Hz, C3’ or C3” ),
110.8 (d, J 2 Hz, C5’ or C5” ), 110.9 (d, J 3  Hz, C5’ or C5” ), 115.7 (d, J  12 Hz, C l” ), 119.8 
(d, J1 3 H z , C l ’), 125.4 (d, J 6 H z ,  C2), 130.4 (d, J  5 Hz, C6” ), 132.7 (d, J  4 Hz, C6’), 136.6 
(s, C3), 162.7 (d, J  12 Hz, C4” ), 162.8 (d, J  253 Hz, C2’ or C2” ), 163.0 (d, 7  252 Hz, C2’ or 
C2” ), 164.4 (d, J  12 Hz, C4’), 187.2 (d, J 4  Hz, C l); (Found [M+H]+, 305.0983, C 17H 1503F2 
requires [M+H]+, 305.0984).
(£)-3-(3” -Fluoro-4,,-methoxyphenyl)-l-(2,-fluoro-4’-methoxyphenyl)propeii-l-one
(142)240
F 0
Yellow crystals (26%); m.p. 105-107 °C; (Found: C, 67.08; H, 4.32. C17H 14O3F2 requires C, 
67.11; H, 4.61%); vraax(CHCl3) 3440m, 1614s, 1515m, 1441w, 1279m, 1117m, 758s cm '; 
'H NMR 5 (400 MHz; CDCb), 3.89 (3H, s, OMe), 3.91 (3H, s, OMe), 6.66  (1H, dd, .7 2.4, 13.0 
Hz, H3’), 6.69 (1H, dd, J  2.4, 8.8 Hz, H5’), 6.98 (1H, dd, J  8.5, 8.5 Hz, H5” ), 7.32 (1H, dd, J
2.7, 15.5 Hz, H2), overlapping 7.34 (1H, dd, J  2.0, 8.5 Hz, H6 ” ), 7.40 (1H, dd, J  2.0, 12 Hz, 
H2” ), 7.69 (1H, d, J  15.5 Hz, H3), 7.89 (1H, dd, J  8.7, 8.7 Hz, H6 ’); 19F NMR 5 (283 MHz; 
CDCI3), -107.0 (IF, m), -134.2 (IF, m); 13C NMR § (100 MHz; CDCI3), 55.9 (s, OMe), 56.2 
(s, OMe), 101.8 (d, J  27 Hz, C3’), 110.4 (d, J 3 H z ,  C5’), 113.1 (d, J  2 Hz, C5” ), 114 .8 (d ,J  
18 Hz, C2” ), 1 1 9 .6 (d ,J13H z, C l ’), 124.4 (d ,J9 H z ,C 2 ) , 126.1 (d, J 3  Hz, C6 ” ), 128.2 (d ,J  
7 Hz, C l” ), 132.6 (d ,7 5  Hz, C6 ’), 142.6 (s, C3), 149.6 ( d ,7 11 Hz, C4” ), 152.4 (d ,7245 Hz,
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C3” ), 163.1 (d, J  252 Hz, CT) ,  164.5 (d, J  11 Hz, C4’), 186.8 (d, J  4 Hz, C l); (Found 
[M+H]+, 305.0984, C 17H 15O3F2 requires [M+H]+, 305.0984).
(£ )-l-(2 ’-Fluoro-4’-methoxyphenyl)-3-(3” -hydroxy-4” -methoxyphenyl)propen-l-one
(143)
F O
OH
o '
Yellow crystals (30%); m.p. 116-118 °C; (Found: C, 67.28; H, 4.96. C 17H 15O4F requires C, 
67.55; H, 4.96%); (CHC13) 3358m, 1648s, 1613s, 1504s, 1266s, 1096m, 1018m, 797m
cm '1; lH NMR 8 (400 MHz; CDC13), 3.90 (3H, s, OMe), 3.96 (3H, s, OMe), 5.69 (1H, s, OH)
6.67 (1H, dd, J  2.4, 13.0 Hz, H3’), 6.81 (1H, dd, J  2.4, 8.7 Hz, H5’), 6.88 (1H, d, J  8.3 Hz, 
H5” ), 7.15 (1H, dd, J2 .0 , 8.4 Hz, H6 ” ), 7.29 (1H, d, J 2 . 0  Hz, H2” ), 7.35 (1H, d d ,J2 .8 , 15.5 
Hz, H2), 7.73 (1H, dd, J 2 . \ ,  15.5 Hz, H3), 7.90 (1H, dd, J 8 .7 , 8.7 Hz, H6 ’); 19F NMR 8 (283 
MHz; CDCI3), -106.5 (IF, m); 13C NMR 8 (100 MHz; CDC13), 55.9 (s, OMe), 56.0 (s, OMe),
101.8 (d, J 2 7  Hz, C3’), 110.6 (s, C2” ) 110.8 ( d ,J 3  Hz, C5’), 113.2 (s, C5” ), 119.8 (d, J  13 
Hz, C l’), 122.9 (s, C6 ” ), 123.7 (d, J 9  Hz, C2), 128.6 (s, C l” ), 132.6 ( d ,J 5  Hz, C6 ’), 144.0 
(s, C3), 145.9 (s, C3” ), 148.8 (s, C4” ), 163.0 (d, J  252 Hz, C2’), 164.4 (d, J  12 Hz, C4’),
187.2 (d, J 4  Hz, C l); (Found [M+H]+, 303.1030, Ci7H 1604F requires [M+H]+, 303.1027).
(£)-3-Benzo[ly3]dioxol-5-yl-l-(2’-fluoro-4,-methoxyphenyl)propen-l-one (144)
F O
Yellow crystals (64%); m.p. 133-135 °C; (Found: C, 66.78; H, 4.30. C 17HBO4F requires C, 
68.00; H, 4.33%); vmax(CHCl3) 1654w, 1589s, 1495w, 1237s, 834m cm '1; ‘H NMR 8 (400 
MHz; CDC13), 3.90 (3H, s, OMe), 6.05 (2H, s, CH2), 6.66  (1H, dd, J  2.4, 13.0 Hz, H3’), 6.81 
(1H, dd, J  2.4, 8.7 Hz, H5’), 6.86  (1H, d, J  8.0 Hz, H5” ), 7.13 (1H, dd, J  1.6, 8.0 Hz, H6 ” ), 
7.17 (1H, d, J  1.6 Hz, H2” ), 7.31 (1H, dd, J  2.9, 15.5 Hz, H2), 7.72 (1H, dd, 7  2.1, 15.5 Hz, 
H3), 7.90 (1H, dd, J  8.7, 8.7 Hz, H6 ’); 19F NMR 5 (283 MHz; CDC13), -106.9 (IF, m); l3C 
NMR 8 (100 MHz; CDCI3), 55.9 (s, OMe), 101.6 (s, OCH2O), 101.9 (d, J  23 Hz, C3’), 106.7 
(s, C2” ), 108.6 (s, C5” ), 110.8 (d, J 3 Hz, C6 ’), 119.8 (d, J  13 Hz, C l ’), 123.6 (d ,7 9  Hz, C2),
125.3 (s, C6 ” ), 129.4 (s, C l” ), 132.6 (d, 7  5 Hz, C6 ’), 143.8 (s, C3), 148.3 (s, C4” ), 149.8 (s,
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C3” ), 163.0 (d, J  252 Hz, C2’), 164.4 (d, J  12 Hz, C4’), 187.0 (d, J  4 Hz, C l); (Found 
[M+H]+, 301.0872, C 17H 14O4F requires [M+H]+, 301.0871).
(/0-3-(3” -Bromo-4” -methoxy phenyl)-!-(2’-fluoro-4’-methoxy pheny I )propen-l-one (145)
F O
Pale yellow powder (70%); m.p. 117-120 °C; CHN analysis failed -  sample did not combust 
completely; v ^ C H C fe )  3452w, 1656w, 1614s, 1495m, 1235m, 753m c m 1; 'H NMR 5 (400 
MHz; CDCI3), 3.86 (3H, s, OMe), 3.91 (3H, s, OMe), 6.67 (1H, dd, J 2 .3 , 13.1 Hz, H3’), 6.80 
(1H, dd, J  2.4, 8.8 Hz, H 5’), 6.93 (1H, d, J  8.6  Hz, H5” ), 7.34 (1H, dd, J  2.7, 15.6 Hz, H2), 
7.54 (1H, dd, J  2.1, 8.6 Hz, H6 ” ), 7.68 (1H, dd, J  2.0, 15.4 Hz, H3), 7.86 (1H, d, J  2.1 Hz, 
H2” ), overlapping 7.88 (1H, dd, J  8.7, 8.7 Hz, H6 ’); 19F NMR 6 (283 MHz; CDC13), -106.5 
(IF, m); 13C NMR §(100 MHz; CDCI3), 55.9 (s, OMe), 56.4 (s, OMe), 101.8 (d, J  27 Hz, 
C3’), 110.8 (d, 7  3 Hz, C5’), 111.8 (s, C5” ), 112.3 (s, C3” ), 119.6 (d, J  13 Hz, C l ’), 124.4 (d, 
J  8 Hz, C2), 129.0 (s, C l” ), 129.7 (s, C6 ” ), 132.6 (d, J  5 Hz, C6 ’), 132.8 (s, C2” ), 142.2 (s, 
C3), 157.5 (s, C4” ), 163.1 (d, 7  252 Hz, C2’), 164.6 (d, J  12 Hz, C4’), 186.9 ( d ,J  4 Hz, C l); 
(Found [M+H]+, 365.0185, Ci7H ,50 3 F79Br requires [M+H]+, 365.0183).
(£ )-l-(2 ’-Fluoro-4’-methoxyphenyl)-3-(4” -trifIuoromethylphenyl)propen-l-one (146)
F O
Yellow powder (12%); m.p. 82-84 °C; CHN analysis failed -  sample did not combust 
completely; VmaxCCHCb) 3367m, 1660m, 1617s, 1324s, 1283w, 1118s, 847w c m 1; 
]H NMR 5 (400 MHz; CDCI3), 3.75 (3H, s, OMe), 6.60 ( 1H, dd, J  2.3, 13.2 Hz H3’), 6.74 
(1H, dd, J  2.3, 8.9 Hz, H5’), 7.46 (1H, dd, J  3.0, 15.6 Hz, H2), 7.59 (2H, d, J  8.3 Hz, H3”  and 
H5” ), 7.65 (2H, d, J  8.3 Hz, H2”  and H6 ” ), 7.71 (1H, dd, J  2, 15.6 Hz H3), 7.84 (1H, dd, J
8.8, 8.8 Hz, H6 ’); 19F NMR 5 (283 MHz; CDCI3), -62.8 (3F, s), -106.2 (IF, m); 13C NMR 
6(100 MHz; CDCI3), (Insufficient sample for clear 13C NMR); (Found [M+H]+, 325.0849, 
C17HBO2F4 requires [M+H]+, 325.0846).
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9.2 a-Me 19F Chalcones
1-(2’-Fluoro-4’-methoxyphenyl)propan-l-ol (147)241
F OH
2-FIuoro-4-methoxybenxaldehyde (2 g, 13 mmol) was dissolved in dry THF (20 ml) and 
slowly added via cannula to EtMgBr (15 ml of a 1M solution in THF) in ice. The mixture was 
then stirred at room temperature overnight, cooled in ice again and quenched with sat. NH4CI 
(10 ml). It was extracted with ether, dried over MgSC>4 and evaporated under vacuum. 
Purification by silica column chromatography (3:7 EtOAc:hexane) gave a yellow oil (2.1 g, 
88%) ]H NMR 5 (400 MHz; CDCI3), 0.84 (3H, t, J  7.5 Hz, H3), 1.64-1.81 (2H, m, H2), 3.72 
(3H, s, OMe), 4.76-4.80 (1H, m, HI), 6.51 (1H, dd, J  2.5, 12.8 Hz, H3’), 6.62 (1H, dd, J  2.5,
8.8 Hz, H5’), 7.26 (1H, dd, J  8.6 , 8.6 Hz, H6 ’).
l-(2’-Fluoro-4’-methoxyphenyl)propan-l-one (148)241
F O
l-(2-Fluoro-4-methoxyphenyl)propan-l-ol (147, 2 g, 11 mmol) and KMn04  (3.5 g, 22 mmol) 
were dissolved in DCM and refluxed at 50 °C for 4 hours. The resulting mixture was filtered 
and the solvent removed under vacuum. Recrystallisation from MeOH yielded 148 as white 
crystals (1.95 g, 97%). m.p. 30-35 °C; *H NMR 8 (400 MHz; CDCI3), 1.11 (3H, t, J  7.5 Hz, 
H3), 2.86 (2H, dq, J  3.3, 7.5 Hz, H2), 3.78 (3H, s, OMe), 6.53 (1H, dd, J  2.3, 13.2 Hz, H3’),
6.67 (1H, dd, y  2.3, 8.9 Hz, H5’), 7.82 ( 1H, dd, 8.9, 8.9 Hz, H6 ’).
General procedure for the synthesis of a-methyl chalcones— l-(2-Fluoro-4-methoxy- 
phenyl)-propan-l-one (148, 0.18 g, 1.0 mmol) and aldehyde (1.0 mmol) were dissolved in 
ethanol (5 ml) at room temperature and piperidine (1 ml, 10 mmol) and glacial acetic acid (0.5 
ml) were added. The mixture was refluxed for 48 hours, cooled to room temperature, the 
solvent removed under vacuum and the residue partitioned between DCM and water. The 
DCM fraction was dried over MgSCU, evaporated under vacuum and purified by silica column 
chromatography (4:6 EtOAc:hexane).)
(E)-3-(2” ,4” -Dimethoxyphenyl)-l-(2’-fluoro-4’-niethoxyphenyl)-2-methylpropen-l-one
(149)
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F O
Yellow oil (23%); v™* (CHC13) 3471m, 2966w, 1617s, 1443m, 1270s, 1116m, 1031m, 950w, 
836m cm '1; ‘H NMR 5 (400 MHz; CDC13), 2.11 (3H, s, Me), 3.73 (3H, s, OMe), 3.76 (3H, s, 
OMe), 3.79 (3H, s, OMe), 6.54-6.59 (2H, m, H3”  and H5” ), 6.66-6.70 (2H, m, H3’ and H5’), 
7.16 (1H, s, H3), 7.33-7.42 (2H, m, H6 ’ and H6 ” ); l9F NMR § (283 MHz; CDCI3), -109.0 (IF, 
m); l3C NMR 5 (100 MHz; CDCI3), 12.9 (s, Me), 55.4 (s, OMe), 55.6 (s, OMe), 56.3 (s, OMe),
100.0 (s, C3” ), 101.4 (d, J 2 6  H z,C3’), 105.9 (s, C5” ), 109.5 (d, J 2  Hz, C5’), 113.4 ( s ,C l” ),
116.2 (d, J 1 2 H z , C l ’), 128.9 (s, C6” ), 132.0 (s, C2), 132.4 (d, J  16 Hz, C6 ’), 139.4 (s, C3), 
155.5 (s, C2” ), 159.3 (s, C4” ), 164.2 (d, J  253 Hz, C2’), 168.3 (d, J  12 Hz, C4’), 191.1 (s, 
C 1); (Found [M+H]+, 331.1342, C19H2o0 4F requires [M+H]+, 331.1340).
(£)-l-(2’-Fluoro-4,-methoxyphenyI)-2-methyl-3-(2” ,3” ,4” -trimethoxyphenyl)propen-l- 
one (150)
F O
Yellow oil (20%); v ^ ( C H C h )  2941w, 1681w, 1590s, 1495m, 1464m, 1290s, 1095s, 1009w 
cm’1; *H NMR 6 (400 MHz; CDC13), 2.12 (3H, s, Me), 3.68 (3H, s, OMe), 3.82 (3H, s, OMe), 
3.83 (3H, s, OMe), 3.97 (3H, s, OMe), 6.58 (1H, dd, J  2.3, 11.8 Hz, H3’), 6.66 (1H, d, J  8.8 
Hz, H5” ), 6.69 (1H, dd, J  2.3, 8.6 Hz, H5’), 7.13 (1H, d, J  8.8 Hz, H6 ” ), 7.30 (1H, s, H3), 
7.39 (1H, dd, J  8.6 , 8.6 Hz, H6 ’); 19F NMR 5 (283 MHz; CDCI3), -109.3 (IF, m); 13C NMR 
5(100 MHz; CDCI3), (Insufficient sample for clear 13C NMR); (Found [M+H]+, 361.1449, 
C20H22O5F requires [M+H]+, 361.1446).
(jE)-3-(3” -Fluoro-4” -methoxy-phenyl)-l-(2’-fluoro-4,-methoxyphenyl)-2-methyl-propen- 
1-one (151)
142
Chapter 9 Experimental Section C4
White powder (53%); m.p. 105-107 °C; (Found: C, 67.41; H, 5.00. C 18H16O3F2 requires C, 
67.92; H, 5.03%); v™, (CHC13) 2937w, 1614s, 1515m, 1442w, 1281s, 1126m, 1013m c m 1; 
'H NMR 8. (400 MHz; CDCI3), 2.16 (3H, s, CH,), 3.80 (3H, s, OMe), 3.86 (3H, s, OMe), 6.57 
(1H, dd, J  2.4, 11.8 Hz, H3’), 6.69 (1H, dd, J  2.4, 8.6 Hz, H5’), 6.90 (1H, dd, J  8 .6 , 8.6 Hz, 
H5” ), 7.00 (1H, s, H3), 7.08 (1H, d, J  8.7 Hz, H6 ” ), 7.14 (1H, dd, J2 .0 , 12.4 Hz, H2” ), 7.38 
(1H, dd, J  8.4, 8.4 Hz, H6 ’); 19F NMR 8 (283 MHz; CDCI3), -109.0 (IF, m), -135.0 (IF, m); 
13C NMR 8 (100 MHz; CDCI3), 13.6 (s, Me), 55.8 (s, OMe), 56.3 (s, OMe), 101.8 (d, J  26 Hz, 
C3’), 110.2 (d, J  3 Hz, C5’), 113.0 (d, J  2 Hz, C5” ), 117.3 (d, J  19 Hz, C2” ), 119.9 (d, 7  15 
Hz, C l ’), 126.7 (d, J 3 Hz, C6 ” ), 128.9 (d, J 1  Hz, C l” ). 131.8 (d, J 5  Hz, C6 ’), 137.1 (s, C2),
140.9 (s,C 3), 148.0 (d, J l l  Hz, C4” ), 152.0 (d, J  245 Hz, C3” ), 161.1 (d, J  250 Hz, C2’),
163.1 (d, J  11 Hz, C4’), 195.3 (s, C l); (Found [M+H]+, 319.1140, C 18H,7 0 3F2 requires 
[M+H]+, 319.1139).
(£)-3-Benzo[1,3] dioxol-5-yl-l-(2-fluoro-4-methoxyphenyl)-2-methyIpropen- 1-one (152)
Yellow oil (18%); v ^ C H C 1 3) 1654w, 1589s, 1495w, 1237s, 834m c m 1; *H NMR 6 (400 
MHz; CDCI3), 2.16 (3H, s, CH3), 3.79 (3H, s, OMe), 5.94 (2H, s, CH2), 6.57 (1H, dd, .7 2.4,
11.7 Hz, H3’), 6.69 (1H, dd, J2.4,  8.6 Hz, H5’), 6.77 (1H, d, J  8.1 Hz, H5” ), 6.84 (1H, dd, J
1.4, 8.1 Hz, H6 ” ), 6.90 (1H, d, J  1.4 Hz, H2” ), 7.03 (1H, s, H3), 7.37 (1H, dd, J  8.4, 8.4 Hz, 
H6 ’); 19F NMR $(283 MHz; CDC13), -109.2 (IF, m); 13C NMR 6(100 MHz; CDC13), 
(Insufficient sample for clear 13C NMR); (Found [M+H]+, 315.1030, C 18H 16O4F requires 
[M+H]+, 315.1027).
(£)-3-(3” -Bromo-4” -methoxyphenyl)-l-(2’-fluoro-4’-methoxyphenyl)-2-methylpropeii-l- 
one (153)
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Yellow needles (61%); m.p. 88-90 °C; (Found: C, 56.20; H, 5.38. CjgH^C^FBr requires C, 
56.99; H, 4.22%); (CHC13) 2942w, 1614s, 1496s, 1440w, 1256s, 1156m, 1012m, 812w
cm '1; *H NMR 6 (400 MHz; CDC13), 2.25 (3H, s, CH3), 3.88 (3H, s, OMe), 3.95 (3H, s, OMe), 
6.66 (1H, dd, J  2.3, 11.8 Hz, H3’), 6.78 (1H, dd, J  2.3, 8.4 Hz, H5’), 6.94 (1H, d, J  8.6 Hz, 
H5” ), 7.09 (1H, d, J  2.1 Hz, H2” ), 7.39 (1H, dd, J  2.1, 8.6 Hz, H6 ” ), 7.47 (1H, dd, J  8.4, 8.4 
Hz, H6 ’), 7.64 (1H, d, J  2.1 Hz, H3); 19F NMR 5 (283 MHz; CDC13), -109.0 (IF, m); 13C 
NMR 5(100 MHz; CDC13), 13.6 (s, Me), 55.8 (s, OMe), 56.3 (s, OMe), 101.8 (d, J  26 Hz, 
C3’), 110.2 (d, J 3 Hz, C5’), 111.6 (s, C3” ), 111.7 (s, C5” ), 119.8 (d, J  15 Hz, C l ’), 129.8 (s, 
C2), 130.4 (s, C2” ), 131.8 (d, J  5 Hz, C6 ’), 134.8 (s, C3), 137.2 (s, C l” ), 140.7 ( d ,J 2 H z ,  
C6 ” ), 156.1 (s, C4” ), 161.1 (d, J 250 Hz, C2’), 163.2 (d, J l l  Hz, C4’), 195.3 (s ,C l); (Found 
[M+H]+, 379.0339, C ]8Hi70 3F79Br requires [M+H]+, 379.0340).
(£’)-l-(2 ,-Fluoro-4’-methoxy pheny l)-2-methyl-3-(4” -trifluoromethylphenyl)propen-l-one 
(154)
F O
CF
Yellow needles (40%); m.p. 64-66 °C; (Found: C, 62.80; H, 4.07. C18H 14O2F4 requires C, 
63.91; H, 4.17%); vmax(CHCl3) 2940w, 1615s, 1444w, 1325s, 1260m, 1162m, 1118s, 1068m, 
101 lw, 838w cm '1; ‘H NMR 5 (400 MHz; CDClj), 2.13 (1H, s, CH3), 3.79 (3H, s, OMe), 6.59 
( 1H, dd, J  2.3, 9.4 Hz H3’), 6.72 (1H, dd, J  2.3, 8.6 Hz, H5’), 7.09 (1H, s, H3), 7.42 (2H, d, J
7.6 Hz, H3” and H5” ), overlapping 7.46 (1H, dd, J  8.3, 8.3 Hz, H6 ’), 7.58 (2H, d, J  7.6 Hz, 
H2” and H6” ); 19F NMR 5 (283 MHz; CDC13), -62.8 (3F, s), -108.2 (IF, m); 13C NMR 5 (100 
MHz; CDCh), 13.8 (s, Me), 55.8 (s, OMe), 101.8 (d, J  26 Hz, C3’), 110.4 (d, J  3 Hz, C5’),
119.3 (d, J  15 Hz, C l ’), 123.8 (q, J  240 Hz, CF3), 125.3 (d, J 4 H z ,  C3”  and C5” ), 128.0 (s, 
C2), 129.7 (s, C2” and C6 ” ), 130.2 (q, J  32 Hz, C4” ), 132.1 (d, J  4 Hz, C6 ’), 139.4 (s, C3),
140.0 (s, C l” ), 161.4 (d, J  250 Hz, C2’), 163.6 (d, J  11 Hz, C4’), 195.2 (s, C l); (Found 
[M+H]+, 339.1005, C 1SH 1502F4 requires [M+H]+, 339.1003).
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Chapter Ten
10.1 Trifluorostyrenes
General procedure for the synthesis of trifluorostyrenes242—Zinc chloride (4.0 g, 29 mmol) 
was added to a two-necked round bottomed flask, this was then attached to a high vacuum and 
heated with a Bunsen burner to remove all traces of water. The flask was then filled with 
nitrogen and allowed to cool to room temperature. Dry THF (30 ml) was added and the 
suspension was cooled to -78 °C in dry ice/acetone. 1,1,1,2-tetrafluoroethane (3.5 ml, 40 
mmol) was condensed into the flask and stirred at -78 °C. Dry diisopropyl amine (10 ml, 71 
mmol) was added to another round bottomed flask, followed by dry THF (30 ml), this was 
cooled in ice and BuLi (28 ml of a 2.5 M solution in hexanes) was added with stirring. This 
LDA solution was then added drop-wise via cannula to the zinc chloride and 1,1,1,2- 
tetrafluoroethane, and the resulting mixture was stirred for 1 hour at -78 °C, before being 
allowed to warm to room temperature. Aryl iodide (20 mmol) and Pd(PPh3)4 (0.5 g, 0.4 mmol) 
were then added and the mixture was refluxed at 80 °C overnight, filtered, extracted with ethyl 
acetate, dried over MgS04 and evaporated under vacuum. Purification by silica 
chromatography using a 1:9 mixture of EtOAc : hexane yielded the following trifluorostyrenes.
1 -Methoxy-4-trifluoroviny lbenzene (168)243
F
Colourless oil (82%); ]H NMR 5 (400 MHz; CDC13), 3.80 (3H, s, OMe), 6.92 (2H, d, J  8.8 Hz, 
H2 and H6), 7.36 (2H, d, J  8.8 Hz, H3 and H5); 19F NMR 5 (283 MHz; CDC13), -102.1 (IF, 
dd, J 2 5 ,44 Hz), -117.2 (IF, d d ,J 4 4 ,170 Hz), -175.4 (IF, dd, J25,  170 Hz).
l-M ethyl-3-trifluorovinylbenzene (169)244
F
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Colourless oil (58%); 'H  NMR 8 (400 MHz; CDClj), 2.36 (3H, s, Me), 7.14 (1H, d, J  7.1 Hz, 
H6 ), 7.26-7.33 (2H, m, H4 and H5), 7.53 (1H, s, H2); l9FN M R 8(283 MHz; CDC1,), -99.8 
(IF, dd,,/26 ,44 Hz), -114.6 (IF, dd, J4 4 , 170 Hz), -176.5 (IF, d d ,./2 6 ,170 Hz).
1,2-Dimethoxy-4-trifluorovinylbenzene (170)
F
Colourless oil (63%); 'H  NMR 5 (400 MHz; CDClj), 3.79 (3H, s, OMe), 3.80 (3H, s, OMe), 
6.79 (1H, d, J  8.5 Hz, H6 ), 6.84 (1H, d, J  1.9 Hz, H3), 6.92 (1H, dd, J  1.9, 8.5 Hz H5); 
19F NMR 8 (283 MHz; CDC13), -101.5 (IF, dd, J  25, 44 Hz), -117.0 (IF, dd, J  44, 170 Hz), -
175.0 (IF, dd, J  25, 170 Hz). (Found [M +Hf, 219.0630, C 10H,o0 2F3 requires [M+H]+, 
219.0627
4-Iodo-l,2-dimethoxybenzene (172)245
I
TV-iodosuccinamide (1.8 g, 8.0 mmol) was dissolved in acetonitrile (20 ml) and stirred at room 
temperature under nitrogen. Veratrol (0.9 ml, 7.2 mmol) was added, followed by trifluoroacetic 
acid (0.15 ml, 2.2 mmol) and the resulting mixture was stirred overnight. The solvent was then 
removed under vacuum and the residue partitioned between DCM and water. The DCM 
fraction was dried over MgSC>4 and evaporated under vacuum. Recrystallisation from ethanol 
yielded white crystals (1.84 g, 97%); m.p. 33-35 °C (lit.246 m.p. 34-35 °C); *H NMR 5 (400 
MHz; CDCI3), 3.88 (3H, s, OMe), 3.89 (3H, s, OMe), 6.65 (1H, d, J 8.5 Hz, H6), 7.14 (1H, d, J
1.9 Hz, H3), 7.25 (1H, dd, J  1.9, 8.5 Hz, H5).
General procedure for the addition of amines to trifluorostyrenes—Amine (1.4 mmol) was 
dissolved in dry THF (10 ml) and cooled in ice. BuLi (0.6 ml of a 2.5 M solution in hexanes) 
was added and the mixture was warmed slowly to room temperature, with stirring. The 
appropriate trifluorostyrene (1.4 mmol) in THF (5 ml) was then added and the mixture was 
stirred overnight. The solvent was then removed under vacuum and the residue partitioned
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between ether and water. The ether fraction was dried over MgSC>4 and evaporated under 
vacuum. Purification by silica chromatography using a 1:1 mixture of EtOAc : hexane yielded 
the following amides.
A/,Ar-Diethyl-2-fluoro-2-(4-methoxyphenyl)acetamide (173)
Pale yellow oil (11%); vmax (CHC13) 2932s, 1702m, 1654s, 1512m, 1459w, 1249m, 1177w, 
1032m, 824w c m 1; 'H NMR 5 (400 MHz; CDC13), 0.93 (3H, t, J  7.1 Hz, CH3), 1.07 (3H, t, J 
7.1 Hz, CH3), 3.06-3.13 (2H, m, CH2), 3.31-3.37 (2H, m, CH2), 3.75 (3H, s, OMe), 5.88 (1H, 
d, J  49.8 Hz, CHF), 6.85 (2H, d, J  8.6 Hz, H3 and H5), 7.32 (2H, dd, J  1.8, 8.6 Hz, H2 and 
H6 ); ,9F NMR 8 (283 MHz; CDC13), -166.4 (IF, dd, J  1.8, 49.8 Hz); 13C NMR 8 (100 MHz; 
CDClj), 12.7 (s, CH3), 13.8 (s, CH3), 40.4 (s, CH2), 41.2 (s, CH2), 55.3 (s, OMe), 89.7 (d, J  
180 Hz, CF), 114.3 (s, C3andC 5), 126 .8(d ,J20  H z,C l), 129.0 (d, J 4  Hz, C2 and C6 ), 160.5 
(s, C4), 167.1 (d, J  23 Hz, CO); (Found [M+H]+, 240.1392, Ci3H19N 0 2F requires [M+H]+, 
240.1394).
2-Fluoro-2-(4-methoxy phenvl)-l-pyrrolidin-l-yl-ethanone (174)
Yellow crystals (19%); m.p. 86-89 °C; (Found; C, 65.57; H, 6 .86; N, 5.95. Ci3H16N 0 2F 
requires C, 65.82; H, 6.75; N 5.91%); v™, (CHCI3) 3468s, br, 2971m, 1651s, 1513m, 1451s, 
1248s, 1177m, 1029m, 824w c m 1; ■H NMR 8 (400 MHz; CDCI3), 1.69-1.82 (4H, m, H3’ and 
H4’), 3.09-3.53 (4H, m, H2’ and H5’), 3.75 (3H, s, OMe), 5.78 (1H, d, J  49.2 Hz, CHF), 6.85 
(2H, d, J  8.5 Hz, H3 and H5), 7.35 (2H, dd, J  1.7, 8.5 Hz, H2 and H6); 19F NMR 8 (283 MHz; 
CDCI3), -167.8 (IF, dd, J  1.7, 49.2 Hz); 13C NMR 8 (100 MHz; CDCI3), 23.6 (s, C3’), 26.2 (s, 
C4’), 45.8 (s, C2’), 46.5 (s, C5’), 55.3 (s, OMe), 89.9 (d ,./ 180 Hz, CF), 114.7 (s, C3 and C5),
126.3 (d, J  21 Hz, C l), 129.2 (d, J  5 Hz, C2 and C6 ), 160.6 (s, C4), 166.7 (d, J  25 Hz, CO); 
(Found [M+H]+, 238.1236, C,3H17N 0 2F requires [M+H]+, 238.1238).
2>FIuoro-2-(4-methoxyphenyI)-l-piperidin-l-yl-ethanone (175)
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Yellow oil (13%); VmaxCCHClj) 2358m, 1644s, 1512w, 1444w, 1245m, 998w, 842w cm"1; 
'H NMR 8  (400 MHz; CDCI3), 1.42-1.56 (6 H, m, H3’, H4’ and H5’), 3.14-3.71 (4H, m, H2’ 
and H6 ’), 3.76 (3H, s, OMe), 5.94 (1H, d, J  49.8 Hz, CHF), 6 . 8 6  (2H, d, J  8 . 8  Hz, H3 and H5), 
7.32 (2H, dd, J  1.7, 8 . 8  Hz, H2 and H6 ); 19F NMR 8  (283 MHz; CDCI3), -167.2 (IF, dd, J  1.7,
49.8 Hz); 13C NM R 8(100 MHz; CDCI3), 24.3 (s, C3’), 25.5 (s, C5’), 25.8 (s, C4’), 43.4 (s, 
C2’), 46.1 (s, C6 ’), 55.3 (s, OMe), 90.4 (d ,./ 180 Hz, CF), 114.3 (s, C3andC5), 126.7 (d, 7  20 
Hz, Cl), 128.9 (d, J  5 Hz, C2 and C6 ), 160.5 (s, C4), 166.1 (d, J  23 Hz, CO); (Found [M+H]+, 
252.1396, C14H19NO2F requires [M+H]+, 252.1394).
10.2 Chiral Amines
General procedure for the synthesis of proline esters247—Proline (0.5 g, 4.3 mmol) was 
dissolved in the appropriate alcohol (10 ml) and warmed to 60 °C. SO2 CI (0.42 ml, 5.7 mmol) 
was added drop-wise and the mixture was stirred overnight. The solvent was then removed 
under vacuum to yield the following products.
(S)-Pyrrolidine-2-carboxyIic acid ethyl ester (176)247
White crystals (94%); m.p. 54-56 °C; *H NMR 5 (400 MHz; CDCI3 ), 1.29 (3H, t, J  7.2 Hz, 
CH3), 1.72-2.19 (4H, m, H3 and H4), 2.94-3.15 (2H, m, H5) overlapping 3.18 (1H, s, NH), 
3.78-3.82 (1H, m, H2), 4.20 (2H, q, J7.2  Hz, CH2).
(5)-Pyrrolidine-2-carboxylic acid isopropyl ester (177)247
° Y
White crystals (85%); m.p. >200 °C; *H NMR 6  (400 MHz; CDC13), 1.14-1.19 (6 H, m, CH3), 
1.64-2.08 (4H, m, H3 and H4), 2.14 (1H, s, NH), 2.81-3.03 (2H, m, H5), 3.62-3.65 (1H, m, 
H2), 4.97 (1H, h,J6.2  Hz, CH).
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(5)-PyrroIidine-2-car boxy lie acid butyl ester (178)248
H O
Pale oil (88%); !H NMR 8 (400 MHz; CDC13), 0.82 (3H, dt, J  1.7, 7.4 Hz, H4’), 1.25-1.31
LiAlHt (1.3 g, 34.2 mmol) was stirred in dry ether (50 ml) at -10  °C, proline (2 g, 17.4 mmol) 
was suspended in dry ether (30 ml) and added in small portions. The resulting mixture was 
warmed to room temperature and stirred overnight. It was then cooled to -10 °C again and 
water (2 ml) followed by 1M NaOH (5 ml) were added very slowly, it was then filtered and the
oil (1.5 g, 88%); ]H NMR 8 (400 MHz; CDCI3), 1.22-1.30 (1H, m, H3 and H4), 1.53-1.69 (3H,
Pyrrolidin-2-yl-methanol (179, 0.5 g, 5 mmol) was dissolved in dry pyridine (20 ml), trityl 
chloride (1.5 g, 5.4 mmol) was added and the mixture was refluxed at 120 °C overnight. The 
pyridine was then evaporated under vacuum and the resulting oil washed with hexane and 
filtered. The solid residue was partitioned between DCM and 1 M NaOH and the DCM 
fraction dried over MgS04 and evaporated under vacuum to give a yellow oil (0.72 g, 42%); 
vmax (CHCI3) 3057w, 2961m, 1596w, 1490m, 1448s, 1219w, 1069s, 908m, 706s cm'1; 
]H NMR 8 (400 MHz; CDC13), 1.68-1.73 (2H, m, H3), 1.80-1.84 (2H, m, H4), 2.84-2.94 (2H, 
m, H5), 3.05-3.11 (2H, m, CH2), 3.30-3.33 (1H, m, H2), 7.21-7.45 (15H, m, ArH);
(4H, m, H3’ and H4), 1.49-1.56 (4H, m, H2’ and H3), 2.74-2.80 (1H, m, H5), 2.93-2.99 (1H, 
m, H5), 3.63 (1H, dd, .75.5, 8.5 Hz, H2), 4.01 (2H, t, J 6.7 Hz, H I’).
(S)-Pyrrolidin-2-yl-methanoI (179)249
H
solvent removed under vacuum. The resulting residue was partitioned between DCM and water 
and the DCM fraction was dried over MgS04  and evaporated under vacuum to yield a brown
m, H3 and H4), 2.70-2.79 (3H, m, H2 and H5), 2.90 (1H, s, NH), 3.13-3.20 (2H, m, CH2OH); 
13C NMR 8 (100 MHz; CDC13), 25.8 (s, C4), 27.7 (s, C3), 46.5 (s, C5), 60.3 (s, C2), 64.6 (s, 
CH2).
(S)-2-T rityloxymethyl-pyrrolidine (180)
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l3C NMR 8 (100 MHz; CDC13), 25.1 (s, C4 ), 28.1 (s, C3), 46.3 (s, C5), 58.4 (s, C2), 66.5 (s, 
CH2), 86.3 (s, CPh3), 126.9 (s, C4’), 127.8 (s, C2’ and C6 ’), 127.9 (s, C3’ and C5’), 144.2 (s, 
C l ’); (Found [M+H]+, 344.2017, C24H25NO requires [M+H]+, 344.2014).
OSJWV-BOC-Proline (181)250
< A > “
Proline (5 g, 43.5 mmol) and NaOH (1.8 g, 45 mmol) were stirred together in dry THF (50 ml) 
and cooled to 0 °C. BOC anhydride (10 g, 46 mmol) was added slowly and the mixture was 
warmed to 60 °C and stirred overnight. The mixture was then quenched with 2M HC1 (50 ml) 
and extracted into ethyl acetate, dried over MgS04  and evaporated under vacuum to give 181 
as white crystals (7.9 g, 85%); m.p. 135-138 °C; (lit.251 m.p. 138-140 °C); !H NMR 6 (400 
MHz; CDCI3), 1.48 and 1.53 (9H, s, C(CH3)3), 1.95-2.36 (4H, m, H3 and H4), 3.42-3.57 (2H, 
m, H5), 4.36 (1H, s, H2).
(5>7V-BOC-Proline methyl ester (182)252
0 ^ 0 ° '
1-Hydroxybenzotriazole (1.9 g, 14 mmol) and (S)-2V-Boc-proline (181, 3.0 g, 14 mmol) were 
dissolved in DCM (40 ml) at room temperature, methanol (10 ml) was added and the solution 
was cooled to 0 °C. DCC (2.9 g, 14 mmol) in DCM (10 ml) was added via cannula and the 
mixture was stirred at room temperature overnight. The mixture was then diluted with DCM 
(30 ml), washed three times with sat. Na2C0 3 solution, dried over MgSC>4 and evaporated 
under vacuum. Purification by flash chromatography using a 1:1 mixture of EtOAc : hexane 
yielded a brown oil (2.4 g, 74%). *H NMR 6 (400 MHz; CDC13), 1.40 and 1.44 (9H, s, 
C(CH3)3), 1.71-2.20 (4H, m, H3 and H4), 3.48-3.59 (2H, m, H5), 3.95 (3H, s, OMe), 4.19-4.25 
(1H, m, H2).
(5)-7V-BOC-2-(Diphenylhydroxymethyl)-pyrrolidine (183)252
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■A,°B
The BOC ester 182 (1.0 g, 4.4 mmol) was dissolved in dry THF (20 ml) and added drop-wise 
via a pressure equalised dropping funnel to PhMgBr (10.0 ml of a 1 M solution in THF) in an 
ice bath. The mixture was warmed to room temperature and stirred for four hours, then cooled 
to -10 °C. Water (10 ml) was added slowly and the mixture warmed to room temperature 
again, it was then filtered and the filtrate washed with water and sat. NaCl solution, dried over 
MgSC>4 and evaporated under vacuum. Purification by flash chromatography using a 1:3 
mixture of EtOAc : hexane yielded white crystals (1.0 g, 64%) m.p. 103-105 °C; (lit.252 m.p. 
101-103 °C); *H NMR 5 (400 MHz; CDC13), 1.44 (9H, s, C(CH3)3), 1.50-2.09 (4H, m, H3 and 
H4), 2.86-3.43 (2H, m, H5), 4.87-4.90 (1H, m, H2), 7.24-7.41 (10H, m, ArH).
(S)-Diphenyl-pyrroIidin-2-yl-methanol (184)252
H OH
The tertiary alcohol 183 (0.5 g, 1.4 mmol) and KOH (0.75 g, 13.4 mmol) were dissolved in a 
mixture of DMSO (20 ml) and MeOH (3 ml), heated to 65 °C and stirred overnight. Water (20 
ml) was added and the mixture was extracted into hexane, dried over MgSC>4 and the solvent 
removed under vacuum to yield a white solid (0.13 g, 38%) m.p 79-80 °C; (lit.253 m.p. 79-79.5 
°C); *H NMR 8 (400 MHz; CDC13), 1.02-1.96 (4H, m, H3 and H4), 3.16-3.70 (2H, m, H5), 
4.46-4.50 (1H, m, H2), 7.27-7.47 (10H, m, ArH).
General procedure for the addition of chiral amines to l-methoxy-4- 
trifluorovinylbenzene under neutral conditions—Amine (1.4 mmol) was dissolved in dry 
THF (10 ml) and cooled in ice. l-Methoxy-4-trifluorovinylbenzene (0.26 g, 1.4 mmol) in THF 
(5 ml) was then added and the mixture was refluxed at 85 °C and stirred overnight. The solvent 
was then removed under vacuum and the residue partitioned between ether and water. The 
ether fraction was dried over MgSC>4 and evaporated under vacuum. Purification by silica 
chromatography using a 1:1 mixture of EtOAc : hexane yielded the following dimer.
l,2-(4’-methoxyphenyl)-hexafluorocyclobutane (185)254
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\
VmaxCCHCls) 2962w, 1612m, 1518s, 1463w, 1372w, 1261s, 1182s, 1118w, 1020m, 832m cm'1;
NMR 5 (400 MHz; CDCI3), 3.71 (3H, s, OMe, cw-stereoisomer), 3.78 (3H, s, OMe, trans- 
stereoisomer), 6.74 (2H, d, J  8.8 Hz, H3’ and H5’, c/s-stereoisomer), 6.91 (2H, d, J  8.8 Hz, 
H3’ and H5’, /Amy-stereo isomer), 7.09 (2H, d, J  8.8 Hz, H2’ and H6 \  cw-stereoisomer), 7.93 
(2H, d, J  8.8 Hz, H 2’ and H6 ’, rram-stereoisomer); 19F NMR 8 (283 MHz; CDC13), 121.5 (2F, 
d, J  255 Hz, c/s-stereoisomer), 124.6 (4F, s, />vms’-stereoisomer), 128.4 (2F, d, J  255 Hz, cis- 
stereoisomer), 156.7 (2F, s, /nms-stereoisomer), 162.8 (2F, s, cw-stereoisomer). (Found [M- 
F f ,  357, C 18H 14F5O2 requires [M-F]+, 357).
General procedure for the addition of chiral amines to l-methoxy-4- 
trifluorovinylbenzene under basic conditions—Amine (1.4 mmol) was dissolved in dry THF
(10 ml) and cooled in ice. BuLi (0.6 ml o f a 2.5 M solution in hexanes) was added and the 
mixture was warmed slowly to room temperature, with stirring. The appropriate 
trifluorostyrene (0.26 g, 1.4 mmol) in THF (5 ml) was then added and the mixture was stirred 
overnight. The solvent was then removed under vacuum and the residue partitioned between 
ether and water. The ether fraction was dried over MgSC>4 and evaporated under vacuum. 
Repeated chromatography failed to isolate pure amide product.
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Appendix I, Crystal data for 42c
.OH
OEt
Table 1. Crystal data and structure
Identification code
Empirical formula
Formula w eight
Temperature
W avelength
Crystal system
Space group
Unit cell dim ensions
V olum e
Z
D ensity (calculated)
Absorption coefficient 
F (000)
Crystal size
Theta range for data co llection  
Index ranges 
R eflections collected  
Independent reflections 
C om pleteness to theta =  27 .4 9 °  
Absorption correction  
Max. and min. transm ission  
R efinem ent m ethod  
Data /  restraints /  parameters 
G oodness-of-fit on F2 
Final R indices [I>2sigm a(I)]
R indices (all data)
Largest diff. peak and hole
refinem ent for 42c.
nj!0410
C 22 H 24 0 8  
416.41  
150(2) K  
0 .71073  A 
T riclinic  
P - l
a =  11 .0780(2) A a= 86.948(2)°.
b =  13 .5738(3) A p= 70 .898(2)°.
c =  15 .1885(4) A y = 7 4 .8980 (10 )c
2 0 8 2 .3 3 (8 ) A3 
4
1.328 M g/m 3 
0.101 m m '1 
880
0 .3 0  x 0 .28  x 0 .15  m m 3 
2.93  to 27 .49°.
-1 4< = h < =  1 4 ,-1 7<=k< =  17, -1 9<=1<= 19 
37438
9 4 1 6  [R (int) =  0 .1679]
98 .3  %
Sem i-em pirical from  equivalents 
0 .9 8 4 9  and 0 .9702  
Full-m atrix least-squares on F2 
9 4 1 6 / 0 / 5 5 3  
1.015
R1 = 0 .0 6 5 5 , w R 2 =  0 .1557  
R1 = 0 .1 3 7 2 , w R 2 =  0 .1889  
0.281 and -0 .363  e.A'3
Table 2. A tom ic coordinates ( x 104) and equivalent isotropic d isplacem ent parameters (A2x 103) 
for 42c. U (eq) is defined as one third o f  the trace o f  the orthogonal ized U'j tensor.
x y z U (eq)
C O D 91 4 (3 ) 2 1 4 6 (2 ) 211 8 (2 ) 35(1 )
C (I2 ) 4 9 0 (3 ) 5 36 7 (2 ) 1903(2) 48(1 )
C (13) 2 5 1 3 (3 ) 5 79 8 (2 ) -1 359 (2 ) 60(1)
a  14) 1912(2 ) 2 5 1 7 (2 ) 2 13 (2 ) 24(1)
a  15) 1706(2 ) 3 2 3 1 (2 ) 9 04(2 ) 24(1 )
C (16) 1864(2) 4 2 0 8 (2 ) 662 (2 ) 26(1 )
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C( 17) 2 1 7 4 (2 ) 4476 (2 ) -276(2 ) 28(1)
C( 18) 2 3 4 3 (2 ) 3774(2) -957(2) 26(1)
C (19) 2 2 3 2 (2 ) 2793 (2 ) -714(2) 24(1)
C (110) 2 4 1 6 (2 ) 2047 (2 ) -1467(2 ) 23(1)
C (1 U ) 2 4 8 8 (2 ) 936 (2 ) -1250(1 ) 22(1)
C (1 12) 3 8 2 8 (2 ) 324(2 ) -1280(2) 26(1)
C (1 13) 5 2 9 1 (2 ) -1 342 (2 ) -1394(2) 34(1)
C (1 14) 5 2 8 0 (3 ) -2 396 (2 ) -1638(2 ) 40(1)
C (1 15) 1491(2) 4 99 (2 ) -1112(1) 24(1)
C (1 16) 9 7 (2 ) 9 89 (2 ) -997(1) 23(1)
C (1 17) -7 0 2 (2 ) 3 86 (2 ) -1090(2) 25(1)
C( 118) -2 0 2 3 (2 ) 807(2 ) -990(2 ) 25(1 )
C (119) -2 5 8 2 (2 ) 1857(2) -804(2 ) 24(1)
C (120) -1 8 1 7 (2 ) 24 6 6 (2 ) -692(2 ) 29(1)
C( 121) -4 9 8 (2 ) 2 0 3 3 (2 ) -781 (2 ) 29(1 )
C (122) -4 4 3 1 (3 ) 32 9 4 (2 ) -697(2) 39(1)
0 (1 1 ) 1351(2) 30 5 6 (1 ) 1835(1) 34(1)
0 (1 2 ) 1798(2) 4 8 9 3 (1 ) 1324(1) 34(1)
0 (1 3 ) 2 3 0 3 (2 ) 5 4 47 (1 ) -428 (1 ) 43(1 )
0 (1 4 ) 2 5 4 5 (2 ) 2 31 0 (1 ) -2261 (1 ) 33(1)
0 (1 5 ) 4 6 8 8 (2 ) 719 (1 ) -1272 (1 ) 35(1)
0 (1 6 ) 3 9 8 6 (2 ) -6 8 1 (1 ) -1320 (1 ) 32(1)
0 (1 7 ) -2 7 5 9 (2 ) 177(1) -1071 (1 ) 43(1)
0 (1 8 ) -3 8 9 2 (2 ) 2 2 1 0 (1 ) -726(1 ) 30(1)
C (21) 5 8 4 7 (3 ) 2 1 3 6 (2 ) -2 870 (2 ) 33(1)
C (22) 6 8 5 4 (3 ) 5 0 32 (2 ) -3 045 (2 ) 50(1)
C (23) 6 9 6 3 (3 ) 598 6 (2 ) -6 234 (2 ) 34(1)
C (24) 6 7 7 6 (2 ) 2 5 9 2 (2 ) -4 753 (2 ) 22(1)
0 (2 5 ) 6 4 2 6 (2 ) 3 3 1 7 (2 ) -4 043 (2 ) 26(1)
0 (2 6 ) 6 3 9 8 (2 ) 4 3 4 1 (2 ) -4 251 (2 ) 27(1 )
C (27) 6 6 9 6 (2 ) 4 6 2 7 (2 ) -5 181 (2 ) 26(1 )
C (28) 702 1 (2 ) 3 9 0 9 (2 ) -5 8 9 2 (2 ) 23(1 )
C (29) 7 0 6 2 (2 ) 28 9 3 (2 ) -5 673 (2 ) 21(1 )
C (210) 7 3 6 7 (2 ) 2 1 4 1 (2 ) -6 449 (2 ) 23(1)
C (2 1 1) 7 4 2 7 (2 ) 1026(2) -6 2 4 6 (1 ) 22(1)
C (212) 8 7 65 (2 ) 4 1 8 (2 ) -6 269 (1 ) 23(1 )
C (213) 10257(2 ) -1 2 2 6 (2 ) -6 393 (2 ) 30(1 )
C (214) 10324(3 ) -2 2 7 8 (2 ) -6 682 (2 ) 43(1 )
C (215) 6 4 3 1 (2 ) 591 (2 ) -61 2 2 (1 ) 22(1 )
C (216) 503 6 (2 ) 1069(2) -6 019 (1 ) 22(1 )
C (217) 4 2 4 7 (2 ) 4 3 6 (2 ) -6 066 (2 ) 26(1 )
C (218) 2 9 1 9 (2 ) 828(2 ) -5 9 6 0 (2 ) 24(1)
C (219) 2 3 3 7 (2 ) 1879(2) -5 7 9 0 (2 ) 23(1 )
C (220) 3 0 9 2 (2 ) 2 5 1 9 (2 ) -5 7 3 1 (2 ) 26(1 )
C (221) 4 4 2 7 (2 ) 2 1 1 5 (2 ) -58 4 1 (2 ) 27(1)
C (222) 4 0 0 (2 ) 3 2 7 2 (2 ) -5 6 3 8 (2 ) 36(1)
0 (2 1 ) 6 0 5 8 (2 ) 312 4 (1 ) -3 1 1 5 (1 ) 33(1)
0 (2 2 ) 59 7 7 (2 ) 50 8 7 (1 ) -35 5 9 (1 ) 39(1)
0 (2 3 ) 66 3 9 (2 ) 564 1 (1 ) -53 0 6 (1 ) 33(1)
0 (2 4 ) 76 0 0 (2 ) 2 3 9 4 (1 ) -7 2 5 7 (1 ) 33(1)
0 (2 5 ) 9 6 0 9 (2 ) 817(1) -6 2 3 3 (1 ) 33(1)
0 (2 6 ) 8 9 48 (2 ) -5 88 (1 ) -6 3 3 5 (1 ) 29(1 )
0 (2 7 ) 21 8 4 (2 ) 177(1) -6 004 (1 ) 37(1)
0 (2 8 ) 1003(2) 21 9 3 (1 ) -5673 (1 ) 28(1 )
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Table 3. B ond lengths [A] and an g les [°] for 42c. C (122)-H (12F ) 0 .9 8 0 0
0 (1 7 )-H (1 7 ) 0 .8 4 0 0
C (2 1 )-0 (2 1 ) 1 .430(3 )
C ( l l ) - 0 ( 1 1 ) 1 .4 3 7 (3 ) C (21)-H (21 A ) 0 .9 8 0 0
C (11)-H (11 A ) 0 .9 8 0 0 C (21)-H (21B ) 0 .9 8 0 0
C (1 1 )-H (U B ) 0 .9 8 0 0 C (21)-H (21C ) 0 .9 8 0 0
C (11)-H (11C) 0 .9 8 0 0 C (2 2 )-0 (2 2 ) 1 .420(3 )
C (1 2 )-0 (1 2 ) 1 .4 2 3 (3 ) C (22)-H (22A ) 0 .9 8 0 0
C (12)-H (12A ) 0 .9 8 0 0 C (22)-H (22B ) 0 .9 8 0 0
C (12)-H (12B ) 0 .9 8 0 0 C (22)-H (22C ) 0 .9 8 0 0
C (12)-H (12C ) 0 .9 8 0 0 C (2 3 )-0 (2 3 ) 1 .421(2 )
C (1 3 )-0 (1 3 ) 1 .4 3 2 (3 ) C (23)-H (23A ) 0 .9 8 0 0
C (13)-H (13A ) 0 .9 8 0 0 C (23)-H (23B ) 0 .9 8 0 0
C (13)-H (13B ) 0 .9 8 0 0 C (23)-H (23C ) 0 .9 8 0 0
C (13)-H (13C ) 0 .9 8 0 0 C (24)-C (25) 1 .386(3)
C (14)-C (15) 1 .3 8 8 (3 ) C (24)-C (29) 1 .391(3 )
C (14)-C (19) 1 .3 9 1 (3 ) C (24)-H (24) 0 .9 5 0 0
C (14)-H (14) 0 .9 5 0 0 C (2 5 )-0 (2 1 ) 1 .364(2 )
C (1 5 )-0 ( l 1) 1 .3 6 4 (2 ) C (25)-C (26) 1 .403(3 )
C (15)-C (16) 1 .3 9 7 (3 ) C (2 6 )-0 (2 2 ) 1 .375(3 )
C (1 6 )-0 (1 2 ) 1 .3 7 8 (3 ) C (26)-C (27) 1 .401(3 )
C (16)-C (17) 1 .4 0 3 (3 ) C (2 7 )-0 (2 3 ) 1 .367(2 )
C (1 7 )-0 (1 3 ) 1 .3 6 2 (3 ) C (27)-C (28) 1 .385(3 )
C (17)-C (18) 1 .3 7 8 (3 ) C (28)-C (29) 1 .395(3 )
C (18)-C (19) 1 .3 8 8 (3 ) C (28)-H (28) 0 .9 5 0 0
C (18)-H (18) 0 .9 5 0 0 C (29)-C (210) 1 .494(3)
C( 19)-C ( 1 0 ) 1 .4 9 7 (3 ) C (210)-O (24) 1 .217(2 )
C (110)-O (14) 1 .2 1 4 (2 ) C (210 > C (2 1 1 ) 1 .518(3 )
C (1 1 0 ) -C ( l l l ) 1 .5 1 3 (3 ) C (211)-C (215) 1 .339(3 )
C (111)-C (115) 1 .3 3 9 (3 ) C (211 )-C (212 ) 1 .487(3 )
C (1 11 )-C (l 12) 1 .4 8 7 (3 ) C (2 1 2 )-0 (2 5 ) 1 .213(3 )
C (1 1 2 )-0 (1 5 ) 1 .2 1 3 (3 ) C (2 1 2 )-0 (2 6 ) 1 .332(3 )
C (1 1 2 )-0 (1 6 ) 1 .3 3 2 (3 ) C (2 1 3 )-0 (2 6 ) 1 .460(3 )
C (1 1 3 )-0 (1 6 ) 1 .4 6 1 (3 ) C (213)-C (214) 1 .492(3 )
C (113)-C (114) 1 .5 0 1 (3 ) C (213)-H (21D ) 0 .9 9 0 0
C (113)-H (l ID ) 0 .9 9 0 0 C (213)-H (21E ) 0 .9 9 0 0
C (113)-H (l IE ) 0 .9 9 0 0 C (214)-H (21F ) 0 .9 8 0 0
C (114)-H (l IF) 0 .9 8 0 0 C (214)-H (21G ) 0 .9 8 0 0
C (114)-H (l 1G) 0 .9 8 0 0 C (214> H (21H ) 0 .9 8 0 0
C (114)-H (l 1H) 0 .9 8 0 0 C (2 1 5 > C (2 1 6 ) 1 .470(3 )
C (115)-C (116) 1 .4 6 9 (3 ) C (215 )-H (215 ) 0 .9 5 0 0
C (115)-H (115) 0 .9 5 0 0 C (216 )-C (217 ) 1 .395(3)
C (116)-C (l 17) 1 .3 9 4 (3 ) C (216 )-C (221 ) 1 .402(3)
C (116)-C (121) 1 .4 0 5 (3 ) C (217 )-C (218 ) 1 .385(3 )
C (117)-C (l 18) 1 .3 8 6 (3 ) C (217 )-H (217 ) 0 .9 5 0 0
C (117)-H (l 17) 0 .9 5 0 0 C (2 1 8 )-0 (2 7 ) 1 .366(3)
C (1 1 8 > 0 (1 7 ) 1 .3 6 1 (3 ) C (218 )-C (219 ) 1 .404(3 )
C (118)-C (119) 1 .4 0 1 (3 ) C (219)-C (220) 1 .378(3)
C (1 1 9 )-0 (1 8) 1 .3 7 2 (3 ) C (2 1 9 )-0 (2 8 ) 1 .380(3 )
C (119)-C (120) 1 .3 8 0 (3 ) C (220 )-C (221 ) 1 .393(3 )
C (120)-C (121) 1 .3 8 9 (3 ) C (220 )-H (220 ) 0 .9 5 0 0
C (120)-H (120) 0 .9 5 0 0 C (221)-H (221) 0 .9 5 0 0
C (121)-H (121) 0 .9 5 0 0 C (2 2 2 )-0 (2 8 ) 1 .439(3)
C (1 2 2 )-0 (1 8 ) 1 .4 3 4 (3 ) C (222)-H (22D ) 0 .9 8 0 0
C (122)-H (12D ) 0 .9 8 0 0 C (222)-H (22E ) 0 .9 8 0 0
C (122)-H (12E ) 0 .9 8 0 0 C (222)-H (22F ) 0 .9 8 0 0
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Appendices________________________________________________________________________X-rav crystal data
C (29)-C (24)-H (24) 120.3
0 (2 1  )-C (25)-C (24) 1 2 4 .8 (2 )
0 (2 1  )-C(25 )-C (26) 1 1 4 .8 (2 )
C (24)-C (25)-C (26) 1 2 0 .4 (2 )
0 (2 2 )-C (2 6 )-C (2 7 ) 1 1 8 .9 (2 )
0 (2 2 )-C (2 6 > C (2 5 ) 1 2 1 .6 (2 )
C (27)-C (26)-C (25) 1 1 9 .3 (2 )
0 (2 3 )-C (2 7 )-C (2 8 ) 1 2 4 .8 9 (1 9 )
0 (2 3 )-C (2 7 )-C (2 6 ) 1 1 4 .5 (2 )
C (28)-C (27 )-C (26) 1 2 0 .6 (2 )
C (27)-C (28)-C (29) 1 1 9 .3 (2 )
C (27)-C (28 )-H (2 8) 120 .3
C (29)-C (28)-H (28) 120.3
C (24)-C (29)-C (28) 1 2 1 .0 (2 )
C (24 )-C (29 )-C (210) 1 2 0 .8 0 (1 9 )
C (28)-C (29)-C (210) 1 1 8 .1 8 (1 9 )
0 (2 4 )-C (2 1 0 )-C (2 9 ) 1 2 1 .7 (2 )
0 (2 4 )-C (2 1 0 )-C (2 1 1) 1 1 8 .2 (2 )
C (2 9 )-C (210 )-C (2 11) 1 2 0 .1 1 (1 8 )
C (2 15 )-C (211 )-C (2 12) 1 2 1 .8 (2 )
C (215)-C (211)-C (210) 1 2 5 .2 (2 )
C (2 12 )-C (2 11 )-C (2 10) 1 1 2 .8 3 (1 8 )
0 ( 2  5 )-C (2 12 )-0 (2 6 ) 1 2 3 .6 (2 )
0 (2 5 )-C (2 1 2 )-C (2 1 1) 1 2 2 .1 (2 )
0 (2 6 )-C (2 1 2 )-C (2 1 1) 1 1 4 .3 2 (1 9 )
0 (2 6 )-C (2 1 3 )-C (2 1 4 ) 1 0 7 .2 (2 )
0 (2 6 ) -C (2 13 )-H (21D ) 110.3
C (2 14 )-C (2 13 )-H (2 1D ) 110.3
0 (2 6 ) -C (2 13 )-H (21E) 110 .3
C (2 14 )-C (2 13 )-H (21E) 110 .3
H (2 1 D )-C (213 )-H (21E ) 108 .5
C (2 13 )-C (2 14)-H (21F ) 109 .5
C (2 13 )-C (214)-H (2 1G) 109 .5
H (2 1 F )-C (214 )-H (2 1G) 109.5
C (213 )-C (214)-H (2 1H ) 109 .5
H (2 1 F )-C (214 )-H (2 1H ) 109 .5
H (2 1 G )-C (214)-H (21H) 109.5
C (211)-C (215)-C (216) 1 2 9 .5 (2 )
C (2 11 )-C (2 15)-H (215) 1 15 .2
C (216)-C (215)-H (215) 1 1 5 .2
C (2 17 )-C (2 16 )-C (2 2 1) 1 1 7 .4 (2 )
C (217> C (216 )-C (215 ) 1 1 8 .0 (2 )
C (221)-C (216)-C (215) 1 24 .6 (2 )
C (2 18 )-C (217 )-C (2 16) 1 2 1 .4 (2 )
C (218)-C (217)-H (217) 119 .3
C (2 16)-C (217)-H (217) 119 .3
0 (2 7 ) -C (2 1 8 )-C (217) 1 1 9 .2 (2 )
0 (2 7 ) -C (2 18 )-C (219) 1 2 0 .7 (2 )
C (2 1 7 )-C (2 18 )-C (2 19) 1 2 0 .1 (2 )
C (22 0 )-C (2 19 )-0 (2 8 ) 1 2 4 .5 (2 )
C (2 2 0 )-C (2 19 )-C (2 18) 1 1 9 .7 (2 )
0 (2 8 )-C (2 1 9 )-C (2 1 8) 11 5 .8 (2 )
C (2 19)-C (220 )-C (221) 1 1 9 .6 (2 )
C (2 19)-C (220)-H (220) 120 .2
C (221 )-C (220)-H (220) 120 .2
C (220)-C (221 )-C (216) 1 2 1 .9 (2 )
C (220)-C (221 )-H (221 ) 119.1
C (2 16)-C (221 )-H (2 2 1) 119.1
0 (2 8 )-C (2 2 2 )-H (2 2 D ) 109 .5
0 (2 8 )-C (2 2 2 )-H (2 2 E ) 109 .5
H (22D )-C (222)-H (22E ) 109 .5
0 (2 8 )-C (2 2 2 )-H (2 2 F ) 109.5
H (22D )-C (222)-H (22F ) 109 .5
H (22E )-C (222)-H (22F ) 109 .5
C (2 5 )-0 (2 1 )-C (2 1) 1 1 6 .3 3 (1 8 )
C (2 6 )-0 (2 2 )-C (2 2 ) 114 .5 (2 )
C (2 7 )-0 (2 3 )-C (2 3 ) 117 .8 8 (1 7 )
C (2 12 )-0 (2 6 )-C (2 13) 116 .9 9 (1 7 )
C (2 1 8 )-0 (2 7 )-H (2 7 ) 109.5
C (2 1 9 )-0 (2 8 )-C (2 2 2 ) 1 1 7 .99 (18 )
Sym m etry transformations used  to generate 
equivalent atoms:
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Table 4. A nisotrop ic  d isp la cem en t param eters (A 2x  103)for 42c. T h e an isotrop ic  
d isp lacem en t factor ex p o n en t takes th e  form: -2 tc2[ h2a*2U u  +  ... +  2 h k a* b* U 12 ]
U 11 U 22 u33 U23 u13 u12
C ( l l ) 4 7 (2 ) 3 4 (2 ) 2 7 (1 ) 8 (1 ) -5 (1 ) -2 3 (1 )
C (12) 4 0 (2 ) 3 4 (2 ) 6 3 (2 ) -1 3 (1 ) -1 1 (2 ) -2 (1 )
C (13) 112(3) 4 0 (2 ) 4 9 (2 ) 2 4 (2 ) -3 8 (2 ) -4 5 (2 )
C (14) 2 4 (1 ) 2 0 (1 ) 3 1 (1 ) 6 (1 ) -9 (1 ) -1 0 (1 )
C (15) 2 2 (1 ) 2 5 (1 ) 2 6 (1 ) 5 (1 ) -6 (1 ) -8 (1 )
C (16) 2 6 (1 ) 2 1 (1 ) 3 4 (1 ) 0 (1 ) -1 2 (1 ) -9 (1 )
C (17) 2 8 (2 ) 2 3 (1 ) 3 8 (1 ) 8 (1 ) -1 4 (1 ) -1 2 (1 )
C (18) 2 8 (1 ) 2 6 (1 ) 2 9 (1 ) 6 (1 ) -1 2 (1 ) -1 1 (1 )
C (19) 18(1) 2 5 (1 ) 3 1 (1 ) 4 (1 ) -9 (1 ) -8 (1 )
C (110 ) 17(1) 2 6 (1 ) 2 9 (1 ) 4 (1 ) -7 (1 ) -9 (1 )
C ( l l l ) 2 0 (1 ) 2 3 (1 ) 2 4 (1 ) 2 (1 ) -7 (1 ) -7 (1 )
C (1 12) 2 3 (1 ) 2 6 (1 ) 2 9 (1 ) 4 (1 ) -7 (1 ) -1 0 (1 )
C (1 13) 2 1 (1 ) 3 2 (2 ) 4 4 (2 ) 2 (1 ) -9 (1 ) 0 (1 )
C (1 14) 4 1 (2 ) 3 1 (2 ) 4 2 (2 ) -6 (1 ) -1 6 (1 ) 4 (1 )
C (1 15) 2 2 (1 ) 2 2 (1 ) 2 8 (1 ) 0 (1 ) -8 (1 ) -6 (1 )
C (1 16) 2 1 (1 ) 2 2 (1 ) 2 7 (1 ) 4 (1 ) -7 (1 ) -9 (1 )
C ( 117) 2 2 (1 ) 2 0 (1 ) 3 6 (1 ) 1 (1 ) -1 0 (1 ) -7 (1 )
C (1 18) 2 2 (1 ) 2 3 (1 ) 3 3 (1 ) -1 (1 ) -1 0 (1 ) -9 (1 )
C (119 ) 17(1) 2 5 (1 ) 2 6 (1 ) 0 (1 ) -5 (1 ) -4 (1 )
C (120 ) 2 4 (1 ) 2 2 (1 ) 3 8 (1 ) -4 (1 ) -6 (1 ) -3 (1 )
C (121) 23 (1 ) 2 5 (1 ) 4 3 (1 ) -3 (1 ) -1 1 (1 ) -1 0 (1 )
C (122 ) 32 (2 ) 3 1 (2 ) 5 2 (2 ) -3 (1 ) -1 8 (1 ) 4 (1 )
0 ( 1 1 ) 4 6 (1 ) 3 2 (1 ) 2 5 (1 ) 4 (1 ) -7 (1 ) -2 0 (1 )
0 ( 1 2 ) 34 (1 ) 2 8 (1 ) 3 9 (1 ) -6 (1 ) -1 0 (1 ) -1 1 (1 )
0 ( 1 3 ) 7 6 (2 ) 2 5 (1 ) 3 9 (1 ) 9 (1 ) -2 4 (1 ) -2 7 (1 )
0 ( 1 4 ) 4 2 (1 ) 3 3 (1 ) 2 7 (1 ) 6 (1 ) -1 1 (1 ) -1 5 (1 )
0 ( 1 5 ) 2 3 (1 ) 3 3 (1 ) 5 3 (1 ) 9 (1 ) -1 5 (1 ) -1 4 (1 )
0 ( 1 6 ) 2 0 (1 ) 2 4 (1 ) 4 9 (1 ) 1(1 ) -1 1 (1 ) -4 (1 )
0 ( 1 7 ) 2 5 (1 ) 2 6 (1 ) 8 4 (1 ) -6 (1 ) -2 5 (1 ) -8 (1 )
0 ( 1 8 ) 19(1) 2 8 (1 ) 4 3 (1 ) -3 (1 ) -1 0 (1 ) -3 (1 )
0 (2 1 ) 3 9 (2 ) 2 9 (1 ) 2 9 (1 ) 7 (1 ) -8 (1 ) -1 4 (1 )
C (22) 7 5 (2 ) 3 3 (2 ) 5 5 (2 ) 3 (1 ) -3 1 (2 ) -2 2 (2 )
C (23 ) 37 (2 ) 2 3 (1 ) 3 9 (1 ) 9 (1 ) -7 (1 ) -1 2 (1 )
0 (2 4 ) 2 1 (1 ) 19 (1 ) 3 0 (1 ) 4 (1 ) -9 (1 ) -9 (1 )
0 (2 5 ) 2 5 (1 ) 2 7 (1 ) 2 7 (1 ) 6 (1 ) -9 (1 ) -9 (1 )
C (26) 2 8 (1 ) 19 (1 ) 3 2 (1 ) -1 (1 ) -9 (1 ) -5 (1 )
C (27) 2 3 (1 ) 2 0 (1 ) 3 6 (1 ) 5 (1 ) -1 0 (1 ) -6 (1 )
C (28) 2 0 (1 ) 2 5 (1 ) 2 7 (1 ) 5 (1 ) -7 (1 ) -9 (1 )
C (29) 15(1) 2 0 (1 ) 2 9 (1 ) 3 (1 ) -6 (1 ) -6 (1 )
C (210) 13(1) 2 3 (1 ) 2 9 (1 ) 3 (1 ) -4 (1 ) -5 (1 )
C (2 1 1) 2 1 (1 ) 2 1 (1 ) 2 4 (1 ) 0 (1 ) -6 (1 ) -6 (1 )
C (212 ) 2 0 (1 ) 2 4 (1 ) 2 4 (1 ) 2 (1 ) -3 (1 ) -9 (1 )
C (213) 2 1 (1 ) 2 5 (1 ) 3 8 (1 ) 0 (1 ) -8 (1 ) 2 (1 )
C (214 ) 4 1 (2 ) 3 1 (2 ) 4 8 (2 ) -5 (1 ) -1 4 (1 ) 6 (1 )
C (215 ) 2 3 (1 ) 19 (1 ) 2 5 (1 ) 2 (1 ) -6 (1 ) -7 (1 )
C (216 ) 2 3 (1 ) 2 1 (1 ) 2 5 (1 ) 3 (1 ) -7 (1 ) -8 (1 )
C (217) 2 4 (1 ) 2 0 (1 ) 3 3 (1 ) 2 (1 ) -1 0 (1 ) -6 (1 )
C (218 ) 2 4 (1 ) 2 3 (1 ) 3 1 (1 ) 2 (1 ) -9 (1 ) -1 3 (1 )
C (219) 19(1) 2 5 (1 ) 2 7 (1 ) 3 (1 ) -8 (1 ) -6 (1 )
C (220 ) 2 6 (1 ) 16(1 ) 3 7 (1 ) -1 (1 ) -1 1 (1 ) -5 (1 )
C (221 ) 2 4 (1 ) 2 1 (1 ) 4 0 (1 ) KO -1 1 (1 ) -1 0 (1 )
C (222) 2 3 (1 ) 2 7 (1 ) 5 4 (2 ) -3 (1 ) -1 4 (1 ) 1(1)
0 ( 2 1 ) 4 8 (1 ) 2 6 (1 ) 2 7 (1 ) 6 (1 ) -9 (1 ) -1 8 (1 )
0 ( 2 2 ) 52 (1 ) 2 6 (1 ) 4 0 (1 ) -4 (1 ) -1 9 (1 ) -7 (1 )
0 ( 2 3 ) 50 (1 ) 19 (1 ) 3 3 (1 ) 6 (1 ) -1 2 (1 ) -1 5 (1 )
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0 ( 2 4 ) 4 2 (1 ) 2 9 (1 ) 2 8 (1 ) 6 (1 ) -8 (1 ) -1 4 (1 )
0 ( 2 5 ) 2 2 (1 ) 2 9 (1 ) 5 0 (1 ) 6 (1 ) -1 3 (1 ) -1 1 (1 )
0 ( 2 6 ) 2 1 (1 ) 19 (1 ) 4 6 (1 ) -2 (1 ) -1 1 (1 ) -2 (1 )
0 ( 2 7 ) 2 2 (1 ) 2 3 (1 ) 7 1 (1 ) -4 (1 ) -1 9 (1 ) -8 (1 )
0 ( 2 8 ) 19(1 ) 2 3 (1 ) 4 2 (1 ) 0 (1 ) -1 1 (1 ) -4 (1 )
X-ray crystal data
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Table 5. H yd rogen  co o rd in a tes ( x  104) and isotrop ic d isp lacem en t param eters ( A ^  103) 
for 42  c.
X y z U (eq )
H (11A ) 181 2147 1891 53
H (11B ) 615 21 2 6 2 8 0 0 53
H (11C ) 1646 1545 1855 53
H (12A ) - 2 2 5742 1517 72
H (12B ) 524 5841 2 3 5 4 72
H (12C ) 68 4843 2 2 3 7 72
H (13A ) 3 3 4 9 5379 -1 775 89
H (1 3 B ) 2551 6 5 1 2 -1371 89
H (13C ) 1784 57 4 4 -1 5 6 8 89
H (14 ) 1834 1845 373 29
H (18 ) 25 3 4 3961 -1 5 9 0 31
H (11D ) 5463 -1 3 3 6 -7 9 4 41
H(1 IE ) 5 9 8 7 -1 1 0 7 -1 885 41
H (11F ) 4521 -2 5 8 6 -1 1 8 6 6 0
H (11G ) 6 0 9 9 -2 883 -1 6 2 2 60
H (11H ) 5 2 1 2 -2 4 0 8 -2 2 6 4 6 0
H (1 15) 1715 -2 2 4 -1 085 2 9
H (1 17) -3 3 4 -3 2 6 -1 225 31
H (120 ) -2 1 8 9 3 1 7 7 -5 5 6 35
H (121 ) 17 2 4 5 6 -6 9 2 35
H (1 2 D ) -4 3 9 5 3 5 9 5 -1 3 6 59
H (12E ) -5351 3 4 4 4 -683 59
H (12F ) -3 913 3585 -1 2 5 2 59
H (17 ) -3 4 9 6 528 -1091 6 4
H (2 1 A ) 5191 2 0 1 9 -3 1 2 8 4 9
H (2 1 B ) 5524 2 0 9 9 -2 1 9 0 4 9
H (21C ) 6681 1614 -3 1 2 4 4 9
H (22A ) 69 1 4 4 4 0 0 -2 7 0 0 75
H (2 2 B ) 6523 56 1 9 -2 605 75
H (22C ) 7733 5 0 3 9 -3 4 7 4 75
H (23A ) 7 8 7 0 5621 -6 5 9 0 51
H (23B ) 6 8 9 2 6 7 2 0 -6 2 2 4 51
H (23C ) 6 3 5 2 5853 -6 5 2 8 51
H (24 ) 6821 1896 -4613 2 7
H (2 8 ) 7213 4 1 0 8 -6 5 2 2 28
H (2 1 D ) 10393 -1 2 3 2 -5 7 8 0 36
H (21E ) 10950 -9 6 0 -6 8 5 6 36
H (21F ) 9585 -2 5 0 9 -6 2 4 8 64
H (2 1G) 11161 -2 7 4 2 -6 6 7 4 64
H (21H ) 10269 -2 2 7 3 -7 313 64
H (2 15) 6 6 5 9 -1 3 2 -6 0 9 8 2 7
H (217 ) 4 6 2 7 -2 7 8 -6 1 7 2 31
H (220 ) 2 7 0 5 3231 -5 6 1 6 31
H (221 ) 4 9 3 9 2 5 6 0 -5 7 9 4 33
H (22D ) 4 9 6 3 5 9 6 -5 1 1 2 54
H (22E ) -541 3 3 8 6 -5 5 5 9 54
H (22F ) 834 3 5 6 9 -6 2 2 0 54
H (27) 1437 515 -6 0 1 4 55
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Appendix II, Crystal data for 83c
o
OH
refinement for 83c.Table 1. Crystal data and structure
Identification c o d e
Em pirical form ula
Form ula w eigh t
Tem perature
W avelength
Crystal system
Space group
U nit ce ll d im en sio n s
V olu m e
Z
D ensity  (ca lcu lated)
A bsorption co e ffic ien t  
F (0 0 0 )
Crystal s ize
T heta range for data c o lle c t io n
Index ranges
R eflection s co llec ted
Independent reflections
C om p leten ess to  theta =  2 7 .4 2 °
A bsorption correction
M ax. and m in. transm ission
R efin em ent m ethod
Data /  restraints /  param eters
G ood n ess-o f-fit on  F2
Final R  in d ices [I>2sigm a(I)]
R  in d ices  (all data)
E xtinction  coe ffic ien t  
Largest diff. peak and h o le
nj10401
C 1 9 H 1 9 F 1  0 6
3 6 2 .3 4  
1 5 0 (2 ) K  
0 .7 1 0 7 3  A 
T riclin ic  
P - l
a = 8 .5 7 0 5 ( 3 )  A a=
b =  1 0 .3 1 8 9 (4 )  A J3:
c =  1 0 .5 7 0 7 (5 )  A y ;
8 6 2 .0 6 (6 )  A3 
2
1 .3 9 6  M g /m 3 
0.111 mm-1 
3 8 0
0 .3 3  x  0 .2 0  x  0 .0 8  m m 3 
3 .5 8  to 2 7 .4 2 ° .
-1 0 < = h < = 1 0 , -1 3 < = k < =  13, -13<= 
1 0 7 0 0
3 8 1 4  [R (in t) =  0 .0 8 3 2 ]
9 7 .0  %
S em i-em pirica l from  eq u iva len ts  
0 .9 9 1 2  and 0 .9 6 4 4  
F ull-m atrix  least-squ ares on  F2 
3 8 1 4 / 0 / 2 4 1  
1 .0 3 6
R1 = 0 .0 5 9 9 ,  w R 2  =  0 .1 3 4 3  
R1 = 0 .1 1 4 0 ,  w R 2  =  0 .1 5 8 1  
0 .0 4 5 (6 )
0 .2 7 3  and -0 .2 4 9  e.A'3
7 3 .5 1 6 (2 )° .
7 4 .6 2 5 (2 )° .
8 1 .8 1 2 (4 )° .
1<=13
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Table 2. A to m ic  co o rd in a tes ( x  104) and eq u iva len t isotrop ic d isp lacem en t param eters ( A ^  103) 
for 83c. U (eq ) is  d efin ed  as o n e  third o f  the trace o f  the orth ogon a lized  U'-> tensor.
X y z U (eq )
C (1) 6 7 5 2 (3 ) 4 4 5 (3 ) 5 7 3 0 (3 ) 3 6 (1 )
C (2) 2 8 4 0 (3 ) 3 5 4 2 (3 ) 7 3 6 5 (2 ) 3 2 (1 )
C (3) 1 4 8 6 (3 ) 6 3 0 8 (3 ) 3 7 8 3 (3 ) 3 8 (1 )
C (4) 5 8 5 2 (3 ) 2 4 8 7 (2 ) 3 5 4 9 (2 ) 2 5 (1 )
C (5) 4 9 1 1 (3 ) 2 2 5 8 (2 ) 4 8 8 0 (2 ) 2 5 (1 )
C (6) 3 5 4 4 (3 ) 3 1 0 0 (2 ) 5 2 0 8 (2 ) 2 2 (1 )
C (7) 3 1 3 9 (3 ) 4 2 4 6 (2 ) 4 2 3 6 (2 ) 2 4 (1 )
C (8) 4 0 6 8 (3 ) 4 4 9 7 (2 ) 2 9 1 4 (2 ) 2 5 (1 )
C (9) 5 3 9 9 (3 ) 3 6 0 9 (2 ) 2 5 7 5 (2 ) 2 4 (1 )
C (10) 6 4 3 0 (3 ) 4 0 2 2 (2 ) 1 1 64 (2 ) 2 6 (1 )
C ( l l ) 7 3 5 2 (3 ) 2 9 9 8 (3 ) 4 5 9 (2 ) 2 7 (1 )
C (12) 6 9 9 1 (3 ) 1 7 5 3 (2 ) 5 9 0 (2 ) 2 5 (1 )
C (13) 7 7 6 4 (3 ) 7 9 5 (2 ) -2 1 9 (2 ) 2 3 (1 )
C (14) 7 0 8 2 (3 ) -4 2 8 (2 ) 3 4 (2 ) 2 6 (1 )
C (15) 7 7 6 9 (3 ) -1 3 7 2 (2 ) -7 1 0 (2 ) 2 7 (1 )
C (16) 9 1 8 8 (3 ) -1 1 1 2 (2 ) -1 7 1 9 (2 ) 2 4 (1 )
C (17) 9 9 0 5 (3 ) 1 0 8 (2 ) -1 9 7 8 (2 ) 2 3 (1 )
C (18) 9 2 0 5 (3 ) 1 0 3 4 (2 ) -1 2 4 4 (2 ) 2 4 (1 )
C (19) 9 3 4 6 (3 ) -3 2 3 9 (3 ) -2 2 3 3 (3 ) 4 7 (1 )
0 ( 1 ) 5 2 3 6 (2 ) 1 2 3 6 (2 ) 5 9 4 8 (2 ) 3 3 (1 )
0 ( 2 ) 2 5 4 1 (2 ) 2 7 9 8 (2 ) 6 5 0 1 (2 ) 2 5 (1 )
0 ( 3 ) 1 8 3 1 (2 ) 5 0 4 9 (2 ) 4 7 0 4 (2 ) 3 2 (1 )
0 ( 4 ) 6 5 3 4 (2 ) 5 2 2 6 (2 ) 5 6 7 (2 ) 3 5 (1 )
0 ( 5 ) 1 1 3 1 7 (2 ) 2 9 3 (2 ) -2 9 5 2 (2 ) 3 2 (1 )
0 ( 6 ) 9 9 8 0 (2 ) -1 9 5 6 (2 ) -2 5 1 1 (2 ) 3 2 (1 )
F ( l ) 8 6 2 4 (2 ) 3 5 5 6 (1 ) -5 4 6 (2 ) 4 0 (1 )
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Table 3. B o n d  len g th s [A ] and a n g les  [°] for 83c. C (5)-C (4 )-C (9 ) 1 1 8 .1 (2 )
0 (1 )-C (5 )-C (6 ) 11 4 .7 (2 )
C ( l ) - 0 ( 1 ) 1 .4 3 4 (3 ) 0 (1 ) -C (5 )-C (4 ) 12 4 .8 (2 )
C (2 )-0 (2 ) 1 .4 3 9 (3 ) C (6 )-C (5 )-C (4 ) 12 0 .5 (2 )
C (3 )-0 (3 ) 1 .4 3 2 (3 ) C (5 )-C (6 )-0 (2 ) 120 .0 (2 )
C (4)-C (5) 1 .3 9 6 (3 ) C (5 > C (6 )-C (7 ) 1 2 0 .7 (2 )
C (4)-C (9) 1 .4 0 0 (3 ) 0 (2 )-C (6 )-C (7 ) 1 1 9 .2 (2 )
C ( 5 ) - 0 ( l ) 1 .3 6 8 (3 ) 0 (3 ) -C (7 )-C (8 ) 1 2 5 .2 (2 )
C (5)-C (6) 1 .3 8 3 (3 ) 0 (3 )-C (7 )-C (6 ) 1 1 5 .3 (2 )
C (6 )-0 (2 ) 1 .3 8 4 (3 ) C (8 )-C (7 )-C (6 ) 1 1 9 .5 (2 )
C (6)-C (7) 1 .3 9 9 (3 ) C (7 )-C (8 )-C (9 ) 1 1 9 .5 (2 )
C (7 )-0 (3 ) 1 .3 6 4 (3 ) C (8 )-C (9 )-C (4 ) 1 2 1 .6 (2 )
C (7)-C (8) 1 .3 8 4 (3 ) C (8 )-C (9 )-C (1 0 ) 1 1 6 .1 (2 )
C (8 )-C (9 ) 1 .3 9 3 (3 ) C (4 )-C (9 )-C (1 0 ) 1 2 1 .9 (2 )
C (9)-C (10) 1 .4 9 5 (3 ) O (4 )-C (1 0 )-C (l 1) 11 8 .6 (2 )
C (10)-O (4) 1 .2 2 7 (3 ) O (4 )-C (1 0 )-C (9 ) 1 2 0 .3 (2 )
C (1 0 ) -C ( l l) 1 .4 8 1 (3 ) C (1 1 )-C (1 0 )-C (9 ) 1 2 1 .1 (2 )
C (11)-C (12) 1 .3 2 4 (3 ) C (1 2 )-C (l l ) - F ( l ) 120 .3 (2 )
C ( l l ) - F ( l ) 1 .3 6 6 (3 ) C (1 2 )-C ( l l) -C (1 0 ) 1 2 8 .9 (2 )
C (12 )-C (13 ) 1 .4 6 3 (3 ) F ( l ) -C ( l  1 )-C (10) 1 1 0 .3 (2 )
C (13)-C (14) 1 .3 9 4 (3 ) C (1 1 )-C (1 2 )-C (1 3 ) 1 2 9 .6 (2 )
C (13 )-C (18 ) 1 .4 0 9 (3 ) C (1 4 )-C (1 3 )-C (1 8 ) 1 1 7 .4 (2 )
C (14)-C (15) 1 .3 9 3 (3 ) C (1 4 )-C (1 3 )-C (1 2 ) 1 1 9 .6 (2 )
C (15 )-C (16 ) 1 .3 9 0 (3 ) C (1 8 )-C (1 3 )-C (1 2 ) 1 2 3 .1 (2 )
C (1 6 )-0 (6 ) 1 .3 6 5 (3 ) C (1 5 )-C (1 4 )-C (1 3 ) 1 2 1 .8 (2 )
C (16)-C (17) 1 .4 0 5 (3 ) C ( 16 )-C ( 15 )-C ( 14) 1 1 9 .8 (2 )
C (1 7 )-0 (5 ) 1 .3 6 2 (3 ) 0 (6 ) -C (1 6 )-C (1 5 ) 1 2 5 .4 (2 )
C (17)-C (18) 1 .3 7 3 (3 ) 0 (6 ) -C (1 6 )-C (1 7 ) 1 1 5 .4 (2 )
C (1 9 )-0 (6 ) 1 .4 2 7 (3 ) C (1 5 )-C (1 6 )-C (1 7 ) 1 1 9 .3 (2 )
0 (5 ) -C (1 7 )-C (1 8 ) 1 2 3 .0 (2 )
0 (5 ) -C (1 7 )-C (1 6 ) 1 1 6 .8 (2 )
C (1 8 )-C (1 7 )-C (1 6 ) 1 2 0 .2 (2 )
C (1 7 )-C (1 8 )-C (1 3 ) 1 2 1 .5 (2 )
C (5 ) -0 ( 1 ) -C ( l ) 1 1 7 .7 6 (1 8 )
C (6 )-0 (2 )-C (2 ) 1 1 3 .2 2 (1 7 )
C (7 )-0 (3 )-C (3 ) 1 1 7 .0 4 (1 8 )
C ( 16 ) -0 (6 ) -C (  19) 1 1 7 .3 3 (1 9 )
Sym m etry transform ations u sed  to  generate  
eq u iv a len t atom s:
171
Appendices X-ray crystal data
Table 4. A nisotropic d isp lacem en t param eters ( A ^  103)for 83c. T he anisotropic  
displacem ent factor exp on en t takes th e  form: -27i2[ h^a*2! ^ 1 +  ... +  2 h k a* b* U 12 ]
U 11 u 22 u 33 u 23 u 13 u 12
C(l) 41 (2 ) 30 (2 ) 31 (2 ) -1 (1 ) -9 (1 ) 5(1)
C (2) 39(2 ) 31 (2 ) 25 (1 ) -8 (1 ) -2 (1 ) -10(1 )
C (3) 37(2 ) 27 (2 ) 3 8 (2 ) 3 (1 ) -5 (1 ) 5(1)
C (4) 25(1 ) 22 (1 ) 2 6 (1 ) -5 (1 ) -1 (1 ) -3(1)
C (5) 31(1) 2 1 (1 ) 2 2 (1 ) 1(1) -7 (1 ) -6(1)
C (6) 24(1 ) 23 (1 ) 19(1) -2 (1 ) -1 (1 ) -9(1)
C (7) 22(1 ) 2 2 (1 ) 2 5 (1 ) -5 (1 ) -2 (1 ) -5(1)
C (8) 28(1 ) 2 1 (1 ) 2 7 (1 ) -2 (1 ) -8 (1 ) -7(1)
C (9) 27(1 ) 22 (1 ) 2 2 (1 ) -4 (1 ) -4 (1 ) -8(1)
C (10) 31(1) 2 4 (1 ) 2 2 (1 ) -2 (1 ) -7 (1 ) -6(1)
C ( l l ) 29 (1 ) 2 7 (1 ) 19(1) -1 (1 ) 1 0 ) -7(1)
C (12) 25(1 ) 2 6 (1 ) 2 0 (1 ) -1 (1 ) -2 (1 ) -4(1)
C (13) 23(1 ) 2 0 (1 ) 2 4 (1 ) -1 (1 ) -6 (1 ) -1(1)
C (14) 22(1) 2 6 (1 ) 2 6 (1 ) 0 (1 ) -2 (1 ) -7(1)
C (15) 28(1 ) 21 (1 ) 2 9 (1 ) -3 (1 ) -6 (1 ) -6(1)
C (16) 28 (1 ) 2 2 (1 ) 2 2 (1 ) -4 (1 ) -7 (1 ) -1(1)
C (17) 23(1 ) 2 4 (1 ) 17(1) 2 (1 ) -2 (1 ) -6(1)
C (18) 30(1 ) 18(1) 2 1 (1 ) 1(1) -7 (1 ) -5(1)
C (19) 53(2) 3 2 (2 ) 58 (2 ) -2 4 (2 ) 5 0 ) -17 (1 )
0 (1 ) 37(1 ) 29 (1 ) 2 4 (1 ) 0 (1 ) -4 (1 ) 6 (1 )
0 (2 ) 28(1 ) 2 2 (1 ) 2 1 (1 ) -4 (1 ) 1(1) -9(1)
0 (3 ) 26 (1 ) 2 6 (1 ) 33 (1 ) 0 (1 ) -2 (1 ) 4 (1 )
0 (4 ) 46 (1 ) 24 (1 ) 26 (1 ) -1 (1 ) 1(1) -7(1)
0 (5 ) 35(1) 25 (1 ) 31 (1 ) -9 (1 ) 7 (1 ) -11 (1 )
0 (6 ) 36(1 ) 24 (1 ) 35 (1 ) -1 1 (1 ) 0 (1 ) -9(1)
F(l) 48 (1 ) 2 9 (1 ) 34 (1 ) -7 (1 ) 14(1) -14 (1 )
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Table 5. H ydrogen coord inates ( x  104) and isotropic d isp lacem ent parameters ( A ^  103) 
for 83c.
X y z U (eq)
H(1 A ) 6 7 6 0 -85 5091 54
H (1B ) 6 8 9 2 -1 7 0 6595 54
H (1C ) 7642 1048 5354 54
H (2A ) 39 1 0 3241 7557 48
H (2B ) 2005 3381 8219 48
H (2C ) 28 0 9 4 5 1 2 6909 48
H (3A ) 2442 6 8 3 8 3460 57
H (3B ) 570 6 8 1 7 4250 57
H (3C ) 1210 6131 3008 57
H (4) 6774 1897 3311 30
H (8) 37 9 9 5268 2244 30
H (12) 60 9 7 1435 1318 30
H (14) 6123 -6 2 4 733 31
H (15) 7269 -2191 -528 32
H (18) 9704 1855 -1 432 29
H (19A ) 9 3 7 0 -3 755 -1 304 70
H (19B ) 10008 -3 7 4 2 -2 8 7 4 70
H (19C ) 8225 -3103 -2 332 70
H (5) 11717 9 9 0 -2951 48
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F =
o /
-o
0 0
Table 1. Crystal data and structure refinem ent for 139.
Identification cod e nj10409
Empirical formula C 1 8 H 1 7 F 0 4
Formula w eight 3 1 6 .3 2
Temperature 1 50 (2 ) K
W avelength 0 .7 1 0 7 3  A
Crystal system T riclin ic
Space group P - l
U nit ce ll d im ensions a =  8 .3101  (2 ) A a =  109 .4530(10)°. 
b =  9 .9 4 0 7 (2 )  A p=  9 7 .2 5 4 0 (1 0 )°  
c =  1 1 .3 1 6 2 (3 ) A y = 1 1 3 .2 1 6 0 (1 0 ) °
V olum e 7 7 3 .4 7 (3 )  A3
Z 2
D ensity  (calculated) 1 .358  M g/m 3
Absorption coeffic ien t 0 .103  mm"1
F (000) 3 3 2
Crystal size 0 .5 0  x  0 .3 0  x  0 .2 5  m m 3
Theta range for data co llec tion 3 .2 6  to 30 .06°.
Index ranges -11 < = h < = l 1, -1 4 < = k < = l 3 , -1 5<=1< =15
R eflections co llected 12 4 5 6
Independent reflections 4 4 4 9  [R (int) =  0 .0 5 6 4 ]
C om pleteness to theta =  3 0 .0 6 ° 9 8 .0  %
Absorption correction Sem i-em pirical from equivalents
M ax. and min. transm ission 0 .9 7 4 7  and 0 .9 5 0 2
R efinem ent m ethod Full-m atrix least-squares on  F2
Data /  restraints /  parameters 4 4 4 9 / 0 / 2 1 1
G oodness-of-fit on F2 1 .037
Final R  indices [I>2sigm a(I)] R1 = 0 .0 4 9 1 , w R 2 =  0 .1 2 7 7
R  indices (all data) R1 =  0 .0 5 8 0 , w R 2 =  0 .1 3 4 2
Largest diff. peak and h o le 0 .3 4 9  and -0 .2 1 5  e.A"3
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Table 2. A tom ic coord inates ( x 104) and equ iva len t isotropic d isp lacem ent parameters ( A ^  103) 
for 139. U (eq) is defined  as o n e  third o f  the trace o f  the orthogonalized  U ’j tensor.
X y z U (eq)
C ( l) 7 9 6 5 (2 ) 14117(1) 657 (1 ) 23 (1 )
C (2) 9 0 8 4 (2 ) 15709 (1 ) 1580(1) 25 (1 )
C (3) 9 2 6 3 (2 ) 16050 (1 ) 2 8 9 5 (1 ) 25(1 )
C (4) 8 3 5 5 (2 ) 14836(1) 3 289 (1 ) 24 (1 )
C (5) 7 2 3 3 (2 ) 13278 (1 ) 2 3 4 7 (1 ) 22 (1 )
C (6) 7 0 2 6 (2 ) 12876 (1 ) 1000(1) 21(1 )
C (7) 5 8 7 4 (2 ) 11174 (1 ) -28 (1 ) 21 (1 )
C (8) 3 8 3 9 (2 ) 10266 (1 ) -81(1 ) 21 (1 )
C (9) 2 4 5 0 (2 ) 10028 (1 ) -1 2 3 2 (1 ) 2 4 (1 )
C (10) 533 (2 ) 8 6 9 0 (1 ) -1 6 8 9 (1 ) 22 (1 )
C ( l l ) -5 1 5 (2 ) 8 0 7 8 (1 ) -2 9 9 8 (1 ) 24 (1 )
C (12) -2 2 4 7 (2 ) 6 7 7 2 (1 ) -35 1 3 (1 ) 26 (1 )
C (13) -2 9 9 0 (2 ) 6 0 1 9 (1 ) -2 7 2 5 (1 ) 25 (1 )
C (14) -2 0 3 3 (2 ) 6 6 3 5 (1 ) -1 4 0 7 (1 ) 24 (1 )
C (15) -3 0 4 (2 ) 7 9 5 0 (1 ) -938 (1 ) 22 (1 )
C (16) 1 1224(3) 18842 (2 ) 35 4 7 (2 ) 52(1)
C (17) 6 4 1 8 (2 ) 12316(2) 3 9 7 4 (1 ) 35 (1 )
C (18) -5 3 2 0 (2 ) 3 7 3 0 (2 ) -2 6 2 1 (2 ) 39 (1 )
F ( l) 586 (1 ) 8 5 3 0 (1 ) 3 5 7 (1 ) 2 7 (1 )
0 (1 ) 10273 (1 ) 1 7 567 (1 ) 3 9 0 2 (1 ) 35 (1 )
0 (2 ) 6 2 7 1 (1 ) 12012 (1 ) 2 6 3 2 (1 ) 27 (1 )
0 (3 ) 2 8 6 6 (1 ) 10922 (1 ) -1 7 9 1 (1 ) 34 (1 )
0 (4 ) -4 6 4 9 (1 ) 4 6 8 0 (1 ) -3 3 3 1 (1 ) 32 (1 )
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Table 3. B ond  lengths [A ] and an g les [°] for 139. C (16)-H (16C ) 0 .9 8 0 0
C (1 7 )-0 (2 ) 1 .4243(14)
C (17)-H (17A ) 0 .9 8 0 0
C (l)-C (6 ) 1 .3 8 5 1 (1 5 ) C (17)-H (17B ) 0 .9 8 0 0
C (l)-C (2 ) 1 .3 9 7 6 (1 5 ) C (17)-H (17C ) 0 .9 8 0 0
C (l) -H ( l) 0 .9 5 0 0 C (1 8 )-0 (4 ) 1 .4317(16)
C (2)-C (3) 1 .3 8 6 1 (1 6 ) C (18)-H (18A ) 0 .9 8 0 0
C (2)-H (2) 0 .9 5 0 0 C (18)-H (18B ) 0 .9 8 0 0
C (3 ) -0 ( l) 1 .3 7 5 7 (1 4 ) C (18)-H (18C ) 0 .9 8 0 0
C (3)-C (4) 1 .3 9 6 4 (1 6 )
C (4)-C (5) 1 .3 8 3 8 (1 5 ) C (6 )-C (l)-C (2 ) 122 .91(10)
C (4)-H (4) 0 .9 5 0 0 C (6 )-C (l) -H (l) 118 .5
C (5 )-0 (2 ) 1 .3 6 7 5 (1 3 ) C (2 )-C (l) -H (l) 118.5
C (5)-C (6) 1 .4 0 9 2 (1 5 ) C (3 )-C (2 )-C (l) 1 1 8 .21 (10 )
C (6)-C (7) 1 .5 0 4 5 (1 5 ) C (3)-C (2)-H (2) 120 .9
C (7)-C (8) 1 .5 5 3 2 (1 5 ) C (l)-C (2 )-H (2 ) 120 .9
C (7)-C (8)# l 1 .5 8 0 8 (1 5 ) 0 (1 )-C (3 )-C (2 ) 12 4 .3 8 (1 1 )
C (7)-H (7) 1 .0 0 0 0 0 (1 )-C (3 )-C (4 ) 1 1 4 .68 (10 )
C (8)-C (9) 1 5 1 2 5 (1 5 ) C (2)-C (3)-C (4) 1 2 0 .9 2 (1 0 )
C (8)-C (7)# l 1 .5 8 0 8 (1 5 ) C (5)-C (4)-C (3) 1 1 9 .31 (10 )
C (8)-H (8) 1.0000 C (5)-C (4)-H (4) 120.3
C (9 )-0 (3 ) 1 .2 2 2 9 (1 4 ) C (3)-C (4)-H (4) 120.3
C (9)-C (10) 1 .4 9 5 7 (1 5 ) 0 (2 )-C (5 )-C (4 ) 1 2 3 .71 (10 )
C (10)-C (15) 1 .3 8 2 6 (1 5 ) 0 (2 )-C (5 )-C (6 ) 114 .70 (9 )
C (1 0 )-C (l l) 1 .4 0 6 8 (1 5 ) C (4)-C (5)-C (6) 1 2 1 .58 (10 )
C ( ll) -C (1 2 ) 1 .3 8 1 6 (1 6 ) C (l)-C (6 )-C (5 ) 117 .05 (10 )
C (11)-H (11) 0 .9 5 0 0 C (l)-C (6 )-C (7 ) 120 .90(9 )
C (12)-C (13) 1 .3 9 8 4 (1 6 ) C (5)-C (6)-C (7) 122 .04 (10 )
C (12)-H (12) 0 .9 5 0 0 C (6)-C (7)-C (8) 118 .28(9)
C (1 3 )-0 (4 ) 1 .3 6 0 3 (1 4 ) C (6 )-C (7 )-C (8 )# l 121 .31(9 )
C (13)-C (14) 1 .3 9 3 0 (1 6 ) C (8 )-C (7 )-C (8 )# l 88 .88(8 )
C (14)-C (15) 1 .3 8 5 2 (1 6 ) C (6)-C (7)-H (7) 108.9
C (14)-H (14) 0 .9 5 0 0 C (8)-C (7)-H (7) 108.9
C (1 5 )-F (l) 1 .3 6 1 0 (1 2 ) C (8 )# l -C (7)-H (7) 108.9
C (1 6 )-0 ( l) 1 .4 2 1 6 (1 8 ) C (9)-C (8)-C (7) 115 .00(9 )
C (16)-H (16A ) 0 .9 8 0 0 C (9 )-C (8 )-C (7 )# l 122 .36(9 )
C (16)-H (16B ) 0 .9 8 0 0 C (7)-C (8)-C (7)# l 91 .11 (8 )
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C (9)-C (8)-H (8) 109 .0
C (7)-C (8)-H (8) 1 0 9 .0
C (7)# l-C (8)-H (8) 10 9 .0
O (3)-C (9)-C (10) 1 1 9 .4 2 (1 0 )
0 (3 )-C (9 )-C (8 ) 1 2 0 .9 6 (1 0 )
C (10)-C (9)-C (8) 1 1 9 .6 2 (9 )
C (15)-C (10)-C (l 1) 1 1 6 .0 3 (1 0 )
C (15)-C (10)-C (9) 1 2 5 .3 5 (1 0 )
C (ll)-C (1 0 )-C (9 ) 1 1 8 .6 0 (1 0 )
C (1 2 )-C (ll)-C (1 0 ) 1 2 1 .7 7 (1 0 )
C (12)-C (l 1 )-H (11) 119.1
C (1 0 )-C (ll)-H (l 1) 119.1
C (ll)-C (1 2 )-C (1 3 ) 1 1 9 .7 0 (1 0 )
C (ll)-C (1 2 )-H (1 2 ) 120.1
C( 13 )-C( 12)-H ( 12) 120.1
0 (4 )-C (13 )-C (14 ) 1 2 3 .8 1 (1 1 )
0 (4 )-C (13 )-C (12 ) 1 1 5 .9 2 (1 0 )
C (14)-C (13)-C (12) 1 2 0 .2 6 (1 0 )
C (15)-C (14)-C (13) 1 1 7 .6 8 (1 0 )
C (15)-C (14)-H (14) 121 .2
C( 13 )-C (14)-H (l 4) 121 .2
F (l)-C (15 )-C (10 ) 1 1 9 .4 1 (1 0 )
F (l)-C (15 )-C (14 ) 1 1 6 .1 7 (1 0 )
C (10)-C (15)-C (14) 1 2 4 .4 1 (1 0 )
0 (  1 )-C( 16)-H ( 16 A ) 109 .5
0 (  1 )-C( 16)-H ( 16B ) 109 .5
H (16A )-C (16)-H (l 6B ) 109 .5
0 (1  )-C( 16)-H ( 16C ) 109 .5
H (16A )-C (16)-H (l 6C ) 109 .5
H ( 16B )-C ( 16)-H ( 16C ) 109.5
0 (2 ) -C ( l 7 )-H (l 7 A) 109 .5
0 (2 ) -C ( l 7 )-H (l 7B ) 109 .5
H (17A )-C (17)-H (17B ) 109 .5
0 (2 )-C ( 17)-H ( 17C) 109 .5
H (17A )-C (17)-H (l 7C ) 109.5
H (17B )-C (17)-H (l 7C ) 109 .5
0 (4 ) -C ( l 8 )-H (l 8 A) 109 .5
0 (4 ) -C ( l 8 )-H (l 8B ) 109.5
H (18A )-C (18)-H (18B ) 109.5
0 (4 )-C (1 8 )-H (1 8 C ) 109.5
H (18A )-C (18)-H (18C ) 109.5
H (18B )-C (18)-H (18C ) 109.5
C (3 )-0 ( l) -C (1 6 ) 116 .64 (10 )
C (5 )-0 (2 )-C (1 7 ) 118 .18(9 )
C (1 3 )-0 (4 )-C (1 8 ) 1 1 7 .57 (10 )
Sym m etry transform ations used  to  generate 
equivalen t atoms:
#1 -x + l,-y + 2 ,-z
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Table 4. A nisotropic d isp lacem en t parameters ( A ^  103)for 139. T he anisotropic  
d isp lacem ent factor exp on en t takes the form: -27t2[ h2a*2U 11 +  ... +  2 h k a* b* U 12 ]
U 11 U 22 U 33 U 23 u 13 u 12
C ( l) 25(1 ) 2 3 (1 ) 2 1 (1 ) 10(1) 7 (1 ) 10(1)
C (2) 25(1 ) 2 1 (1 ) 2 7 (1 ) 11(1) 6 (1 ) 8(1)
C (3) 26(1 ) 2 0 (1 ) 2 4 (1 ) 6 (1 ) 1(1) 8(1)
C (4) 27(1 ) 2 3 (1 ) 19(1) 7 (1 ) 5 0 ) 11(1)
C (5) 23 (1 ) 2 1 (1 ) 2 1 (1 ) 9 (1 ) 6 (1 ) 9 (1 )
C (6) 22(1 ) 2 0 (1 ) 2 0 (1 ) 8 (1 ) 5 (1) 8 (1)
C (7) 22(1) 19(1) 19(1) 7 (1 ) 5(1) 7(1)
C (8) 22(1) 18(1) 19(1) 7 (1 ) 5 (1 ) 7 (1)
C (9) 24(1 ) 2 2 (1 ) 24 (1 ) 10(1) 6 (1 ) 10(1)
C (10) 2 3 (1 ) 2 1 (1 ) 2 1 (1 ) 9 (1 ) 6 (1 ) 10(1)
C ( l l ) 2 6 (1 ) 2 8 (1 ) 2 3 (1 ) 13(1) 7 (1 ) 13(1)
C (12 ) 25(1 ) 2 9 (1 ) 2 1 (1 ) 10(1) 5(1) 12(1)
C (13 ) 19(1) 2 7 (1 ) 2 6 (1 ) 10(1) 5 (1 ) 10(1)
C (14) 23(1 ) 2 8 (1 ) 2 4 (1 ) 12(1 ) 8 (1 ) 12(1)
C (15) 2 4 (1 ) 2 5 (1 ) 18(1) 8 (1 ) 5(1) 13(1)
C (16) 65(1) 2 0 (1 ) 4 1 (1 ) 9 (1 ) 1(D 1(1)
C (17) 41 (1 ) 3 6 (1 ) 2 3 (1 ) 16(1) 10(1) 9 (1 )
C (18) 24 (1 ) 4 1 (1 ) 4 5 (1 ) 2 4 (1 ) 5 (1) 5(1)
F(l) 29(1) 30 (1 ) 17(1) 9 (1 ) 5(1) 10(1)
0 ( 1 ) 43 (1 ) 19(1) 2 6 (1 ) 5 (1) -1 (1 ) 5(1)
0 ( 2 ) 33(1 ) 24 (1 ) 2 0 (1 ) 11(1) 8 (1 ) 7 (1 )
0 ( 3 ) 30 (1 ) 33 (1 ) 4 0 (1 ) 2 4 (1 ) 5 (1) 8 (1 )
0 ( 4 ) 21(1 ) 3 5 (1 ) 30 (1 ) 14(1) 2 (1 ) 5(1)
Table 5.
for 139.
H ydrogen coordinates ( x  10 4) and isotrop ic d isp lacem en t parameters (A2* 10 3)
X y z U (eq)
H(l) 7843 13875 -246 28
H (2) 9706 16535 1312 30
H (4) 8507 15077 41 9 4 29
H (7) 5922 11158 -910 25
H (8) 3654 10863 752 25
H (1 1) -17 8577 -3543 29
H (12) -2 9 3 0 63 8 6 -4 3 9 9 31
H (14) -2 5 4 9 61 7 0 -849 29
H (16A ) 12125 18638 3137 78
H (16B ) 11857 19864 43 3 4 78
H (16C ) 10348 18901 29 2 6 78
H (17A ) 7 706 12775 4 4 6 6 53
H (17B ) 5696 11303 40 3 6 53
H (17C ) 5953 13080 4341 53
H (18A ) -4423 3393 -2362 58
H (18B ) -6485 2774 -3181 58
H(18C) -5510 4373 -1836 58
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Appendix IV, Crystal data for 155
Table 1. Crystal data and structure refinem ent for
Identification code
Empirical formula
Formula w eight
Temperature
W avelength
Crystal system
Space group
U nit cell d im ensions
V olum e
Z
D ensity  (calculated)
A bsorption coefficient 
F (000)
Crystal size
Theta range for data co llec tion
Index ranges
R eflections co llected
Independent reflections
C om pleteness to theta =  2 7 .4 8 °
A bsorption correction
Max. and min. transm ission
R efinem ent m ethod
Data /  restraints /  parameters
G oodness-of-fit on F2
Final R  ind ices [I>2sigm a(I)]
R  indices (all data)
Largest diff. peak and h o le
155
nj10408
C 3 6 H 3 4 F 2  0 8
6 3 2 .6 3  
150 (2 ) K  
0 .7 1 0 7 3  A 
T riclin ic  
P - l
a = 7 .3 4 4 9 (2 )  A 
b =  1 1 .9 6 1 3 (3 ) A 
c =  1 8 .3 5 1 6 (5 ) A 
1 5 1 9 .7 0 (7 ) A3 
2
1.383 M g/m 3 
0 .1 0 5  m m '1 
66 4
0 .3 8  x  0 .3 8  x  0 .2 0  m m 3 
2 .9 4  to 27 .4 8 ° .
-9 < = h < = 9 , -1 5<=k<==l 5, -23<=1<=23  
2 6 7 0 2
6 9 4 6  [R (int) =  0 .1 0 2 7 ]
9 9 .5  %
Sem i-em pirical from equivalents  
0 .9 7 9 3  and 0 .9 6 1 2  
Full-m atrix least-squares on  F 2 
6 9 4 6 / 0 / 4 2 1
1 .027
R1 =  0 .0 5 5 4 , w R 2 =  0 .1 2 3 4  
R1 =  0 .0 9 4 3 , w R 2 =  0 .1421  
0 .4 4 2  and -0 .2 6 6  e.A'3
cc= 80 .2740 (10 )° . 
p= 87 .6480 (10 )° . 
y =  73 .0120 (10 )° .
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Table 2. A tom ic coord inates ( x  104) and equ ivalen t isotropic d isp lacem ent parameters ( A ^  103) 
for 155. U (eq) is defined  as o n e  third o f  the trace o f  the orthogonalized  U ‘1 tensor.
X y z U (eq)
C ( l l ) 2 7 5 1 (3 ) 10059(2 ) 1418(1) 2 9 (1 )
C (12) 1699 (3 ) 11193(2) 1481(1) 30 (1 )
C (13) 1506 (3 ) 11557(2 ) 2 1 67 (1 ) 28 (1 )
C (14) 2 3 9 5 (3 ) 10789(2) 2 7 8 9 (1 ) 29 (1 )
C (15) 3 4 5 9 (3 ) 9 6 3 8 (2 ) 271 9 (1 ) 26 (1 )
C (16) 3 6 4 1 (3 ) 9 2 4 0 (2 ) 203 4 (1 ) 27 (1 )
C (17) 4 6 9 5 (3 ) 8 0 1 3 (2 ) 1994(1) 28 (1 )
C (18) 5 0 4 4 (3 ) 7 4 7 5 (2 ) 1400(1) 30 (1 )
C (19) 6 0 9 4 (3 ) 6 2 0 6 (2 ) 1475(1) 30 (1 )
C (110) 6 7 6 7 (3 ) 565 3 (2 ) 8 07 (1 ) 26 (1 )
C ( l l l ) 7 1 4 5 (3 ) 4 4 1 8 (2 ) 869(1 ) 30 (1 )
C (112) 7 7 0 6 (3 ) 3 8 4 0 (2 ) 27 8 (1 ) 31(1 )
C (1 13) 7 9 3 7 (3 ) 4 4 7 3 (2 ) -411 (1 ) 28 (1 )
C (1 14) 7 6 5 0 (3 ) 5 68 6 (2 ) -495 (1 ) 2 8 (1 )
C (1 15) 7 0 6 4 (3 ) 6 2 3 0 (2 ) 112(1) 2 6 (1 )
C (116) 177(3 ) 13130 (2 ) 2 8 6 1 (1 ) 37(1 )
C (1 17) 4 1 4 4 (3 ) 9 1 3 7 (2 ) 4 0 2 3 (1 ) 3 9 (1 )
C (118) 8 6 6 3 (3 ) 4 4 3 8 (2 ) -1 691 (1 ) 40 (1 )
F ( l l ) 6 7 9 8 (2 ) 7 4 2 5 (1 ) 2 (1 ) 38(1 )
0 (1 1 ) 4 2 6 (2 ) 12699(1) 2 1 7 4 (1 ) 3 5 (1 )
0 (1 2 ) 4 3 9 8 (2 ) 8 8 3 7 (1 ) 32 9 6 (1 ) 32(1 )
0 (1 3 ) 6 3 9 2 (2 ) 557 5 (1 ) 2 0 8 8 (1 ) 4 2 (1 )
0 (1 4 ) 8 4 6 3 (2 ) 3 8 2 3 (1 ) -9 6 7 (1 ) 36 (1 )
0 (2 1 ) 3 2 1 9 (3 ) 56 2 2 (2 ) 3 5 9 1 (1 ) 27 (1 )
C (22) 2 1 4 2 (3 ) 6 7 4 5 (2 ) 366 3 (1 ) 29 (1 )
C (23) 1300(3 ) 69 6 4 (2 ) 4 3 3 7 (1 ) 27 (1 )
C (24) 1574(3 ) 60 6 2 (1 ) 4 9 4 6 (1 ) 26 (1 )
0 (2 5 ) 2 6 7 2 (3 ) 4 9 2 0 (2 ) 4 8 6 4 (1 ) 24 (1 )
C (26) 3 5 0 8 (2 ) 4 6 6 8 (2 ) 4 1 8 5 (1 ) 2 4 (1 )
C (27) 4 6 0 9 (3 ) 3 4 6 7 (2 ) 4 1 1 5 (1 ) 25 (1 )
C (28) 539 6 (3 ) 3 0 6 7 (2 ) 3 5 0 3 (1 ) 27 (1 )
C (29) 6 3 7 5 (3 ) 1796 (2 ) 352 0 (1 ) 28 (1 )
C (210) 6 7 9 8 (3 ) 1298 (2 ) 2 8 2 1 (1 ) 25 (1 )
C (211) 804 3 (3 ) 159(2 ) 2 8 3 8 (1 ) 29 (1 )
C (212) 8 4 9 1 (3 ) -3 6 8 (2 ) 2 2 1 3 (1 ) 32 (1 )
C (213) 769 2 (3 ) 2 5 4 (2 ) 1535(1) 32 (1 )
C (214) 6 4 1 5 (3 ) 1366 (2 ) 1499(1) 30 (1 )
C (215) 59 93 (3 ) 1850 (2 ) 2 1 3 0 (1 ) 26 (1 )
C (216) -7 1 5 (3 ) 8 3 8 9 (2 ) 5 022 (1 ) 39(1 )
C (217) 2 2 4 1 (3 ) 4 1 8 6 (2 ) 6 1 3 9 (1 ) 31 (1 )
C (218) 9 2 7 1 (3 ) -1 3 1 3 (2 ) 8 80 (1 ) 46 (1 )
F (21) 4 6 5 3 (2 ) 2 9 2 6 (1 ) 2 0 5 7 (1 ) 35(1)
0 (2 1 ) 195(2 ) 809 6 (1 ) 4 3 4 7 (1 ) 35(1 )
0 (2 2 ) 2 9 8 3 (2 ) 3 9 8 0 (1 ) 5 427 (1 ) 30(1)
0 (2 3 ) 6 8 6 0 (2 ) 1132(1) 4 1 1 6 (1 ) 41 (1 )
0 (2 4 ) 806 1 (2 ) -139 (1 ) 8 71 (1 ) 44(1 )
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Table 3. B on d  lengths [A ] and an g les [°] for 155.
C (11)-C (12) 1 .3 7 1 (2 )
C (ll) -C (1 6 ) 1 .4 0 7 (2 )
C (11)-H (11) 0 .9 5 0 0
C (12)-C (13) 1 .3 9 0 (3 )
C (12)-H (12) 0 .9 5 0 0
C (1 3 )-0 ( l 1) 1 .3 6 6 (2 )
C (13)-C (14) 1 .3 9 0 (2 )
C (14)-C (15) 1 .3 9 5 (2 )
C (14)-H (14) 0 .9 5 0 0
C (1 5 )-0 (1 2 ) 1 .3 5 8 (2 )
C (15)-C (16) 1 .4 0 5 (3 )
C (16)-C (17) 1 .4 5 7 (2 )
C (17)-C (18) 1 .3 3 8 (3 )
C (17)-H (17) 0 .9 5 0 0
C (18)-C (19) 1 .4 7 4 (2 )
C (18)-H (18) 0 .9 5 0 0
C (1 9 )-0 (1 3 ) 1 .2 3 3 (2 )
C (19)-C (110) 1 .4 8 9 (3 )
C (110)-C (115) 1 .3 8 5 (3 )
C (1 1 0 ) -C ( l l l ) 1 .4 0 6 (2 )
C ( l l l ) -C (1 1 2 ) 1 .3 7 0 (3 )
C (1 11 )-H (l 11) 0 .9 5 0 0
C (112)-C (113) 1 .3 9 0 (3 )
C (112)-H (l 12) 0 .9 5 0 0
C (1 1 3 )-0 (1 4 ) 1 .3 6 3 (2 )
C (113)-C (114) 1 .3 8 6 (2 )
C (114)-C (115) 1 .3 7 6 (2 )
C (114)-H (l 14) 0 .9 5 0 0
C (1 1 5 )-F ( ll) 1 .3 6 5 1 (1 9 )
C (1 1 6 )-0 ( l 1) 1 .4 2 5 (2 )
C (116)-H (l 1A) 0 .9 8 0 0
C (116)-H (l IB ) 0 .9 8 0 0
C (116)-H (l 1C) 0 .9 8 0 0
C (1 1 7 )-0 (1 2 ) 1 .4 3 0 (2 )
C (117)-H (l ID ) 0 .9 8 0 0
C (117)-H (l IE ) 0 .9 8 0 0
C (117)-H (l IF) 0 .9 8 0 0
C (1 1 8 )-0 (1 4 ) 1 .4 3 0 (2 )
C (118)-H (11G ) 0 .9 8 0 0
C (118)-H (11H ) 0 .9 8 0 0
C (118)-H (111) 0 .9 8 0 0
C (21)-C (22) 1 .3 7 0 (2 )
C (21)-C (26) 1 .4 1 2 (2 )
C (21)-H (21) 0 .9 5 0 0
C (22)-C (23) 1 .3 9 1 (3 )
C (22)-H (22) 0 .9 5 0 0
C (2 3 )-0 (2 1 ) 1 .3 6 3 (2 )
C (23)-C (24) 1 .3 9 2 (2 )
C (24)-C (25) 1 .3 9 8 (2 )
C (24)-H (24) 0 .9 5 0 0
C (2 5 )-0 (2 2 ) 1 .3 6 3 (2 )
C (25)-C (26) 1 .4 0 6 (3 )
C (26)-C (27) 1 .4 5 2 (2 )
C (27)-C (28) 1 .338(2 )
C (27)-H (27) 0 .9 5 0 0
C (28)-C (29) 1 .475(2 )
C (28)-H (28) 0 .9 5 0 0
C (2 9 )-0 (2 3 ) 1 .235(2 )
C (29)-C (210) 1 .489(3 )
C (210)-C (215) 1 .393(2)
C (210)-C (211) 1 .398(2 )
C (211)-C (212) 1 .383(3)
C (211)-H (211) 0 .9 5 0 0
C (212)-C (213) 1 .392(3 )
C (212)-H (212) 0 .9 5 0 0
C (2 1 3 )-0 (2 4 ) 1 .369(2 )
C (213)-C (214) 1 .379(3 )
C (214)-C (215) 1 .366(2 )
C (214)-H (214) 0 .9 5 0 0
C (215)-F (21) 1 .3619(19)
C (2 1 6 )-0 (2 1 ) 1 .431(2 )
C (216)-H (21A ) 0 .9 8 0 0
C (216 )-H (21B ) 0 .9 8 0 0
C (216)-H (21C ) 0 .9 8 0 0
C (2 1 7 )-0 (2 2 ) 1 .428(2 )
C (217 )-H (21D ) 0 .9 8 0 0
C (217)-H (21E ) 0 .9 8 0 0
C (217)-H (21F ) 0 .9 8 0 0
C (2 1 8 )-0 (2 4 ) 1 .424(2 )
C (218)-H (21G ) 0 .9 8 0 0
C (218)-H (21H ) 0 .9 8 0 0
C (218)-H (21I) 0 .9 8 0 0
C (1 2 )-C (l 1 )-C (l 6) 1 21 .8 0 (1 7 )
C (1 2 )-C (l 1 )-H (1 1) 119.1
C (1 6 )-C (l 1 )-H (1 1) 119.1
C (11 )-C (12 )-C (13 ) 119 .78 (16 )
C( 11 )-C (l 2 )-H ( 12) 120.1
C (1 3 )-C (l 2 )-H (l 2) 120.1
0 ( 1 1)-C (13)-C (12) 11 5 .52 (15 )
0 ( 1 1)-C (13)-C (14) 123 .90 (17 )
C (1 2 )-C (l 3 )-C (l 4 ) 120 .58 (16 )
C (13 )-C (14 )-C (l 5) 119 .11 (17 )
C (1 3 )-C (l 4 )-H (l 4 ) 120 .4
C (15 )-C (14 )-H (14 ) 120.4
0 ( 1 2 )-C (l 5 )-C (l 4) 122 .97(16)
0 ( 1 2 )-C (l 5 )-C (l 6) 115 .61(15)
C (1 4 )-C (l 5 )-C (l 6) 121 .41(15)
C (15 )-C (16 )-C (l 1) 117 .28 (16 )
C (15 )-C (16 )-C (17 ) 119 .45(15)
C (11)-C (16)-C (17) 123 .26(17)
C (1 8 )-C (l 7 )-C (l 6) 128 .38(16)
C (18)-C (17)-H (17) 115.8
C (16 )-C (l 7 )-H (l 7) 115.8
C (17)-C (18)-C (19) 120 .37 (16 )
C( 17 )-C (l 8 )-H (l 8) 119.8
C (19)-C (18)-H (18) 119.8
0 (1 3 )-C (1 9 )-C (1 8 ) 120 .94(17)
0 ( 1 3 )-C (l 9 )-C (l 10) 118 .63 (16 )
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C (18)-C (19)-C (110) 1 2 0 .4 0 (1 6 ) C (25)-C (26)-C (27) 120 .13 (15 )
C (115)-C (110)-C (111) 1 1 5 .0 7 (1 7 ) C (2 1 )-C (26)-C (27) 122 .69(17)
C (115)-C (110)-C (19) 1 2 6 .7 4 (1 6 ) C (28)-C (27)-C (26) 127 .62 (16 )
C (1 11)-C (110)-C (19) 1 1 8 .1 9 (1 6 ) C (28)-C (27)-H (27) 116.2
C( 112 )-C (l 11 )-C( 110) 1 2 2 .1 5 (1 7 ) C (26)-C (27)-H (27) 116.2
C (112)-C (111 )-H( 111) 118 .9 C (27)-C (28)-C (29) 120 .61 (16 )
C (110)-C (11 1)-H (111) 118 .9 C (27)-C (28)-H (28) 119 .7
C (111 )-C (l 12)-C (113) 1 2 0 .0 8 (1 7 ) C (29)-C (28)-H (28) 119.7
C( 111 )-C (l 12)-H ( 112) 120 .0 0 (2 3  )-C (29)-C (28) 1 2 0 .33 (17 )
C (113)-C (l 12)-H (112) 1 2 0 .0 0 (2 3 )-C (2 9 )-C (2 1 0) 1 1 9 .13 (15 )
0 (  14)-C ( 113 )-C( 114) 1 2 4 .2 8 (1 7 ) C (28 )-C (2 9 )-C (2 10) 120 .54 (15 )
0 (1 4 )-C (1 1 3 )-C (1 12) 1 1 5 .6 9 (1 6 ) C (215 )-C (2 1 0 )-C (2 1 1) 1 1 4 .97 (16 )
C (114)-C (113)-C (112) 1 2 0 .0 3 (1 7 ) C (2 15 )-C (2 10)-C (29) 1 25 .73 (15 )
C (115)-C (l 14 )-C (113) 1 1 7 .7 7 (1 7 ) C (211)-C (210)-C (29) 1 1 9 .25 (16 )
C (115)-C (114)-H (114) 121.1 C (2 12 )-C (2 11 )-C (2 10) 122 .62 (17 )
C (113)-C (l 14)-H (114) 121.1 C (2 12 )-C (2 11 )-H (2 11) 118 .7
F (11)-C (115)-C (114) 1 1 5 .6 4 (1 5 ) C (2 10 )-C (2 11 )-H (2 11) 118 .7
F ( l l ) -C ( l  15)-C (110) 1 1 9 .5 2 (1 6 ) C (211 )-C (212 )-C (213 ) 119 .33 (16 )
C (1 1 4 )-C (ll 5)-C( 110) 1 2 4 .8 4 (1 6 ) C (2 11 )-C (2 12 )-H (2 12) 120.3
0 ( 1 1)-C (116)-H (11 A) 109 .5 C (2 13 )-C (2 12 )-H (2 12) 120.3
0 ( 1 1)-C(116)-H(1 IB ) 109 .5 0 (2 4 )-C (2 1 3 )-C (2 1 4 ) 114 .60 (17 )
H (11 A )-C (l 16)-H(1 IB ) 109 .5 0 (2 4 )-C (2 1 3 )-C (2 1 2 ) 1 2 5 .60 (17 )
0 (1 1 )-C (116> H (11C ) 109.5 C (2 14 )-C (2 13 )-C (2 12) 119 .80 (18 )
H (11 A )-C (l 16 )-H (11C) 109 .5 C (2 15 )-C (2 14 )-C (2 13) 1 1 9 .01 (17 )
H (11B )-C (116)-H (11C) 109 .5 C (2 15 )-C (2 14 )-H (2 14) 120.5
0 (  12)-C ( 117)-H ( 11D ) 109.5 C (2 13 )-C (2 14 )-H (2 14) 120.5
0 ( 1 2 )-C (l 17 )-H (l 1E) 109 .5 F (2 1 )-C (2 15 )-C (2 14) 1 15 .6 0 (1 5 )
H( 11 D )-C ( 117)-H ( 11E) 109 .5 F(21 )-C (2 15)-C (210) 1 2 0 .18 (15 )
0 (  12)-C ( 117)-H ( 11F) 109 .5 C (2 14 )-C (2 15 )-C (2 10) 1 2 4 .19 (16 )
H( 11 D )-C ( 117)-H ( 11F) 109 .5 0 (2 1  )-C (2 1 6 )-H (2 1 A ) 109.5
H (11E)-C (117)-H (1 IF ) 109 .5 0 (2 1  )-C (2 16)-H (2  IB ) 109.5
0 (  14)-C ( 118)-H ( 11G) 109.5 H (2 1 A )-C (2 16 )-H (2 1B ) 109.5
0 (  14)-C ( 118)-H ( 11H ) 109.5 0 (2 1  )-C (2 1 6 )-H (2 1C) 109.5
H( 11 G)-C( 118)-H ( 11H) 109.5 H (2 1 A )-C (2 16 )-H (2 1C ) 109.5
0 (  14)-C ( 118)-H ( 111) 109 .5 H (2 1 B )-C (2 16 )-H (2 1C) 109.5
H( 11 G)-C( 118)-H ( 111) 109 .5 0 (2 2 ) -C (2 17 )-H (2 1D ) 109.5
H (11H )-C (118)-H (111) 109 .5 0 (2 2 ) -C (2 17 )-H (2 1E) 109.5
C (1 3 ) -0 ( l l  )-C( 116) 1 1 8 .3 4 (1 4 ) H (2 1 D )-C (2 17 )-H (2 1E) 109.5
C (1 5 )-0 ( l 2 )-C (l 17) 1 1 8 .9 9 (1 4 ) 0 (2 2 ) -C (2 17)-H (2 IF) 109.5
C (1 1 3 )-0 (1 4 )-C (1 18) 1 1 7 .8 8 (1 4 ) H (2 1 D )-C (2 17 )-H (2 1F) 109.5
C (22)-C(21 )-C (26) 1 2 1 .8 7 (1 8 ) H (2 1 E )-C (2 17)-H (2  IF ) 109.5
C (22)-C (21 )-H (21) 119.1 0 (2 4 ) -C (2 18 )-H (2 1G) 109.5
C(26)-C(21 )-H (21) 119.1 0 (2 4 ) -C (2 18 )-H (2 1H ) 109.5
C (21)-C (22)-C (23) 1 1 9 .7 2 (1 7 ) H (2 1 G )-C (218 )-H (2 1H ) 109.5
C (21)-C (22>H (22) 120.1 0 (2 4 ) -C (2 18 )-H (2 11) 109.5
C (23)-C (22>-H (22) 120.1 H (2 1 G )-C (218 )-H (2 11) 109.5
0 (2 1  )-C(23 )-C (22) 1 1 5 .4 7 (1 6 ) H (2 1 H )-C (218 )-H (2 11) 109.5
0 (2 1  )-C(23 )-C (24) 1 2 3 .7 0 (1 7 ) C(23 ) - 0 ( 2 1 )-C (2 16) 118 .65(14)
C (22)-C (23)-C (24) 1 2 0 .8 1 (1 6 ) C (2 5 )-0 (2 2 )-C (2 17) 118 .48(13)
C (23)-C (24)-C (25) 1 1 8 .8 5 (1 7 ) C (2 1 3 )-0 (2 4 )-C (2 1 8) 117 .21 (16 )
C (23)-C (24>H (24) 120 .6
C (25)-C (24)-H (24) 120 .6
0 (2 2 )-C (2 5 > C (2 4 ) 1 2 2 .7 6 (1 7 ) Sym m etry transformations used to generate
0 (22 )-C (25 )-C (26 ) 1 1 5 .6 9 (1 5 ) equivalen t atoms:
C (24)-C (25 )-C (26) 1 2 1 .5 4 (1 6 )
C (25)-C (26)-C (21) 1 1 7 .1 8 (1 5 )
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T ab le  4 . Anisotropic displacement parameters (A 2* 103)for 155. The anisotropic 
displacement factor exponent takes the form: -27t2[ h2^ *2^ 1 +  ... +  2  h k a* b* U 12 ]
y i i u 22 U33 U23 U 13 u 12
C ( l l ) 29 (1 ) 35 (1 ) 2 6 (1 ) -5 (1 ) 2 (1 ) -13 (1 )
C (12) 30 (1 ) 31 (1 ) 2 7 (1 ) 1(1) -4 (1 ) -9(1)
C (13) 25(1 ) 2 6 (1 ) 33 (1 ) -2 (1 ) 1(1) -9(1)
C(14) 32(1 ) 30 (1 ) 2 8 (1 ) -5 (1 ) 0(1 ) -14 (1 )
C (15) 27 (1 ) 2 6 (1 ) 2 7 (1 ) 1(1) -3 (1 ) -11 (1 )
C (16) 24(1 ) 31 (1 ) 2 7 (1 ) -3 (1 ) 1(1) -11(1 )
C (17) 28(1 ) 30 (1 ) 2 4 (1 ) 0 (1 ) -1 (1 ) -9(1)
C (18) 30 (1 ) 3 0 (1 ) 2 5 (1 ) -1 (1 ) -1 (1 ) -6(1)
C (19) 27 (1 ) 34 (1 ) 27 (1 ) -4 (1 ) 2 (1 ) -8(1)
C(UO) 23 (1 ) 2 6 (1 ) 2 7 (1 ) -3 (1 ) -2 (1 ) -6(1)
C ( l l l ) 30(1 ) 30 (1 ) 2 9 (1 ) 0 (1 ) 2 (1 ) -7(1)
C (1 12) 33(1 ) 24 (1 ) 36 (1 ) -4 (1 ) 0 (1 ) -7(1)
C (1 13) 24 (1 ) 33 (1 ) 2 7 (1 ) -7 (1 ) -2 (1 ) -7(1)
C (114) 31(1 ) 30 (1 ) 23 (1 ) -2 (1 ) -3 (1 ) -9(1)
C (1 15) 29 (1 ) 2 3 (1 ) 2 7 (1 ) -2 (1 ) -4 (1 ) -8(1)
C (116) 39(1 ) 33 (1 ) 35 (1 ) -6 (1 ) 5(1) -7(1)
C (117) 58(1) 34 (1 ) 2 4 (1 ) -2 (1 ) -5 (1 ) -13 (1 )
C (1 18) 51(1) 40 (1 ) 2 5 (1 ) -10 (1 ) -2 (1 ) -3(1)
F ( l l ) 62 (1 ) 26 (1 ) 28 (1 ) -4 (1 ) 4 (1 ) -15(1 )
0 (1 1 ) 38(1) 26 (1 ) 34 (1 ) -2 (1 ) -2 (1 ) -3(1)
0 (1 2 ) 43 (1 ) 28 (1 ) 23 (1 ) 0 (1 ) -4 (1 ) -7(1)
0 (1 3 ) 57(1) 35 (1 ) 2 5 (1 ) 0 (1 ) 4 (1 ) -2(1)
0 (1 4 ) 48 (1 ) 32 (1 ) 2 9 (1 ) -10 (1 ) 1(1) -7(1)
0 (2 1 ) 27 (1 ) 32 (1 ) 2 4 (1 ) -6 (1 ) 1(1) -12 (1 )
C (22) 31(1 ) 29 (1 ) 26 (1 ) 0 (1 ) -1 (1 ) -10 (1 )
C (23) 27(1 ) 24 (1 ) 31 (1 ) -6 (1 ) -2 (1 ) -7(1)
0 (2 4 ) 26(1 ) 28 (1 ) 2 4 (1 ) -7 (1 ) 0 (1 ) -8(1)
0 (2 5 ) 25 (1 ) 27 (1 ) 22 (1 ) -2 (1 ) -4 (1 ) -10(1 )
C (26) 22 (1 ) 28 (1 ) 2 2 (1 ) -4 (1 ) -2 (1 ) -9(1)
C (27) 27 (1 ) 28 (1 ) 23 (1 ) -1 (1 ) -3 (1 ) -11 (1 )
C (28) 30 (1 ) 26 (1 ) 25 (1 ) -2 (1 ) -1 (1 ) -8(1)
C (29) 26(1 ) 27 (1 ) 29 (1 ) -4 (1 ) -2 (1 ) -8(1)
C (210) 24(1 ) 25 (1 ) 28 (1 ) -5 (1 ) 1(1) -10(1 )
C (211) 27 (1 ) 26 (1 ) 34 (1 ) -3 (1 ) -3 (1 ) -7(1)
C (212) 28 (1 ) 26 (1 ) 4 4 (1 ) -1 1 (1 ) 1(1) -6(1)
C (213) 31 (1 ) 37 (1 ) 34 (1 ) -1 4 (1 ) 3 (1 ) -13 (1 )
C (214) 31(1 ) 31 (1 ) 28 (1 ) -5 (1 ) -1 (1 ) -9(1)
C (215) 24 (1 ) 23 (1 ) 32 (1 ) -6 (1 ) 2 (1 ) -7(1)
C (216) 45 (1 ) 31 (1 ) 33 (1 ) -9 (1 ) 2 (1 ) 1(1)
C (217) 33(1) 35 (1 ) 23 (1 ) -1 (1 ) -1 (1 ) -9(1)
C (218) 44 (1 ) 41 (1 ) 54(2) -23 (1 ) 0 (1 ) -6(1)
F (21) 41 (1 ) 26 (1 ) 32 (1 ) -4 (1 ) -5 (1 ) 0(1 )
0 (2 1 ) 42 (1 ) 24 (1 ) 34 (1 ) -5 (1 ) 0 (1 ) -2(1)
0 (2 2 ) 36(1 ) 28 (1 ) 21 (1 ) -1 (1 ) 1(1) -6(1)
0 (2 3 ) 55(1) 32 (1 ) 30 (1 ) -2 (1 ) -7 (1 ) -2(1)
0 (2 4 ) 47 (1 ) 42 (1 ) 42 (1 ) -19 (1 ) 2 (1 ) -3(1)
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T ab le  5. H ydrogen coord inates ( x  104) and isotropic d isp lacem ent parameters ( A ^  103) 
for 155.
X y z U (eq)
H (1 1) 28 8 2 9821 946 35
H (12) 1105 11727 1056 36
H (14) 22 7 9 11044 3256 35
H (17) 5198 7 5 3 4 24 4 9 33
H (18) 4613 79 1 4 926 36
H ( l l l ) 70 0 6 3 9 7 0 1337 36
H (1 12) 7938 3005 338 37
H (1 14) 7 852 6 1 2 7 -957 33
H (11A ) -334 12604 3226 55
H (11B ) -713 13930 2793 55
H (11C ) 1407 13151 3036 55
H (11D ) 4 6 3 8 98 0 9 4043 58
H(1 IE) 4835 8454 4381 58
H (11F) 2 7 8 6 9352 4142 58
H (11G ) 7441 5012 -1 8 5 6 61
H (11H ) 9 0 5 9 3868 -2 0 3 4 61
H (11I) 9626 4855 -1 6 7 9 61
H (21) 3 7 8 7 5481 3127 32
H (22) 1971 7371 3254 34
H (24) 1024 6220 5409 31
H (27) 4791 2 8 9 9 4555 31
H (28) 5325 3 6 0 6 3054 33
H (211) 8603 -271 3297 35
H (212) 9336 -1 147 22 4 6 39
H (214) 5837 1790 1041 36
H (21A ) -1 512 7 868 5191 58
H (21B ) -1 5 0 9 9215 4 9 3 9 58
H (21C ) 255 8284 5399 58
H (21D ) 2 799 4742 6317 46
H (21E ) 2 562 3435 6485 4 6
H (21F) 855 4522 61 0 4 46
H (21G ) 10500 -1393 1104 69
H (21H ) 9 467 -1 478 372 69
H (21I) 8677 -1 8 7 8 1169 69
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Appendix V, Crystal data for 140
F O
refinem ent for 140.T ab le  1. Crystal data and structure
Identification cod e
Empirical formula
Formula w eight
Temperature
W avelength
Crystal system
Space group
U nit ce ll d im ensions
V olum e
Z
D ensity  (calculated)
A bsorption coeffic ien t 
F (000)
Crystal s ize
Theta range for data co llec tion  
Index ranges 
R eflections co llected  
Independent reflections 
C om pleteness to theta =  2 7 .4 1 °  
A bsorption correction  
M ax. and min. transm ission  
R efinem ent m ethod  
Data /  restraints /  parameters 
G oodness-of-fit on F 2 
Final R  indices P>2sigm a(I)]
R  indices (all data)
Largest diffi peak and h o le
nj10406
C 1 9 H 1 9 F 0 5
3 4 6 .3 4
150 (2 ) K
0 .7 1 0 7 3  A
T riclin ic
P - l
a =  8 .1 4 6 3 (2 )  A ot=
b =  9 .6 8 5 1 (3 ) A p=
c =  1 1 .4 7 0 8 (4 ) A y
8 2 5 .2 4 (4 )  A3 
2
1 .394  M g/m 3 
0 .1 0 8  m m -1 
3 6 4
0 .23  x  0 .15  x  0 .1 0  m m 3
3.63  to  27 .4 1 °.
-1 0 < = h < = 1 0 , -1 2 < = k < = 1 2 , -1 4 < : 
1 2 3 8 6
3 7 1 8  [R (int) =  0 .1 4 6 5 ]
9 8 .7  %
Sem i-em pirical from equivalents 
0 .9 8 9 3  and 0 .9 7 5 7  
Full-m atrix least-squares on  F 2 
3 7 1 8 / 0 / 2 3 0  
1.053
R1 =  0 .0 6 3 2 , w R 2 =  0 .1 5 6 9  
R1 =  0 .0 7 6 5 , w R 2 =  0 .1 6 7 3  
0 .4 0 8  and -0 .321  e.A'3
83 .9070 (10 )° .
7 8 .4650 (10 )° .
68 .632 (2 )° .
1<=14
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T ab le  2 . A tom ic coord inates ( x  104) and equiva len t isotropic d isp lacem ent parameters ( A ^  103) 
for 140. U (eq) is defined  as o n e  third o f  the trace o f  the orthogonalized  U'l tensor.
X y z U (eq)
C (l) 7 8 0 7 (3 ) 10395(2 ) -340(2 ) 32(1 )
C (2) 10492(3) 13053(2) -1 676 (2 ) 43 (1 )
C (3) 7 5 1 7 (3 ) 15300(2 ) -4802 (2 ) 34 (1 )
C (4) 6 5 7 5 (2 ) 12897(2 ) -980(1) 23 (1 )
C (5) 7 7 0 2 (2 ) 13141(2 ) -1 999 (2 ) 24 (1 )
C (6) 6 9 9 5 (2 ) 14162(2) -2 893 (1 ) 25 (1 )
C (7) 5 1 6 6 (2 ) 14924 (2 ) -27 5 8 (2 ) 26 (1 )
C (8) 4 0 5 1 (2 ) 14663(2 ) -1 734 (2 ) 25 (1 )
C (9) 4 7 0 9 (2 ) 13654(2) -831(1 ) 2 4 (1 )
C (10) 3 4 1 9 (2 ) 13430(2 ) 186(2) 25 (1 )
C ( l l ) 3 6 7 7 (2 ) 12543(2) 1160(2) 27 (1 )
C (12) 2 1 4 2 (2 ) 12457 (2 ) 2 062 (2 ) 2 7 (1 )
C (13) 2 5 0 2 (2 ) 11358 (2 ) 3 087 (2 ) 2 5 (1 )
C (14) 3 8 6 8 (2 ) 9 9 8 4 (2 ) 3 067 (1 ) 26 (1 )
C (15) 4 1 0 0 (2 ) 9 0 0 0 (2 ) 401 8 (2 ) 29 (1 )
C (16) 2 9 3 9 (2 ) 9 4 0 5 (2 ) 5101 (2 ) 27 (1 )
C (17) 1556 (2 ) 10780 (2 ) 5 183 (2 ) 30 (1 )
C (18) 1341(2 ) 11707(2 ) 4 1 8 3 (2 ) 29 (1 )
C (19) 2 1 6 4 (3 ) 8 7 8 9 (2 ) 71 5 4 (2 ) 34(1 )
F ( l) 5 043 (1 ) 9 5 3 5 (1 ) 2 0 3 0 (1 ) 35(1 )
0 (1 ) 7 3 4 4 (2 ) 11931(1) -104 (1 ) 25 (1 )
0 (2 ) 9 5 1 4 (2 ) 12341 (1 ) -21 4 4 (1 ) 28 (1 )
0 (3 ) 8 2 2 0 (2 ) 14333 (1 ) -38 5 2 (1 ) 31 (1 )
0 (4 ) 5 97 (2 ) 13269 (2 ) 2 0 1 7 (1 ) 37 (1 )
0 (5 ) 3 2 7 0 (2 ) 838 4 (1 ) 6 0 1 2 (1 ) 35 (1 )
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T ab le  3 . B ond  lengths [A ] and an g les [°] for 140. 0 (2 )-C (2 )-H (2 A ) 109.5
0 (2 )-C (2 )-H (2 B ) 109.5
H (2A )-C (2)-H (2B ) 109.5
C ( l) -0 (1 ) 1 .4 3 6 (2 ) 0 (2 )-C (2 )-H (2 C ) 109.5
C (1)-H (1A ) 0 .9 8 0 0 H (2A )-C (2)-H (2C ) 109.5
C (1)-H (1B ) 0 .9 8 0 0 H (2B )-C (2)-H (2C ) 109.5
C (1)-H (1C ) 0 .9 8 0 0 0 (3 )-C (3 )-H (3 A ) 109.5
C (2 )-0 (2 ) 1 .4 3 1 (2 ) 0 (3 )-C (3 )-H (3 B ) 109.5
C (2)-H (2A ) 0 .9 8 0 0 H (3A )-C (3)-H (3B ) 109.5
C (2)-H (2B ) 0 .9 8 0 0 0 (3 )-C (3 )-H (3 C ) 109.5
C (2)-H (2C ) 0 .9 8 0 0 H (3A )-C (3)-H (3C ) 109.5
C (3 )-0 (3 ) 1 .4 2 6 (2 ) H (3B )-C (3)-H (3C ) 109.5
C (3)-H (3A ) 0 .9 8 0 0 0 (1 )-C (4 )-C (5 ) 1 1 7 .96 (15 )
C (3)-H (3B ) 0 .9 8 0 0 0 (1 )-C (4 )-C (9 ) 1 2 1 .08 (14 )
C (3)-H (3C ) 0 .9 8 0 0 C (5)-C (4)-C (9) 1 2 0 .93 (15 )
C (4 )-0 ( l) 1 .3 7 9 (2 ) 0 (2 )-C (5 )-C (4 ) 1 1 9 .68 (15 )
C (4)-C (5) 1 .3 9 2 (2 ) 0 (2 )-C (5 )-C (6 ) 1 2 0 .05 (14 )
C (4)-C (9) 1 .4 1 0 (2 ) C (4)-C (5)-C (6) 1 2 0 .25 (15 )
C (5 )-0 (2 ) 1 .3 7 9 (2 ) 0 (3 )-C (6 )-C (7 ) 124 .7 3 (1 5 )
C (5)-C (6) 1 .4 0 2 (2 ) 0 (3 )-C (6 )-C (5 ) 1 1 5 .64 (15 )
C (6 )-0 (3 ) 1 .3 7 0 1 (1 9 ) C (7)-C (6)-C (5) 1 1 9 .63 (15 )
C (6)-C (7) 1 .3 8 5 (2 ) C (6)-C (7)-C (8) 1 1 9 .52 (16 )
C (7)-C (8) 1 .3 9 5 (2 ) C (6)-C (7)-H (7) 120 .2
C (7)-H (7) 0 .9 5 0 0 C (8)-C (7)-H (7) 120 .2
C (8)-C (9) 1 .3 9 4 (2 ) C (9)-C (8)-C (7) 1 2 2 .31 (16 )
C (8)-H (8) 0 .9 5 0 0 C (9)-C (8)-H (8) 118 .8
C (9)-C (10) 1 .460 (2 ) C (7)-C (8)-H (8) 118 .8
C (1 0 )-C (ll) 1 .3 3 8 (2 ) C (8)-C (9)-C (4) 1 1 7 .37 (15 )
C (10)-H (10) 0 .9 5 0 0 C (8)-C (9)-C (10) 1 17 .83 (15 )
C (ll) -C (1 2 ) 1 .477 (2 ) C (4)-C (9)-C (10) 1 2 4 .78 (16 )
C ( l l ) -H ( l  1) 0 .9 5 0 0 C (11)-C (10)-C (9) 1 30 .24 (17 )
C (1 2 )-0 (4 ) 1 .225 (2 ) C (ll) -C (1 0 )-H (1 0 ) 114 .9
C (12)-C (13) 1 .499 (2 ) C (9)-C (10)-H (10) 114 .9
C (13)-C (14) 1 .388 (2 ) C (1 0 )-C (ll) -C (1 2 ) 1 2 0 .74 (16 )
C (13)-C (18) 1 .404 (2 ) C (1 0 )-C (l 1 )-H (11) 119 .6
C (14)-C (15) 1 .366 (3 ) C (1 2 )-C (l 1 )-H (11) 119 .6
C (1 4 )-F (l) 1 .3 6 7 8 (1 7 ) 0 ( 4 ) -C ( 1 2 ) -C ( l l ) 122 .5 6 (1 6 )
C (15)-C (16) 1 .3 9 8 (2 ) 0 (4 ) -C (1 2 )-C (1 3 ) 1 18 .99 (15 )
C (15)-H (15) 0 .9 5 0 0 C (11 )-C (12 )-C (13 ) 118 .43 (15 )
C (1 6 )-0 (5 ) 1 .3 5 7 (2 ) C ( 14)-C ( 13 )-C (l 8) 115 .21 (16 )
C (16)-C (17) 1 .394 (3 ) C (14 )-C (13 )-C (12 ) 126 .53(15)
C (17)-C (18) 1 .3 7 8 (3 ) C ( 18)-C ( 13 )-C (l 2 ) 118 .25 (15 )
C (17)-H (17) 0 .9 5 0 0 C (1 5 )-C (1 4 )-F (l) 116 .41 (15 )
C (18)-H (18) 0 .9 5 0 0 C (15 )-C (14 )-C (l 3) 124 .19(15)
C (1 9 )-0 (5 ) 1 .437 (2 ) F (l)-C (1 4 )-C (1 3 ) 119 .36 (15 )
C (19)-H (19A ) 0 .9 8 0 0 C ( 14 )-C ( 15 )-C ( 16) 118 .75(17)
C (19)-H (19B ) 0 .9 8 0 0 C (14)-C (15)-H (15) 120.6
C (19)-H (19C ) 0 .9 8 0 0 C (16)-C (15)-H (15) 120.6
0 (5 )-C (1 6 )-C (1 7 ) 124 .75 (15 )
0(1)-C (1)-H (1  A) 109 .5 0 (5 )-C (1 6 )-C (1 5 ) 115 .50(16)
0 (1 )-C (1 )-H (1B ) 109.5 C (17)-C (16)-C (15) 119 .75(16)
H ( 1 A )-C ( 1 )-H ( 1B ) 109.5 C( 18 )-C (l 7)-C ( 16) 119 .06(16)
0 (1 )-C (1)-H (1C ) 109.5 C( 18 )-C (l 7 )-H (l 7) 120.5
H(1 A )-C (l )-H (l C) 109.5 C (16 )-C (l 7 )-H (l 7) 120.5
H (1B )-C (1)-H (1C ) 109.5 C (17)-C (18)-C (13) 122 .97(17)
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C (17)-C (18)-H (l 8) 118 .5
C (13)-C (18)-H (18) 118 .5
0 (5 )-C ( 19)-H ( 19 A ) 109 .5
0 (5 )-C ( 19)-H ( 19B ) 109 .5
H( 19 A)-C (19)-H ( 19B ) 109 .5
0 (5 )-C ( 19)-H ( 19C ) 109 .5
H (19A )-C (19)-H (l 9C ) 109 .5
H( 19B )-C (19)-H ( 19C ) 109 .5
C (4 )-0 (1 )-C (l) 1 1 3 .7 7 (1 2 )
C (5 )-0 (2 )-C (2 ) 1 1 3 .1 1 (1 3 )
C (6 )-0 (3 )-C (3 ) 1 1 6 .4 1 (1 4 )
C (16 )-0 (5 )-C (19 ) 1 1 7 .1 7 (1 4 )
Symmetry transformations used  to generate  
equivalent atoms:
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Table 4. A nisotropic d isp lacem en t parameters ( A ^  103)for 140. T he anisotropic  
displacem ent factor exp on en t takes the form: -27t2[ h ^ * 2! ^ 1 +  ... +  2 h k a* b* U 12 ]
U 11 U 22 u33 U 23 u13 U 12
C (1) 35(1) 2 3 (1 ) 32 (1 ) 1(1) -4 (1 ) -4(1)
C (2) 25(1) 31(1 ) 72 (2 ) -2 (1 ) -13(1 ) -6(1)
C (3) 32(1) 3 8 (1 ) 29 (1 ) 8 (1 ) -3 (1 ) -10(1 )
C(4) 24(1) 19(1) 2 3 (1 ) -2 (1 ) -4 (1 ) -4(1)
C(5) 20(1) 20 (1 ) 2 8 (1 ) -5 (1 ) -2 (1 ) -2(1)
C(6) 25(1 ) 22 (1 ) 25 (1 ) -2 (1 ) -1 (1 ) -7(1)
C (7) 26(1) 24 (1 ) 26 (1 ) HI) -6 (1 ) -6(1)
C(8) 21(1) 22 (1 ) 30 (1 ) -1 (1 ) -4 (1 ) -4(1)
C(9) 22(1 ) 20 (1 ) 26 (1 ) -3 (1 ) -3 (1 ) -5(1)
C (10) 2 1 0 ) 21 (1 ) 3 1 0 ) -4 (1 ) -2 (1 ) -5(1)
C ( l l ) 23(1) 25 (1 ) 3 0 (1 ) -3 (1 ) 0 (1 ) -7(1)
C (12) 24(1 ) 21 (1 ) 32(1 ) -2 (1 ) -1 (1 ) -6(1)
C (13) 21(1) 23(1 ) 28 (1 ) -3 (1 ) 0 (1 ) -6(1)
C (14) 20(1 ) 26 (1 ) 25 (1 ) -7 (1 ) 5(1) -4(1)
C (15) 24(1 ) 25 (1 ) 30 (1 ) -2 (1 ) 0 (1 ) -1(1)
C (16) 28(1 ) 26 (1 ) 26 (1 ) -1 (1 ) -3 (1 ) -9(1)
C (17) 28(1 ) 29 (1 ) 27 (1 ) -4 (1 ) 2 (1 ) -8(1)
C (18) 24(1 ) 22 (1 ) 32 (1 ) -4 (1 ) 3 (1 ) -3(1)
C (19) 38(1) 37(1 ) 23 (1 ) -1 (1 ) 1(1) -10(1 )
F ( l) 31(1 ) 31(1 ) 26 (1 ) -4 (1 ) 7 (1 ) 2(1 )
0 (1 ) 24 (1 ) 22 (1 ) 25 (1 ) 0 (1 ) -5 (1 ) -2(1)
0 (2 ) 20(1) 25 (1 ) 31 (1 ) -4 (1 ) 0 (1 ) -1(1)
0 (3 ) 25(1 ) 34(1 ) 27 (1 ) 5 (1 ) 1(1) -6(1)
0 (4 ) 24(1) 30(1 ) 45 (1 ) 8 (1 ) 1(1) -2(1)
0 (5 ) 37(1 ) 30(1 ) 27 (1 ) 2 (1 ) 1(1) -2(1)
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Table 5. Hydrogen coord inates ( x 104) and isotropic d isp lacem ent parameters ( A ^  103) 
for 140.
X y z U (eq)
H(1 A) 6715 10190 -339 48
H (1B ) 8 439 9773 27 9 48
H (1C) 8584 10176 -1 1 1 9 48
H (2A ) 10251 14058 -2 032 65
H (2B ) 11776 12482 -1865 65
H (2C) 10119 13108 -810 65
H (3A ) 6776 14903 -5 1 4 2 52
H (3B ) 8506 15377 -5 4 2 0 52
H (3C ) 6787 16286 -4 498 52
H (7) 4675 15619 -3 3 5 8 31
H (8) 2799 15191 -1 6 5 0 31
H (10) 2203 14006 149 30
H (1 1) 4861 11962 1273 32
H (15) 5033 8057 3945 35
H (17) 773 11074 5918 35
H (18) 364 12624 42 3 8 34
H (19A ) 2243 9702 7394 51
H (19B ) 2575 7989 7744 51
H (19C ) 919 8953 7105 51
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Appendix VI, Crystal data for 146
F 0
Table 1. Crystal data and structure refinem ent for 146. 
Identification cod e  
Empirical formula 
Formula w eight 
Temperature 
W avelength  
Crystal system  
Space group  
U nit ce ll d im ensions
V olum e
Z
D ensity (calculated)
Absorption coefficient 
F (000)
Crystal s ize
Theta range for data co llection
Index ranges
R eflections co llected
Independent reflections
C om pleteness to theta =  2 7 .5 5 °
Absorption correction
Max. and min. transm ission
R efinem ent m ethod
Data /  restraints /  parameters
G oodness-of-fit on F2
Final R  indices [I>2sigm a(I)]
R  indices (all data)
Largest diff. peak and h ole
nj 10405
C 1 7 H 1 2 F 4  0 2
3 2 4 .2 7  
1 50 (2 ) K  
0 .7 1 0 6 9  A 
T riclin ic  
P-l
a =  5 .9 1 0 (5 ) A a
b =  9 .3 2 9 (5 ) A p=
c =  1 3 .9 2 0 (5 ) A y
7 1 4 .8 (8 ) A3 
2
1 .507  M g/m 3 
0 .133  m m '1 
332
0 .3 0  x  0 .23  x  0 .0 7  m m 3 
3 .1 9  to  27 .5 5 °.
-7 < = h < = 7 , -1 2 < = k < = 1 2 , -18<=1<  
11479
3 2 0 4  [R (int) =  0 .0 9 9 7 ]
9 6 .8  %
Sem i-em pirical from  equivalents  
0 .9 9 0 8  and 0 .9 6 1 3  
Full-m atrix least-squares on  F2 
3 2 0 4  /  0  /  2 0 9  
1.033
R1 =  0 .0 6 1 7 , w R 2 =  0 .1 5 7 2  
R1 =  0 .0 7 9 2 , w R 2 =  0 .1 6 9 8  
0.671  and -0 .2 9 7  e.A'3
107 .392(5 )°.
94 .719 (5 )° .
99 .669 (5 )° .
= 18
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Table 2. A tom ic coordinates ( x  10 4) and equivalent isotropic d isp lacem ent parameters ( A ^  103) 
for 146. U (eq) is defined  as o n e  third o f  the trace o f  the orthogonalized  U ‘J tensor.
X y z U (eq)
C (l) -14 4 6 (3 ) 1169(2) 2738 (2 ) 36(1 )
C(2) -23 5 1 (3 ) 1305(2) 1823(2) 36(1 )
C (3) -934 (3 ) 2 0 6 0 (2 ) 1310(1) 35(1 )
C(4) -1 8 5 7 (4 ) 2 1 8 8 (2 ) 311(2 ) 41 (1 )
C(5) 1388(4) 2 6 7 2 (2 ) 1704(2) 39 (1 )
C(6) 2 2 7 1 (3 ) 2 5 4 1 (2 ) 2 6 1 6 (2 ) 38 (1 )
C(7) 871 (3 ) 1789(2) 315 3 (1 ) 33 (1 )
C(8) 1742(3) 1608(2) 4 1 2 1 (2 ) 35 (1 )
C(9) 390 5 (3 ) 2 1 1 7 (2 ) 460 0 (1 ) 35 (1 )
C (10) 46 0 6 (3 ) 1815(2 ) 5555 (1 ) 33 (1 )
C ( l l ) 6 9 51 (3 ) 2 5 6 1 (2 ) 615 0 (1 ) 31 (1 )
C (12) 8471 (4 ) 3 7 9 3 (2 ) 603 7 (1 ) 36 (1 )
C (13) 10626(4) 4 4 0 5 (2 ) 6 6 0 1 (2 ) 39 (1 )
C (14) 11346(3) 3 7 8 7 (2 ) 73 37 (1 ) 33 (1 )
C (15) 9 8 87 (3 ) 2 5 7 3 (2 ) 749 7 (1 ) 36 (1 )
C (16) 7746 (3 ) 1989(2 ) 690 6 (1 ) 34 (1 )
C (17) 14335(4) 3 7 8 6 (3 ) 859 4 (2 ) 46 (1 )
0 (1 ) 3307(2 ) 9 2 2 (2 ) 58 48 (1 ) 42 (1 )
0 (2 ) 13514(3) 4 4 4 1 (2 ) 785 6 (1 ) 43 (1 )
F ( l) -4153(2 ) 2 1 1 0 (2 ) 199(1) 67 (1 )
F(2) -1467(3 ) 1093(2 ) -482 (1 ) 74 (1 )
F(3) -934(3) 3 5 2 0 (2 ) 186(1 ) 61 (1 )
F(4) 7823 (3 ) 4 5 0 1 (2 ) 5 3 68 (1 ) 60 (1 )
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Table 3. B ond  lengths [A ] and an g les [°] for 146. C (6)-C (5)-C (3) 119 .95(17)
C (6)-C (5)-H (5) 120 .0
C (3)-C (5)-H (5) 120 .0
C (l)-C (2) 1 .3 8 9 (3 ) C (5)-C (6)-C (7) 121 .0 1 (1 8 )
C (l)-C (7) 1 .396 (3 ) C (5)-C (6)-H (6) 119.5
C (l) -H ( l) 0 .9 5 0 0 C (7)-C (6)-H (6) 119.5
C (2)-C (3) 1 .3 8 1 (3 ) C (l)-C (7 )-C (6 ) 118 .0 5 (1 7 )
C(2)-H (2) 0 .9 5 0 0 C (l)-C (7 )-C (8 ) 1 1 9 .02 (16 )
C (3)-C (5) 1 .391 (3 ) C (6)-C (7)-C (8) 1 2 2 .92 (18 )
C (3)-C (4) 1 .497 (3 ) C (9)-C (8)-C (7) 1 2 5 .81 (17 )
C (4)-F(2) 1 .327 (3 ) C (9)-C (8)-H (8) 117.1
C (4)-F(3) 1 .338 (2 ) C (7)-C (8)-H (8) 117.1
C (4 )-F (l) 1 .340 (3 ) C (8)-C (9)-C (10) 121 .0 3 (1 7 )
C (5)-C (6) 1 .379 (3 ) C (8)-C (9)-H (9) 119.5
C (5)-H (5) 0 .9 5 0 0 C (10)-C (9)-H (9) 119.5
C (6)-C (7) 1 .399 (3 ) O (l)-C (1 0 )-C (9 ) 1 2 0 .42 (18 )
C (6)-H (6) 0 .9 5 0 0 O ( l) -C (1 0 ) -C ( l l ) 119 .4 4 (1 6 )
C (7)-C (8) 1 .469 (3 ) C (9 )-C (10 )-C (l 1) 1 2 0 .10 (16 )
C (8)-C (9) 1 .3 3 1 (3 ) C (1 2 )-C (l 1 )-C (l 6) 1 1 5 .1 2 (1 7 )
C (8)-H (8) 0 .9 5 0 0 C (1 2 )-C (ll) -C (1 0 ) 126 .8 6 (1 6 )
C (9)-C (10) 1 .480 (3 ) C (1 6 )-C (l 1 )-C (10) 118 .0 2 (1 6 )
C (9)-H (9) 0 .9 5 0 0 F (4 )-C (12 )-C (13 ) 1 1 6 .04 (17 )
C (1 0 )-0 ( l) 1 .220(2 ) F (4 )-C (1 2 )-C (l 1) 120 .1 7 (1 7 )
C (1 0 )-C (ll) 1 .494(3 ) C (13 )-C (12 )-C (l 1) 123 .7 4 (1 7 )
C (ll) -C (1 2 ) 1 .391 (3 ) C ( 12 )-C (l 3 )-C (l 4) 118 .9 8 (1 8 )
C (ll) -C (1 6 ) 1 .397 (2 ) C (12)-C (13)-H (13) 120 .5
C (12)-F(4) 1 .359(2 ) C ( 14 )-C (l 3 )-H ( 13) 120 .5
C (12)-C (13) 1 .374(3 ) 0 (2 )-C (1 4 )-C (1 3 ) 1 1 5 .6 4 (1 7 )
C (13)-C (14) 1 .389(3 ) 0 (2 ) -C (1 4 )-C (1 5 ) 1 2 4 .4 6 (1 7 )
C (13)-H (13) 0 .9 5 0 0 C (13 )-C (14 )-C (15 ) 1 19 .9 1 (1 8 )
C (1 4 )-0 (2 ) 1 .363(2) C ( 16)-C ( 15 )-C ( 14) 1 18 .9 8 (1 7 )
C (14)-C (15) 1 .389(3 ) C ( 16 )-C (l 5 )-H ( 15) 120.5
C (15)-C (16) 1 .380(3 ) C (14)-C (15  )-H ( 15) 120.5
C (15)-H (15) 0 .9 5 0 0 C (15 )-C (16 )-C (l 1) 1 2 3 .27 (17 )
C (16)-H (16) 0 .9 5 0 0 C ( 15 )-C (l 6 )-H ( 16) 118 .4
C (1 7 )-0 (2 ) 1 .434(2 ) C ( l l ) - C ( l  6 )-H ( 16) 118 .4
C (17)-H (17A ) 0 .9 8 0 0 0 (2 ) -C (  17)-H ( 17 A ) 109.5
C (17)-H (17B ) 0 .9 8 0 0 0 (2 ) -C ( l  7 )-H (l 7B ) 109.5
C (17)-H (17C ) 0 .9 8 0 0 H (17A )-C (17 )-H (l 7B ) 109.5
0 (2 ) -C ( l  7 )-H (l 7C ) 109.5
C (2)-C (l)-C (7) 121 .22 (17 ) H (17A )-C (17 )-H (l 7C ) 109 .5
C (2 )-C (l)-H (l) 119 .4 H (17B )-C (17)-H (17C ) 109 .5
C (7 )-C (l)-H (l) 119 .4 C ( 14 )-0 (2 )-C  (17 ) 116 .7 7 (1 6 )
C (3)-C (2)-C (l) 119 .61(18)
C (3)-C (2)-H (2) 120.2
C (l)-C (2)-H (2) 120.2 Sym m etry transform ations used to  generate
C (2)-C (3)-C (5) 120 .15(18) equivalent atom s.
C (2)-C (3)-C (4) 120 .54(18)
C (5)-C (3)-C (4) 119 .28 (17 )
F(2)-C (4)-F (3) 1 06 .22 (18 )
F (2)-C (4)-F (l) 1 05 .89 (19 )
F (3)-C (4)-F (l) 1 05 .29 (17 )
F (2)-C (4)-C (3) 1 13 .12 (17 )
F (3)-C (4)-C (3) 1 1 2 .73 (17 )
F (l)-C (4)-C (3) 1 12 .95 (17 )
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T ab le  4. Anisotropic displacement parameters (A ^  103)for 146. The anisotropic 
displacement factor exponent takes the form: -27i2[ h ^ *2!!11 +  ... +  2  h k a* b* U 12 ]
U 11 U 22 U 33 u 23 U 13 U 12
C (l) 34(1) 35 (1 ) 42 (1 ) 18(1) 8(1) 5(1)
C(2) 33(1) 35 (1 ) 40 (1 ) 13(1) 2(1 ) 5 0 )
C(3) 42(1 ) 31 (1 ) 33(1 ) 11(1) 6 (1 ) H O )
C(4) 49(1 ) 38 (1 ) 38(1 ) 14(1) 5(1) 10(1)
C(5) 41(1) 41 (1 ) 40 (1 ) 20 (1 ) 12(1) 7(1)
C(6) 32(1) 44 (1 ) 41 (1 ) 18(1) 4 (1 ) 5(1)
C(7) 34(1) 32 (1 ) 36 (1 ) 13(1) 6 (1 ) 10(1)
C(8) 36(1) 35 (1 ) 39 (1 ) 17(1) 9 (1 ) 9(1)
C(9) 39(1) 34 (1 ) 34 (1 ) 13(1) 7 (1 ) 5(1)
C (10) 36(1) 31 (1 ) 34 (1 ) 11(1) 9 (1 ) 10(1)
C ( l l ) 37(1) 29 (1 ) 30 (1 ) 9 (1 ) 8(1) 10(1)
C (12) 47(1 ) 31 (1 ) 31 (1 ) 14(1) 1(1) 7(1)
C (13) 47(1 ) 33 (1 ) 37 (1 ) 15(1) 2(1 ) 0 (1)
C(14) 38(1) 29 (1 ) 31 (1 ) 7 (1 ) 3(1 ) 8(1)
C (15) 44(1 ) 35 (1 ) 33 (1 ) 15(1) 7 (1 ) 13(1)
C(16) 40(1 ) 31(1 ) 37 (1 ) 16(1) 10(1) 8(1)
C (17) 47(1 ) 47 (1 ) 45 (1 ) 18(1) -4 (1 ) 12(1)
0 (1 ) 38(1) 48 (1 ) 48 (1 ) 27 (1 ) 8(1) 4(1 )
0 (2 ) 44(1 ) 41 (1 ) 41 (1 ) 16(1) -4 (1 ) 4(1 )
F ( l) 49(1 ) 104(1) 59(1) 4 5 (1 ) -3 (1 ) 13(1)
F(2) 124(2) 67 (1 ) 36 (1 ) 12(1) 9 (1 ) 45 (1 )
F(3) 75(1) 54(1) 58(1 ) 36 (1 ) -5 (1 ) 2 (1 )
F(4) 72(1) 50(1) 57(1 ) 3 5 (1 ) -19(1 ) -11(1 )
T ab le  5. 
for 146.
Hydrogen coordinates ( x  104) and isotrop ic d isp lacem en t parameters ( A ^  103)
X y z U (eq)
H ( l ) -2423 644 3087 43
H(2) -3934 881 1553 43
H (5) 2364 3179 1346 4 6
H (6) 3855 2969 2883 46
H (8) 665 1081 4 4 3 2 42
H (9) 5016 2682 4325 4 2
H (13) 11609 5239 6489 47
H (15) 10356 2152 8005 43
H (16) 6762 1156 7019 41
H (17A ) 13393 3953 9150 69
H (17B ) 15958 4274 8865 6 9
H (17C ) 14216 2682 8271 69
